[
  {
    "page": 1,
    "content": "1141\nDental Implant Maintenance\nPART VIII\n41.  \u0007Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, \n­Etiologies, and Therapies, 1142\n42.  \u0007Implant Maintenance: Long-term Implant Success, 1192"
  },
  {
    "page": 2,
    "content": "1142\n41\nPeri-Mucositis and  \nPeri-Implantitis Diagnosis, \nClassification, Etiologies, \nand Therapies\nJON B. SUZUKI AND KEVIN R. SUZUKI\nI\nmplant dentistry has evolved into an evidence-based, \nclinical science with well-documented research to validate \npreviously unsupported clinical practice procedures. Sig-\nnificant efforts that focus on the biology and biomechanics of \nimplant dentistry have helped to develop and refine clinical \ntechniques based on peer-reviewed findings. However, despite \nimproved and predictable clinical successes in implantol-\nogy, peri-implant diseases have been diagnosed with increas-\ning incidence. The evolution of research and understanding \nof biologic concepts in implant dentistry and implant rescue \nhas caused many areas of debate and controversy. Innovative \ntheories have been developed that have resulted in technique \nmodifications. Science has spurred implant dentistry to new \npinnacles of success, which is highly based upon essential \nprinciples of periodontal regeneration.\nThe tremendous expansion of knowledge in implant dentistry \nhas created new ideas and terminology that is redefined based on \nnew applications to implant dentistry. In many instances new \nresearch may contradict established paradigms. It may be chal-\nlenging for clinicians to select correct protocols, procedures, \narmamentarium, and techniques. As materials and techniques \nare further investigated, dogma may undergo criticism and con-\ntroversy. Experienced clinicians consistently introduce and refine \ntechniques and instruments to maintain clinical excellence as \ntechnology and research advance.\nOne area of expansion of knowledge and views relates to \nthe maintenance of dental implants. Early research explored \ntechniques and instruments that were current for the methods \nand materials of that era. Although many of those implants \nare still in function in patients today, research and advances in \ntechnology have given us newer materials, implant design, and \nprotocols to maintain dental implant health.\nAn understanding of the mucoepithelial implant attachment \nis essential before commencing maintenance procedures. Contro-\nversies and parameters for probing and crestal bone loss are impor-\ntant for clinicians to recognize. There are anatomic and histologic \ndifferences between the attachment apparatus of teeth compared \nwith implants that are osseointegrated. The bacterial plaque bio-\nfilm on these implant-tissue attachments may be significant to \nclinical success.\nWhen the clinician understands the parameters of implants \nand teeth, specific maintenance plans may be established for the \npatient to minimize the possibility of developing peri-implant dis-\nease. Clinicians should inform patients of expectations and out-\ncomes during treatment, and demonstrate oral hygiene options \nappropriate during each stage. Patients need to recognize the \nimportance of maintenance protocols, and clinicians should assess \ncompliance to home care routines. Patients also should be com-\npetent to perform home maintenance. These strategies would cer-\ntainly minimize risks for peri-implant disease and implant failures.\nAs the acceptance of and demand for dental implants increase, \nthe need to understand the importance of maintenance as it relates \nto long-term implant success also increases. The role of the dental \nhygienist in implant maintenance and care as well as diagnosing \nperi-implant disease is increasing and becoming more defined.\nImplants and associated prostheses are much different from nat-\nural teeth and may require adjunctive procedures and instruments \nfor professional and patient care. Complications may arise when \nclinicians fail to comprehend these differences, because they may \nadversely impact the implant’s outcome, increasing the morbidity \nof treatment. The techniques and protocols used must be effective \nat removing biofilms and accretions, and procedures performed by \npatients and clinicians should avoid damage to the components of \nthe implant, abutment, restoration, and associated tissue.\nEstablishment and maintenance of the soft tissue seal around \nthe transmucosal portion of the implant enhances the success of \nan implant. This barrier is fundamentally a result of appropriate \nwound healing and connection of epithelial attachments. The \nmaintenance of healthy peri-implant tissues contributes to implant \nsuccess and minimizes peri-implant disease. In addition, tissues \nfree of inflammation and a biofilm-controlled implant sulcus will \nsupport the patient’s general and oral health."
  },
  {
    "page": 3,
    "content": "1143\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nPeri-implant Disease\nOne important, but often neglected, component of comprehen-\nsive dental implant treatment is the postprosthetic evaluation and \ntreatment of peri-implant issues. There are many conflicting opin-\nions and controversies on the diagnosis and treatment of these \ncomplications. Failure to effectively and promptly diagnose and \ntreat peri-implant disease with dental implants leads to an increase \nin implant and prosthetic failure.\nDental professionals are initially trained to have a firm under-\nstanding of the disease processes associated with the natural denti-\ntion. A variety of tests, indices, and radiographic signs are used to \ndetermine the health of a natural tooth. Dental implants and their \nrelated prostheses have fundamentally different relationships to \nthe oral environment than teeth, and these differences necessitate \na change in diagnostic protocol for the determination of health. \nFailure to understand these processes may lead to undiagnosed \ndisease states and potential morbidity of the implant system.\nThe implant clinician must have a strong understanding of the \nanatomic and histologic differences between natural dentition and \nthe dental implant as they pertain to periodontal structures. By \nhaving this foundation, the clinician may appreciate these neces-\nsary differences and will be better equipped to effectively diagnose \nperi-implant disease processes. With the increase in the number \nof dental implants being placed each year, a resultant increase in \nthe incidence of peri-implant disease has been seen. Two condi-\ntions of peri-implant disease are peri-implant mucositis and peri-\nimplantitis.1 The 6th European Workshop on Periodontology in \n2008 concluded that peri-implant diseases are infectious in nature \nand are defined by “changes in the level of crestal bone, presence of \nbleeding on probing, and/or suppuration; with or without deep-\nening of the peri-implant pockets.”2\nIn differentiation between these two peri-implant conditions, \nboth have been shown to be localized around implants and dem-\nonstrate features similar to adult chronic periodontal disease.3 \nThese conditions may be analogous to gingivitis (peri-mucositis) \nand periodontitis (peri-implantitis). However, biologic differences \nexist between the natural teeth and implants. Basically, peri-\nimplant tissues are more susceptible to infections, due to differ-\nences in soft tissue attachment and biofilms that may advance to \nthe alveolar-implant complex (see discussion in Chapter 42).4\nGingivitis is a bacteria-induced inflammation involving the \nregion of the marginal gingiva above the crest of bone and adjacent \nto a natural tooth. The most common forms are associated with \nplaque and may be classified as: (1) acute necrotizing, (2) ulcerative, \n(3) hormonal, (4) drug induced, or (5) spontaneously occurring.5 \nThese categories may also relate to the gingival tissues around an \nimplant.6,7 The classification of gingivitis and periodontitis has cur-\nrently been updated by the American Academy of Periodontology.8\nThe bacteria responsible for gingivitis around a tooth may \naffect the epithelial attachment, without loss of connective tissue \nattachment. Because the connective tissue attachment of a tooth \nextends an average of 1.07 mm above the crestal bone, at least 1 \nmm of protective barrier above the bone is present. In contrast, \nno connective tissue attachment zone exists around an implant \nbecause there is an absence of connective fibers that extend into \nthe implant surface. Therefore no connective tissue barrier exists \nto protect the crestal bone around an implant.9\nPeriodontitis around teeth is characterized by apical movement \nof junctional epithelium and periodontal attachment, coupled \nwith loss of alveolar bone. Bacteria are thought to be responsible \nby stimulating the body’s immune response, which results in an \noverall resorptive effect on the periodontal attachment appara-\ntus. The American Academy of Periodontology (2018) recognizes \nstages of periodontitis: stage 1, stage 2, stage 3, and stage 4. For-\nmer specific subtypes10 for each category such as adult chronic \nperiodontitis, rapidly progressive periodontitis, localized juvenile, \nand prepubertal periodontitis are now encompassed within stage \n1, stage 2, and stage 3 of periodontitis.\nIn contrast with teeth, early crestal bone loss around an implant \nbody prosthetically may not always be caused by pathogens. In \nmany cases, the associated bone loss may result from stress fac-\ntors too great for the immature, incompletely mineralized bone-\nimplant interface or an extension of the biologic width onto a \nsmooth metal crest module.11 Therefore, an implant may exhibit \nearly crestal bone loss with a different mechanism or cause, com-\npared with natural teeth. However, bacteria in some cases may be \nthe primary factor, because anaerobic bacteria have been observed \nin the microgap between the implant and the abutment or in the \nsulcus of implants. This is especially evident when sulcus depths \nare greater than 5 mm (Box 41.1).12 A systematic review13 high-\nlights potential etiologies of early crestal bone loss around recently \nosteointegrated implants.\nIn summary, periodontal disease that develops around dental \nimplants has been classified into two separate entities: peri-implant \nmucositis and peri-implantitis. Peri-implant mucositis is defined as a \nreversible inflammatory reaction in the peri-implant tissues surround-\ning an implant. Peri-implantitis is defined as an inflammatory reac-\ntion, with loss of supporting bone around an implant (Fig. 41.1).\nThe Role of Biofilm in Peri-Implant Disease\nThe oral biofilm originates from bacteria and saliva, which result \nin sticky masses of bacteria with a polysaccharide matrix that accu-\nmulate on hard and soft surfaces in the oral cavity. The bacterial \nand biofilm formation may adhere to any implant surfaces in the \noral cavity and have been reported to result in pocket formation \nand loss of the supporting bone.14-16 Di Giulio et al.17 determined \nthat biofilm is one of the major causes of implant failure. The \nConsensus of the 7th European Workshop on Periodontology \nstated that peri-implant infections are always caused by plaque \nand its by-products (i.e., biofilm).18\nThe role of biofilms has been heavily studied and has been \nreported to be responsible for approximately 65% of peri-implant \ndiseases.19 After exposure of the implant surface to the oral cav-\nity, a pellicle is formed in less than 30 minutes.20 The pellicle is \nderived from the saliva, various bacteria present in the oral cavity, \nand also host tissue products. After formation of the pellicle, bac-\nterial attachment occurs by cell-to-cell adhesion on the implant \nsurface.21 Most bacteria use biofilm as the primary method of \nShallow\n • \u0007Gram-positive facultative cocci, rods\n • \u0007Gram-negative anaerobic cocci, rods\n • \u0007Motile rods\n • \u0007Spirochetes\n • \u0007Black-pigmented bacteroides\n • \u0007Fusobacterium\nDeep\n • \u0007Vibrios organisms\n\t • BOX 41.1\t    \u0007Common Bacteria Associated With \nPocket Depths"
  },
  {
    "page": 4,
    "content": "1144\nPART VIII    Dental Implant Maintenance\ngrowth, because they facilitate nutrient exchange and prevent \ncompeting microorganisms.22 Studies have shown the process of \nbiofilm colonization is the same on teeth as with dental implants.23\nTherefore the most ideal solution to prevent microbial infec-\ntions is to decrease the colonization of bacteria on implant sur-\nfaces. Unfortunately, many characteristics (e.g., material, surface \nroughness) of prosthetic and implant surfaces directly affect the \nbacterial adhesion and biofilm formation.24\nFor reversal of the peri-implant disease process, the biofilm \nmust be removed with mechanical debridement or chemical oblit-\neration. If not removed, mature plaque will form. It has been \nshown that bacteria will migrate from teeth to implants and from \nimplant to implant. Similar to teeth, clinical findings of failing \nimplants include inflammation, pocket formation, and progres-\nsive bone loss.25\nThe microorganisms may initiate an inflammatory release of \ncytokines that will enhance accumulation of neutrophils to the \nimplant lesion. This process will continue to attract more leuko-\ncytes and continue to facilitate more peri-implant tissue damage \nand inflammation.26,27 If the inflammation progresses, it will lead \nto peri-implantitis, with the characteristic feature of bone loss \naround the implant. If left untreated, stromal tissue cells may \nalso propagate, leading to an increase in infiltrates of proinflam-\nmatory cells that promotes further tissue breakdown,28-30 which \nmay eventually lead to loss of osseointegration, implant mobility, \nand ultimately implant failure.31-33 In addition to the results of a \nsystematic review, there is evidence that the pathogens Prevotella \nintermedia, Campylobacter rectus, Aggregatibacter actinomycetem-\ncomitans, and Treponema denticola have been implicated in the \npathogenesis of peri-implantitis.34,35\nCurrent chemotherapeutics cannot penetrate thick biofilm, \nbecause rough surfaces have been found to hold more biofilm \nthan smooth surfaces.36 Bacterial deposits produce exotoxins and \nlipopolysaccharides (endotoxins) that inhibit fibroblast and osteo-\nblastic growth, and thus prevent proximal regeneration onto the \nimplant surface. Although it is impossible to guarantee 100% ste-\nrility of exposed implant surfaces, the body is capable of removing \nsmall amounts of bacterial deposit via host defense mechanisms.37\nCarefully removing macrodeposits of plaque biofilm and irri-\ngating with antimicrobial solution is generally sufficient to allow \na favorable environment for new attachment formation. It is rec-\nommended that patients complete a full-mouth debridement to \nreduce bacterial colonies, including plaque biofilms on exposed \nimplant surfaces (Box 41.2). \nPeri-implant Mucositis\nPeri-implant mucositis is an inflammatory condition of the soft tis-\nsue surrounding an implant, which is similar to gingivitis around \nnatural teeth. In both animal and human studies, peri-implant \nmucositis has been shown clinically and histologically to be com-\nparable to gingivitis around natural teeth.184 This has been defined \nA\nB\nC\nD\n• Fig. 41.1  (A) Spongiotic gingivitis exhibiting erythematous marginal tissue with cyanotic tissue. (B) Peri-\nodontitis: mandibular anterior exhibiting severe horizontal bone loss. (C) Peri-mucositis: erythematous buc-\ncal gingiva with associated bleeding around implant crown. (D) Peri-implantitis: significant bone loss with  \nerythematous tissue with significant plaque accumulation. (From Suzuki JB, Misch CE. Periodontal and \nmaintenance complications. In: Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implan-\ntology. St. Louis, MO: Elsevier; 2018.)"
  },
  {
    "page": 5,
    "content": "1145\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nBacteria\nPrevotella intermedia\nPorphyromonas gingivalis\nAggregatibacter actinomycetemcomitans\nTannerella forsythia (formerly Bacteroides forsythus)\nTreponema denticola\nPrevotella nigrescens\nFusobacterium nucleatum\nEtiology\n • \u0007Poor Oral Hygiene\n • \u0007Poor Compliance with Supportive Procedures\n • \u0007Poor Prosthesis Design\n • \u0007Poor Fit of Prosthesis\n • \u0007Non-ideal Implant Position\n • \u0007Lack of Non-Keratinized Peri-Implant Mucosa\n • \u0007Retained Cement\n\t • BOX 41.2\t    \u0007Bacteria and Etiology of Peri-Implant \nMucositis\nA\nB\nC\n• Fig. 41.2  Peri-mucositis.  (A) Bleeding on probing without bone loss with a diagnosis of peri-mucositis. \n(B) Inflammation on the buccal aspect of the mandibular first molar implant. (C) Maxillary overdenture causing \nperi-mucositis and fungal infections.\nimplant level.39 Clinically, bleeding on peri-implant probing with \nmucositis may be present without suppuration. If peri-mucositis \nis allowed to progress, peri-implantitis may result, which includes \nloss of bone and possible loss of osseointegration, similar to loss of \nattachment and bone with periodontitis. The relationship between \nplaque accumulation and peri-implant mucosal inflammation has \nbeen proven through numerous studies (Fig. 41.2).40-42\nEtiology\nMost cases of peri-implant mucositis are due to poor oral hygiene, \ninability to clean the implant or prosthesis, nonideal implant \nposition, poor fit of the prosthesis, and retained cement. Poorly \nplaced implants or overcontoured prostheses may lead to difficulty \nor inability to properly clean the implants (Fig. 41.3). In addition, \nperi-implant mucositis may also be caused by titanium alloy hyper-\nsensitivity. Most dental implants today are covered by a titanium \ndioxide layer that gives the implant a high surface energy that \nfacilitates the interaction between the host tissues and the dental \nimplant. When the implant becomes exposed to the oral environ-\nment, a lower surface energy may provoke a type IV hypersensitiv-\nity reaction that may contribute to peri-implant mucositis.43 \nPrevention\nBecause of the high prevalence of peri-implant mucositis, it is \nimperative that the clinician be able to assess the risk profile of \neach patient and integrate these considerations when treatment \nas a reversible condition with no loss of attachment or bone loss. \nThe prevalence rate of peri-implant mucositis (bleeding on prob-\ning and no loss of bone) in systemic reviews has been shown to \nbe approximately 30% of implants and 47 % of patients.38  How-\never, other studies have reported the incidence to be as high as \n80% of patients and 50 % of implants observed. Ferreira et al. \nreported a prevalence of  64.6% at the patient level and 62.6% at"
  },
  {
    "page": 6,
    "content": "1146\nPART VIII    Dental Implant Maintenance\nplanning is initiated. A consensus report by the Academy of Peri-\nodontology has shown risk factors to include poor oral hygiene, \nhistory of periodontal disease, smoking, retained cement, and \nocclusal disharmonies. Therefore, a comprehensive medical his-\ntory should be evaluated for any risk factors and the patient should \nbe informed of possible associated complications.\nTobacco smoking leads to the end product of nicotine and nor-\nnicotine that increases cytokine levels and reactive oxygen species. \nIncreased smoking has been shown to result in increased levels of \nalveolar bone loss with dental implants.44 Diabetes mellitus has also \nbeen shown to increase the risk for peri-implant disease compared \nwith healthy individuals.45 This is due to elevated blood sugar levels \nthat compromise wound healing and the host immune system. \nManagement\nPeri-implant mucositis is a reversible inflammatory process. How-\never, if not treated properly, the persistent inflammatory condition \nmay progress to peri-implantitis that results in irreversible bone \nloss. In most cases peri-implant mucositis is a precursor for the \ndevelopment of peri-implantitis.46\nNonsurgical (closed debridement) mechanical debridement \nto remove plaque and calculus from the implant surface using \nmechanical instruments such as scalers and curettes coupled with \nantimicrobial rinse therapies is the primary therapeutic approach \nfor peri-implant mucositis.47\nIn a systematic review, nonsurgical mechanical debridement is \neffective in the management of peri-implant mucositis. Use of anti-\nseptics increased the observed outcomes.48 It is crucial to implement a \ncomprehensive patient and professional oral hygiene program to man-\nage peri-implant mucositis. Power brushes, interproximal and irriga-\ntion power devices, dentifrices, and antimicrobials have been shown \nto be highly effective in the management of peri-implant mucositis.\nProfessional Mechanical Debridement\nFor the removal of supragingival and subgingival biofilm and bacteria, \ndebridement of the exposed implant surface and implant abutment \nmust be completed. There exist many different debridement systems.\nCurettes. The selection of scalers for titanium implant debride-\nment is important to minimize surface changes after treatment. \nVarious types of curettes are available for debridement procedures \n(Fig. 41.4):\nA\nB\n• Fig. 41.3  Prosthesis-Related Peri-mucositis.  (A) Hygiene difficulty because of an (B) When prostheses \nare fixed, usually hygiene will be more difficult.\nA\nB\nC\nD\n• Fig. 41.4  (A) Titanium curette. (B) Carbon-reinforced curette. (C) Teflon/plastic. (D) Steel curette. (A and \nB, Courtesy Salvin Dental Specialties, Inc., Charlotte, N.C.)"
  },
  {
    "page": 7,
    "content": "1147\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\n • \u0007Titanium-coated curettes are specifically made for dental \nimplant debridement because they have a similar hardness to \nthe titanium surface and will not scratch or mar the surface.\n • \u0007Carbon-fiber curettes are softer than the implant surfaces and \nwill not damage the implant surface. These types of curettes are \nprone to fracture.\n • \u0007Teflon curettes are similar to carbon-reinforced curettes and \nwill not scratch the surface of the implant.\n • \u0007Plastic curettes have been advocated as the instrument of \nchoice to prevent damage from the implant surface.\n • \u0007Stainless-steel curettes are much harder than titanium alloy and \nare not recommended for use around dental implants because \nthey may alter the implant surface.49\n • \u0007Amorphous resin scalers come with unfilled or filled resin. Unfilled \nresin scalers have no reinforcements for shape or stiffness, whereas \nfilled resin fillers may use materials such as silica, graphite, or glass. \nThese scalers have replacement tips on stainless-steel handles.\n • \u0007Titanium brush burs insert into implant motors. They have a \nvariety of shapes, allowing them to adapt around the implant \nor prosthesis surface circumferentially, around a single surface, \nand for groove cleaning. Brushes are used at 600 rpm and \nadapted against the implant surface to remove debris.\nHasturk et al. evaluated six different types of scaler materials \nto scratch surfaces of different brands of implants abutments, \nand they were compared with scanning electron microscopy. The \nresults showed glass-filled resin curettes caused the most scratches, \nwhereas the unfilled resin scalers had the least surface alteration. \nHowever, these studies are on smooth titanium abutments and \nnot on the rough implant surface.50\nThere may not be clinical relevance regarding whether curettes \nscratch implant surfaces. Anastassiadis et al. reported that metal \nscalers do not readily scratch cementum; it is questionable that \na titanium implant surface, which has a higher Mohs hardness, \nshould be of any concern.51\nFurthermore, scalers as a whole may be effective in removing large \ncalculus particles or granulation tissues but are rather ineffective try-\ning to navigate the perimeter and grooves of an exposed implant \nsurface. For that reason, curette material may not be a significant \nconcern, but rather the activity of curetting may be (Fig. 41.5). \nUltrasonic Devices\nUltrasonic devices with special polyetheretherketone-coated tips \nhave been used to debride the implant surface. This tip is made of \na plastic material with a stainless-steel core. This ultrasonic device \nallows the debridement of plaque and calculus, while leaving a \nsmooth and clean surface.\nAlthough metal tips are not recommended, plastic tips may be \nat an increased risk of shredding when cleaning around implant \nA\nB\n• Fig. 41.5  Peri-mucositis Treatment.  (A,B) Scaling technique around an implant with peri-implant inflam-\nmation."
  },
  {
    "page": 8,
    "content": "1148\nPART VIII    Dental Implant Maintenance\ngrooves and threads. Tips made of PEEK material (Hu-Friedy, \nChicago, Ill.) have been shown to be resistant to shredding and \nmay be considered (Fig. 41.6). \nAntimicrobials\nAntiseptics are defined as antimicrobial substances that are non-\ndamaging to living tissue/skin while reducing the possibility of \ninfection, sepsis, or putrefaction. Several types of antiseptics are \nready for dental use: chlorhexidine 0.12% or 0.2%, cetylpyri-\ndinium chloride, sodium hypochlorite 1.0%, hydrogen peroxide \n3.0%, citric acid 40.0%, Ethylenediamine tetraacetic acid (EDTA) \n24%, povidone-iodine 10%, and phenols/essential oils.52,53\nFor management of peri-mucositis, several qualities are \nneeded for antiseptics to be effective: biofilm penetration, long \nsubstantivity, tissue biocompatibility, and low resistance. Removal \nof macrodeposits should be performed with scalers first.\nChlorhexidine applied on a cotton pellet and burnished \nagainst a machined surface has shown a 92.9% Porphyromonas \ngingivalis endotoxin reduction.54 Povidone-iodine has high anti-\nseptic capability but has a highly irritating effect if any residue \ncomes in contact with an osseous structure. Several of the anti-\nseptics and their effectiveness on Staphylococcus epidermidis, Can-\ndida albicans, and S. sanguinis have been investigated. Although \nsodium hypochlorite was most effective in the reduction of \nall three bacterial biofilms, it has the highest tissue toxicity. \nHydrogen peroxide was active against only C. albicans, whereas \nchlorhexidine gluconate and phenols/essential oils had activity \nagainst only Streptococcus sanguinis and C. albicans55 (Fig. 41.7). \nPatient At-Home Mechanical Debridement\nImplant patients must understand their role in maintaining their \ndental implants and implant prosthesis. An individualized home \ncare assessment and protocol must be developed for each patient, \nand it must be customized according to the tissue condition, \nimplant position, and type of prosthesis. Home care devices that \nhave been shown to be safe around implant surfaces include tooth-\nbrushes (manual or powered), floss (e.g., plastic, braided nylon, \ncoated, stiffened ends to clean under pontic areas, and dental \ntape). In addition, oral irrigators, interdental brushes, and end-tuft \nbrushes may be used. (See Chapter 42 for a complete list of home \ncare aids.) A strong home care regimen may significantly reduce \nthe amount and composition of subgingival microbiota around \nteeth. This reduction most likely will translate to a decreased risk \nfor periodontal disease initiation or recurrence. Furthermore, the \ndecreased prevalence of periodontal pathogens in supragingival \nplaque decreases potential reservoirs of these species.63 \nPeri-implantitis\nThe American Academy of Periodontology has defined peri-\nimplantitis as an “inflammatory reaction associated with the \nloss of supporting bone beyond initial biologic bone remodeling \n• Fig. 41.6  Ultrasonic scalers may be used to treat peri-mucositis.\nA\nB\n• Fig. 41.7  (A) Chlorhexidine: used as a rinse or locally applied (Peridex; 3M ESPE Dental Products, St. \nPaul, Minn.). (B) Local application of chlorhexidine to implant surface."
  },
  {
    "page": 9,
    "content": "1149\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\naround an implant in function.”64 Peri-implantitis has been \nshown to exhibit similar microbial flora as chronic periodontitis. \nAlthough there is no consensus regarding microorganisms, Perez-\nChaparro et al.65 identified three commonly occurring pathogens \nassociated with peri-implantitis: Porphyromonas gingivalis, Trepo-\nnema denticola, and Tannerella forsythia. The dental implant may \nexhibit all the signs of peri-implant diseases, including exudate, \nincreased pocket depths, and crater-like osseous defects, which are \nstrictly localized around the implant. If left untreated, significant \nbone loss, infection, and mobility could result, leading to loss of \nimplant osseointegration. Additional clinical signs include radio-\ngraphic vertical bone loss greater than 2 mm, bleeding on prob-\ning (with or without exudate), mucosal swelling and erythema, \nand an absence of pain (Box 41.4). The crestal bone loss may be \ninduced by stress, bacteria, or a combination of both. A system-\natic review on peri-implantitis66 identifies acknowledged etiolo-\ngies and related causes of peri-implantitis.\nAfter bone loss from stress or bacteria occurs, the sulcu-\nlar crevice deepens and a decrease in oxygen tension is pres-\nent. Anaerobic pathogenic bacteria may become the primary \npromoters of the continued bone loss. An exudate or abscess \nindicates exacerbation of the peri-implant disease and possible \naccelerated bone loss. Studies have shown the prevalence rate of \nperi-implantitis has been found in 28% to 56% of subjects and \n12% to 43% of implant sites (Fig. 41.9).67\nEtiology\nPeri-implantitis has been associated with a gram-negative anaer-\nobic microbiota, similar to that found in severe periodontitis \naround natural teeth.68 Peri-implantitis encompasses similar clini-\ncal signs of peri-implant mucositis, but loss of bone and attach-\nment is observed. A stabilized implant that continues to exhibit \nloss of bone levels is indicative of peri-implantitis.\nBiofilm\nAlthough bacterial biofilm insult is identified as the main cause \nof peri-implant mucositis, peri-implantitis is considered to be \ninitiated by stress factors caused by poor biomechanical forces. \nIn addition, several other etiologic factors exist, such as poor \nimplant placement, poor oral hygiene, residual cement, host \nresponse, poor implant surface, unfavorable osseous density, \nuntreated periodontitis, alcohol excess, smoking, untreated end-\nodontic lesions, diabetes, among others. Monje et al.,69 in a sys-\ntemic review, confirmed that peri-implantitis may be prevented \nwith a strong peri-implant maintenance program, along with a \ncomprehensive patient, clinical, and implant-related evaluation. \nThey concluded a minimum recall and hygiene program be tai-\nlored to the patient’s risk profiling and at a minimum of a 5- to \n6-month interval. \nOcclusal Stress\nUnfavorable stress factors can initiate crestal bone loss, and \nbacterial biofilm challenges may further enhance the rate \nof osseous destruction. In recent studies, bacterial biofilms \nattached onto the surface of implants were shown to create a \nhighly acidic environment that causes corrosion, pitting, crack-\ning, etc.70 Furthermore, recent studies have shed light on the \nrelease of titanium ions from the implant surface, which results \nin a significant increase in a local inflammatory response71 \n(Table 41.1). \nHistory of Periodontitis\nMost long-term studies and systemic reviews have concluded that \npatients with a history of periodontitis had a higher incidence of peri-\nimplantitis in comparison with periodontally healthy patients.72,73 \nPapantonopoulos et al.74 have reported on two implant phenotypes \nthat are directly related to peri-implantitis. A peri-implantitis-suscep-\ntible phenotype was associated with fewer teeth and younger age, and \nwas predominantly in the mandible. A peri-implantitis-resistant phe-\nnotype was mainly found in the maxilla.74 \nSmoking/Tobacco Use\nAlthough many conflicting studies exist on the relationship \nbetween smoking and peri-implantitis, most reports have shown \nstatistically significant differences between smokers and non-\nsmokers. Rinke et al.75 reported that smokers had an approxi-\nmate odds ratio of 31.58 in development of peri-implantitis. The \noverall peri-implantitis rate in their study population was 11.2% \nand as high as 53% for patients who smoked and had a history \nof periodontitis. \nDiabetes\nThe relationship between diabetes and periodontal disease is well \nestablished. Poorly controlled diabetes has also been associated \nwith peri-implantitis.76,77 Venza et al.78 reported that the long-\nterm prognosis for dental implants is more favorable when the \npatient’s glycosylated hemoglobin (HbA1c) is less than 7%.\nCanullo et al.79 proposed an evidence-based classification for \ndifferent clinical subtypes of peri-implantitis, including: (1) sur-\ngically triggered peri-implantitis, (2) prosthetically driven peri-\nimplantitis, and (3) plaque-induced peri-implantitis. They state \nthat these three subtypes of peri-implantitis are separate, differ-\nent entities that may be distinguished with predictive profiles. \nIn addition, various risk factors can act synergistically with a \nclinical scenario, which make the causative factors more difficult \n(Table 41.2).79 \nPrevention\nHome Care\nAn effective oral hygiene program is paramount to minimize peri-\nimplant disease. This has been shown through various studies. \nDirect correlations between poor oral hygiene and peri-implant \nbone loss in a 10-year follow-up study were reported.80 Other stud-\nies have shown a correlation with poor oral hygiene and a higher \nplaque score.81 In addition, patients who have lost their teeth to \nperiodontal disease are more susceptible to peri-implantitis.82 \nProfessional Care\nThorough periodontal charting and review is essential. Patients \nwith periodontitis must have this pathologic condition controlled \nbefore implant placement. Patients who do not demonstrate the \n• \u0007Vertical bone loss (radiographic, probing, or both)\n• \u0007Peri-Implant pockets\n• \u0007Bleeding on probing\n• \u0007Exudate\n• \u0007Mucosal swelling\n• \u0007Erythema\n• \u0007Usually no associated pain\n\t• BOX 41.4\t   \u0007Clinical Symptoms Associated With  \nPeri-Implantitis"
  },
  {
    "page": 10,
    "content": "1150\nPART VIII    Dental Implant Maintenance\nability to maintain oral hygiene need to be educated and put on \nstringent professional care regimens. \nProsthetic Design\nA thoroughly evaluated cone beam computed tomography scan \nstudy with favorable biomechanical design for prosthetics is man-\ndatory. Ideal implant position is paramount to allow for a properly \ndesigned prosthesis that is cleansable. \nCementation Technique\nThe meticulous use of cements when delivering a prosthe-\nsis is imperative, or the clinician can choose to use a screw-\nretained prostheses. If a cementable prosthesis is utilized, \nthe clinician must take precautions to prevent retainment \nof cement. Conventional cementable techniques that are \nnormally used for natural teeth are not recommended (See \nFig. 41.5). \nA\nB\nC\nD\nE\n• Fig. 41.9  Peri-Implantitis.  (A and B) Clinical images depicting bone loss. (C) Radiograph showing sig-\nnificant bone loss around implant. (D) Cratering bone loss. (E) Implant failure caused by calculus formation."
  },
  {
    "page": 11,
    "content": "1151\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\n  \u0007Human Studies on Peri-Implantitis Treatment\nAuthor\nProcedure\nNumber of Patients \nand Implants and \nTime of Follow Up\nTreatment\nOutcome\nLeonhardt \net al 2003\nAccess surgery\n9 patients\n26 implants\n60 months\nSystemic antibiotics (according to micro-\nbiologic analysis) + access surgery + \ndecontamination of the implant surface \nusing 10% hydrogen peroxide\n0.2% CHX 2× a day rinse\nHealing: 58% of the implants\n7 implants lost\n4/19 ongoing bone loss\n6/19 bone gain\nMean gingival bleeding was reduced from \n100%–5%\nDisease progression at 2 other implants\nRomeo et al \n2007\nApically repositioned \nflap surgery + \nimplant surface \nmodification\nResective surgery\n19 patients\n38 implants (11 hol-\nlow screw and 7 \nsolid screw)\n12–24–36 months\nSystemic antibiotics (amoxicillin for 8 days) \n+ full mouth disinfection\n9 patients with resective surgery and 10 \nwith resective surgery and modification \nof surface topography\nImplant surface decontamination with \nmetronidazole gel, tetracycline hydro-\nchloride, and saline\nRadiographic assessment:\nImplantoplasty is an effective treatment \nprocedure\nSignificantly better results w/apical reposi-\ntion flap surgery + implant surface \nmodification\nBehneke et al \n1997\nBone grafts and bone \ngraft substitutes \nsurgery\n \n• \u0007Nonsubmerged\n10 patients\n14 implants\n6 months–2 years\nIrrigation with iodine + systemic antibiotics \n(Ornidazole 500 mg × 2 for 7 days)\nImplant surface treated with air powder \nand irrigation with saline\n7 implants with 2–3 wall defects got bone \nchips and 7 implants with 1 wall defect \ngot bone blocks\nClinical: (6 months/14 implants)\nBI: 2.4–0.3\nPD: 5.9–2.3 mm\nClinical: (2 years/5 implants)\nBI: 2.4–0.4\nPD: 5.9–2.5 mm\nRadiographic: (3–12 months/14 implants)\nAverage bone fill: 3 mm\nBehneke et al \n2000\nBone grafts and bone \ngraft substitutes \nsurgery\n \n• Nonsubmerged\n25 implants\n6 months to 3 years\nIrrigation with iodine for 1 month + \ndebridement with mucoperiosteal flap \nsurgery\nImplant surface decontamination with air \nabrasive instruments for 30 seconds + \nsaline irrigation + 7 bone chips and 18 \nbone blocks (Metronidazole 400 × 2 \nfor 7 days)\nClinical: (1 year/18 implants)\nPD: 5.3–2.2 mm\nClinical: (3 year/10 implants)\nPD: 5.3–1.6 mm\nRadiographic: (1 year/18 implants)\nMean bone fill: 3.9 mm\nRadiographic: (3 year/10 implants)\nMean bone fill: 4.2 mm\nAughtun et al \n1992\nBarrier membranes\n \n• Nonsubmerged\n12 patients\n15 implants\n6–12 months\nePTFE membrane + systemic antibiotics \n(tetracycline 200 mg × 1 for 12 days) \n+ implant detoxification (air powder) + \nirrigation with saline\nClinical:\nPI: 1.9–1.0\nBI: 1.1–1.1\nPD: 5.2–4.1 mm\nRadiographic\nMean bone loss: 0.8 mm\nMinor improvements on soft tissue \n­conditions\nMembrane exposure\nJovanovic \net al 1992\nBarrier membranes\n \n• Nonsubmerged\n7 patients\n10 implants\n6 months to 3 years\nePTFE membrane + systemic antibiotics \n(Tetracycline 250 mg × 4 for 7 days) \n+ implant detoxification (air-powder + \nchloramine T + saline irrigation)\nClinical:\nPI: 1.7–0.6\nGI: 2.1–0.3\nPD: 6.8–4.1 mm\nAll clinical signs improved\nRadiographically:\n7 defects showed bone fill\n3 defects: no bone fill\nTABLE \n41.1\nContinued"
  },
  {
    "page": 12,
    "content": "1152\nPART VIII    Dental Implant Maintenance\nAuthor\nProcedure\nNumber of Patients \nand Implants and \nTime of Follow Up\nTreatment\nOutcome\nKhoury and \nBuchmann \n2001\nGrafting materials  \n+ barrier  \nmembranes\n25 patients\n41 implants\n36 months\nSystemic antibiotics\nGroup 1 (12 implants): detoxification with \nchlorhexidine irrigation + citric acid \n+ hydrogen peroxide + saline + bone \nblocks and particulate bone\nGroup 2 (20 implants): treatments as group \n1 + ePTFE\nGroup 3 (9 implants): treatments as group \n1 + collagen membrane (submerged)\nClinical:\n1: PD reductions: 5.1 mm\n2. PD reductions: 5.4 mm\n3. PD reductions: 2.61 mm\nRadiographic:\n2.4 mm bone fill\n2.8 mm bone fill\n1.9 mm bone fill\n58.6% of the barrier treated implant sites \nwere compromised by early post \ntherapy complications\nThe additional application of barriers does \nnot improve the overall treatment \noutcomes 3 years following therapy\nMattout et al \n1995\nWith and without graft-\ning material\n19 patients\n23 defects: ePTFE alone\n11 defects: ePTFE + DFDBA + hydrated \ntetracycline\nPostoperative: 0.1% CHX + amoxicillin 500 \nmg (2× for 8 days)\nMean success rate 68% for the membrane \ngroup and 90% for the membrane + \nbone allograft\nSchwarz et al \n2006\nGrafting materials  \n+ barrier  \nmembranes\n \n• Nonsubmerged\n22 patients\n22 implants\n6 months\nGranulation tissue removed + implant sur-\nface debridement with plastic curettes \n+ irrigation with saline\nGroup 1: Nanocrystalline HA\nGroup 2: Bovine xenograft + resorbable \ncollagen membrane\nClinical:\n1: PD: reductions: 2.1 mm\n2. PD: reductions: 2.6 mm\n“In both groups, radiologic observation \nrevealed a decreased translucency \nwithin the intrabony component of the \nrespective peri-implant bone defect.”\nAdditionally, both treatments resulted in \nclinically reductions in PD and gains of \nCAL at 6 months after surgery\nSchwarz et al \n2008\nGrafting materials  \n+ barrier  \nmembranes\n \n• Nonsubmerged\n22 patients\n2 years\nGroup 1: Access flap surgery + nanocrys-\ntalline hydroxyapatite\nGroup 2: Access flap surgery + natural \nbone mineral + collagen membrane\n2 patients in NHA: severe pus formation at \n12 months\nClinically:\nPD:\nGroup 1: 1.5 ± 0.6 mm\nGroup 2: 2.4 ± 0.8 mm\nCAL gains:\nGroup 1: 1.0 ± 0.4 mm\nGroup 2: 2.0 ± 0.8 mm\nBoth treatments showed efficacy over 2 \nyears. Natural bone mineral + collagen \nmembrane showed better clinical \nimprovements\nRoos-­\nJansaker \net al 2007a\nGrafting materials  \n+ barrier  \nmembranes\n \n• Nonsubmerged\n36 patients\n65 implants\n12 months\nSystemic antibiotic (amoxicillin 375 × 3 + \nmetronidazole 400 mg × 2) for 10 days \nstarting 1 day before surgery\nDebridement of the granulation tissue, \nimplant surface decontamination with \nhydrogen peroxide and irrigated with \nsaline\nGroup I: Bone substitute + resorbable \nmembrane\nGroup 2: Bone substitute but no membrane\nGroup 1:\nPD reduction: 2.9 mm\nMean bone fill: 1.5 mm\nGroup 2:\nPD reduction: 3.4 mm\nMean bone fill: 1.4 mm\n  \u0007Human Studies on Peri-implantitis Treatment—cont’d\nTABLE \n41.1"
  },
  {
    "page": 13,
    "content": "1153\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nAuthor\nProcedure\nNumber of Patients \nand Implants and \nTime of Follow Up\nTreatment\nOutcome\nRoos-­\nJansaker \net al 2007b\nGrafting materials  \n+ barrier  \nmembranes\nSubmerged\n12 patients\n16 implants\n12 months\nSystemic antibiotics (amoxicillin 375 × 3 + \nmetronidazole 400 mg × 2) for 10 days \nstarting 1 day before surgery. Debride-\nment of granulation tissue. Implant \nsurface decontamination with hydrogen \nperoxide and irrigation with saline Bone \nsubstitute + resorbable membrane\nClinical and radiographic improvements \nwere observed.\nPD reduction: 4.2 mm\nMean bone fill: 2.3 mm\nHaas et al \n2000\nDiode Laser  \ntreatment  \nduring surgery\n17 patients\n24 implants\n3–9.5 months\nImplant surface decontamination with \ncurettage + laser + defect filled with \nautogenous bone + ePTFE membrane + \nsystemic antibiotics for 5 days\nRadiographically:\n3 months from time of membrane \nremoval: 21.8%\n9.5 months: mean bone gain: 36.4%\nBach et al \n2000\nDiode Laser  \ntreatment  \nduring surgery\n30 patients\n5 years\nGroup 1: Scaling + 1.5% CHX + open flap \ndebridement, apical repositioning the \nflap + osseous augmentation and/or \nmucogingival corrections\nGroup 2: Treatments as group 1 + laser \ndecontamination with diode laser (810 \nnm w/6 W)\nGroup 1:\n18 months: no increased PD, BOP or \nsign of inflammatory process\n2 years: 2 patients with increase PD, \nBOP and clinical sign of inflam-\nmation\n4 years: 5 patients with increase PD, \nBOP and clinical sign of inflam-\nmation\nBetween 3 and 5 years:\n4 implants removed\nGroup 2:\n3 years: no relapse\n5 years: 5 patients with increase PD \nand clinical signs of inflammation\nNo implant removed\nSignificant reduction of gram-negative, \nanaerobic bacteria in laser group \nthan conventional group\nDortbudak \net al 2001\nDiode laser  \ntreatment  \nduring surgery\n15 patients\n15 implants\nImplant surface: Curettage + rinsing with \nsaline for 1 minute, then stained with \ntoluidine\nHalf of the implants further treated with \ndiode laser for 1 minute\nTBO alone results in a significant bacterial \nreduction of P. intermedia and AA on \nplasma flame-sprayed contaminated \nimplant surfaces, while a combined \ntreatment leads to a reduction to AA,  \nP. gingivalis, and P. intermedia. \n­Complete elimination of bacteria was \nnot achieved\nRomanos and \nNentwig \n2008\nCO2 laser + bone \naugmentation + \nmembrane\n15 patients\n27.10 ± 17.83 \nmonths\nOpen flap debridement w/ titanium curettes \n+ CO2 laser (2.84 ± 0.83 watts) for 1 \nminute\nBone augmentation (bovine or autogenous \nbone) and collagen membrane\nNo systemic antibiotics\nPI:\nPreoperative: 1.01 ± 1.37\nPostoperative: 0.98 ± 1.20\nBI:\nPreoperative: 2.76 ± 0.35\nPostoperative: 1.03 ± 0.85\nPD:\nPreoperative: 6.00 ± 2.03 mm\nPostoperative: 2.48 ± 0.63 mm\nKeratinized tissue\nBI:\nPreop: 2.30 ± 1.45 mm\nPostop: 2.41 ± 1.39 mm\n  \u0007Human Studies on Peri-implantitis Treatment—cont’d\nTABLE \n41.1\nContinued"
  },
  {
    "page": 14,
    "content": "1154\nPART VIII    Dental Implant Maintenance\nAuthor\nProcedure\nNumber of Patients \nand Implants and \nTime of Follow Up\nTreatment\nOutcome\nDeppe et al \n2007\nCO2 laser + bone \naugmentation\n32 patients\n73 implants\n4 months and 5 years\nGroup 1 (19 implants): Soft tissue resection \n+ conventional decontamination\nGroup 2 (15 implants): Treatment as group \n1 + βTCP + autogenous bone grafts\nGroup 3 (22 implants): Soft tissue resection \n+ CO2 laser decontamination\nGroup 4 (17 implants): Treatment as group \n3 + βTCP + autogenous bone\n3 implants lost in group 1\n4 implants lost in group 2\n2 implants lost in group 3\n4 implants lost in group 4\nBeginning of hygiene phase\nPI:\nGroup 1: 1.8 ± 1.2\nGroup 2: 1.4 ± 1.2\nGroup 3: 1.4 ± 0.9\nGroup 4: 2.6 ± 0.5\nBI:\nGroup 1: 2.7 ± 0.9\nGroup 2: 2.3 ± 1.4\nGroup 3: 2.8 ± 1.2\nGroup 4: 3.3 ± 0.6\nPD:\nGroup 1: 6.2 ± 1.8\nGroup 2: 5.1 ± 1.7\nGroup 3: 5.7 ± 1.4\nGroup 4: 5.7 ± 1.4\nImmediately before surgery\nPI:\nGroup 1: 0.7 ± 0.8\nGroup 2: 0.9 ± 0.4\nGroup 3: 0.7 ± 0.8\nGroup 4: 0.5 ± 0.6\nBI:\nGroup 1: 0.7 ± 0.8\nGroup 2: 0.5 ± 0.8\nGroup 3: 0.6 ± 0.3\nGroup 4: 1.2 ± 0.6\nPD:\nGroup 1: 5.1 ± 1.3\nGroup 2: 4.8 ± 1.4\nGroup 3: 6.1 ± 1.6\nGroup 4: 5.0 ± 1.3\n4 months\nPI:\nGroup 1: 0.6 ± 0.7\nGroup 2: 0.6 ± 0.6\nGroup 3: 0.8 ± 0.6\nGroup 4: 0.5 ± 0.4\nBI:\nGroup 1: 0.9 ± 0.5\nGroup 2: 0.6 ± 0.6\nGroup 3: 0.7 ± 0.6\nGroup 4: 0.9 ± 0.8\nPD:\nGroup 1: 3.2 ± 0.9\nGroup 2: 2.4 ± 0.7\nGroup 3: 2.1 ± 1.3\nGroup 4: 1.0 ± 0.7\n5 years\n  \u0007Human Studies on Peri-implantitis Treatment—cont’d\nTABLE \n41.1"
  },
  {
    "page": 15,
    "content": "1155\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nAuthor\nProcedure\nNumber of Patients \nand Implants and \nTime of Follow Up\nTreatment\nOutcome\nPI:\nGroup 1: 0.8 ± 0.8\nGroup 2: 1.1 ± 0.8\nGroup 3: 1.0 ± 1.3\nGroup 4: 1.2 ± 1.3\nBI:\nGroup 1: 1.1 ± 1.2\nGroup 2: 2.1 ± 1.4\nGroup 3: 1.8 ± 1.1\nGroup 4: 1.9 ± 1.0\nPD:\nGroup 1: 4.3 ± 1.2\nGroup 2: 2.5 ± 1.1\nGroup 3: 3.4 ± 1.5\nGroup 4: 2.5 ± 1.4\nTreatment of peri-implantitis may be ac-\ncelerated by using a CO2 laser + soft \ntissue resection\nLong-term results in augmented defects, \nno difference between laser and \nconventional decontamination\nFroum et al \n2012\nRegenerative approach\nBiologics + bone + \nmembrane\n51 implants\n38 patients\n3–7.5 years\nSystemic antibiotics (2000 mg amoxicillin \nor 600 mg clindamycin) 1 hr before \nsurgery and continue 500 mg amoxicil-\nlin tid or clindamycin 150 mg qid for \nadditional 10 days\nSurface decontamination w/ bicarbonate \npowder for 60 seconds (air abrasive \ndevice), 60-second irrigation with ster-\nile saline, tetracycline (50 mg/mL with \ncotton pellets or brush for 30 seconds, \nthen second bicarbonate air abrasion \n60 seconds, application of 0.12% \nCHX for 30 seconds, then 60 seconds \nreirrigation with sterile saline + enamel \nmatrix derivatives + anorganic bovine \nbone soaked in platelet derived growth \nfactor for at least 5 minutes or min-\neralized freeze-dried bone + collagen \nmembrane or subepithelial CT graft at \narea (<2 mm KG)\nGroup 1: Greatest defect depth radiographi-\ncally\nGroup 2: Greatest bone loss on the facial \nof implant\n•No implant lost\n•PD reduction:\nGroup 1: 5.4 mm\nGroup 2: 5.1 mm\n•Bone level gain:\nGroup 1: 3.75 mm\nGroup 2: 3 mm\nAA, Aggregatibacter actinomycetemcomitans; BI, Bleeding index; BOP, Bleeding on probing; BTCP, Beta Tricalcium Phosphate; CAL, Clinical attachment level; CHX, Chlorhexidine; DFDBA, Demineralized \nfreeze-dried bone allograft; ePTFE, expanded polytetrafluoroethylene; GI, Gingival Index; HA, Hydroxyapatite; KG, Keratinized gingiva; NHA, Nanocrystalline Hydroxyapatite; PD, Probing depth; PI, Plaque \nindex; TBO, toluidine-blue-O.\nFrom Suzuki JB, Misch CE. Periodontal and maintenance complications. In: Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St. Louis, MO: Elsevier; 2018.\n   \n  \u0007Human Studies on Peri-implantitis Treatment—cont’d\nTABLE \n41.1\nControl of Parafunctional Forces\nAn occlusal guard is crucial in preventing unfavorable occlusal \nstress. The night guard is adjusted to be on a flat plane occlusion \nto disperse stress. Careful discussion should be conducted with \nthe dental laboratory to convey the desired design for successful \nclinical outcomes. \nManagement\nThe objective of treatment for peri-implantitis is for osseous regen-\neration of the implant-bone defect. However, such treatment has \nbeen challenging because the implant surface needs to be detoxi-\nfied, along with modifying the soft and hard tissues. This may \ninvolve nonsurgical and surgical treatment."
  },
  {
    "page": 16,
    "content": "1156\nPART VIII    Dental Implant Maintenance\nNonsurgical Management of Peri-Implantitis\nNonsurgical treatment of peri-implant mucositis is often success-\nful. In contrast, the nonsurgical treatment for peri-implantitis \nis not as predictable. This is most likely due to the inability to \nremove the bacterial biofilm from the exposed implant surface. \nSuch difficulty has been especially observed with rough surface \ndental implants.83 A systematic review illustrated that implant \nsurfaces and diameter are potential risk factors for bone loss and \nperi-implantitis.84\nThe nonsurgical treatment of peri-implantitis usually involves \nthe debridement and detoxification of implant surfaces, similar to \nthe treatment of peri-implant mucositis. However, the issue that \narises is that these exposed surfaces usually have concurrent sub-\ngingival pockets.\nLow-Abrasive Amino Acid Glycine Powder. Low-abrasive \namino acid glycine powder has been shown to be an effective treat-\nment for removing biofilm without damaging the implant surface, \nand hard and soft tissues of the periodontium. This technique uses \na special handpiece with a plastic tube nozzle with three orthogo-\nnally oriented holes. An air-powder mixture with reduced pressure \nis expelled through the nozzle, which prevents the formation of air \nemphysema complications. The nozzle is moved in a circumferen-\ntial movement around the implant surface.85\nAlthough more extensive studies need to be conducted as to \ntechnique efficacy, glycine powder can be incorporated into a \ntreatment regimen. The clinician should be careful to use the pow-\nder only in areas where access is available, including a posttreat-\nment rinse to remove any residue. This modality is best used in \ncases with a buccal dehiscence and/or horizontal bone loss with-\nout crater or infrabony pocketing. An air-powder unit (Hu-Friedy, \nChicago, Ill.) that adapts to a slow-speed handpiece is available \nand may be used effectively (Fig. 41.10). \nUltrasonic Devices. For treatment of peri-implantitis, tip \nmodifications (i.e., carbon fiber, silicone, or plastic) must be used. \nCare must be exercised not to use metal tips as they may alter \nthe implant surface. Ultrasonic devices should be used only when \nplastic tips are available. Irrigation and meticulous cleaning are \nrecommended in treatment for either open flap debridement or \nclosed flap irrigation. \nLasers. One of the newer and least invasive methodologies to \ntreat peri-implant mucositis and peri-implantitis involves the use \nof laser photonic energy, a coherent form of infrared or visible \nlight, usually of a single wavelength. Lasers have been used effec-\ntively for decades in oral implantology in second-stage recovery \nof implants through the ablation and vaporization of overlying \nsoft tissue.86\nLaser Protocols. Similar to their use in treating periodontal \ndisease, lasers provide different treatment approaches for peri-\nimplantitis: nonsurgical, surgical, antimicrobial photodynamic \ntherapy, and photobiomodulation.\n • \u0007Nonsurgical: In the nonsurgical modality, lasers are used \nadjunctively to help remove calculus, reduce inflammation and \nremove diseased soft tissue, and reduce subgingival pathogens. \nUsing different types of lasers, such as the diode, Nd:YAG \n(neodymium-doped yttrium aluminum garnet), erbium, or \ncarbon dioxide laser, the laser beam is directed at the inflamed \nsoft tissue within the sulcus, using noncontact overlapping \nstrokes to disrupt the biofilm, reduce the microbial popula-\ntion, and decontaminate the pocket epithelium. Erbium lasers \nhave also been shown to remove calculus from the implant \nsurface.87-95\n • \u0007Surgical: Minimally invasive laser-assisted surgical techniques \ninvolve removal of diseased epithelial lining. More invasive \nsurgical procedures involve conventional elevation of a full-\nthickness flap for surgical access, followed by laser-assisted \ndegranulation, surface debridement and decontamination, \nand osseous tissue removal or recontouring. As indicated, bone \naugmentation may be performed through placement of bone-\ngrafting material.96-103\n • \u0007Antimicrobial Photodynamic Therapy: Antimicrobial photody-\nnamic therapy in periodontology is a light-based approach to ter-\nminating bacteria. A photoactivatable substance (photosensitizer) \nis applied to the targeted area (i.e., within the sulcus) and then \nactivated by laser light. Singlet oxygen and other cytotoxic reac-\ntive agents are produced to reduce periodontopathogens.104-109\n • \u0007Photobiomodulation: is a form of light therapy that uses non-\nionizing forms of light, including lasers in the visible and \ninfrared spectrum. The nonthermal technique is used to elicit \nphotophysical and photochemical events. In implantology, it is \nused to promote wound healing and tissue regeneration. It has \nalso been shown to increase osteoblastic proliferation, collagen \ndeposition, and bone neoformation.110-115\nAlthough laser-based peri-implantitis treatment techniques \nare generally positive, some studies indicate adjunctive use \nof lasers have limited or no extra beneficial effect compared \nwith conventional treatment methodologies. Additional well-\ndesigned, long-term, randomized controlled trials are needed \nto verify the clinical and microbiologic outcomes of laser \nuse.116-118\nAssurance of positive therapeutic outcomes is facilitated by an \ninformed clinical technique, prudent use of proper laser operating \nparameters, and awareness of all laser wavelengths. However, when \nused inappropriately, laser energy can adversely alter implant sur-\nfaces and/or induce undesirable temperature increases, which may \nbe detrimental to implant health119-122 (Fig. 41.11).\nIn 2014 a human clinical study consisting of 16 patients was \npublished, using a pulsed 1064-nm Nd:YAG laser (PerioLase \nMVP-7; Millennium Dental Technologies, Cerritos, Calif.). The \ntechnique introduced is known as the Laser-Assisted Peri-Implan-\ntitis Protocol (LAPIP) to manage patients with peri-implantitis123 \nwithout the use of bone augmentation (Fig. 41.12). (LAPIP is \n  \u0007Predictive Profiles Associated With  \nPeri-Implantitis223,224\nRisk Factor\nPredictive Profiles\nType 1: surgical factors\n • \u0007Presence of plaque associated with \norovestibular and mesiodistal implant \nmalpositioning\n • Failed bone reconstruction\nType 2: prosthetic \nfactors\n • \u0007Plaque associated with retained cement \nremnants\n • \u0007Nonideal finish line margin (≥2 mm \nbelow soft tissue margin)\n • Occlusal overloading\n • Prosthesis material fracture\n • Abutment screw loosening\n • Implant fracture\nType 3: plaque-induced\nGeneralized bone-level recession associated \nwith plaque accumulation, without any \nsurgical/prosthetic complication\n   \nTABLE \n41.2"
  },
  {
    "page": 17,
    "content": "1157\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\na registered trademark of Millennium Dental Technologies, Inc., \nCerritos, Calif.)\nThe clinicians used a modification of a well-defined surgical pro-\ncedure, the Laser-Assisted New Attachment Protocol (LANAP), \nused for treating periodontitis. This technique was defined as a \nminimally invasive surgical therapy that may be appropriate for \nmultiple periodontal defects and possibly as a first line of manage-\nment of periodontal disease.124 In two recent histologic studies, \nthe LANAP has shown evidence of new attachment and tissue \nregeneration.125,126 Based on this evidence, in 2016 the U.S. Food \nand Drug Administration granted marketing clearance for the \nPerioLase MVP-7 Laser for a first-of-its-kind clinical indication \nfor use: periodontal regeneration, that is, true regeneration of the \nattachment apparatus (new cementum, new periodontal ligament, \nand new alveolar bone) on a previously diseased root surface when \nused specifically in the LANAP.\nFor the treatment of peri-implantitis, the LAPIP follows the \nstep-by-step sequence defined in the LANAP procedure, but with \na reduced light dose (energy) around implants.\n\t1.\t \u0007Surgical probings are performed under local anesthesia to \nrecord the depths of all bony defects around the implant. \nPocket depth and phenotype help to determine the amount of \nlaser energy to be delivered during the ablation and hemostasis \napplications.\n\t2.\t \u0007The laser fiber is then inserted into the periodontal pocket, \noriented in a prescribed fashion, and the laser is activated at \nparticular settings to ablate (remove) the diseased epithelial lin-\ning and granulomatous tissue, to denature pathologic proteins, \nand to create bacteria antisepsis.\n\t3.\t \u0007Ultrasonic scalers are used to remove foreign substances \n(including calculus and cement) from the implant surfaces.\n\t4.\t \u0007Bone is modified, removed, reshaped, and decorticated in a \nprescribed manner to stimulate the release of blood, stem cells, \nand growth factors from the bone.\n\t5.\t \u0007The laser is then used again at specifically adjusted settings in \nhemostasis mode to form a thick, stable fibrin clot, activate \ngrowth factors, and upregulate gene expression.\n\t6.\t \u0007Coronal soft tissue is approximated against the implant using \nfinger pressure to achieve adhesion. No sutures are used because \nthis is a flapless procedure.\n\t7.\t \u0007Removal of occlusal interference is performed to reduce trau-\nmatic forces and mobility.\nThe technique has been shown to produce healing in an envi-\nronment conducive to true regeneration of new alveolar bone. \nReosseointegration of the implant is anticipated.\nThe study analyzed 16 cases, 9 females and 7 males, with an \naverage age of 54 years and a range of 32 to 79 years. Median \ntime that had elapsed between the date of implant placement and \nthe date of LAPIP treatment was 4 years (3 months to 16 years). \nFollow-up data ranged from 8 to 36 months after LAPIP treat-\nment. All clinicians reported control of the peri-implantitis infec-\ntion, reversal of bone loss, and rescue of the incumbent implant.\nRadiographic evidence combined with three-dimensional geo-\nmetric modeling was used to estimate the rate of addition of new \nbone to the alveolar crest. The rate of bone deposition was deter-\nmined to be 14.9 mm2 in cross-sectional area per year. In two \ncases, new bone deposition was observed at rates of 0.62 and 1.6 \nmm3 per month, respectively. Complete recovery (resolution of \nA\nC\nD\nB\nE\n• Fig. 41.10  (A) Low-Abrasive Powder.  Hu-Friedy glycine powder jet used to debride titanium implant surfaces, (B) Titanium Brushes, (C) Clinical image \nof titanium brushes applying detioxification agent, (D) Implantplasty Kit for removal of implant threads, (E) Implant with threads removed."
  },
  {
    "page": 18,
    "content": "1158\nPART VIII    Dental Implant Maintenance\nA\nB\nC\nD\n• Fig. 41.11  Laser Treatment.  (A) Initial evaluation of peri-implantitis. (B) Laser tip activated around sulcular \nmargins of implant. (C) Immediate postsurgical appearance. (D) Two weeks postoperatively with granula-\ntion tissue re-forming around implant collar. (From Suzuki JB, Misch CE. Periodontal and maintenance \ncomplications. In: Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St. \nLouis, MO: Elsevier; 2018.)\nA\nB\nC\nD\nE\nF\nG\nH\n• Fig. 41.12  Artists sketch of sequence of clinical steps for  Laser-Assisted Peri-Implantitis Protocol (LAPIP) \nprocedure using the PerioLase MVP-7 pulsed neodymium-Yttrium Aluminum garnet (Nd:YAG) laser. (per-\nmission from Millenium, Cerritos, CA USA and From Suzuki JB. Salvaging implants with an Nd:YAG laser: \na novel approach to a growing problem. Compend Contin Educ Dent. 2015;36:756-761.)"
  },
  {
    "page": 19,
    "content": "1159\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nperi-implantitis) averaged 1 to 3 years, depending on the size \nof the initial lesion. Analysis of collected data revealed that bone \ndeposition is not linear. Large defects healed more rapidly at first, \nbut the rate slowed as the defect diminished. A modest trend was \nshown for larger lesions to heal more rapidly.\nAlthough the results of this clinical study appear promising, \nfurther study of the predictability and effectiveness of the LAPIP \ntechnique is warranted. The effectiveness of the 1064-nm Nd:YAG \nlaser wavelength in achieving its successful clinical outcomes with \nthe LAPIP protocol may be attributed to a variety of factors.127 \nThese include the Nd:YAG laser’s ability to:\n • \u0007selectively remove inflamed pocket epithelium, with no signifi-\ncant damage to underlying connective tissue,128-131\n • \u0007reduce pathogenic microorganisms in the periodontal \npocket,132-136\n • \u0007produce an antiinflammatory effect,137-140 and\n • \u0007stimulate alveolar bone growth at the cellular level.141-144\nWhether used adjunctively or as the primary instrument, lasers \noffer the field of oral implantology a number of safe and effec-\ntive clinical applications for the treatment of peri-implant muco-\nsitis and peri-implantitis. Techniques range from nonsurgical and \nsurgical uses, to antimicrobial photodynamic therapy and photo \nbiostimulation. Additional investigations will further determine \nthe underlying mechanisms of their action. Proper training and \nscrupulous adherence to specific laser-based protocols will help \nassure favorable therapeutic patient outcomes.\nLaser settings are specific to each individual laser according to \nmanufacturers’ protocols. Care should be exercised to cover all \nexposed surfaces (i.e., each exposed thread) for the detoxification \nprocess. Use of regenerative material (allografts and extended resorb-\nable membranes) is highly recommended. Tissues are modified and \nsutured to reapproximate tissue for tension-free primary closure.\nIt is critical to limit time exposure of the implant surface with \nthe laser application to avoid overheating or charring. This may \nincrease implant morbidity and possibly lead to premature loss of \nthe implant because of bone disintegration.\nLocally Applied Antibiotics. The recommended locally applied \nantibiotic (LDA) during surgical implant rescue is tetracycline at \n50 mg/mL solution. Tetracycline capsules can be opened and mixed \nwith small amounts of saline solution to create a paste. This paste \nis burnished onto implant surfaces for 60 seconds, then thoroughly \nrinsed with saline. Tetracycline is bacteriostatic, as it targets the 30s \nribosomal subunit in the messenger RNA translation complex of bac-\nterial protein synthesis. Because tetracycline has an inhibitory effect \non matrix metalloproteinases, the tetracycline paste needs to be com-\npletely removed. A study with pure tetracycline application showed \nreosseointegration after 4 months.56 It is highly recommended to \nincorporate tetracycline in surgical rescue therapy for peri-implantitis.\nTetracycline capsules (two 500-mg capsules) may be mixed \nwith a few drops of saline to form a viscous consistency. It should \nstay gelled when applied to exposed implant surfaces during sur-\ngery. The mixture is allowed to sit on the implant surface for 1 \nminute, then is thoroughly rinsed off. It allows proximal contact \nof antibiotics to implant surface colonies and may assist in success \nin treatment of peri-implantitis.\nAnother option of local antibiotic administration is with mino-\ncycline, which is a tetracycline derivative. Minocycline is manu-\nfactured in an encapsulated microsphere of poly(lactic-coglycolic \nacid), a biodegradable polymer called Arestin (OraPharma, Warm-\ninster, Pa.).57 The subgingival application of minocycline micro-\nspheres has been shown to maintain therapeutic levels for 14 days. \nWilliams et al.58 reported on a 9-month study that showed the \ntherapeutic efficacy of minocycline microspheres in significantly \nreducing probing depth in conjunction with scaling. Oringer \net al.59 concluded that minocycline microspheres induce a potent \nshort-term reduction in the gingival crevicular fluid molecular \nmarkers of bone resorption (Fig. 41.8). \nSystemic Antibiotics. The use of systemic antibiotics has been \nestablished for management of periodontitis.60 However, peri-\nmucositis treatment studies with use of systemic antibiotics are \nlacking. It is known that patients with periodontitis are three \ntimes more likely to experience peri-implantitis, but the bacte-\nrial colonies found in peri-implantitis and periodontitis share few \ncharacteristics. Still, many studies have demonstrated the most \neffective antibiotic combination is amoxicillin and metronidazole.\nMetronidazole is bactericidal to anaerobic organisms and disrupts \nDNA synthesis. It has been shown to be especially effective against A. \nactinomycetemcomitans, P. gingivalis, and P. intermedia.61 The combi-\nnation of amoxicillin and metronidazole has also been shown to have \nlong-term effects against A. actinomycetemcomitans62 (Box 41.3).\nFor patients who are allergic to amoxicillin, alternative systemic \nantibiotics are clindamycin, ciprofloxacin, metronidazole, or azithro-\nmycin. Local drug delivery systems such as minocycline (Arestin, off \nU.S. Food and Drug Administration label) may be considered. \nSurgical Management of Peri-Implantitis\nAlthough nonsurgical treatment of peri-implantitis may be \neffective in some cases, the majority of cases require a more inva-\nsive approach to ensure an effective treatment outcome. There \nare various surgical techniques (see later) to treat peri-implan-\ntitis, depending on the final objective.145 Surgical management \nis completed with curettes, specialized titanium brushes with \nan implant handpiece, and/or a glycine polishing handpiece. \nAlong with mechanical decontamination, a chemical decon-\ntamination process should be followed, using compounds such \nas doxycycline/tetracycline or citric acid. The flaps are then \n• Fig. 41.8  Locally Applied Antibiotic.  Arestin placed into the sulcus area \nfor the treatment of peri-mucositis.\nAmoxicillin 500 mg tid (three times per day), total of 21 capsules\nMetronidazole 250 mg, 21 tablets tid, until all consumed by the patient\nMinocycline (Arestin) applied subgingivally around implants with pockets\n\t • BOX 41.3\t    \u0007Antibiotic Prescription Formulation"
  },
  {
    "page": 20,
    "content": "1160\nPART VIII    Dental Implant Maintenance\nreapproximated in their original position, using horizontal \nmattress sutures, which adapt tissue around the implant while \ncreating a ferrule effect. Interrupted sutures will also serve this \npurpose (Fig. 41.13).\nIt is possible to also complete a subepithelial tissue augmenta-\ntion while performing the access flap debridement. Simultaneous \ntissue grafting with debridement had a significant reduction of \nbleeding on probing, pocket depth, and clinical attachment loss at \na 6-month postoperative evaluation.146\n\t1.\t \u0007Sulcular incision around desired dentition being careful to \nextend at least one tooth mesial and one tooth distal in antici-\npation to the area of treatment\n\t2.\t \u0007Full-thickness flap reflection is complete past the mucogingival \njunction on both buccal and palatal/lingual if necessary\n\t3.\t \u0007Implants are detoxified with tetracycline paste, EDTA, or citric \nacid, cleaned with curettes and titanium brushes\n\t4.\t \u0007Air powder glycine to further clean implant threads previously \nexposed\nA\nB\nC\nD\nE\n• Fig. 41.13  Peri-implantitis Treatment.  (A) Clinical view of localized edematous tissue. (B) Radiograph \ndepicting circumferential bone loss. (C) Three months post-LANAP treatment. (D and E) Nine months post-\nLANAP treatment. (Courtesy Allen Honigman, DDS)"
  },
  {
    "page": 21,
    "content": "1161\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\n\t5.\t \u0007Flaps are readapted over osseous structure and should be in \nrelatively similar position\n\t6.\t \u0007Horizontal mattress sutures or interrupted sutures may be \nused, being cautious not to exert excess tension, which causes \nbunching of tissues; tissue does not have to be completely \napproximated; new tissue will form and granulate in the \nwound site\nHeitz-Mayeld et  al.147 reported on a 12-month prospec-\ntive study with antiinfective surgical therapy outcomes for peri-\nimplant disease. Thirty-six patients with moderate to advanced \nperi-implantitis had access flap disinfection, followed with a com-\nbination of systemic antibiotics (amoxicillin and metronidazole). \nAt 1 year, 92% of patients had stable crestal bone height, and all \nhad a marked reduction of probing depth. On probing, 47% had \ncomplete resolution of bleeding.147\nRegenerative Procedures. For peri-implantitis cases where a \ncrater-like defect is present, regeneration is recommended (Fig. \n41.14). Even though regeneration is an ideal treatment modality \nfor all peri-implantitis cases, there are criteria that must be ful-\nfilled to allow successful treatment. In a similar principle to bone \nA\nB\nC\nD\nE\n• Fig. 41.14  Regenerative Procedures.  (A) Radiograph depicting significant bone loss surrounding implant \nin the first molar position. (B) Full-thickness reflection showing extent of defect with retained cement. (C) \nDetoxification with tetracycline hydrochloride, after removal of cement. (D) Augmentation with allograft. (E) \nPostoperative radiograph 2 years postoperatively. (Courtesy Dr. Nolen Levine.)"
  },
  {
    "page": 22,
    "content": "1162\nPART VIII    Dental Implant Maintenance\nregeneration for natural teeth, the greater number of osseous walls \nremaining in a defect, the better the anticipated clinical outcomes.\nAlso, the prosthesis must be free from any premature contacts \nthat may introduce excessive force to the implant interface. Ide-\nally, especially in single-tooth implant cases, removal of the crown \nwould be performed to ensure proper healing. A sulcular incision \nis performed from one tooth mesial to one tooth distal of the \nimplant. A full-thickness mucoperiosteal flap is reflected to gain \nadequate access to defect. Thorough removal of granulation tis-\nsue is vital. Mechanical debridement is then initiated. A titanium \nbrush with a small tip may be needed to access the implant surface \nif the osseous crater around the implant has little access.\nAfter thorough mechanical debridement, freeze-dried bone \nallograft may be packed in with a resorbable membrane. Soft tis-\nsue augmentation may also be included, which will enhance heal-\ning. Flap advancement is usually indicated to achieve soft tissue \nprimary closure around implants. A high tensile suture material \nsuture is recommended to ensure the flap does not open prema-\nturely. Implants should be free from any pressure or premature \ncontacts that may introduce excessive force to the implant inter-\nface. Ideally, especially in single-tooth implant cases, any occlusal \nprematurities should be removed.\nIn addition to the steps listed earlier, enamel matrix protein, \nplatelet-derived growth factor, and human allograft or bovine xeno-\ngraft in conjunction with a collagen membrane or subepithelial tis-\nsue graft was suggested to enhance regeneration. Systematic reviews \non the merits of clinical regeneration, of platelet concentrates148 and \nbone marrow aspirates have been published recently.149 \nRegenerative Technique\n\t1.\t \u0007Sulcular incision is made around the clinical site with one \ntooth mesial and one tooth distal.\n\t2.\t \u0007Full-thickness mucoperiosteal flap is reflected past the mucogin-\ngival junction to ensure enough tension release from flap tissue. \nIt is essential to produce adequate release so there is minimal \ntension when closing the flap. Inadequate reflection will result in \nincision line opening, which will increase morbidity of the graft.\n\t3.\t \u0007The bone surface is curetted to clean and remove all soft tissue \nremnants. Bone surface is curetted, being careful to remove all \nremnants of soft tissue. Detoxification:\n\t\na.\t \u0007Tetracycline paste, EDTA, or citric acid is applied to the \nexposed surface for 30 to 60 seconds.\n\t\nb.\t \u0007Rinse with sterile saline for 30 seconds.\n\t4.\t \u0007A full-thickness flap is reflected to gain adequate access to the \ndefect and implant threads. Thorough removal of granulation \ntissue is critical. Bone graft of choice (i.e., ideally an autograft \nor allograft) is placed on defect.\n\t5.\t \u0007A resorbable membrane (extended resorbable collagen mem-\nbrane: 4–6 months) is then draped over bone graft, being care-\nful to cover 3 mm past all edges of bone graft.\n\t6.\t \u0007Tissue tension is reduced via tissue-stretching techniques. Flaps \nare sutured (i.e., high-tensile strength suture material [polygly-\ncolic acid (PGA) sutures, 4–0]), being careful to provide ten-\nsion-free closure to produce maximal contact between tissue \nedges (primary closure) (Fig. 41.15). \nApically Repositioned Surgical Technique. This surgical \ntechnique is used for implants that have generalized horizontal \nbone loss greater than one to two threads. An internal bevel inci-\nsion or sulcular incisions circumscribing buccal and lingual con-\ntours of the implant are made. Two vertical incisions are added \non the mesial and distal of the implant, creating a pyramidal flap. \nThe clinician should recognize the importance of the blood sup-\nply of the flap, and a wide base is necessary to ensure the sulcular \nmargin of the flap does not slough. On the lingual/palatal a gin-\ngivectomy may be performed at the level of the anticipated final \ngingival height. Submarginal incisions may be performed in cases \nwhere keratinized gingival tissue is adequate (e.g., palate). Ideally a \npartial-thickness flap is recommended because it will improve api-\ncal flap adaptation. Full-thickness flaps elevation technique may \nbe easier in difficult-to-access clinical sites.\nOnce reflected, similar treatment as the access flap may be vital. \nGranulation tissue needs to be completely removed, followed by \nthorough cleaning of implant surfaces. A chemical detoxification \ncan similarly be performed. A decision may be made to remove \nimplant threads with a handpiece if significant loss of osseous \nsupport is present and regeneration is unlikely. The final flap is \nsutured to the underlying periosteal tissue if a split-thickness flap \nwas used. If a full-thickness flap was performed, it can be adapted \napically via individual interrupted sutures. The goal is to readapt \ntissue back onto remaining osseous support to minimize thick-\nness of a soft tissue collar, thereby minimizing probing depth.\nSteps of Flap Access, Debridement, and Resective Surgery are \ndescribed below:\n\t1.\t \u0007Sulcular incision is made around desired dentition, being care-\nful to extend at least one tooth mesial and one tooth distal in \nanticipation to the area of treatment.\n\t2.\t \u0007Full-thickness flap reflection is complete past the mucogingival \njunction on both buccal and palatal/lingual if necessary.\n\t3.\t \u0007Osseous recontouring is complete at this time to create a posi-\ntive architecture.\n\t4.\t \u0007Implants are detoxified with tetracycline paste, EDTA, or citric \nacid, cleaned with curettes and titanium brushes.\n\t5.\t \u0007Air-powder glycine treatment of exposed implant threads is \nperformed.\n\t6.\t \u0007Flaps are readapted over remaining osseous structure and \nshould be apical in comparison with the original flap position.\n\t7.\t \u0007Horizontal mattress sutures or interrupted sutures can be used, \nbeing careful not to exert too much tension that causes bunch-\ning of tissues. Tissues do not have to be completely approximated. \nNew tissue will form and granulate in the wound site (Table 41.3). \nPlatelet Concentrate Growth Factors. In implant dentistry \nthe two most common platelet concentrates are termed under the \ngeneral acronyms of PRP (platelet-rich plasma) or PRF (platelet-\nrich fibrin). These products are often considered growth factors \nand used in regenerative medicine. Although protocols vary, most \nplatelet concentrates are blood extracts from a whole blood sample \nthat is processed via centrifugation. The processing technique sep-\narates the blood components into usable (e.g., fibrinogen/fibrin, \nplatelets, growth factors, and leukocytes in liquid plasma) or unus-\nable (e.g., red blood cells).150\nThe use of platelet concentrates (e.g., PRP and PRF) for the \ntreatment of peri-implant defects has been widely researched, with \nvarying results. Unfortunately, the literature on this topic is con-\ntroversial and conclusions are extremely variable.\nPlatelet-Rich Plasma. PRP with and without bone substitutes \nhas been studied with the treatment of peri-implant defects. In \nvarious dog research models, most researchers have not found ben-\neficial results with PRP alone,151 in combination with xenograft \nbone,152-154 and with guided bone regeneration procedures.155 In \ngeneral the literature as a whole has not shown a significant benefit \nin the treatment of peri-implant defects. Simonpieri et al.,156 in a \ncomprehensive review, stated that PRP does not show conclusive \nresults. A possible reason for this is that natural bleeding from the \nsurgery site is sufficient to saturate the area with blood growth fac-\ntors and allow for increased healing ability."
  },
  {
    "page": 23,
    "content": "1163\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nA\nB\nC\nE\nD\n• Fig. 41.15  Treatment of Peri-implantitis.  (A) Maxillary right canine exhibiting bone loss and peri-implantitis. \n(B) Clinical view. (C) Full-thickness reflection depicting the circumferential and buccal bone loss. (D) Lingual \nview of defect and thread removal. (E) Removal of soft tissue remnants with titanium brush."
  },
  {
    "page": 24,
    "content": "1164\nPART VIII    Dental Implant Maintenance\nH\nG\nF\nI\nJ\nK\nL\nM\nFig. 41.15, cont’d  (F) Citric acid powder mixed with saline. (G) Citric acid applied to implant surface for \ndetoxification. (H) Irrigation with saline. (I) Tetracycline paste. (J) Tetracycline mixed with saline. (K) Tetracy-\ncline paste applied to implant surface. (L) Irrigation with saline. (M) Tissue tension evaluated."
  },
  {
    "page": 25,
    "content": "1165\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nP\nQ\nO\nN\nFig. 41.15, cont’d  (N) Decortication. (O) Confirmation of bleeding from cortical holes. (P) Acellular dermis \nmodified and placed with tacks. (Q) Autograft harvested from tuberosity."
  },
  {
    "page": 26,
    "content": "1166\nPART VIII    Dental Implant Maintenance\nPlatelet-Rich Fibrin. In contrast, PRF is used as a “generic” \nname for the second-generation platelet concentrates, which are \nderivatives of PRP. The original protocol by Dohan, Choukroun, \net al.157 used no anticoagulants and was termed L-PRF (leuko-\ncyte- and platelet-rich fibrin). Later, they have been modified to \ninclude advanced-PRF (A-PRF) and injectable-PRF (i-PRF), as \nwell as several other groups of products.\nThe L-PRF fibrin matrix contains mostly platelets and leu-\nkocytes (e.g., lymphocytes). The L-PRF clot is created without \nblood modification (i.e., no anticoagulants) and is the result of the \nnatural coagulation process during centrifugation.158 Because of \nits strong fibrin network and bone growth cell factors (leukocytes, \nplatelet aggregates, circulating stem cells), the L-PRF clot has been \nshown to have beneficial results, with bone substitutes in the fill-\ning of peri-implant defects.\nWith respect to bone regeneration and treatment of defects, \nL-PRF has been shown to be beneficial when added to bone \nsubstitute material.159 Also, when L-PRF is used as a regener-\nated membrane, increase soft tissue healing is seen. Numerous \nstudies have confirmed increased benefits of soft tissue stimula-\ntion and promotion of gingival remodeling.160,161 The L-PRF \nhas also been shown to regulate the interactions between the \nbone and soft tissue, thereby promoting healing and remodeling \nof the tissue.162\nBecause peri-implantitis involves an inflammatory and bac-\nteria-laden defect, the exposed implant surface is contaminated \nwith a bacterial biofilm and altered surface characteristics. The \ntitanium oxide surface is destroyed with peri-implant disease, \nnew bone growth can be initiated only after complete decon-\ntamination of the implant surface. Therefore, if the contami-\nnated surface is not restored, bone grafting will most likely not \nbe successful. Multiple protocols have been suggested to clean \n(i.e., detoxify) the implant surface. Although dependent on the \ntype of implant surface, the use of PRF in the bone regeneration \ntechnique has been shown to heal compromised peri-implant \ndefects.163 \nProtocol. \n\t1.\t \u0007A full-thickness reflection is completed to expose the osse-\nous and mucogingival defect. Debridement is completed to \nremove nonvital hard tissue, together with granulation ­tissue.\n\t2.\t \u0007The implant surface is then detoxified with citric acid, \nEDTA, and/or tetracycline paste. A titanium brush may be \nused with a latch-type handpiece to aid in the decontamina-\ntion process.\n\t3.\t \u0007A whole blood sample is collected in a 10-mL tube without an \nanticoagulant.\n\t4.\t \u0007The blood sample is immediately centrifuged for 12 minutes \nat approximately 2700 rpm. Because there is no anticoagulant, \nthe platelets are activated and trigger the coagulation cascade \nwhen they contact the tube walls. There will exist three distinct \nlayers: (1) top layer—platelet-poor plasma (PPP); (2) middle \nlayer—PRF; and (3) bottom layer—red blood cells.\n\t5.\t \u0007The fibrinogen is transformed into a fibrin network via the cir-\nculating thrombin. The resultant fibrin clot is located in the \ncenter of the tube, which is concentrated with acellular plasma \nand platelets.\nR\nS\nT\nU\nV\nFig. 41.15, cont’d  (R) Autograft placed as first layer. (S) Allograft placed as second layer. (T) PRF membrane \nplaced over acellular dermis. (U) Platelet-rich fibrin syringed under flap. (V) Final closure."
  },
  {
    "page": 27,
    "content": "1167\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\n  \u0007Treatment of Peri-mucositis and Peri-implantitis\nTABLE \n41.3\nPeri-Mucositis\nPatient Self-Administered\nPlaque Control\n • Toothbrushes (manual or powered)\n • Toothpastes\n • Antimicrobial rinses\n • Flossing/oral irrigators\n • Topical application of gel\n • Systemic antibiotics\n • Probiotic Lactobacillus reuteri–containing tablets\nProfessional\nMechanical plaque control\n \n• Hand instruments\n \n• Powered instruments\nChemical plaque control\n \n• Local delivery of antibiotics\n \n• Chlorhexidine (antimicrobials)\n \n• Phosphoric acid\n \n• Ozone, oxygen, and saline solution\nMucogingival debridement\nProsthesis alteration\nPeri-Implantitis\nNon-Surgical\nMechanical instruments\n \n• Nonmetal instruments\n \n• Rubber cups\n \n• Air abrasive\n \n• Metal instruments\n \n• Burs\nAdjunctive treatments\n \n• Microbiologic test\n \n• Local antimicrobials\n \n• Systemic antimicrobials\nDisinfect titanium surfaces\n \n• Antiseptics\n \n• Chemical\n \n• Air polishing\n \n• Laser\nMucogingival debridement\nProsthesis alteration\nSurgical\n • Open flap debridement\n • Surface decontamination\n • Regenerative approaches\n • Biologics\n • Guided tissue regeneration\n • Guided bone regeneration\n • Systemic antibiotics\nRetrograde Peri-implantitis (Maintenance and Prevention)\nPatient self-administered preventive regimens\nSupportive periodontal therapy/maintenance (professionally)\n • Mechanical nonsurgical therapy\n \n• Mucogingival Debridement\n \n• Prosthesis Alteration\nAdapted from Suzuki JB, Misch CE. Periodontal and maintenance complications. In: Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St. Louis, MO: Elsevier; 2018.\n\t6.\t \u0007The acellular plasma (PPP), which is the top layer, may be \nremoved with a pipette into a syringe. The PRF fibrin clot is \nthen placed into a PRF box and processed into a membrane. The \nliquid part (PRF) of the PRF box is then collected and placed in \nwith the graft material. If additional liquid is indicated for the \ngraft material, the acellular plasma (PPP) may be added, as a \nsmall number of platelets are present in this ­concentrate.\n\t7.\t \u0007After grafting the defect, the PRF membrane is placed over the \ndefect. If a second membrane is used (e.g., collagen), then the \nmembrane may be moistened with acellular plasma.\n\t8.\t \u0007The soft tissue flaps are approximated and closed with a high-\ntensile-strength suture material (e.g., Vicryl, polytetrafluoro-\nethylene [PTFE]).\nIn conclusion, the L-PRF technique is a simple, effective, \nand nonexpensive technique to enhance the soft and hard tissues \naround peri-implant defects. When added to the bone substitute \nmaterial, there exist immune and antibacterial properties that ben-\nefit the healing process.164,165 The use of L-PRF as a membrane \nallows the peri-implant defect to create a healthy, thick, and stable \nsoft tissue interface for increased soft tissue health. \nSuzuki-Resnik Peri-Implant Disease Protocol\nTo simplify the treatment of peri-implant disease and maintenance \nprotocols, Suzuki and Resnik have formulated a comprehensive \ntreatment regimen. This consists of four protocols with associated \ndetailed step-by-step regimen.\nPROTOCOL 1:\n< 3mm probing depths\nNo Plaque or No Bleeding on Probing (BOP)\nTreatment\n • Maintain Regular Home Care\n • 3 - 6 month hygiene recall \nPROTOCOL 2: (Peri-Implant Mucositis)\n< 3mm probing depths\nPlaque presence / Bleeding on Probing (BOP)   \nOr\n   \n3 – 5 mm probing depths\nPlaque presence / Bleeding on Probing (BOP)\nTreatment\n • Follow Treatment Regimen A\n • Increase Hygiene Recall Frequency (∼ 3 months)\n • Increase Home Care Education\n • If no resolution, proceed to Protocol 3"
  },
  {
    "page": 28,
    "content": "1168\nPART VIII    Dental Implant Maintenance\nPROTOCOL 3: (Peri-Implantitis)\n> 5 mm probing depths\nPlaque presence / Bleeding on Probing\nCrestal Bone Loss > 2 mm\nTreatment\n • Follow Treatment Regimen A, B, C, & D\n • Increase Hygiene Recall Frequency (∼ 3 months)\n • Increase Home Care Education\n • Rx \nPROTOCOL 4: Implant Mobility\nPain upon function\nBone loss > 50% of implant length\nUncontrolled exudate\nTreatment\n • Follow Treatment Regimen E \nPeri-Implant Disease Treatment  \nRegimen\nTreatment Regimen A: Mechanical Closed \nDebridement (Acceptable Instrumentation)\n • \u0007Resin, Titanium, Graphite, Carbon-Fiber, and Gold-tipped \ninstruments can be used to remove deposits\n • Prophy Cup/Brush\n • \u0007Air-Polisher with Glycine Powder (Hu-Friedy), Prophy Jet \n(Dentsply)\n • Cavitron (use blue implant tip)\n • Rx: Chlorhexidine (0.12%, 0.2%) or cetylpyridinium chloride\n • Check Occlusion \nTreatment Regimen B: Antiseptic Therapy\n • \u0007Subgingival antiseptic irrigation (0.12%, 0.2% Chlorhexidine) \nis added to the mechanical therapy\n\t\n○\t \u0007Irrigate intracrevicularly to disrupt and dislodge the bio-\nfilm, then thoroughly debride the implant surface with a \ncurette. Irrigate a 2nd time to rinse out the debris and fur-\nther detoxify the subgingival area. Pressure is then applied \nfor one minute to obtain intimate soft tissue/restoration \ncontact.\n • Alternative Antiseptic; diluted sodium hypochlorite (NAOCl).\n\t\n-\t \u0007Diluted (.25%) NAOCl solution = one teaspoon (5ml) \nof standard 6% household bleach (Clorox) and diluting it \nwith 4 oz (125ml) of water.\n • Check Occlusion, possible occlusal guard \nTreatment Regimen C: ANTIBIOTICS\n • \u0007Add systemic and/or local antibiotic treatment\nSystemic : Amoxicillin, Metronidazole (500 mg, 3 times/daily \nfor 8 days)\nAlternative: Clindamycin, Augmentin, Tetracycline, Bactrim, \nCiprofloxacin\nLocal : Tetracycline\nAlternative: , Doxycycline, Minocycline spheres (Arestin®)\nTreatment Regimen D: SURGERY (Access, Open \nDebridement, Bone Graft, Closure)\nStep 1: Access Flap, Open Debridement with Hand Instruments, \nImplantoplasty (Salvin Bur Kit)\nStep 2: Detoxify With:\n • 1. Apply 0.12% or 0.2% Chlorhexidine with cotton pellet for \n60 sec. (rinse with saline)\n+\n • \u00072a. Apply 20-40% Citric Acid with cotton pellet or spatula or \ntitanium brushes (Salvin) for 60 sec.(rinse with saline)\nOR\n • \u00072b. Apply Tetracycline Paste with titanium brushes (Salvin) \nfor 60 sec. (rinse with saline)\n\t\n-\t \u0007Other Detoxification Agents: EDTA, Hydrogen Peroxide, \n0.25% NAOCl\n\t\n-\t \u0007Er:YAG laser\n(diode laser alone results in an unacceptable increase in implant \nbody temperature)\n   \nStep 3: Bone Graft with Mineralized/Demineralized (70/30) + \nAutograft (if indicated)\nStep 4: Cross-Linked Collagen (Extended Collagen)\nStep 5: Tension-Free Closure with Vicryl (PGA) or PTFE sutures   \nTreatment Regimen E: IMPLANT REMOVAL\nLack of Keratinized Tissues\nLack of a zone of keratinized gingiva around teeth and oral \nimplants is now recognized as serving an important clinical func-\ntion for implant health. Direct clinical evidence confirms the need \nfor nonmobile keratinized tissue next to natural teeth. However, \nthe tooth with the least amount of keratinized tissue is often the \nmandibular first premolar.166 Yet this tooth is rarely the first tooth \nlost from periodontal disease. If all other periodontal indices are \nnormal, the amount or absence of keratinized gingiva has little to \ndo with the expected longevity of the tooth. In longitudinal stud-\nies, the lack of adequate keratinized and attached tissue does not \ncompromise the long-term health of soft and hard tissue, as long \nas patients maintain good oral hygiene.167,168\nMany clinicians consider keratinized attached gingiva important \nto maintaining gingival health.169 Mucogingival considerations in \nrestorative dentistry have been considered.170 They concluded that if \nsubgingival restorations were to be placed in areas of minimal keratin-\nized gingiva with less than optimal plaque control, augmentation to \nwiden the zone of keratinized tissue may be warranted.\nAlthough keratinized tissue around a tooth may not be manda-\ntory for long-term health, a number of benefits are present with \nkeratinized mucosa. The color, contour, and texture of the soft tis-\nsue drape should be similar around implants and teeth when in the \nesthetic zone. The interdental papillae should ideally fill the inter-\nproximal spaces. A high smile line often exposes the free gingival \nmargin and interdental papillae zones. The keratinized tissue is more \nresistant to abrasion. As a result, hygiene aids are more comfortable \nto use, and mastication is less likely to cause discomfort.\nThe degree of gingival recession appears related to the absence \nof keratinized gingiva. Root sensitivity and esthetic concerns may \nbe associated with gingival recession. From a restorative dental \naspect, keratinized mucosa is more manageable during the retrac-\ntion and impression-making process. Subgingival margin place-\nment is improved, as is long-term stability in the presence of"
  },
  {
    "page": 29,
    "content": "1169\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nA\nB\n• Fig. 41.16  Ideal Keratinized Tissue.  (A) Healthy tissue surrounding \nimplant. (B) Preoperative evaluation measuring the amount of attached \ntissue.\nkeratinized tissue. Many of these benefits directly apply to the soft \ntissue around an implant.\nNatural teeth have two primary types of tissue: attached, kera-\ntinized gingiva and unattached, nonkeratinized mucosa. The type \nof tissue around a dental implant is more varied than natural teeth. \nAfter bone loss in the maxilla, excess tissue is often found, and \nthe tissue is usually keratinized, unattached gingiva. An implant \nplaced in the region may also have keratinized, unattached tissue. \nThe tissues around the implant may also be similar to most natural \nteeth, surrounded by keratinized, attached gingiva (Fig. 41.16). \nThe tissues may be nonkeratinized, unattached mucosa, more \noften in the mandible after bone height loss or after a bone graft \nand flap advancement to approximate the gingiva (Fig. 41.17). \nThe nonkeratinized tissue may also be attached when acellular \ndermal matrix tissue (Oracell; Salvin Dental Specialities) is posi-\ntioned under the periosteum and bounds the overlying tissues to \nthe bone. In theory, structural differences in implants compared \nwith teeth make them more susceptible to the development of \ninflammation and bone loss when exposed to plaque accumula-\ntion or microbial invasion (e.g., less vascular supply, fewer fibro-\nblasts, lack of connective tissue attachment, cementation).171\nSome reports indicate that the lack of keratinized tissue may \ncontribute to implant failure. Kircsch et al. reported the most \nimportant criterion for implant health in the posterior man-\ndible was related to the absence or presence of keratinized gin-\ngiva.172 In this report mobile, nonkeratinized mucosa exhibited \ngreater probing depths, which was histologically confirmed. A \nstudy in monkeys found that an absence of keratinized mucosa \nincreases the susceptibility of peri-implant regions to plaque-\ninduced destruction.173\nThe presence of keratinized tissue next to an implant presents \nsome unique benefits, compared with natural teeth. Keratinized \ngingiva has more hemidesmosomes; the junctional epithelial \nattachment zone may be of benefit when in keratinized tissue. \nWhereas the orientation of collagen fibers in the connective tis-\nsue zone of an implant may appear perpendicular to the implant \nsurface, these fibers in mobile nonkeratinized tissue run parallel to \nthe surface of the implant.\nMobile mucosa may disrupt the implant-epithelial attach-\nment zone and contribute to an increased risk for inflammation \nfrom plaque (Fig. 41.18).174 In addition to the general advantages \nof keratinized tissue stated for teeth, keratinized tissue around \nimplants may also be beneficial in several other ways. In a two-\nstage protocol the implant is less likely to become exposed dur-\ning the healing process. The formation of an interdental/implant \npapillae is completely unpredictable with mobile nonkeratinized \ntissues. When the nonkeratinized tissue is mobile, several reports \nstate that this is unsatisfactory.\nA\nB\n• Fig. 41.17  (A and B) Implants placed to retain a lower overdenture that are malpositioned with minimal \nattached tissue present. In these type of cases, the tissue will usually remain irritated, inflamed, and painful."
  },
  {
    "page": 30,
    "content": "1170\nPART VIII    Dental Implant Maintenance\nA classification of attached gingiva and surgical alternatives to \nimprove soft tissue types in edentulous sites for implant place-\nment is critical for long-term implant survival.175 Ideal adequate \nkeratinized tissue should be established clinically before implant \nplacement, especially in the posterior regions.\nInterestingly, the studies that have advocated for the need for \nkeratinized mucosa around dental implants have primarily inves-\ntigated implants with rough surfaces. Failure of rough-surface \nimplants (e.g., hydroxyapatite-coated and plasma-sprayed cylinder-\nshaped implants) has been related to a lack of keratinized mucosa.176\nA meta-analysis reported 20% fewer instances of peri-implantitis \nin smooth-surface implants compared with rough-surface \nimplants.177 Another benefit of keratinized tissue is the clini-\ncal ease of treatment to reduce pocket depths if crestal bone loss \noccurs. Probing depths of 6 mm or more are more often associated \nwith anaerobic bacteria. If the implant is out of the esthetic zone, \na gingivectomy to reduce pocket depth is predictable. An apically \npositioned flap with nonkeratinized mucosa is less predictable and \nis more difficult to perform.\nThe significance of keratinized mucosa in the maintenance of \ndental implants with different surface conditions cannot be under-\nestimated. All 69 patients and 339 implants in the study had \nimplant restorations for at least 3 years, and as long as 24 years, with \nan average of 8.1 years. Bleeding index, modified plaque index, gin-\ngival index, probing depth, width of attached keratinized mucosa, \nand amount of attached mucosa were recorded. In addition, average \nannual bone loss was calculated, using past and present radiographs. \nGingival inflammation and plaque accumulation were significantly \nhigher in patients with less than 2 mm of keratinized mucosa or \n1 mm of attached mucosa. The surface condition of the implant \nwas not statistically significant in this study, although the smooth \nimplants with less than 2 mm of keratinized mucosa were less stable \nthan other groups relative to the soft tissue profile.\nIn this study the average annual bone loss was not influenced \nby the amount of keratinized or attached mucosa or the type of \nimplant surface configuration (smooth versus rough). The great-\nest amount of bone loss was observed with rough implants in \nkeratinized mucosa of less than 1 mm, but the difference was not \nstatistically significant. The presence of keratinized mucosa \nwas most significantly advantageous in the soft tissue health of \n­posterior implants, as indicated by the gingival index. Posterior \nimplants, even in the presence of keratinized tissue, had a 3.5-fold \nhigher annual bone loss than anterior implants in this study (0.14 \nversus 0.04 mm). Implant location appears to be more important \nthan the presence or absence of keratinized mucosa.\nIn most clinical situations attached keratinized gingiva is \nmore desirable. A fixed prosthesis (FP-1) in the esthetic zone \nrequires keratinized mucosa to develop the soft tissue drape \naround the implant restorations. Mandibular overdentures also \nbenefit from a vestibule and zone of nonmobile keratinized tis-\nsue around the implant abutments to minimize the possibility \nof painful tissue.\nManagement of Lack of Keratinized Tissue\nSeveral surgical techniques to increase the amount of keratin-\nized tissue around dental implants have been described in the \nliterature:\n\t1.\t \u0007Autogenous free gingival graft\n\t2.\t \u0007Autogenous subepithelial connective tissue graft\n\t3.\t \u0007Allogenic soft tissue grafts from human cadavers (e.g., Oracell; \nSalvin Dental)\n\t4.\t \u0007Xenogenic soft tissue grafts from animals\nAugmentation can be completed before surgery, concurrent \nwith surgery, or after implant surgery. The most ideal time to graft \nis before surgery.\nPresurgical Augmentations\n\t1.\t \u0007A trapezoidal flap is reflected from the desired areas of grafting.\n\t2.\t \u0007Full-thickness mucoperiosteal flap is the design of choice.\n\t3.\t \u0007Autogenous or acellular dermal matrix (Oracell; Salvin Dental) \nis modified to the desired dimensions.\n\t4.\t \u0007PGA or chromic suture is used (5–0 recommended) to secure \nallogenic dermal matrix (AlloDerm) to the recipient site.\n\t5.\t \u0007Flap is modified to be tension free and pulled over to cover \nacellular dermal matrix and sutured with 4–0 or 5–0 with PGA \nor PTFE sutures (Fig. 41.19). \nConcurrent Augmentation\nThe steps for concurrent augmentation are as follows:\n\t1.\t \u0007The full-thickness flap is reflected at the site of desired implant \nposition (one tooth mesial and one tooth distal).\n\t2.\t \u0007After implant placement and/or bone augmentation, autog-\nenous or acellular dermal matrix is layered over the augmen-\ntation site.\n\t3.\t \u0007It is critical to have abundant tissue release (i.e., tension-free \nclosure) to allow coverage of soft tissue over bone graft.\n\t4.\t \u0007The flap is sutured with no tension and secured for primary \nintention healing with 4–0 or 5–0 with PGA or PTFE sutures \n(Figs. 41.20 and 41.21). \nA\nB\n• Fig. 41.18  (A and B) Maxillary implants with inadequate attached tissue."
  },
  {
    "page": 31,
    "content": "1171\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nA\nB\nC\nD\nE\n• Fig. 41.19  Free Gingival Graft.  (A) Mandibular left first molar with compromised attached tissue. (B) \nRecipient site modified. (C) Palatal graft removed. (D) Palatal tissue graft. (E) Tissue graft sutured in place.\nA\nB\n• Fig. 41.20  Acellular Dermis.  (A) Bone graft with inadequate attached tissue. (B) Acellular dermis placed \naround implant healing abutments."
  },
  {
    "page": 32,
    "content": "1172\nPART VIII    Dental Implant Maintenance\nPost-implant Tissue Augmentation\nAfter the soft tissue flap has healed, the soft tissue augmentation \ncan be performed during the abutment change appointment or \nuncovery appointment (3 months of healing). The steps are as \nfollows:\n\t1.\t \u0007A full-thickness flap is reflected, being wide enough to cover the \nsize of the autogenous or acellular dermal matrix membrane.\n\t2.\t \u0007Dermal matrix is ideally positioned and sutured to neighboring \nattached tissue (chromic 5–0).\n\t3.\t \u0007The flap is advanced over the matrix, being careful to cover the \nentire allograft tissue (5–0 sutures are preferred). \nRetained Cement Peri-implant Disease\nCemented implant prostheses are used in implant dentistry \nbecause of the lower cost, relative simplicity, more passive fit, \nimproved esthetics, and similarity to traditional prosthetics. How-\never, with all of these advantages comes a significant disadvantage, \nthe retention of postoperative cement. The retained cement has \nbeen shown to harbor bacteria (similar to calculus with a natural \ntooth), which leads to peri-implant disease (Fig. 41.22).\nDuring implant restoration cementation, it is possible that \nexcess cement can become extruded into the gingival sulcus \naround the implant. The presence of cement in the sulcus has \nbeen shown to cause complications such as discomfort, inflamma-\ntion, soft tissue swelling, and bleeding or exudate on probing.178 \nIt has been reported that cement can extrude at the implant abut-\nment-interface when subgingival margins are present. Subgingi-\nval cement associated with an implant is more difficult to remove \ncompared with a natural tooth, and various instruments used for \nthis purpose have been shown to result in damage to implant abut-\nments.179 It has been proposed that any mass of foreign material \npresent adjacent to a dental implant has the potential to negatively \nimpact health and survival of the implant. The specific material \nitself may determine how a disease process can manifest. Further, \nthe use of cements intended for natural teeth may not be appro-\npriate for use with implant restorations.180\nStudies suggest that excess cement has been shown to be a \npossible cause of implant failure.181 Incidence of excess cement \nextrusion into peri-implant soft tissues and its adverse effects are \nwell documented in the literature.182,183 Cement retains micro-\nbial flora similar to organisms responsible for inflammatory \nperiodontal diseases. The surface of retained cement has a rough \ntopography, making removal of these microbes difficult, and can \nalso result in accumulation significant enough to form a peri-\nimplant biofilm similar to natural teeth.185,186 Clinical studies that \nhave analyzed retained methacrylate-based cement samples from \npatients for bacterial colonization have shown a strong tendency \nfor bacterial invasion by pathogens and opportunistic species.187 \nRemnant cement from implant restorations has been associated \nwith consequences of increased bleeding on probing, suppura-\ntion, and peri-implant attachment loss.188 It is the formation of \na peri-implant biofilm that can cause the initiation and progres-\nsion of peri-implant mucositis and peri-implantitis diseases.189-191 \nPeri-Implantitis has been documented in several studies with a \nprevalence rate that ranges from 6% to as high as 47% of patients \nwho have implants and have been followed over periods of 9 to \n14 years.192-194\nThe problem of excess cement has been associated with \ngreater than 80% of cases of peri-implant disease. No particu-\nlar difference or correlation could be associated with the type \nof cement used to lute the restoration in regard to either the \npresence of disease or treatment response (when comparing resin \ncement, resin-modified glass ionomer, zinc polycarboxylate, \nand glass ionomer). Further, the presence of cement retention \nand inflammation was not dependent on the type of implant \nsurface; titanium plasma–sprayed or sand-blasted large-grit \nacid-etched surfaces and titanium dioxide–blasted surfaces were \nA\nB\nC\n• Fig. 41.21  Acellular Dermis.  (A) Five implants placed in the anterior \nmandible. (B) Dermis modified to fit over healing abutments. (C) Dermis \nplaced over implants and healing abutments."
  },
  {
    "page": 33,
    "content": "1173\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\ncompared.195 In cases where cement is inadvertently left as an \noverhang or expressed into the peri-implant tissues, it should be \ndetected and removed.\nEtiology\nThe etiology of cement-retained peri-implantitis is as follows:\nCement: The retained cement acts as a nidus for bacterial accu-\nmulation and proliferation. The roughened surface of the ce-\nment inhibits the hygienic removal of the bacteria, which leads \nto peri-implant disease. Cement acts the same way as the etio-\nlogic factor in periodontal disease.\nSulcus-Teeth Versus Implant: Around natural teeth the junction-\nal epithelium and connective tissue attachment insert perpen-\ndicularly into the cementum, which tends to prevent the flow \nof excess cement into the sulcus. In contrast, the connective tis-\nsue around dental implants runs parallel, with no attachment \ninto the implant surface. The flow of cement is not restricted, \nand it easily migrates apically (Fig. 41.23).\nSubmucosal Margins: Margins of implant restorations are often \nplaced more than 2 mm subgingivally for a better emergence \nprofile and esthetics. However, studies have shown the deeper \nthe margins, the more difficult the removal of cement. In mar-\ngins that are greater than 1.5 mm subgingivally, it is almost \nimpossible to remove the cement totally.197\nLocation: Retained cement may attach to the following: (1) \ncrown, (2) abutment, and (3) bone. If the cement is pushed \ninto the sulcular area and reaches the bone, significant chronic \nissues will arise (Fig. 41.24).\nTiming: Perhaps one of the most interesting, yet troubling as-\npects of cement-associated peri-implant disease is the range \nof time that can and has historically passed before obvious \nsigns of an inflammatory disease response is evident during \nclinical detection. Wilson and Thomas196 have shown that \nthe time it takes for retained cement to become problematic \nand to eventually be diagnosed is in a range of 4 months to \n9.3 years, with an average of 3 years. Another group showed \ndetection ranging from several weeks to 4 years postcementa-\ntion. This documented that delayed detection in inflamma-\ntory signs of peri-implant disease indicates a premise that ce-\nmented implant restorations should be examined periodically \nfor disease.199\n   \nA\nB\nC\n• Fig. 41.22  Retained Cement.  (A) Radiograph depicting retained subgingival cement. (B) Six months \npostoperatively. (C) Cement retention leading to failure of implant."
  },
  {
    "page": 34,
    "content": "1174\nPART VIII    Dental Implant Maintenance\nRadiographic Evaluation: Several techniques are described \nin the literature to locate excess cement around implant restora-\ntions. These include use of a dental endoscope and an invasive \nmethod of open flap debridement for direct observation.200,201 \nRadiographic examination has been shown to be effective at \ndetecting excess cement overhangs in tooth-supported restora-\ntions and can serve as a less invasive method of detection for \ncement-retained implant-supported restorations.202,203 Radio-\ngraphic examination is valuable in cement detection only if the \nluting agent has a high-enough radiodensity level.204\nIt is significant to note that with respect to restoration lut-\ning cements and radiopacity, there is no currently established \nminimum radiopacity standard (however, there is currently a \nnational standard radiopaque value mandated for all endodon-\ntic sealer cements; American National Standards Institute/ADA \nspecification No. 57). Therefore there is a broad range of radio-\ngraphic visibility for restorative luting cements from having a \nhighly radiopaque appearance to being completely undetect-\nable.205 Ideally, the luting agent should be more radiographi-\ncally dense than the titanium alloys. Cements that are zinc based \n(i.e., Fleck’s, Temp-Bond, Tempbond NE) have been shown \nto be most readily detectable radiographically with the higher \ngray level values. Studies have shown that many non-zinc-based \ncements are not detected radiographically, such as self-adhesive \nresin cement (RelyX Unicem), resin cement (Improv and Pre-\nmier Implant Cement), glass ionomer (RelyX), and calcium \nhydroxide (Dycal). Being able to evaluate the presence of excess \ncement and then determining whether removal is indicated is \ncrucial to facilitate appropriate restorative protocols.206 After \nrestoration cementation, residual excess cement has the high-\nest likelihood of detection at the interproximal aspects. It is at \nthese sites where the accumulation of the bulk of excess cement \nproduces the effect of an enhanced radiopacity described by one \ngroup as the “peripheral egg shell effect.”207\n   \nA\nB\n• Fig. 41.23  Different Attachment Systems for Implant Versus Tooth.  (A) \nCircular fibers attach into the cementum, minimizing the possibility of \ncement retention. (B) Because an endosseous implant does not contain \nan attachment system with the tissue, retained cement can be easily \nextruded into the sulcular area. (From Resnik RR. Fixed prosthodontics \ncomplications. In: Resnik RR, Misch CE, eds. Misch’s Avoiding Complica-\ntions in Oral Implantology. St. Louis, MO: Elsevier; 2018; adapted from \nLeBeau J. Maintaining the long-term health of the dental implant and the \nimplant-borne restoration. Compend Contin Educ Oral Hyg. 1997;3:3–10.)\nA\nB\n• Fig. 41.24  Cement Attachment Location.  (A) Retained cement may adhere to the crown/abutment, \nperi-implant tissues, or the bone. (B) Implant with deep pathologic pocket associated with retained cement."
  },
  {
    "page": 35,
    "content": "1175\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nType of cement: Many types of cement are used today in implant \ndentistry to retain implant-supported crowns. Agar et  al.208 \nhave shown that cement with resin components is the most \ndifficult to remove from the abutment surface after cementa-\ntion. Cements containing zinc have been shown to be ideal \nfor cementing implant crowns because they are the easiest to \nsee radiographically. Zinc phosphate is a well-known popular \ncement choice, which makes retrievability difficult. In addi-\ntion, because of its solubility in the oral environment, a dry \nfield is definitely needed. Provisional cements are also popular \nin cementing implant crowns because they allow for retrieval. \nHowever, because provisional cements exhibit weaker reten-\ntive strengths, uncementation of the implant prosthesis may \nbe problematic.\nCememt Thickness: There is a large variation in the radiographic \ndetection ability of cements. Some cements have a very high ra-\ndiographic density, which allows for detection on radiographs. \nHowever, many cannot be detected, even at greater thickness \n(≈2 mm).\nCementation technique: A common reason for retained cement \nis the cervical cementation technique, which usually parallels \nthe technique for cementation on natural teeth.\n   \nMost clinicians place an excessive amount of cement within \nthe internal surface of the crown, which leads to extrusion in the \nsulcular area. \nPrevention\nSupragingival Margins. Excess retained cement may be mini-\nmized by designing the abutment margins supragingivally. How-\never, dentists are reluctant to place the margins at this level, \nespecially if the crowns are in the esthetic zone. Studies have \nshown margins placed 1 mm supragingival or at the gingival mar-\ngins allow for ease of cement removal without a decreased chance \nof retention.209 \nIdeal Application of Cement. Controlling the amount \nof cement that is placed in the implant crown will allow for a \ndecreased possibility of cement retention. Clinicians are reluctant \nto use a small amount of cement because this translates into the \npossibility of leakage and loss of retention.\nExcess cement may lead to improper seating, alteration of \nocclusion, and difficulty in cement removal. Ideally a uniform \nthickness of 40 μm over the intaglio surface is ideal; however, in \na clinical setting, this is very difficult. The internal surface of the \ncrown may sometimes be irregular, and unequal flow patterns may \nexist between parallel and nonparallel surfaces.\nAdditional factors that complicate ideal cementation are the \ncement’s flow properties, viscosity, dimensional stability, and wet-\ntability of the surfaces. \nScrew-Retained Prostheses. Although screw-retained implant \nprostheses have the disadvantages of higher cost and compro-\nmised esthetics in some cases, the lack of cement is a significant \nadvantage. \nImplant Abutment Modification. To reduce the amount of \nexcess cement, studies have shown that modification of the abut-\nment leads to less pressure and extruded cement. Ideally the abut-\nment should be vented with two 0.75-mm radius vent holes, \nplaced 3 mm apical to the occlusal area of the abutment and 180 \ndegrees apart. This technique by Wadhwani et  al.210 has been \nshown to limit the amount of cement extruded into the gingival \nsulcus of implant-retained crowns. \nTechniques\nVarious techniques to reduce retained cement have been discussed \nin the literature. A popular technique is the abutment copy tech-\nnique, which uses Teflon tape inside the intaglio surface before \ncopying the abutment with a polyvinyl siloxane material. The \ncement-filled final implant crown is seated on the copied abut-\nment for excess cement removal before it is quickly transferred \nintraorally to be fully seated. This technique minimizes the pos-\nsibility of retained cement; however, it has limitations when \ncementing a multiple splinted implant prosthesis211 (Fig. 41.25).\nThe Resnik technique (lubrication technique) uses water-sol-\nuble petroleum jelly placed on the outer surfaces of the crown or \nprosthesis and below the implant margin (i.e., sulcular area). A \ncontrolled cementation technique is utilized which controls the \namount of cement used and also allows for the removal of excess \ncement prior to final cementation. The advantage of this tech-\nnique allows for the prevention of cement from adhering to the \ncrown, sulcus, or underlying bone (Box 41.5 and Fig. 41.26). \nRemoval of Retained Implant Cement\nEven the most diligent and skilled implant clinician may leave resid-\nual cement in the sulcular area of implant crowns. The importance \nof postoperative appointments for implant patients after cementa-\ntion of the restoration cannot be overemphasized. Regular main-\ntenance is extremely crucial for cement-retained crowns. Possible \nsymptoms that may warrant an evaluation for retained cement are \nlocalized inflammation, bleeding on probing, exudate, progressively \nincreased probing depths, and radiographic bone loss.\nNonsurgical\nNonsurgical treatment includes regular curettage with hand \ninstruments. It should be noted it is very difficult to remove all \ncement non-surgically. \nSurgical\nIn many cases, surgical access is necessary for complete cement \nremoval, which includes flap, curettage, and detoxification with \npossible grafting. In cases of peri-implant disease the detection and \nremoval of excess cement have frequently (76% of afflicted patients) \nresulted in resolution of clinical inflammatory signs in as little as a \nmonth posttreatment. This was possibly due to removal of cement \nirritants causing both bacterial and mechanical insult. Some authors \nadvocate hand scalers, piezoelectric, and magnetostrictive mechani-\ncal devices (along with the benefit of a dental endoscope instrument \nfor direct visualization of cement deposits)212 (Fig. 41.27). \nPeri-implant Mucosal Hyperplasia\nThe gingival overgrowth results in extreme difficulty for the \npatient to maintain adequate hygiene and for the clinician in \nperforming debridement. When gingival overgrowth is asso-\nciated with radiographic bone loss, the resultant periodontal \npockets are expressed as “true” periodontal pockets. If there is no \nassociated bone loss, the pockets are termed “pseudo” pockets or \ngingival pockets.213\nGingival hyperplasia may also result in an esthetic issue for the \npatient. This will require surgical intervention to reduce the tis-\nsue. In addition, gingival hyperplasia may make it impossible for \na prosthesis to be completely seated (i.e., bar overdenture) or give \nrise to chronic tissue soreness."
  },
  {
    "page": 36,
    "content": "1176\nPART VIII    Dental Implant Maintenance\nStep 1: Apply water-soluble petroleum jelly to the outer margin of the crown with a 1-mL tuberculin \nsyringe.\nStep 2: Seal the abutment screw (cotton ball, Teflon tape) without sealing the entire access.\nStep 3: Place a thin layer of petroleum jelly 360 degrees with a 1 mL tuberculin syringe within the \nsulcus and around the implant.\nStep 4: Apply a thin layer (≈40 μm) of cement to the intaglio surface of the crown abutment.\nStep 5: Seat crown, remove crown, remove excess cement adhered to the outer margin surface, and \nremove any sulcular excess cement and petroelum jelly with a brush.\nStep 6: Reseat crown, evaluate for any excess cement.\n\t • BOX 41.5\t    \u0007Cementation Technique (Resnik Technique)\nA\nB\nC\nD\nE\nF\n• Fig. 41.25  Cementation Technique.  (A) Polytetrafluoroethylene tape placed over abutment. (B) Crown \ninserted onto abutment. (C) Polyvinyl impression material added to the internal surface of the crown to \nmake an abutment duplicate. (D) Internal surface of crown: abutment inserted onto implant in the mouth. \n(E) Cement added to crown and placed on polyvinyl abutment duplicate. (F) Excess cement removed, then \ninserted onto abutment in mouth."
  },
  {
    "page": 37,
    "content": "1177\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nA\nB\nC\nD\nE\nF\nG\n• Fig. 41.26  Alternative Cementation Technique.  (A) Outside of the crown is lubricated with water-sol-\nuble petroleum jelly. (B) Illustration-Water-soluble jelly placed within the sulcus with a 1-mL tuberculin \nsyringe. (C) Clinical image after sulcular lubricant placed, (D) Cement is placed into the internal surface of \nthe crown. (E) Crown is inserted into mouth. (F) Crown is removed and excess cement is removed with a \nbrush. (G) Crown is reinserted onto abutment."
  },
  {
    "page": 38,
    "content": "1178\nPART VIII    Dental Implant Maintenance\nA\nB\nC\nD\nE\nF\n• Fig. 41.27  Retained Cement.  (A) Implant restoration in function for 6 months with persistent signs of \nperi-implant mucositis. (B) Radiographically evident manifestation of remnant cement at the restorative \nmargin. (C) Excess cement after instrumentation with titanium and plastic curettes. (D) Peri-implant tissues \nimmediately after instrumentation. (E) Radiograph demonstrating excess cement has been removed. (F) \nCondition of peri-implant tissues at 6-week reevaluation appointment."
  },
  {
    "page": 39,
    "content": "1179\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nEtiology\nAfter clinical diagnosis of implant-related gingival overgrowth, \npotential etiologies must be identified, such as hormonal, medica-\ntion induced, allergy induced, or patient-related habits. Various \nhormonal factors (e.g., related to pregnancy or puberty) and med-\nications have been associated with the gingival overgrowth. Medi-\ncations such as phenytoin (i.e., Dilantin), immunosuppressants \n(e.g., cyclosporine), calcium channel blockers, and amphetamines \nhave been associated with gingival hyperplasia.\nGingival overgrowth has also been associated with patient hab-\nits such as mouth breathing. Allergy-induced hyperplasia is also \nbecoming more prevalent in implant dentistry. With the use of \ntitanium alloys for the fabrication of the dental implants and abut-\nments, exacerbated allergic reactions are becoming a more common \nproblem. Nickel (Ni), combined with titanium or in the final pros-\nthesis, may exacerbate and cause an acute allergic reaction. Alumi-\nnum (Al) and beryllium (Be) have been associated with eczema and \nsoft tissue reactions that result in gingival overgrowth. \nPrevention\nIf a patient is considered to be at high risk for implant-related gin-\ngival hyperplasia (e.g., because of medications), he or she should \nbe instructed to maintain meticulous oral hygiene. In addition, \na more frequent recall protocol (four times per year) should be \nimplemented that includes debridement. The prosthesis should \nbe evaluated and maintained with a minimum of 1 mm of space \nbetween the tissue and the prosthesis, for ease of cleaning and \nprevention of prosthesis-induced irritation. \nManagement\nThe treatment of peri-implant hyperplasia should begin with conven-\ntional periodontal therapies to reduce plaque biofilm and inflamma-\ntion. The surgical management of implant gingival overgrowth may \nrequire gingivectomy (if adequate keratinized gingiva is present) or \napically positioned flaps (without adequate keratinized gingiva).\nThe use of 0.12% or 0.2% chlorhexidine twice per day has \nbeen shown to be successful in reducing tissue overgrowth and \nbacteria counts. When gingival hyperplasia is present around \nimplants associated with overdentures, care should be exercised to \nminimize further enlargement (Fig. 41.28).\nCommonly, practitioners will relieve the denture so the path of \ninsertion does not cause irritation or mucosal injury. This may \nlead to inadequate thickness of acrylic, predisposing the prosthe-\nsis to fracture. Ideally the tissue enlargement should be reduced \nand the causative agent identified and treated accordingly. It is \nimportant to note that even with meticulous care and removal of \netiology, gingival overgrowth may recur. Communication with the \npatient is key to avoid misunderstanding (Box 41.6). \nImplant Quality Scale\nThe criteria for success in implant dentistry remain complex. Most \nclinical studies reporting success and failure do not qualify the type \nof success achieved. Instead, the term success primarily has been used \ninterchangeably with survival of the implant. The term failure has been \nused to indicate the implant is no longer present in the mouth. Nearly \nall reports in the prosthetic literature also report survival as success.\nWhat is success for a natural tooth? In the periodontal literature \na quality of health is presented, and well-established guidelines \nbased on clinical criteria describe the ideal health of natural teeth. \nThe general term success in implant dentistry should be replaced \nwith the concept of quality of health, with a health-disease con-\ntinuum describing the status of implants.\nA\nB\n• Fig. 41.28  Hyperplasia.  (A and B) Hyperplastic tissue growth surround-\ning existing implant prosthesis resulting in home care difficulty. (From \nSuzuki JB, Misch CE. Periodontal and maintenance complications. In: \nResnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implan-\ntology. St. Louis, MO: Elsevier; 2018.)\nAnticonvulsants\nPhenytoin\nPhenobarbital\nLamotrigine\nVigabatrin\nEthosuximide\nTopiramate\nPrimidone\nCalcium channel blockers\nNifedipine\nAmlodipine\nVerapamil\nImmunosuppressant drugs\nCyclosporine\nSystemic factors\nPregnancy\nPuberty\nVitamin C deficiency\nLeukemia\nNeoplasms (fibromas, papillomas, carcinomas)\n\t • BOX 41.6\t    \u0007Pharmacologic Agents That Cause \nGingival Hyperplasia"
  },
  {
    "page": 40,
    "content": "1180\nPART VIII    Dental Implant Maintenance\n  \u0007Implant Quality Scale\nImplant Quality Scales\nClinical Conditions\n Suzuki-Resnik Protocol\nSuccess (optimal health)\nOsseointegration/Stage 0 \n­osseoseparation\nNo pain or tenderness upon function\n0 mobility\n<2 mm radiographic bone loss from initial surgery\nPD < 4 mm\nNo suppuration\nNo BOP\nProtocol 1\nSurvival (satisfactory health)\nStage I osseoseparation\nPeri-mucositis\nNo pain\n0 mobility\n<2 mm radiographic bone loss from initial surgery\nPeri-mucosal inflammation\nPD ± 4 mm (bleeding and/or suppuration on probing)\nProtocol 2\nSurvival (potentially compromised)\nStage II osseoseparation\nEarly peri-implantitis\nNo pain\n0 mobility\n2–4 mm radiographic bone loss\nPD ± 4 mm (bleeding and/or suppuration on probing)\nPeri-mucosal inflammation\nBone loss <25% of the implant length\nProtocol 2 or Protocol 3\nSurvival (compromised health)\nStage III osseoseparation\nModerate peri-implantitis\nVariable pain\n0 mobility\nPeri-mucosal inflammation\nPD ≥6 mm (bleeding and/or suppuration on probing)\nBone loss 25%–50% of the implant length\nProtocol 3\nFailure (clinical failure)\nStage IV osseoseparation\nAdvanced peri-implantitis\nPeri-mucosal inflammation\nPain upon function\nPD >8 mm (bleeding and/or suppuration on probing)\nBone loss >50% of the implant length\nMobility\nUncontrolled exudate\nMaybe no longer in mouth\n Protocol 4\nOthers (such as retrograde  \nperi-implantitis)\nVariable peri-mucosal inflammation\nRadiographically: periapical lesion around implant\nClinical: pain, tenderness, fistula formation or swelling\nSurgical reentry and revision or removal of \nimplant\nBOP, bleeding on probing; PD, probing depth; SPT, supportive periodontal therapy.\nFrom Suzuki JB, Misch CE. Periodontal and maintenance complications. In: Resnik RR, Misch CE, eds. Misch’s Avoiding Complications in Oral Implantology. St. Louis, MO: Elsevier; 2018. Data from Suzuki \nJB, Hsiao YJ, Misch CE. Personal communication, 2017.\n   \nTABLE \n41.4\nSuccess criteria for endosteal implants have been proposed pre-\nviously.214-218 The Misch scale proposes management modalities \ncorresponding to different treatment levels.219\nThe most recent Suzuki-Misch-Hsiao implant health scale was \npublished in Resnik and Misch’s Avoiding Implant Complications \n(2017).220 The Suzuki-Misch-Hsaio scale presented implant qual-\nity of health based on clinical evaluation (Table 41.4). This quality \nof health scale allows the implant dentist to evaluate an implant \nusing the listed criteria, place it in the appropriate category, and \nthen treat the implant accordingly. The prognosis also is related to \nthe quality scale.\nIdeal clinical conditions for natural teeth include absence of \npain, less than 0.1 mm of initial horizontal mobility under lateral \nforces of less than 100 g, less than 0.15 mm of secondary mobility \nwith lateral forces of 500 g, absence of observed vertical mobil-\nity, periodontal probing depths of less than 2.5 mm, radiographic \ncrestal bone height 1.5 to 2.0 mm below the cementoenamel \njunction, intact lamina dura, no bleeding on probing, no exudate, \nand absence of recession or furcation involvement on multirooted \nteeth.\nThe American Dental Association CDT (2018) has defined \nfive periodontal types for diagnosis and treatment of natural \nteeth.221,222 The American Dental Association’s categories of \ndisease do not simply indicate success or failure but rather a \nrange from health to disease. This classification allows a clini-\ncal approach to treatment in each category. A similar scale for \nimplants has been established as an aid to diagnosis and treat-\nment that also proposes management approaches according to \nthe signs and symptoms.\nGroup I: Optimum Health\nGroup I represents implant success with optimum health condi-\ntions. No pain is observed with palpation, percussion, or func-\ntion. No mobility is noted in any direction with loads less than \n500 g of implant movement (IM). Less than 2.0 mm of crestal"
  },
  {
    "page": 41,
    "content": "1181\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nA\nB\n• Fig. 41.29  Group I: Optimum Health.  (A and B) Ideal implants with no associated bone loss.\nbone has been lost since the placement of the implant. This bone \nloss is typically a result of the implant biologic width below the \nabutment connection and surface of the implant. The implant \nhas no history of exudate, and no radiolucency is present around \nthe implant body. The probing depth is equal to or less than 5 \nmm and is stable after the first year. Ideally the bleeding index is \n0 to 1. Group I implants follow a normal maintenance program \nevery 6 months. The prognosis is very good to excellent (Fig. \n41.29). \nGroup II: Satisfactory Health\nGroup II implants exhibit satisfactory health and are stable. \nNo tenderness is observed on palpation, percussion, or func-\ntion. No observable implant mobility was present in the hori-\nzontal or vertical direction with loads less than 500 g. Crestal \nradiographic bone loss is observed between 2 and 4 mm from \nimplant placement. The most common cause is the early load-\ning bone loss related to the amount of occlusal force and the \ndensity of the bone. No pain is observed. Probing depths \nmay be as much as 5 to 6 mm because of the original tissue \nthickness and marginal bone loss, but are stable. Bleeding on \nprobing index is often 1 or even 2. These implants may be con-\nsidered to have peri-implant mucositis. The treatment indicated \nfor group II implants consists of a stress reduction protocol for \nthe implant system, shorter intervals between hygiene appoint-\nments (e.g., 3 months), reinforcement of oral hygiene instruc-\ntions, annual radiographs until the crestal bone has stabilized, \nand gingivoplasty or sulcus reduction procedures where indi-\ncated. The prognosis is good to very good depending on the \ndepth of the implant sulcus.\nFor pockets less than 6 mm in depth, the following can be \nconcluded:\n\t1.\t \u0007Mechanical therapy alone or combined with chlorhexidine \nresults in the clinical resolution of peri-implant mucositis lesions.\n\t2.\t \u0007Histologically both treatments result in minimal inflammation \ncompatible with health.\n\t3.\t \u0007The mechanical effect alone is sufficient to attain clinical and \nhistologic resolution of mucositis lesions (Fig. 41.30). \nA\nB\n• Fig. 41.30  Group II: Satisfactory Health.  (A and B) Implants exhibit satisfactory health and are stable, \nbut tenderness is observed on palpation, percussion, or function."
  },
  {
    "page": 42,
    "content": "1182\nPART VIII    Dental Implant Maintenance\nA\nB\n• Fig. 41.31  Group III: Compromised Survival.  (A and B) Implants are classified as compromised survival \nand exhibit a slight-to-moderate peri-implantitis and compromised health status.\nGroup III: Compromised Survival\nGroup III implants are classified as compromised survival and exhibit \na slight-to-moderate peri-implantitis and compromised health status. \nPeri-implantitis is defined as an inflammatory process affecting the \ntissue around an implant that results in loss of supporting bone.\nGroup III implants are characterized by radiographically evi-\ndent vertical bone loss, peri-implant pocket, bleeding on probing \n(plus occasional suppuration), and mucosal swelling and redness \nbut no pain on function.\nThese implants warrant more aggressive clinical therapy. No \npain is apparent in function, but tenderness may be slight on \npercussion or function. No vertical or initial horizontal mobil-\nity (IM-0) is evident. Greater than 4 mm of crestal bone loss has \noccurred since implant insertion but less than half the length of \nthe implant. Greater than 7 mm and increasing probing depths \nare also present, usually accompanied by bleeding when probing. \nExudate episodes may have lasted more than 1 to 2 weeks and may \nbe accompanied by a slight radiolucency evident around a crestal \nregion of the implant.\nGroup III implants warrant aggressive surgical and prosthetic \nintervention. Stress factors are also addressed. The prosthesis may \nbe removed in nonesthetic regions. If a bar (used to support and \nretain an overdenture) is present, it may be removed during the \nsurgical therapy. Modification of the occlusal scheme and meth-\nods to decrease the forces in the afflicted regions after hard and \nsoft tissue surgical treatment include decreasing cantilever length, \nocclusal adjustment, and occlusal splint therapy.\nIn cases of rapid bone changes, the prosthesis design may be \nmodified completely from a fixed to a removable restoration to \nstress relief and soft tissue support. Additional implants to support \nthe restoration may be indicated, especially if the patient is unwill-\ning to wear a removable prosthesis.\nSystemic and topical antibiotics and local chemical agents \nsuch as chlorhexidine are indicated in the presence of exudate. \nHowever, this method is usually of short-term benefit if the \ncausative agents of implant failure are not eliminated.\nSurgical management most often consists of soft tissue removal \nor exposure of a portion of the implant. Bone grafts may be used \ntogether with these approaches around the implant. A three-step \napproach is implemented for this category in the following order: \n(1) antimicrobial therapy (local or systemic), (2) stress reduction, \nand (3) surgical intervention.\nThe prognosis is good to guarded, depending on the ability \nto reduce and control stress after the surgical corrections have \nimproved the soft and hard tissue health (Fig. 41.31). \nGroup IV: Clinical Failure\nGroup IV of implant health is clinical or absolute failure. The \nimplant should be removed under any of these conditions: (1) \npain on palpation, percussion, or function; (2) greater than 0.5 \nmm of horizontal mobility; (3) any vertical mobility; (4) uncon-\ntrolled progressive bone loss; (5) uncontrolled exudate; (6) more \nthan 50% bone loss around the implant; (7) generalized radiolu-\ncency; or (8) implants surgically placed but unable to be restored \n(sleepers). Implants that are surgically removed or exfoliated are \nalso in the category of failure.\nThis category also includes implants surgically removed or \nexfoliated and no longer in the mouth. The remaining edentu-\nlous area often is treated with autogenous, synthetic, or other \nsubstitute bone graft materials to replace the missing bone. After \nthe favorable bony conditions are augmented, implants may be \ninserted again with a good prognosis.\nThe terminology for implant failure often is confusing, with \ndifferent terms describing similar situations. Terminology for \nimplant failure using the time period of failure has been suggested \nas a primary criterion. Many implant failures are not described \nideally by the time of the complication and are not addressed in \nthis nomenclature."
  },
  {
    "page": 43,
    "content": "1183\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nA\nB\nC\n• Fig. 41.32  Group IV: Implant Failure.  (A–C) Implants are deemed absolute failures.\nOccasionally the patient will not permit removal of the implant. \nRegardless of whether the patient returns for implant removal, the \nimplant is recorded as a failure in all statistical data. The patient \nshould be warned against the irreversible damage to the surround-\ning bone with implants retained in this condition. Consideration \nshould be given to their removal because future treatment may be \ncompromised (Fig. 41.32). \nConclusion\nOnce the surgical and prosthetic phases of implant therapy have \nbeen completed, the work of the clinician is not over. Patients \nmust be educated regarding proper maintenance of their implant-\nsupported restorations, and routine examinations should be \nperformed to monitor overall health. Many differences exist in \nthe biology of natural teeth compared with implant-supported \nrestorations as they pertain to periodontal status. It is critically \nimportant that the implant clinician recognize these differences, \nproperly diagnose disease states, and effectively manage these \nproblems should they arise. By understanding the etiologies of the \nvarious peri-implant disease states, a clinician can work with the \npatient to build an effective protocol of prevention (Figs. 41.33 \nand 41.34)."
  },
  {
    "page": 44,
    "content": "1184\nPART VIII    Dental Implant Maintenance\nA\nB\nC\nD\nE\nF\nG\nH\nI\n• Fig. 41.33  Peri-implant Disease Protocol.  (A) Maxillary right central incisor implant with associated \nbone loss and poor tissue health. (B) Radiographic evidence of peri-implant disease. (C) Tissue reflection \nrevealing osseous defect. (D) Implantoplasty (removal of surface threads) and detoxification. (E) Bone \ngrafting and collagen membrane placed. (F) Subepithelial connective tissue graft. (G) Final closure. (H) \nImmediate postoperative radiograph. (I) One-year follow-up."
  },
  {
    "page": 45,
    "content": "A\nB\nC\nD\nE\nF\n• Fig. 41.34  Peri-implant Disease Protocol.  (A) Mandibular left first molar bone loss. (B) Bleeding on \nprobing. (C) Implant threads detoxified and titanium brushes used to remove soft tissue remnants. (D) \nTitanium brushes (Salvin Dental Specialties). (E) Laser treatment. (F) Two years postoperatively."
  },
  {
    "page": 46,
    "content": "1186\nPART VIII    Dental Implant Maintenance\nReferences\n\t 1.\t \u0007American Academy of Periodontology. Academy report: peri-\nimplant mucositis and peri-implantitis: a current understand-\ning of their diagnoses and clinical implications. J Periodontol. \n2013;84:436–443.\n\t 2.\t \u0007Mombelli A, Lang NP. The diagnosis and treatment of peri‐\nimplantitis. Periodontology. 2000;17:63–76. 1998.\n 3. \u0007Lindhe J, Meyle J. Peri-implant diseases: consensus report of the \nsixth European workshop on periodontology. J Clin Periodontol. \n2008;35:S282–S285.\n\t 4.\t \u0007Mombelli A, Muller N, Cionca N. The epidemiology of peri-\nimplantitis. Clin Oral Implants Res. 2012;23(suppl 6):67–76.\n 5. \u0007Suzuki JB. Diagnosis and classification of the periodontal diseases; in \nDent Clin N Amer. Philadelphia: Saunders; 1988\n\t 6.\t \u0007Albrektsson T, Canullo L, Cochran D, et al. “Peri-Implantitis”: a \ncomplication of a foreign body or a man-made “disease.” Facts and \nfiction. Clin Implant Dent Relat Res. 2016;18(4):840–849.\n\t 7.\t \u0007Salvi GE, Lang NP. Diagnostic parameters for monitor-\ning peri-implant conditions. Int J Oral Maxillofac Implants. \n2004;19(suppl):116–127.\n\t 8.\t \u0007American Academy of Periodontology. New periodontitis and peri \nimplantitis classification. J Periodontol. 2018;89(suppl 1):S1–S8.\n\t 9.\t \u0007Poli PP, Cicciu M, Beretta M, et al. Peri-implant mucositis and \nperi-implantitis: a current understanding of their diagnosis, clinical \nimplications and a report of treatment using a combined therapy \napproach. J Oral Implantol. 2017;43:45–50.\n 10. \u0007Suzuki JB. Oral microbiology and immunology; in Medical Micro-\nbiology. Patrick Murray, ed., CV Mosby Co., St. Louis, MO. 1990.\n\t11.\t \u0007Oh TJ, Yoon J, Misch CE, et al. The causes of early implant bone \nloss: myth or science. J Periodontol. 2002;73:322–333.\n\t12.\t \u0007Rams TE, Roberts TW, Tatum Jr H, et al. The subgingival micro-\nflora associated with human dental implants. J Prosthet Dent. \n1984;5:529–534.\n\t13.\t \u0007Ting M, Craig J, Balkin BE, Suzuki JB. Peri-implantitis: a com-\nprehensive overview of systematic reviews. J Oral Implantology. \n2018;44(3):225–247.\n\t14.\t \u0007Mombelli A, van Oosten MA, Schurch Jr E, Land NP. The micro-\nbiota associated with successful or failing osseointegrated titanium \nimplants. Oral Microbiol Immunol. 1987;2(4):145–151.\n 15. \u0007Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a \ncommon cause of persistent infections. Science. 1999;284(5418): \n1318–1322.\n\t16.\t \u0007Patel R. Biofilms and antimicrobial resistance. Clin Orthop Relat \nRes. 2005;437:41–47.\n\t17.\t \u0007Di Giulio M, Traini T, Sinjari B, et al. Porphyromonas gingivalis \nbiofilm formation in different titanium surfaces, an in vitro study. \nClin Oral Implants Res. 2016;27(7):918–925.\n\t18.\t \u0007Lang NP, Berglundh T. Working group 4 of seventh european \nworkshop on periodontology. Periimplant diseases: where are we \nnow. 2011:178–181.\n\t19.\t \u0007Renvert S, Roos-Jansaker AM, Claffey N. Non-surgical treatment \nof periimplant mucositis and peri-implantitis: a literature review. J \nClin Periodontol. 2008;35:305–315.\n\t20.\t \u0007Furst MM, Salvi GE, Lang NP, et al. Bacterial colonization imme-\ndiately after installation on oral titanium implants. Clin Oral \nImplants Res. 2007;18:501–508.\n 21. \u0007Costerton JW, Montanaro L, Arciola CR. Biofilm in implant \ninfections: its production and regulation. Int J Artif Organs. \n2005;28:1062–1068.\n\t22.\t \u0007Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic \ntargets. Periodontol. 2000;2002(28):12–55.\n\t23.\t \u0007Violant D, Galofré M, Nart J, Teles RP. In vitro evaluation of a \nmultispecies oral biofilm on different implant surfaces. Biomed \nMater. 2014;9(3):035007.\n\t24.\t \u0007de Avila ED, Avila-Campos MJ, Vergani CE, et al. Structural and \nquantitative analysis of a mature anaerobic biofilm on different \nimplant abutment surfaces. J Prosthet Dent. 2016;115(4):428–436.\n 25. \u0007Ata-Ali J, Flichy-Fernandez AJ, Alegre-Domingo T, et al. Clin-\nical, microbiological, and immunological aspects of healty ver-\nsus peri-implantitis tissue in full arch reconstruction patients: \na prospective cross-sectional study. BMC Oral Health. 2015; \n15:43.\n\t26.\t \u0007Kinane DF. Aetiology and pathogenesis of periodontal disease. Ann \nR Australas Coll Dent Surg. 2000;15:43–50.\n 27. \u0007Javed F, A-Hezaimi K, Salameh Z, et al. Proinflammatory cyto-\nkines in the crevicular fluid of patients with peri-implantitis. Cyto-\nkine. 2011;53:8–12.\n\t28.\t \u0007Perez-Chaparro PJ, Goncalves C, Figueiredo LC, et al. Newly iden-\ntified pathogens associated with periodontitis: a systematic review. \nJ Dent Res. 2014;93:846–858.\n\t29.\t \u0007Klinge B, Meyle J. Peri-implant tissue destruction. The Third EAO \nConsensus Conference 2012. Clin Oral Implants Res. 2012;23(suppl \n11):203–213.\n\t30.\t \u0007Agarwal S, Suzuki JB, Riccelli AE. Role of cytokines in the modula-\ntion of neutrophil chemotaxis in localized juvenile periodontitis. J \nPeriodontal Res. 1994;29(2):127–137.\n\t31.\t \u0007Klinge B, Meyle J. Peri-implant tissue destruction. The Third EAO \nConsensus Conference 2012. Clin Oral Implants Res. 2012;3(suppl \n11):203–213.\n\t32.\t \u0007Rosen P, Clem D, Cochran D, et al. Peri-implant mucositis and \nperi-implantitis: a current understanding of their diagnoses and \nclinical implications. J Periodontal. 2013;84:436–443.\n 33. \u0007Faggion Jr CM, Listl S, Tu YK. Assessment of end-points in studies \non peri-implant treatment. J Dent. 2010;38:443–450.\n\t34.\t \u0007Persson GR, Renvert S. Cluster of bacteria associated with peri-\nimplantitis. Clin Implant Dent Relat Res. 2014;16:783–793.\n\t35.\t \u0007Hutlin M, Gustafsson A, Hallstrom H, et al. Microbiological find-\nings and host response in patients with peri-implantitis. Clin Oral \nImplants Res. 2002;13:349358.\n\t36.\t \u0007Mombelli A, Muller N, Cionca N. The epidemiology of peri-\nimplantitis. Clin Oral Implants Res. 2012;23(suppl 6):67–76.\n 37. \u0007Suzuki JB. Immunology of the periodontal diseases: in Periodon-\ntics. Grant DA, Stern IB, and Listgarten M, eds. CV Mosby Co., \nSt. Louis, MO. 1987.\n\t38.\t \u0007Lee C-T, Huang Y-W, Zhu L, Weltman R. Prevalences of peri-\nimplantitis and peri-implant mucositis: systematic review and \nmeta-analysis. J Dent. 2017;62:1–12.\n 39. \u0007Ferreira SD, Silva GLM, Cortelli JR, Costa JE, Costa FO. Preva-\nlence and risk variables for peri‐implant disease in Brazilian sub-\njects. J Clin Periodontol. 2006;33:929–935.\n\t40.\t \u0007Zitzmann NU, Berglundh T, Marinello CP, Lindhe J. Experimen-\ntal peri-implant mucositis in man. J Clin Periodontol. 2001;28:517–\n523.\n\t41.\t \u0007Salvi GE, Aglietta M, Eick S, Sculean A, Lang NP, Ramseier CA. \nReversibility of experimental peri-implant mucositis compared \nwith experimental gingivitis in humans. Clin Oral Implants Res. \n2012;23:182–190.\n\t42.\t \u0007Meyer S, Giannopoulou C, Courvoisier D, Schimmel M, Mu¨ller \nF, Mombelli A. Experimental mucositis and experimental gingivitis \nin persons aged 70 or over. Clinical and biological responses. Clin \nOral Implants Res. 2017;28(8):1005–1012.\n\t43.\t \u0007Sennerby L, Lekholm U. The soft tissue response to titanium abut-\nments retrieved from humans and reimplanted in rats. A light \nmicroscopic pilot study. Clin Oral Impl Res. 1993;4:23–27.\n\t44.\t \u0007Atieh MA, Alsabeeha NH, Faggion CM, Duncan WJ. The fre-\nquency of peri-implant diseases: a systematic review and meta-anal-\nysis. J Periodontol. 2013;84(11):1586–1598.\n 45. \u0007Javed F, Romanos GE. Impact of diabetes mellitus and glycemic \ncontrol on the osseointegration of dental implants: a systematic lit-\nerature review. J Periodontol. 2009;80:1719–1730.\n\t46.\t \u0007Costa FO, Takenaka-Martinez S, Cota LO, et al. Peri-implant dis-\nease in subjects with and without preventive maintenance: a 5-year \nfollow-up. J Clin Periodontol. 2012;39(2):173–181.\n\t47.\t \u0007Trejo PM, Bonaventura G, Weng D, et al. Effect of mechanical \nand antiseptic therapy on peri-implant mucositis: an experimental \nstudy in monkeys. Clin Oral Implants Res. 2006;17:294–304."
  },
  {
    "page": 47,
    "content": "1187\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\n\t48.\t \u0007Renvert S, Roos-Jansaker AM, Claffey N. Non-surgical treatment \nof peri-implant mucositis and peri-implantitis: a literature review. J \nClin Periodontol. 2008;35:305–315.\n\t49.\t \u0007Fakhraver B, Khocht A, Jefferies SR, Suzuki JB. Probing and scal-\ning instrumentation on implant abutment surfaces: an in  vitro \nstudy. Impl Dent. 2012;21(4):311–316.\n\t50.\t \u0007Bassetti M, Schär D, Wicki B, et al. Anti-infective therapy of peri-\nimplantitis with adjunctive local drug delivery or photodynamic \ntherapy: 12-month outcomes of a randomized controlled clinical \ntrial. Clin Oral Implants Res. 2014;25(3):279–287.\n\t51.\t \u0007Hasturk H, Nguyen DH, Sherzai H, et  al. Comparison of the \nimpact of scaler material composition on polished titanium implant \nabutment surfaces. J Dent Hyg. 2013;87(4):200–211.\n\t52.\t \u0007Anastassiadis PM, Hall C, Marino V, et  al. Surface scratch \nassessment of titanium implant abutments and cementum fol-\nlowing instrumentation with metal curettes. Clin Oral Investig. \n2015;19(2):545–551.\n\t53.\t \u0007Sãnchez-Garcãs M, Gay-Escoda C. Peri-implantitis. Med Oral \nPathol Oral Cir Bucal. 2004;9:63–74.\n\t54.\t \u0007Dennison DK, Huerzeler MB, Quinones C, Caffese RG. Contami-\nnated implant surfaces: an in vitro comparison of implant surface \ncoating and treatment modalities for decontamination. J Periodon-\ntol. 1994;65(10):942–948.\n\t55.\t \u0007Faria G, Cardoso CR, Larson RE, et  al. Chlorhexidine-induced \napoptosis or necrosis in L929 fibroblasts: a role for ndoplasmic \nreticulum stress. Toxicol Appl Pharmacol. 2009;234(2):256–265.\n\t56.\t \u0007Hall EE, Meffert RM, Hermann JS, et al. Comparison of bioactive \nglass to demineralized freeze-dried bone allograft in the treatment \nof intrabony defects around implants in the canine mandible. J \nPeriodontol. 1999;70(5):526–535.\n 57. \u0007Norowski Jr PA, Bumgardner JD. Biomaterial and antibiotic strate-\ngies for peri‐implantitis: a review. J Biomed Mater Res B Appl Bio-\nmater. 2009;88(2):530–543.\n\t58.\t \u0007Williams RC, Paquette DW, Offenbacher S, et al. Treatment of \nperiodontitis by local administration of min ocycline microspheres: \na controlled trial. J Periodontol. 2001;72:1535–1544.\n\t59.\t \u0007Oringer RJ, Al-Shammari KF, Aldredge WA, et al. Effect of locally \ndelivered minocycline microspheres on markers of bone resorption. \nJ Periodontol. 2002;73(8):835–842.\n\t60.\t \u0007Loesch WJ. Nonsurgical treatment of patients with periodon-\ntal disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. \n1996;81:533–543.\n\t61.\t \u0007Guerrero A, Griffiths GS, Nibali L, et al. Adjunctive benefits of \nsystemic amoxicillin and metronidazole in non-surgical treatment \nof generalized aggressive periodontitis: a randomized placebo-con-\ntrolled clinical trial. J Clin Periodontol. 2005;32(10):1096–1107.\n\t62.\t \u0007Pavicic M, Van Winkelhoff AJ, Dougué NH, et al. Microbiologi-\ncal and clinical effects of metronidazole and amoxicillin in Actino-\nbacillus actinomycetemcomitans associated periodontitis: a 2-year \nevaluation. J Clin Periodontol. 1994;21(2):107–112.\n\t63.\t \u0007Haffajee AD, Smith C, Torresyap G, et al. Efficacy of manual and \npowered toothbrushes (II). Effect on microbiological parameters. J \nClin Periodontol. 2001;28(10):947–954.\n\t64.\t \u0007Poli Pier P, Cicciu M, Beretta M, Maiorana C. “Peri-implant muco-\nsitis and peri-implantitis: a current understanding of their diagnosis, \nclinical implications, and a report of treatment using a combined \ntherapy approach. J Oral Implantol. 2017;43(1):45–50.\n\t65.\t \u0007Perez-Chaparro PJ, Duarte PM, Shibli JA, et al. The current weight \nof evidence of the microbiologic profile associated with peri-\nimplantitis: a systematic review. J Periodontol. 2016;87:1295–1304.\n\t66.\t \u0007Ting M, Craig J, Balkin BE, Suzuki JB. Peri-implantitis: a com-\nprehensive overview of systematic reviews. J Oral Implantol. \n2018;44(3):225–247.\n\t67.\t \u0007Mir-Mari J, Mir-Orfila P, Figueiredo R, Valmaseda-Castellón E, \nGay-Escoda C. Prevalence of peri-implant diseases. A cross-sec-\ntional study based on a private practice environment. J Clin Peri-\nodontol. 2012;39(5):490–494.\n\t68.\t \u0007Renvert S, Roos-Jansaker AM, Lindahl C, et al. Infection at tita-\nnium implants with or without a clinical diagnosis of inflamma-\ntion. Clin Oral Implants Res. 2007;18:509–516.\n\t69.\t \u0007Monje A, Aranda L, Diaz KT, et al. “Impact of maintenance ther-\napy for the prevention of peri-implant diseases: a systematic review \nand meta-analysis”. J Dent Res. 2016;95(4):372–379.\n\t70.\t \u0007Rodrigues DC, Valderrama P, Wilson TG, et al. Titanium corro-\nsion mechanisms in the oral environment: a retrieval study. Materi-\nals. 2013;6:5258–5274.\n\t71.\t \u0007Wachi T, Shuto T, Shinohara Y, et al. Release of titanium ions from \nan implant surface and their effect on cytokine production related \nto alveolar bone resorption. Toxicology. 2015;327:1–9.\n\t72.\t \u0007Karoussis IK, Salvi GE, Heitz‐Mayfield LJ, Brägger U, Hämmerle \nCH, Lang NP. Long‐term implant prognosis in patients with and \nwithout a history of chronic periodontitis: a 10‐year prospective \ncohort study of the ITI® Dental Implant System. Clin Oral Implants \nRes. 2003;14(3):329–339.\n\t73.\t \u0007Roos‐Jansåker A, Renvert H, Lindahl C, Renvert S. “Nine‐to \nfourteen‐year follow‐up of implant treatment. Part III: fac-\ntors associated with peri‐implant lesions”. J Clin Periodontol. \n2006;33(4):296–301.\n\t74.\t \u0007Papantonopoulos G, Gogos C, Housos E, Bountis T, Loos BG. \nPrediction of individual implant bone levels and the existence of \nimplant “phenotypes”. Clin Oral Implants Res. 2017;28(7):823–\n832.\n\t75.\t \u0007Rinke S, Ohl S, Ziebolz D, Lange K, Eickholz P. Prevalence of peri-\nimplant disease in partially edentulous patients: a practice‐based \ncross‐sectional study. Clin Oral Implants Res. 2011;22(8):826–833.\n\t76.\t \u0007Nguyen‐Hieu T, Borghetti A, Aboudharam G. Peri‐implantitis: \nfrom diagnosis to therapeutics. J Investig Clin Dent. 2012;3(2):79–\n94.\n\t77.\t \u0007Venza I, Visalli M, Cucinotta M, et  al. Proinflammatory gene \nexpression at chronic periodontitis and peri‐implantitis sites \nin patients with or without type 2 diabetes. J Periodontology. \n2010;81(1):99–108.\n\t78.\t \u0007Venza I, Visalli M, Cucinotta M, et  al. Proinflammatory gene \nexpression at chronic periodontitis and peri‐implantitis sites \nin patients with or without type 2 diabetes. J Periodontology. \n2010;81(1):99–108.\n\t79.\t \u0007Canullo L, Tallarico M, Radovanovic S, Delibasic B, Covani U, \nRakic M. Distinguishing predictive profiles for patient‐based \nrisk assessment and diagnostics of plaque induced, surgically and \nprosthetically triggered peri‐implantitis. Clin Oral Implants Res. \n2016;27(10):1243–1250.\n\t80.\t \u0007Lindquist LW, Carlsson GE, Jemt T. Association between marginal \nbone loss around osseointegrated mandibular implants and smok-\ning habits: a 10-year follow-up study. J Dent Res. 1997;76:1667–\n1674.\n\t81.\t \u0007Wen X, Liu R, Li G, et al. History of periodontitis as a risk factor \nfor long-term survival of dental implants: a meta-analysis. Int J Oral \nMaxillofac Implants. 2014;29:1271–1280.\n\t82.\t \u0007Sgolastra F, Petrucci A, Severino M, et al. Periodontitis, implant \nloss and peri-implantitis. A meta-analysis. Clin Oral Implants Res. \n2015;26:e8–e16.\n\t83.\t \u0007Renvert S, Polyzois I, Claffey N. How do implant surface char-\nacteristics influence peri-implant disease? J Clin Periodontol. \n2011;38(suppl 11):214–222.\n\t84.\t \u0007Ting M, Jefferies SR, Xia W, Engqvist H, Suzuki JB. Classification \nand effects of implant surface modification on the bone: human \ncell-based in-vitro studies. J Oral Implantol. 2017;43:58–83.\n\t85.\t \u0007Petersilka GJ, Steinmann D, Haberlein I, et al. Subgingival plaque \nremoval in buccal and lingual sites using a novel low abrasive air-\npolishing powder. J Clin Periodontol. 2003;30:328–333.\n\t86.\t \u0007Martin E. Lasers in dental implantology. Dent Clin North Am. \n2004;48(4):999–1015.\n\t87.\t \u0007Coluzzi DJ, Aoki A, Chininforush N. Laser treatment of periodon-\ntal and peri-implant disease. Chapter 14. In: Coluzzi DJ, Parker"
  },
  {
    "page": 48,
    "content": "1188\nPART VIII    Dental Implant Maintenance\nSPA, eds. Lasers in Dentistry – Current Concepts. Switzerland: \nSpringer: Cham; 2017:293–316.\n\t88.\t \u0007Bach G, Neckel C, Mall C, Krekeler G. Conventional versus laser-\nassisted therapy of peri-implantitis: a five-year comparative study. \nImplant Dent. 2000;9(3):247–251.\n\t89.\t \u0007Schwarz F, Sculean A, Rothamel D, Schwenzer K, Georg T, \nBecker J. Clinical evaluation of an Er:YAG laser for nonsurgical \ntreatment of peri-implantitis: a pilot study. Clin Oral Implants Res. \n2005;16(1):44–52.\n\t90.\t \u0007Schwarz F, Bieling K, Bonsmann M, Latz T, Becker J. Nonsurgi-\ncal treatment of moderate and advanced peri-implantitis lesions: a \ncontrolled clinical study. Clin Oral Investig. 2006;10(4):279–288.\n\t91.\t \u0007Persson GR, Roos-Jansåker AM, Lindahl C, Renvert S. Microbio-\nlogic results after non-surgical erbium-doped:yttrium, aluminum, \nand garnet laser or air-abrasive treatment of peri-implantitis: A ran-\ndomized clinical trial. J Periodontol. 2011;82(9):1267–1278.\n\t92.\t \u0007Roncati M, Lucchese A, Carinci F. Non-surgical treatment of peri-\nimplantitis with the adjunctive use of an 810-nm diode laser. J \nIndian Soc Periodontol. 2013;17(6):812–815.\n\t93.\t \u0007Al-Falaki R, Cronshaw M, Hughes FJ. Treatment outcome follow-\ning use of the erbium, chromium:yttrium, scandium, gallium, gar-\nnet laser in the non-surgical management of peri-implantitis: a case \nseries. Br Dent J. 2014 24;217(8):453–457.\n\t94.\t \u0007Renvert S, Lindahl C, Roos Jansåker AM, Persson GR. Treatment \nof peri-implantitis using an Er:YAG laser or an air-abrasive device: \na randomized clinical trial. J Clin Periodontol. 2011;38(1):65–73.\n\t95.\t \u0007Abduljabbar T, Javed F, Kellesarian SV, Vohra F, Romanos GE. \nEffect of Nd:YAG laser-assisted non- surgical mechanical debride-\nment on clinical and radiographic peri-implant inflammatory \nparameters in patients with peri-implant disease. J Photochem Pho-\ntobiol B. 2017;168:16–19.\n 96. \u0007Do JH, Klokkevold PR. Supportive implant treatment. Chapter \n83 in. In: Newman MG, Takei HH, Klokkevold PR, Carranza FA, \neds. Carranza’s Clinical Periodontology. 12th ed. St. Louis: Elsevier; \n2015:805–812.\n\t97.\t \u0007Deppe H, Horch HH, Neff A. Conventional versus CO2 laser-\nassisted treatment of peri-implant defects with the concomitant use \nof pure-phase beta-tricalcium phosphate: a 5-year clinical report. \nInt J Oral Maxillofac Implants. 2007;22(1):79–86.\n\t98.\t \u0007Romanos GE, Nentwig GH. Regenerative therapy of deep peri-\nimplant infrabony defects after CO2 laser implant surface decon-\ntamination. Int J Periodontics Restorative Dent. 2008;28(3):245–255.\n\t99.\t \u0007Azzeh MM. Er,Cr:YSGG laser-assisted surgical treatment of peri-\nimplantitis with 1-year reentry and 18-month follow-up. J Peri-\nodontol. 2008;79(10):2000–2005.\n\t100.\t \u0007Badran Z, Bories C, Struillou X, Saffarzadeh A, Verner C, Soueidan \nA. Er: YAG laser in the clinical management of severe peri-implan-\ntitis: a case report. J Oral Implantol. 2011;37:212–217.\n\t101.\t \u0007Schwarz F, John G, Mainusch S, Sahm N, Becker J. Combined sur-\ngical therapy of peri-implantitis evaluating two methods of surface \ndebridement and decontamination. A two-year clinical follow up \nreport. J Clin Periodontol. 2012;39(8):789–797.\n\t102.\t \u0007Papadopoulos CA, Vouros I, Menexes G, Konstantinidis A. The uti-\nlization of a diode laser in the surgical treatment of peri-implantitis. \nA randomized clinical trial. Clin Oral Investig. 2015;19(8):1851–\n1860.\n\t103.\t \u0007Valente NA, Andreana S. Treatment of peri-implantitis using a \ncombined decontaminative and regenerative protocol: case report. \nCompend Contin Educ Dent. 2018;39(2):96–101.\n\t104.\t \u0007Takasaki AA, Aoki A, Mizutani K, et al. Application of antimi-\ncrobial photodynamic therapy in periodontal and peri-implant dis-\neases. Periodontol 2000. 2009;51(1):109–140.\n\t105.\t \u0007Haas R, Baron M, Dörtbudak O, Watzek G. Lethal photosensitiza-\ntion, autogenous bone, and e-PTFE membrane for the treatment of \nperi-implantitis: preliminary results. Int J Oral Maxillofac Implants. \n2000;15(3):374–382.\n\t106.\t \u0007Dörtbudak O, Haas R, Bernhart T, Mailath-Pokorny G. \nLethal photosensitization for decontamination of implant \nsurfaces in the treatment of peri-implantitis. Clin Oral Implants Res. \n2001;12(2):104–108.\n\t107.\t \u0007Thierbach R, Eger T. Clinical outcome of a nonsurgical and surgi-\ncal treatment protocol in different types of peri-implantitis: a case \nseries. Quintessence Int. 2013;44(2):137–148.\n\t108.\t \u0007Bombeccari GP, Guzzi G, Gualini F, Gualini S, Santoro F, Spadari \nF. Photodynamic therapy to treat periimplantitis. Implant Dent. \n2013;22(6):631–638.\n\t109.\t \u0007Bassetti M, Schär D, Wicki B, et al. Anti-infective therapy of peri-\nimplantitis with adjunctive local drug delivery or photodynamic \ntherapy: 12-month outcomes of a randomized controlled clinical \ntrial. Clin Oral Implants Res. 2014;25(3):279–287.\n 110. \u0007Anders JJ, Lanzafame RJ, Arany PR. Low-level light/laser ther-\napy versus photobiomodulation therapy. Photomed Laser Surg. \n2015;33(4):183–184.\n\t111.\t \u0007Pinheiro ALB, Marques AMC, Soares LGP, Barbosa AFS. Bone \nbiomodulation. Chapter 25. In: de Freitas PM, Simões A, eds. \nLasers in Dentistry. Guide for Clinical Practice. Ames, Iowa: John \nWiley & Sons; 2015:196–206.\n\t112.\t \u0007Khadra M. The effect of low level laser irradiation on implant-tissue \ninteraction. In: vivo and in vitro studies. Swed Dent J. 2005;(suppl \n172):1–63.\n 113. \u0007García-Morales JM, Tortamano-Neto P, Todescan FF, de Andrade \nJr JC, Marotti J, Zezell DM. Stability of dental implants after irra-\ndiation with an 830-nm low-level laser: a double-blind randomized \nclinical study. Lasers Med Sci. 2012;27(4):703–711.\n\t114.\t \u0007Tang E, Khan I, Andreana S, Arany PR. Laser-activated transform-\ning growth factor-β1 induces human β-defensin 2: implications for \nlaser therapies for periodontitis and peri-implantitis. J Periodontal \nRes. 2017;52(3):360–367.\n\t115.\t \u0007Torkzaban P, Kasraei S, Torabi S, Farhadian M. Low-level \nlaser therapy with 940 nm diode laser on stability of dental \nimplants: a randomized controlled clinical trial. Lasers Med Sci. \n2018;33(2):287–293.\n\t116.\t \u0007Romanos GE, Weitz D. Therapy of peri-implant diseases. Where is \nthe evidence? J Evid Based Dent Pract. 2012;12(suppl 3):204–208.\n\t117.\t \u0007Aoki A, Mizutani K, Schwarz F, et  al. Periodontal and peri-\nimplant wound healing following laser therapy. Periodontol 2000. \n2015;68(1):217–269.\n\t118.\t \u0007Mizutani K, Aoki A, Coluzzi D, et al. Lasers in minimally inva-\nsive periodontal and peri-implant therapy. Periodontol. 2000. \n2016;71(1):185–212.\n\t119.\t \u0007Kilinc E, Rothrock J, Migliorati E, Drukteinis S, Roshkind DM, \nBradley P. Potential surface alteration effects of laser-assisted peri-\nodontal surgery on existing dental restorations. Quintessence Int. \n2012;43(5):387–395.\n\t120.\t \u0007Stübinger S, Homann F, Etter C, Miskiewicz M, Wieland M, \nSader R. Effect of Er:YAG, CO2 and diode laser irradiation on sur-\nface properties of zirconia endosseous dental implants. Lasers Surg \nMed. 2008;40(3):223–228.\n\t121.\t \u0007Geminiani A, Caton JG, Romanos GE. Temperature increase dur-\ning CO2 and Er:YAG irradiation on implant surfaces. Implant \nDent. 2011;20(5):379–382.\n\t122.\t \u0007Geminiani A, Caton JG, Romanos GE. Temperature change dur-\ning non-contact diode laser irradiation of implant surfaces. Lasers \nMed Sci. 2012;27(2):339–342.\n\t123.\t \u0007Nicholson D, Blodgett K, Braga C, et  al. Pulsed Nd:YAG laser \ntreatment for failing dental implants due to peri-implantitis. In: \nRechmann P, Fried D, eds. Lasers in dentistry XX, Proc. Bellingham, \nWA: SPIE; 8929.\n\t124.\t \u0007Kao RT, Nares S, Reynolds MA. Periodontal regeneration – \nIntrabony defects: a systematic review from the AAP regeneration \nworkshop. J Periodontol. 2015;86(suppl):S77–S104.\n\t125.\t \u0007Yukna RA, Carr RL, Evans GH. Histologic evaluation of an \nNd:YAG laser-assisted new attachment procedure in humans. Int \nJ Periodontics Restorative Dent. 2007;27(6):577–587.\n\t126.\t \u0007Nevins ML, Camela M, Schupbach P, Kim S-W, Kim DM, Nev-\nins M. Human clinical and histologic evaluation of laser-assisted"
  },
  {
    "page": 49,
    "content": "1189\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\nnew attachment procedure. Int J Periodontics Restorative Dent. \n2012;32(5):497–507.\n 127. \u0007Suzuki, Jon B. Salvaging Implants with an Nd:YAG Laser: a novel \napproach to a growing problem. compendium. Nov/Dec 2015.\n\t128.\t \u0007Gold SI, Vilardi MA. Pulsed laser beam effects on gingiva. J Clin \nPeriodontol. 1994;21(6):391–396.\n\t129.\t \u0007Ting CC, Fukuda M, Watanabe T, Sanaoka A, Mitani A, Nogu-\nchi T. Morphological alterations of periodontal pocket epithe-\nlium following Nd:YAG laser irradiation. Photomed Laser Surg. \n2014;34(12):649–657.\n\t130.\t \u0007Harris DM, Yessik M. Therapeutic ratio quantifies antisepsis: abla-\ntion of porphyromonas gingival/s with dental lasers. Lasers Surg \nMed. 2004;35(3):206–213.\n\t131.\t \u0007Giannelli M, Bani D, Viti C, et  al. Comparative evaluation of \nthe effects of different photoablative laser irradiation protocols \non the gingiva of periodontopathic patients. Photomed Laser Surg. \n2012;30(4):222–230.\n\t132.\t \u0007Cobb CM, McCawley TK, Killoy WJ. A preliminary study on the \neffects of the Nd:YAG laser on root surfaces and subgingival micro-\nflora in vivo. J Periodontol. 1992;63(8):701–707.\n\t133.\t \u0007McCawley TK, McCawley MN, Rams TE. LANAP immediate \neffects in vivo on human chronic periodontitis microbiota. J Dent \nRes. 2014;93 (spec issue A):Abstract 428.\n\t134.\t \u0007de Andrade AKP, Feist IS, Pannuti CM, Cai S, Zezell DM, De \nMicheli G. Nd:YAG laser clinical assisted in class II furcation treat-\nment. Lasers Med Sci. 2008;23(4):341–347.\n\t135.\t \u0007Giannini R, Vassalli M, Chellini F, Polidori L, Dei R, Giannelli M. \nNeodymium:yttrium aluminum garnet laser irradiation with low \npulse energy: a potential tool for the treatment of peri-implant dis-\nease. Clin Oral Implants Res. 2006;17(6):638–643.\n\t136.\t \u0007Gonçalves F, Zanetti AL, Zanetti RV, et al. Effectiveness of 980-\nnm diode and 1064-nm extra-long-pulse neodymium-doped \nyttrium aluminum garnet lasers in implant disinfection. Photomed \nLaser Surg. 2010;28(2):273–280.\n\t137.\t \u0007Gómez C, Domínguez A, García-Kass AI, García-Nuñez JA. \nAdjunctive Nd:YAG laser application in chronic periodontitis: \nclinical, immunological, and microbiological aspects. Lasers Med \nSci. 2011;26(4):453–463.\n\t138.\t \u0007Qadri T, Poddani P, Javed F, Tunér J, Gustafsson A. A short-term \nevaluation of Nd:YAG laser as an adjunct to scaling and root plan-\ning in the treatment of periodontal inflammation. J Periodontol. \n2010;81(8):1161–1166.\n\t139.\t \u0007Giannelli M, Bani D, Tani A, et al. In: vitro evaluation of the effects \nof low-intensity Nd:YAG laser irradiation on the inflammatory \nreaction elicited by bacterial lipopolysaccharide adherent to tita-\nnium dental implants. J Periodontol. 2009;80(6):977–984.\n 140. \u0007Javed F, Kellesarian SV, Al-Kheraif AA, et al. Effect of Nd:YAG \nlaser-assisted non-surgical periodontal therapy on clinical peri-\nodontal and serum biomarkers in patients with and without cor-\nonary artery disease: a short-term pilot study. Lasers Surg Med. \n2016;48(10):929–935.\n\t141.\t \u0007Arisu HD, Türköz E, Bala O. Effects of Nd:YAG laser irradiation \non osteoblast cell cultures. Lasers Med Sci. 2006;21(3):175–180.\n\t142.\t \u0007Chellini F, Sassoli C, Nosi D, et al. Low pulse energy Nd:YAG \nlaser irradiation exerts a biostimulative effect on different cells of \nthe oral microenvironment: “An in vitro study”. Lasers Surg Med. \n2010;42(6):527–539.\n\t143.\t \u0007Kim IS, Cho TH, Kim K, Weber FE, Hwang SJ. High power-pulsed \nNd:YAG laser as a new stimulus to induce BMP-2 expression in \nMC3T3-E1 osteoblasts. Lasers Surg Med. 2010;42(6):510–518.\n\t144.\t \u0007Kim K, Kim IS, Cho TH, Seo YK, Hwang SJ. High-intensity \nNd:YAG laser accelerates bone regeneration in calvarial defect \nmodels. J Tissue Eng Regen Med. 2015;9(8):943–951.\n\t145.\t \u0007Romanos E, Javed F, Delgado-Ruiz RA, et al. Peri-implant Dis-\neases. A review of treatment interventions. Dent Clin N Am. \n2015;59:157–178.\n\t146.\t \u0007Schwarz F, Sahm N, Becker J. Combined surgical therapy \nof advanced peri-implantitis lesions with concomitant soft \ntissue volume augmentation. A case series. Clin Oral Implants Res. \n2014;25(1):132–136.\n\t147.\t \u0007Heitz-Mayeld LJA, Salvi GE, Mombelli A, et al. Anti-infective sur-\ngical therapy of peri-implantitis. A 12-month prospective clinical \nstudy. Clin Oral Impl Res. 2012;23:205–210.\n\t148.\t \u0007Ting M, Tadepalli NS, Kondaveeti R, Braid SM, Lee CYS, \nSuzuki JB. Intra-Oral applications of platelet concentrates: \na comprehensive overview of systematic reviews. J Interdiscipl \nMed Dent Sci. 2018;6:233. https://doi.org/10.4172/2376-\n032X.1000233.\n\t149.\t \u0007Ting M, Afshar P, Adhami A, Braid SM, Suzuki JB. Maxillary sinus \naugmentation using chairside bone marrow aspirate concentrates \nfor implant site development: a systematic review of histomorpho-\nmetric studies. Int J Implant Dent. 2018.\n\t150.\t \u0007Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification \nof platelet concentrates: from pure platelet-rich plasma (P-PRP) \nto leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. \n2009;27:158–167.\n\t151.\t \u0007Casati MZ, de Vasconcelos Gurgel BC, Goncalves PF, et al. Plate-\nlet-rich plasma does not improve bone regeneration around peri-\nimplant bone defects—a pilot study in dogs. Int J Oral Maxillofac. \nSurg. 2007;36(2):132–136.\n\t152.\t \u0007Sanchez AR, Eckert SE, Sheridan PJ, Weaver AL. Influence of \nplatelet-rich plasma added to xenogeneic bone grafts on bone min-\neral density associated with dental implants. Int J Oral Maxillofac \nImplants. 2005;20(4):526–532.\n\t153.\t \u0007Sanchez AR, Sheridan PJ, Eckert SE, Weaver AL. Regenerative \npotential of platelet-rich plasma added to xenogenic bone grafts in \nperi-implant defects: a histomorphometric analysis in dogs. J Peri-\nodontol. 2005;76(10):1637–1644.\n\t154.\t \u0007Sanchez AR, Sheridan PJ, Eckert SE, Weaver AL. Influence of \nplatelet-rich plasma added to xenogeneic bone grafts in periimplant \ndefects: a vital fluorescence study in dogs. Clin Implant Dent Relat \nRes. 2005;7(2):61–69.\n\t155.\t \u0007de Vasconcelos Gurgel BC, Goncalves PF, Pimentel SP, et  al. \nPlatelet-rich plasma may not provide any additional effect when \nassociated with guided bone regeneration around dental implants \nin dogs. Clin Oral Implants Res. 2007;18(5):649–654.\n\t156.\t \u0007Simonpieri A, Del Corso M, Vervelle A, et al. Current knowledge \nand perspectives for the use of platelet-rich plasma (PRP) and plate-\nlet-rich fibrin (PRF) in oral and maxillofacial surgery part 2: Bone \ngraft, implant and reconstructive surgery. Curr Pharm Biotechnol. \n2012;13(7):1231–1256.\n\t157.\t \u0007Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi \nJ, et al. Plateletrich fibrin (PRF): a second-generation platelet con-\ncentrate. Part I: technological concepts and evolution. Oral Surg \nOral Med Oral Pathol Oral Radiol Endod. 2006;101:e37e44.\n\t158.\t \u0007Pradeep AR, Shetty SK, Garg G, Pai S. Clinical effectiveness of \nautologous platelet-rich plasma and Peptide-enhanced bone graft \nin the treatment of intrabony defects. J. Periodontol. 2009;80(1): \n62–71.\n\t159.\t \u0007Simonpieri A, Del Corso M, Sammartino G, Ehrenfest DMD. The \nrelevance of Choukroun’s platelet-rich fibrin and metronidazole \nduring complex maxillary rehabilitations using bone allograft. Part \nI: a new grafting protocol. Implant Dent. 2009;18(2):102–111.\n\t160.\t \u0007Del Corso M, Sammartino G, Dohan Ehrenfest DM. Re: “Clinical \nevaluation of a modified coronally advanced flap alone or in com-\nbination with a platelet-rich fibrin membrane for the treatment of \nadjacent multiple gingival recessions: a 6-month study”. J Periodon-\ntol. 2009;80(11):1694–1697.\n 161. \u0007Choukroun J, Diss A, Simonpieri A, et al. Plateletrich fibrin (PRF): \na second-generation platelet concentrate. Part IV: clinical effects on \ntissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. \n2006;101(3):e56–60.\n\t162.\t \u0007Dohan Ehrenfest DM, Diss A, Odin G, Doglioli P, Hippolyte \nMP, Charrier JB. In vitro effects of Choukroun’s PRF (platelet-\nrich fibrin) on human gingival fibroblasts, dermal prekeratinocytes, \npreadipocytes, and maxillofacial osteoblasts in primary cultures."
  },
  {
    "page": 50,
    "content": "1190\nPART VIII    Dental Implant Maintenance\nOral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(3): \n341–352.\n 163. \u0007Choukroun J, Simonpieri A, Del Corso M, Mazor Z, Sammar-\ntino G, Dohan Ehrenfest DM. Controlling systematic periop-\nerative anaerobic contamination during sinus-lift procedures \nby using metronidazole: an innovative approach. Implant Dent. \n2008;17(3):257–270.\n\t164.\t \u0007Bielecki TM, Gazdzik TS, Arendt J, Szczepanski T, Krol W, Wiel-\nkoszynski T. Antibacterial effect of autologous platelet gel enriched \nwith growth factors and other active substances: an in vitro study. J \nBone Joint Surg Br. 2007;89(3):417–420.\n\t165.\t \u0007Cieslik-Bielecka A, Bielecki T, Gazdzik TS, Arendt J, Krol W, Szcz-\nepanski T. Autologous platelets and leukocytes can improve heal-\ning of infected high-energy soft tissue injury. Transfus Apher Sci. \n2009;41(1):9–12.\n\t166.\t \u0007Ainamo J, Löe H. Anatomical characteristics of gingiva. A clinical \nand microscopic study of the free and attached gingiva. The J Peri-\nodontol. 1966;37(1):5–13.\n\t167.\t \u0007Wang HL, Greenwell J. Surgical periodontal therapy. J Periodontal. \n2001;25:89–99.\n 168. \u0007Porter JA, Von Fraunhofer JA. Success or failure of dental implants: \na literature review with treatment considerations. Gen Den. \n2004;53:423–432.\n\t169.\t \u0007Padial-Molina M, Suarez F, Rios HF, et  al. Guidelines for the \ndiagnosis and treatment of peri-implant diseases. Int J Periodontics \nRestorative Dent. 2014;34:e102–111.\n\t170.\t \u0007Vargas-Reus MA, Memarzadeh K, Huang J, et al. Antimicrobial \nactivity of nanoparticulate metal oxides against peri-implantitis \npathogens. Int J Antimicrob Agents. 2012;40:135–139.\n\t171.\t \u0007Waal Y, Raghoebar GM, Huddleston-Slater JJ, et  al. Implant \ndecontamination during surgical peri-implantitis treatment: a ran-\ndomized, double-blind, placebo-controlled trial. J Clin Periodontal. \n2013;40:186–195.\n\t172.\t \u0007Kirsch A, Ackermann KL. The IMZ osteointegrated implant sys-\ntem. Dent Clin North Am. 1989;33:733–791.\n\t173.\t \u0007Warrer K, Buser D, Lang NP, et al. Plaque-induced peri- implanti-\ntis in the presence or absence of keratinized mucosa: an experimen-\ntal study in monkeys. Clin Oral Implants Res. 1995;6:131–138.\n 174. \u0007Choukroun J, Diss A, Simonpieri A, et al. Platelet-rich fibrin (PRF): \na second generation platelet concentrate. Part V: histologic evalua-\ntion of PRF effects on bone allograft maturation in sinus lift. Oral \nSurg Oral Med Oral Pathol Oral Radiol Endod. 2006 e;101:229.\n\t175.\t \u0007He L, Lin Y, Hu X, et al. A comparative study of platelet-rich fibrin \n(PRF) and platelet-rich plasma (PRP) on the effect of proliferation \nand differentiation of rat osteoblasts in vitro. Oral Surg Oral Med \nOral Pathol Oral Radiol Endod. 2009;108:707–713.\n\t176.\t \u0007Meffert RM, Langer B, Fritz ME. Dental implants: a review. J Peri-\nodontol. 1992;63:859–870.\n\t177.\t \u0007Esposito M, Coulthard P, Thomsen P, Worthington HV. The role of \nimplant surface modifications, shape and material on the success of \nosseointegrated dental implants. A Cochrane systematic review. 2005.\n\t178.\t \u0007Pauletto N, Lahiffe BJ, Walton JN. Complications associated with \nexcess cement around crowns on osseointegrated implants: a clini-\ncal report. Int J Oral Maxillofac Implants. 1999;14:865–868.\n 179. \u0007Agar JR, Cameron SM, Hughbanks JC, Parker MH. Cement \nremoval from restorations luted to titanium abutments with simu-\nlated subgingival margins. J Prosthet Dent. 1997;78:43–47.\n\t180.\t \u0007Wadhwani CPK, Schwedhelm ER. The role of cements in dental \nimplant success, part 1. Dentistry Today. 2013:1–11.\n\t181.\t \u0007Gapski R, Neugeboren N, Pemeraz AZ, Reissner MW. Endosseous \nimplant failure influenced by crown cementation: a clinical case \nreport. Int J Oral Maxillofac Implants. 2008;23:943–946.\n\t182.\t \u0007Pauletto N, Lahiffe BJ, Walton JN. Complications associated with \nexcess cement around crowns on osseointegrated implants: a clini-\ncal report. Int J Oral Maxillofac Implants. 1999;14:865–868.\n\t183.\t \u0007Gapski R, Neugeboren N, Pomeranz AZ, Reissner MW. Endosse-\nous implant failure influenced by crown cementation: a clinical case \nreport. Int J Oral Maxillofac Implants. 2008;23:943–946.\n\t184.\t \u0007Pontoriero R, Tonelli MP, Carnevale G, Mombelli A, Nyman SR, \nLang NP. Experimentally induced peri-implant mucositis. A clini-\ncal study in humans. Clin Oral Implants Res. 1994;5:254–259.\n\t185.\t \u0007Berglundh T, Lindhe J, Marinello C, Ericsson I, Liljenberg B. \nSoft tissue reaction to de novo plaque formation on implants and \nteeth. An experimental study in the dog. Clin Oral Implants Res. \n1992;3:1–84.\n\t186.\t \u0007Lang NP, Berglundh T, Heitz-Mayfield LJ, Pjetursson BE, Salvi \nGE, Sanz M. Consensus statements and recommended clinical pro-\ncedures regarding implant survival and complications. Int J Oral \nMaxillofac Implants. 2004;19(suppl):150–154.\n\t187.\t \u0007Korsch M, Walther W, Marten SM, Obst U. Microbial analysis of \nbiofilms on cement surfaces: an investigation in cement-associated \nperi-implantitis. J Appl Biomater Funct Mater. 2014;12(2):70–80.\n\t188.\t \u0007M1 Korsch, Robra BP, Walther W. Predictors of excess cement and \ntissue response to fixed implant-supported dentures after cementa-\ntion. Clin Implant Dent Relat Res. 2013.\n\t189.\t \u0007Augthun M, Conrads G. Microbial findings of deep periimplant \nbone defects. Int J Oral Maxillofac Implants. 1997;12:106–112.\n 190. \u0007Salcetti JM, Moriarty JD, Cooper LF, et al. The clinical, microbial, \nand host response characteristics of the failing implant. Int J Oral \nMaxillofac Implants. 1997;12:32–42.\n\t191.\t \u0007Leonhardt A°, Berglundh T, Ericsson I, Dahle´n G. Putative peri-\nodontal pathogens on titanium implants and teeth in experimental \ngingivitis and periodontitis in beagle dogs. Clin Oral Implants Res. \n1992;3:112–119.\n 192. \u0007Roos-Jansa°ker AM, Lindahl C, Renvert H, Renvert S. Nine- to \nfourteen-year follow-up of implant treatment. Part II: Presence of \nperi-implant lesions. J Clin Peri- odontol. 2006;33:290–295.\n\t193.\t \u0007Marrone A, Lasserre J, Bercy P, Brecx MC. Prevalence and risk fac-\ntors for peri-implant disease in Belgian adults. Clin Oral Implants \nRes. 2012.\n\t194.\t \u0007Koldsland OC, Scheie A, Aass AM. Prevalence of peri-implantitis \nrelated to severity of the disease with different degrees of bone loss. \nJ Periodontol. 2010;81:231–238.\n\t195.\t \u0007Thomas GW. The positive relationship between excess cement and \nperi-implant disease: a prospective clinical endoscopic study. J Peri-\nodontol. 2009;80:1388–1392.\n 196. \u0007Wilson TG, Jr. “The positive relationship between excess cement \nand peri-implant disease: a prospective clinical endoscopic study”. J \nPeriodontol. 2009;80(9):1388–1392.\n\t197.\t \u0007Present S, Levine RA. Techniques to control or avoid cement \naround implant-retained restorations. Compendium. 2013;34(6): \n432–437.\n\t198.\t \u0007Pauletto N, Lahiffe BJ, Walton JN. Complications associated with \nexcess cement around crowns on osseointegrated implants: a clini-\ncal report. Int J Oral Maxillofac Implants. 1999;14:865–868.\n\t199.\t \u0007Daubert DM, Weinstein BF, Bordin S, Leroux BG, Flem-\nming TF. Prevalence and predictive factors for peri‐implant dis-\nease and implant failure: a cross‐sectional analysis. J Periodontol. \n2015;86(3):337–347.\n\t200.\t \u0007Pauletto N, Lahiffe BJ, Walton JN. Complications associated with \nexcess cement around crowns on osseointegrated implants: a clini-\ncal report. Int J Oral Maxillofac Implants. 1999;14:865–868.\n\t201.\t \u0007Gapski R, Neugeboren N, Pomeranz AZ, Reissner MW. Endosse-\nous implant failure influenced by crown cementation: a clinical case \nreport. Int J Oral Maxillofac Implants. 2008;23:943–946.\n\t202.\t \u0007O’Rourke B, Walls AW, Wassell RW. Radiographic detection \nof overhangs formed by resin composite luting agents. J Dent. \n1995;23:353–357.\n\t203.\t \u0007Soares CJ, Santana FR, Fonseca RB, Martins LR, Neto FH. In vitro \nanalysis of the radiodensity of indirect composites and ceramic \ninlay systems and its influence on the detection of cement over-\nhangs. Clin Oral Investig. 2007;11:331–336.\n\t204.\t \u0007Rosenstiel SF, Land MF, Crispin BJ. Dental luting agents: a review \nof the current literature. J Prosthet Dent. 1998;80:280–301.\n\t205.\t \u0007Wadhwani CPK, Schwedhelm ER. The role of cements in dental \nimplant success, part 1. Dentistry Today. 2013;1–11."
  },
  {
    "page": 51,
    "content": "1191\nCHAPTER 41  Peri-Mucositis and Peri-Implantitis Diagnosis, Classification, Etiologies, and Therapies\n\t206.\t \u0007Wadhwani C, Hess T, Faber T, Piñeyro A, Chen CSK. A descriptive \nstudy of the radiographic density of implant restorative cements. J \nProsthet Dent. 2010;103:295–302\n\t207.\t \u0007Wadhwani C, Rapoport D, La Rosa S, et al. Radiographic detec-\ntion and characteristic patterns of residual excess cement associated \nwith cement retained implant restorations: a clinical report. J Pros-\nthet Dent. 2012;107:151–157.\n 208. \u0007Agar JR, Cameron SM, Hughbanks JC, Parker MH. Cement \nremoval from restorations luted to titanium abutments with simu-\nlated subgingival margins. J Prosthet Dent. 1997;78:43–47.\n\t209.\t \u0007Linkevicius T, Vindasiute E, Puisys A, Peciuliene V. The influence \nof margin location on the amount of undetected cement excess \nafter delivery of cement-retained implant restorations. Clin Oral \nImplants Res. 2011;22(12):1379–1384.\n\t210.\t \u0007Wadhwani C, Piñeyro A, Hess T, et al. Effect of implant abutment \nmodification on the extrusion of excess cement at the crown-abut-\nment margin for cement-retained implant restorations. Int J Oral \nMaxillofac Implants. 2011;26(6):1241–1246.\n\t211.\t \u0007Wadhwani C, Piñeyro A. Technique for controlling the cement for \nan implant crown. J Prosthet Dent. 2009;102:57–58.\n\t212.\t \u0007Wilson TG. The Positive relationship between excess cement and \nperi-implant disease: a prospective clinical endoscopic study. J Peri-\nodontol. 2009;80:1388–1392.\n 213. \u0007Suzuki JB. Diagnosis and classification of the periodontal diseases. \nDent Clin North Am. 1988;32(2):195–216.\n\t214.\t \u0007Schnitman PA, Shulman LB. Recommendations of the consen-\nsus development conference on dental implants. J Am Dent Assoc. \n1979;98:373–377.\n\t215.\t \u0007Cranin AN, Silverbrand H, Sher J, et al. The requirements and \nclinical performance of dental implants. In: Smith DC, Williams \nDF, eds. Biocompatibility of Dental Materials. Boca Raton, FL: \nCRC Press; 1982:42–45 (4).\n\t216.\t \u0007McKinney RV, Koth DC, Steflik DE. Clinical standards for dental \nimplants. In: Clark JW, ed. Clinical Dentistry. Harperstown, PA: \nHarper and Row; 1984:78–81.\n\t217.\t \u0007Albrektsson T, Zarb GA, Worthington P, et al. The long-term effi-\ncacy of currently used dental implants: a review and proposed crite-\nria of success. Int J Oral Maxillofac Implants. 1986;1:1–25.\n\t218.\t \u0007Albrektsson T, Zarb GA. Determinants of correct clinical report-\ning. Int J Prosthodont. 1998;11:517–521.\n\t219.\t \u0007Misch CE. Implant quality scale: a clinical assessment of the health-\ndisease continuum. Oral Health. 1998;88:15–25.\n 220. \u0007Suzuki JB, Misch CE. Peri Implantitis. Chapter 18. In: Resnik R, \nMisch CE, eds. Avoiding Implant Comoplications. USA: Elsevier – \nMosby St. Louis; 2017.\n\t221.\t \u0007Council on Dental Care Programs. Reporting periodontal treat-\nment under dental benefit plans. J Am Dent Assoc. 1988;17:371–\n373.\n\t222.\t \u0007Council on Dental Care Programs. Reporting periodontal treatment \nunder dental benefit plans. J Am Dent Assoc. 1988;17:371–373.\n\t223.\t \u0007Canullo L, Tallarico M, Radovanovic S, Delibasic B, Covani U, \nRakic M. Distinguishing predictive profiles for patient‐based risk \nassessment and diagnostics of plaque induced, surgically and pros-\nthetically triggered peri‐implantitis. Clinical oral implants research. \n2016;27(10):1243–1250.\n\t224.\t \u0007Marco T, Canullo L, Wang HL, Cochran DL, Meloni SM. “Clas-\nsification systems for peri-implantitis: a narrative review with a pro-\nposal of a new evidence-based etiology codification”. Int J Mol Sci. \n2018;33(4)."
  },
  {
    "page": 52,
    "content": "1192\n42\nImplant Maintenance: \nLong-Term Implant Success\nJON B. SUZUKI AND DIANA BRONSTEIN\nT\nhe maintenance of endosseous implants has evolved over \nmany decades, from trial and error of various anecdotal \nsupportive therapy methods to evidence-based protocols. \nThese newer maintenance protocols allow for the implant clini-\ncian to implement individualized patient care of the peri-implant \ntissues.1,2 With patients understanding the benefits of dental \nimplants, the dental profession is moving away from traditional \nprosthetics and integrating the latest dental implant technologic \nadvances into treatment plans. Therefore in the future, a greater \nneed will be required by the implant clinician to integrate a com-\nprehensive systemic and supportive protocol to maintain the suc-\ncess and longevity of the implant prosthesis.3\nPrevention of peri-implant disease is now an accepted funda-\nmental cornerstone of effective and predictable treatment strate-\ngies. The preventive approach commences with ideal and realistic \ncase selection, preoperative patient education, and control of risk \nfactors associated with increased implant complication incidence.4 \nThe lifelong professional implant maintenance protocol must be \ncommunicated to and acknowledged by the patient as part of his \nor her presurgical educational process. Patients at a higher risk \nfor the development of peri-implantitis need to be identified and \nmonitored with a stricter maintenance protocol. In addition, \nbecause of the inherent differences between implants and teeth, \npatient education is crucial on the specifics of hygiene with respect \nto the dental implants and the type of prosthesis.5\nAnatomy of Peri-implant Hard and Soft \nTissues\nThe implant clinician must have a strong foundation for the rela-\ntionship between the peri-implant tissues and the signs of disease \nso that early detection and definitive treatment may be rendered. \nIf a disease process goes undiagnosed, hard and soft tissues com-\nplications may lead to an increased morbidity of the implants or \nassociated prosthesis. When evaluating the hard and soft tissues \nsurrounding a dental implant, many differences exist between the \nnatural teeth and dental implants. The support system of natural \nteeth is much better designed to reduce biomechanical forces to \nthe crestal bone region, thereby reducing the possibility of peri-\nimplant disease. Because of the periodontal membrane, nerve and \nblood vessel complex, and occlusal material (enamel), occlusal \noverload is far less in comparison with dental implants.6\nSoft Tissue Differences\nFor a natural tooth the surrounding soft tissue has an average bio-\nlogical width of 2.04 mm between the depth of the sulcus and the \ncrest of the alveolar bone.7 It should be noted that the biological \n“width” is actually a height dimension with a greater range in the \nposterior region compared with the anterior and may be greater \nthan 4 mm in height.8 With natural teeth the biologic width is \ncomposed of a connective tissue attachment (1.07 mm average) \nabove the bone and a junctional epithelial attachment (0.97 mm \naverage) at the sulcus base, with the most consistent value among \nindividuals being the connective tissue attachment.\nThe connective tissue attachment zone of the “biological \nwidth” around a tooth will prevent penetration into the sulcus \nand allows gingival fibers of the connective tissue attachment zone \nto establish direct connection with the cementum of the natural \ntooth. It acts as a physical barrier to the bacteria in the sulcus to \nthe underlining periodontal tissues. Eleven different gingival fiber \ngroups comprise the connective tissue attachment zone observed \naround a natural tooth and tissue: dentogingival (coronal, hori-\nzontal, and apical), alveologingival, intercapillary, transgingival, \ncircular, semicircular, dentoperiosteal, transseptal, periosteogingi-\nval, intercircular, and intergingival.9 At least six of these gingival \nfiber groups insert into the cementum of the natural tooth: the \ndentogingival (coronal, horizontal, and apical), dentoperiosteal, \ntransseptal, circular, semicircular, and transgingival fibers. In addi-\ntion, some crestal fibers from the periodontal fiber bundles also \ninsert into the cementum above the alveolar bone, forming a true \nattachment to the tooth. Clinically this attachment will prevent a \nperiodontal probe from invading the periodontal ligament (PDL) \nspace and minimize the ingress of bacteria (Fig. 42.1).\nIn comparison, the sulcular regions around an implant are \nvery similar in many respects. The rete peg formation within the \nattached gingiva and the histologic lining of the gingiva within the \nsulcus are similar in implants and teeth.10 A free gingival margin \nforms around a tooth or implant, with nonkeratinized sulcular \nepithelium and the epithelial cells. At the base, junctional epi-\nthelial cells are present for both. However, a fundamental differ-\nence characterizes the base of the gingival complex around teeth. \nWhereas a tooth has two primary regions that make up the bio-\nlogical width, an implant has only one (Fig. 42.2).\nThe biological seal for an implant, which is analogous to \nthe epithelial attachment of the tooth, is needed to protect"
  },
  {
    "page": 53,
    "content": "1193\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\nthe implant-bone interface against bacterial irritants, as well \nas mechanical trauma such as restorative materials, prosthesis \ndesign, and occlusal forces. Cochran et al.11 has reported the \nbiologic width to be 3.3 mm for dental implants, but unlike \nthe biological width dimension for teeth, they also included \nthe sulcus depth. In a typical implant gingival region, only \ntwo of the gingival fiber groups are found around a tooth (cir-\ncular and periosteogingival fibers), and no periodontal fibers \nare present.12 These fibers do not insert into the implant body \nbelow the abutment margin as they do into the cementum of \nnatural teeth.13 Instead, the collagen fibers around an implant \nrun parallel to the implant surface, not perpendicular, as with \nnatural teeth.14 Hence the implant has only a junctional epi-\nthelial “attachment” system. The gingival and periosteal fiber \ngroups are responsible for the connective tissue attachment \ncomponent of the biological width around teeth, and these \nare not present around the transosteal region of an implant. \nThe “biological width” around the abutment-implant connec-\ntion should not be similarly compared with the connective tis-\nsue attachment of a tooth. The biological seal around dental \nimplants may to some degree prevent the migration of bacteria \nand endotoxins into the underlying bone. However, an attach-\nment component of the biological width similar to the one \nfound with natural teeth is not present with dental implants \n(Fig. 42.3). \nTooth Versus Implant Movement\nA natural tooth exhibits normal physiologic movements in verti-\ncal, horizontal, and rotational directions. The amount of move-\nment of a natural tooth is related to its surface area and root \ndesign. Therefore the number and length of the roots; their diam-\neter, shape, and position; and the health of the PDL primarily \ninfluence a tooth’s mobility. A healthy tooth normally exhibits \nzero clinical mobility in a vertical direction. Studies have shown \nthe actual initial vertical tooth movement to be approximately 28 \nμm and is the same for anterior and posterior teeth.15 The vertical \nmovement of a rigid implant (i.e., integrated) has been measured \nas 2 to 3 μm under a 10-lb force and is due mostly to the visco-\nelastic properties of the underlying bone (i.e., bone density at the \nbone-implant interface).16\nMuhlemann17 found that horizontal tooth movement may be \ndivided into initial mobility and secondary movement. The initial \nmobility is observed with a light force, occurs immediately, and \nis a consequence of the PDL. Initial horizontal tooth mobility is \ngreater than initial vertical movement. A very light force (500 g) \nhorizontally moves the tooth. The initial horizontal mobility of a \nhealthy, “nonmobile” posterior tooth is less than that of an ante-\nrior tooth and ranges from 56 to 75μm, which is two to nine times \nthe vertical movement of the tooth.\n1mm\nSulcus\n1mm\nEpithelial\nattachment\n1mm\nConnective\ntissue\n• Fig. 42.1  The biologic width for a natural tooth is approximately 1 mm of connective tissue above the \nbone and 1 mm of epithelial attachment between the sulcus and the connective tissue. (From Misch CE. \nAn implant is not a tooth: a comparison of periodontal indices. Dental Implant Prosthetics. 2nd ed. St. \nLouis, MO: Mosby; 2015.)\nF\nCT\nC\n• Fig. 42.2  The soft tissue around an implant (I) has a sulcular region very \nsimilar to a tooth. A free gingival margin (F) with nonkeratinized sulcular \nepithelium and cells at the base (C) has junctional epithelial attachment \nabove the bone (B). CT, Connective tissue."
  },
  {
    "page": 54,
    "content": "1194\nPART VIII    Dental Implant Maintenance\nInitial horizontal mobility is even greater in anterior teeth and \nranges from 70 to 108 μm in health18 (Fig. 42.4).\nThe secondary tooth movement described by Muhlemann17 \noccurs after the initial movement, when greater forces are applied. \nWhen an additional force is applied to the tooth, a secondary \nmovement is also observed, which is related directly to the amount \nof force. The secondary tooth movement is related to the viscoelas-\nticity of the bone and measures as much as 40 μm under consider-\nably greater force (Fig. 42.5).\nWhen evaluating implant movement, “rigid fixation” indicates \nthe absence of clinical mobility of an implant tested with vertical \nor horizontal forces less than 500 g. Rigid fixation is a clinical \nterm, and osseointegration is a histologic term. Osseointegration \nis defined as bone in direct contact with an implant surface at the \nmagnification of a light microscope (Fig. 42.6). Over the years \nthese two terms have been used interchangeably, and implant \nabutment support is most predictable with rigid fixation. Lack \nof implant mobility (IM) does not always coincide with a direct \nbone-implant interface. However, when observed clinically, rigid \nfixation usually means that at least a portion of the implant is in \ndirect contact with bone, although the percentage of bone contact \ncannot be specified. A mobile implant indicates the presence of \nconnective tissue between the implant and bone.\nIncreased tooth mobility may be caused by occlusal trauma or \nbone loss. Increased tooth mobility alone is not a criterion of peri-\nodontal health or pathology. Unlike a tooth, for which mobility \nis not a primary factor for longevity, mobility is a primary deter-\nmining factor for implant health. Rigid fixation is also an excel-\nlent indicator of the implant health status because it is an easy, \n1 mm\n0.5 mm\nBone\ncrest\nFGM\nImplant\nplatform\nCT\nJE\nSulcus\n• Fig. 42.3  An implant has no connective tissue fibers in the connective \ntissue zone that insert into the implant. The peri-implant probe penetrates \nthe sulcus, junctional epithelial attachment (JE), and most of the connec-\ntive tissue zone. CT, Connective tissue; FGM, free gingival margin. (From \nMisch CE. An implant is not a tooth: a comparison of periodontal indices. \nDental Implant Prosthetics. 2nd ed. St. Louis, MO: Mosby; 2015.)\n0.108 mm\n0.028 mm\nPhysiologic\nmovement\n• Fig. 42.4  The physiologic movement of a tooth has been measured as \n28 μm in the apical direction and up to 108 μm in the horizontal direction. \n(From Misch CE. An implant is not a tooth: a comparison of periodontal \nindices. Dental Implant Prosthetics. 2nd ed. St. Louis, MO: Mosby; 2015.)\n15\nmm\n100\n10\n5\n0\n100 g\n500 g\nA\nB\n• Fig. 42.5  A secondary horizontal movement of a tooth occurs after the \ninitial tooth movement when a greater force is applied and is related to \nthe deformation of the alveolar bone. (From Misch CE. An implant is not \na tooth: a comparison of periodontal indices. Dental Implant Prosthetics. \n2nd ed. St. Louis, MO: Mosby; 2015.)\n• Fig. 42.6  Osseointegration is a histologic term that describes a direct \nbone-implant contact at the level of magnification of a light microscope."
  },
  {
    "page": 55,
    "content": "1195\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\nobjective test. As such, rigid fixation is usually the first clinical cri-\nterion and the most important when evaluating a dental implant.\nPast techniques to evaluate primary stability and mobility of \ndental implants have included percussion and mobility tests with \nmirror handles. However, these techniques were very subjective \nand were associated with inaccurate results. In implant dentistry \ntoday, the most common technique to assess the stability of dental \nimplants is the use of resonance frequency analysis (RFA).   Reso-\nnance frequency analysis (RFA) is a non-invasive, reliable, and \nclinically acceptable technique developed by Meredith in 1996.19 \nThis technique includes magnetic pulses being sent to a small \nmetal post that is temporarily attached to the implant.  As the \npost vibrates, the probe reads the resonance frequency which is \ntranslated into a value termed implant stability quotient (ISQ). \nThe ISQ value is evaluated via a scale that ranges from 1 to 100, \nwith high values indicating increased stability.  Usually, acceptable \nranges of stability lie between 55 – 85 ISQ, with values below \n55 indicating possible mobility of the implant.20 This technol-\nogy is advantageous as measurements may be taken at the time \nof implant placement and used as a baseline for future measure-\nments in the evaluation of the health of the dental implant. The \nPenguin RFA® (Glidewell Direct; Irvine, Calif.) is commercially \navailable which uses re-usable multi-pegs that are implant specific. \nIn addition, this device is cordless which is very user friendly for \nthe clinician. When evaluating mobility of the implant, ideally the \nprosthesis should be removed, which allows for the multi-pegs to \nbe directly inserted into the implant body.\nEvaluating the mobility of the prosthesis does not allow for \nan accurate assessment of dental implant health as the associ-\nated mobility is most commonly from a loose abutment screw \n(Box 42.1 and Fig. 42.7).\nA natural tooth with primary occlusal trauma exhibits an \nincrease in clinical mobility and radiographic PDL space. After the \ncause of trauma is eliminated, the tooth may return to zero clinical \nmobility and a normal radiographic appearance. This scenario is \nnot predictable around an implant. The implant clinician should \nnot restore an implant with any clinical mobility, because the \nrisk for failure is great. However, after the prosthesis is completed \nand IM-1 develops, the risk is small to evaluate the implant for a \nfew months and decrease almost all stress during this time frame. \nImplants with slight detectable mobility of approximately 0.1 mm \nof horizontal movement (IM-1), similar to the mobility of a healthy \ncentral incisor, on occasion may return to rigid fixation and zero \nmobility. However, to reachieve rigid fixation, the implant should \nbe taken completely out of occlusion for several months and strictly \nmonitored. The return of rigid fixation of an implant is far greater \nif no mobility is noted before the implant is placed into function.\nAn implant with horizontal movement greater than 0.5 mm \n(IM-3) is at much greater risk than a tooth. A root form implant \nwith greater than 0.5 mm horizontal mobility (IM-3) or any vertical \nmobility (IM-4) should be removed to avoid continued bone loss and \nfuture compromise of the implant site or adjacent teeth (Table 42.1). \nMaintenance Protocol\nMedical and Dental Histories\nThe first step in the maintenance protocol is to update the patient’s \nmedical and dental histories. This is a mandatory component of \nthe maintenance protocol and is crucial in determining whether \nthere presently exist any concomitant conditions that would pre-\ndispose the patient to peri-implant disease.\nMedical History\nMedical conditions may change during the maintenance phase \n(i.e., after implant prosthesis completion) of treatment that have \na direct impact on the morbidity and success of the implants or \nprosthesis. It is imperative the patient relates any updates to his or \nher medical history because many systemic conditions may affect \nthe long-term prognosis of dental implants and the prosthesis.\n\t 1.\t \u0007Xerostomia: The lack of saliva (i.e., dry mouth) is caused by \nhypofunction of the salivary glands and may be caused by \nnumerous medications and systemic conditions. Most com-\nmonly, autoimmune conditions may result in xerostomia, as \nwell as many medications, especially if given concurrently. \nA\nB\n• Fig. 42.7  (A, B) Penguin Resonance Frequency Analysis Unit (Aseptico) \nwhich measures the  ISQ (Implant Stability Quotient) implant stability using \nreusable, calibrated MulTipegs.\nScale\nDescription\n0\nAbsence of clinical mobility with 500 g in any direction\n1\nSlight detectable horizontal movement\n2\nModerate visible horizontal mobility up to 0.5 mm\n3\nSevere horizontal movement greater than 0.5 mm\n4\nModerate-to-severe horizontal and any visible vertical  \nmovement\n\t • BOX 42.1\t    \u0007Mobility Measurements97"
  },
  {
    "page": 56,
    "content": "1196\nPART VIII    Dental Implant Maintenance\nXerostomia has been shown to affect the dental biofilm com-\nposition and intraoral healing of the soft tissues. Immune cells \n(e.g., neutrophils) and immune factors (e.g., lysozyme, secre-\ntory IgA) are normally delivered and distributed in the oral \ncavity through the saliva; therefore a lack of saliva may lead to \nlowered antimicrobial components in the oral cavity.21-24\nProsthetically, patients who acquire xerostomia after completion of \ntreatment may become compromised. For example, a patient with \na soft tissue–borne implant prosthesis (i.e., RP-5 overdenture) may \nexperience soft tissue irritation because of the lack of saliva.\n\t 2.\t \u0007Autoimmune diseases: Selected autoimmune diseases have \nbeen associated with peri-implantitis. For example, lichen \nplanus causes the hemidesmosomal epithelial attachment to \nthe implant surface to become disabled, leading to peri-\nimplant mucositis and possibly progressing to peri-implantitis.25 \nHowever, long-term implant survival, according to current \nresearch, does not seem to be affected.26 With many auto-\nimmune diseases, patients may lose their manual dexterity, \nthereby decreasing hygiene ability and also difficulty in remov-\ning an attachment-dependent overdenture prosthesis. Some of \nthe more common autoimmune disorders and the associated \nsymptoms that may affect the oral cavity are as follows:\n \n• \u0007Sjogren’s syndrome: xerostomia\n \n• \u0007Systemic lupus erythematosus: corticosteroid treatment and \nimmunosuppressive medications\n \n• \u0007Scleroderma: manual dexterity and immunosuppressive \nmedications\n \n• \u0007Rheumatoid arthritis: manual dexterity and immunosup-\npressive medications\n \n• \u0007HIV: compromised lymphocytes and immunosuppressive \nmedications\n\t 3.\t \u0007Bone diseases: Altered bone physiology in conditions such \nas osteoporosis/osteomalacia/osteopenia, Paget’s disease, and \nfibrous dysplasia may significantly increase the risk for com-\nplications for implant patients.27\n\t 4.\t \u0007Diabetes: Poor diabetic control (i.e., > 7% A1c) correlates \nthe inflammatory markers closer to patients with chronic \nperiodontitis when peri-implantitis is present. Patients with \ndiabetes, especially if uncontrolled, are prone to acquire \ninfections and vascular complications. The healing process is \naffected by the impairment of vascular function, chemotaxis, \nand neutrophil function, as well as an anaerobic milieu. Pro-\ntein metabolism is decreased, and healing of soft and hard \ntissue is delayed, which may lead to the susceptibility of \ninfection. Neuropathy and impaired nerve regeneration may \nbe altered, as well as angiogenesis.28\n\t 5.\t \u0007Pregnancy: During the maintenance period, radiographs \nshould be delayed until after birth with pregnant patients. \nMedical clearance should be obtained if radiographs or pro-\ncedures need to be performed on an emergency basis.\n  \u0007Comprehensive Differences Between Natural Teeth and Dental Implants\nNatural Teeth\nDental Implants\nInterface\nPeriodontal membrane\nDirect bone\nJunctional epithelium\nHemidesmosomes and basal lamina (lamina lucida and \nlamina densa zones)\nHemidesmosomes and basal lamina (lamina lucida and lamina \ndensa, and sublamina lucida zones)\nConnective tissue\n12 groups: six insert perpendicular to tooth surfaces\n↓ Collagen, ↑ fibroblasts\nOnly two groups: parallel and circular fibers; no attachment to \nthe implant surface\n↑ Collagen, ↓ fibroblasts\nVascularity\nGreater; supraperiosteal and PDL\nLess; mainly periosteal\nBiologic width\n2.04–2.91 mm\n3.08 mm\nMobility\n+\n−\nPain\n+/− (tooth may be hyperemic)\n−\nAttrition\n+ Wear facets, abfraction, fremitus\n− (∼ porcelain fracture, possible screw loosening)\nRadiographic changes\n+ Increased radiopacity and thickness of cribriform plate\nCrestal bone loss\nInterference awareness\n+ (Proprioception)\n− (Osseoperception)\nNonvertical forces\nRelatively tolerated\nResults in bone loss\nForce-related movement\nPrimary: movement of PDL\nSecondary: osseous movement\nPrimary: osseous movement\nLateral force\nApical third of root surface\nCrestal bone\nLateral movement\n56–108 μm\n10–50 μm\nApical movement\n25–100 μm\n3–5 μm\nTactile sensitivity\nHigh\nLow\nSigns of overloading\nPDL thickening, fremitus, mobility, wear facets, pain\nScrew loosening, screw fracture, abutment fracture, implant \nbody fracture, bone loss\nPDL, Periodontal ligament.\n   \nTABLE \n42.1"
  },
  {
    "page": 57,
    "content": "1197\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\n\t 6.\t \u0007Radiation treatment to the oral cavity: Patients who receive \nradiation to the oral cavity after implant treatment may suf-\nfer from many deficits including oral mucositis, xerostomia, \ncompromised healing, and reduced angiogenesis. This is \na direct result of changes in the vascularity and cellularity \nof hard and soft tissue, damage to the salivary glands, and \nincreased collagen synthesis that results in fibrosis. Therefore \npatients exhibiting these complications should be treated \nsymptomatically. Patients who presently wear a tissue-borne \nprosthesis (RP-5) may benefit from changing the final pros-\nthesis to a fixed (non-tissue-bearing) prosthesis.\n\t 7.\t \u0007Sleep apnea: Patients who are diagnosed with sleep apnea are \noften treated with continuous positive airway pressure(CPAP). \nThe CPAP machine uses a hose and mask that delivers constant \nsteady air pressure. CPAP machines may place an increased \nforce on the oral cavity. Therefore if patients are using a CPAP \nmachine, the implant area should be monitored closely.\n\t 8.\t \u0007Elderly patients: Elderly patients have been shown to have \nmany issues with adapting to the final implant prostheses. \nPostinsertion complications such as muscle control, hygiene \ndifficulty, tissue inflammation, and overdenture seating are \nsignificant in the older population study. During maintenance \nvisits, patient education should be continuously reenforced.\n\t 9.\t \u0007Smoking: The use of tobacco should be closely monitored \nwith implant patients. Studies have shown the detrimental \neffects of the gases and chemicals (e.g., nitrogen, carbon mon-\noxide, carbon dioxide, ammonia, hydrogen cyanide, benzene, \nnicotine) released in cigarette smoke. Multiple retrospective \nstudies have shown that smokers experience almost twice as \nmany implant failures compared with nonsmokers, and there \nexists a strong correlation with peri-implantitis.29 The nega-\ntive effects of smoking on the implants/prosthesis should be \nreenforced at each maintenance visit.\n\t10.\t \u0007Phenytoin (Dilantin): The most common medication to \ncause peri-implant conditions is phenytoin (Dilantin). Dilan-\ntin is associated with a high incidence of gingival overgrowth \n(hyperplasia) of peri-implant soft tissue, implant gingival \nhyperplasia, mucosal proliferation, proliferative gingivitis, and \nimplant-related tissue hyperplasia, and has been recognized as a \nsignificant clinical issue in implant dentistry today. If there is \nno associated bone loss, the pockets are termed pseudopockets \nor gingival pockets. These hyperplasia-induced pockets may \nharbor pathogenic anaerobic bacteria. The plaque biofilm \ncolonization and maturation in implant pockets initiates \ninflammation. The resultant hyperplastic tissue is most com-\nmonly composed of compact collagenous fibers, fibroblasts, \nand inflammatory cells. Management of peri-implant gingival \novergrowth should include the identification of the etiology \n(e.g., medication or humoral). If the etiology is determined \nto be medication induced, consultation with the patient’s \nphysician is recommended for possible alternative treatment.\n\t11.\t \u0007Miscellaneous: Epidemiologic and longitudinal studies have \nfound an association of peri-implantitis prevalence with hepa-\ntitis and cardiovascular disease.30 Cardiovascular disease is \nassociated with periodontitis and peri-implantitis through the \nsystemic-inflammatory-mediator link and appears to be an \nindirect cofactor in patients whose profile identifies them as \nbeing predisposed to inflammatory diseases.31\nInterestingly, genetics has been implicated with aggressive peri-\nodontal diseases, which appear to be correlated with peri-implantitis. \nStudies associate peri-implant disease with the IL-1 gene polymor-\nphism in smokers.32 \nDental History\nThe dental history update is crucial in determining any changes to \nthe patient’s oral condition. Changes in home care practices, along \nwith recent dental treatment, should be documented and evaluated \nfor any impact on the implant prostheses. Of special concern are \nparafunctional habits (e.g., clenching, bruxism), which if present \nor worsening may lead to peri-implant diseases or implant failure. \nClinical Evaluation of the Implant(s)/Prosthesis\nSoft Tissue Assessment\nAn overview of the visual signs of gingival inflammation (e.g., \nredness, edema, alterations of tissue contour, fistula tracts) \nshould be evaluated and documented. Poor tissue tone (i.e., \nthin, friable, flaccid) surrounding an implant may harbor food, \nplaque, and calculus, which increases the possibility of inflam-\nmation and infection. A gingival health index may be used to \nevaluate the soft tissue health. The most common bleeding \ngingival index used for implants is the Loe and Silness gingival \nindex. When used on teeth, this index scores gingival inflamma-\ntion from 0 to 3 on the facial, lingual, and mesial surfaces of all \nteeth. The symptom of bleeding comprises a score of at least 2 \n(Box 42.2). The facial and lingual are already being probed to \nevaluate bone loss that cannot be seen on a radiograph. Because \nthe bleeding index evaluates inflammation, the Loe and Silness \nindex is adequate for implants, and because fewer implants typi-\ncally are used to restore a region compared with the presence \nof natural teeth, one also may evaluate the distal surface when \nbleeding is present33 (Fig. 42.8). \nAssessment of Home Care\nBecause the presence of microbial biofilm has been shown to be \na leading factor in the pathogenesis of peri-implant disease, the \nroutine assessment of plaque accumulation should be a priority \nof each maintenance visit. This objective form of plaque monitor-\ning should ideally be performed and documented at each mainte-\nnance visit. Consistent use of the same plaque index is paramount \nbecause this will allow an easier determination of the presence of \na disease process. High plaque scores have been shown to have a \ndirect correlation with peri-implant mucositis and increased prob-\ning depths.34 Mombelli et al.35 and Lindquist et al.36 have reported \nimplant-specific plaque indices to be used at dental implant main-\ntenance appointments. Mombelli et al.35 suggested a numerical \nscale from 0 to 3, which is dependent on the amount of visible \nplaque present or by running a probe over the implant surface. \nLindquist et al.36 recommended a similar scale (i.e., 0–2) depen-\ndent on the amount of visible plaque (Fig. 42.9 and Box 42.3). \nProbing\nProbing around dental implants is a controversial topic even \nthough it has been shown in the literature to be a reliable and \nimportant factor in determining peri-implant health. The safety of \nprobing, once thought to be detrimental, has been well established \nNormal\n0 = mild inflammation, slight color change and edema, no bleeding\n1 = moderate inflammation, redness, edema, bleeds on probing\n2 = severe inflammation, marked redness and edema ulceration, \nspontaneous bleeding\n\t• BOX 42.2\t   \u0007Loe and Silness Bleeding Index"
  },
  {
    "page": 58,
    "content": "1198\nPART VIII    Dental Implant Maintenance\nand does not jeopardize the integrity of the implant system.37,38 \nEtter et al.39 reported after probing of the implant system, healing \nof the epithelial attachment will occur approximately 5 days after \nclinical probing.\nThe connective tissue zone for an implant has only two fiber \ngroups, and neither of them inserts into the implant. As a result, with \nan implant, the probe goes beyond the sulcus, through the junctional \nepithelium attachment, and through the type III collagen connective \ntissues and reaches closer to the bone.40 Because the probe penetrates \ndeeper next to an implant compared with a tooth, one should take \ncare not to contaminate the implant sulcus with bacteria from a dis-\neased periodontal site. To prevent contamination, the dental probe tip \nmay be placed in chlorhexidine after each reading, thereby reducing \nthe possibility of inoculating the sulcular area of the next probed area. \nIn most cases probing depths of 2 to 4 mm have been established as a \nhealthy condition41 (Figs. 42.10 and 42.11).\nIn addition, there exists controversy concerning the type of \nperiodontal probe to use with dental implants. Many authors \nhave advocated the use of plastic periodontal probes42,43; how-\never, more recent articles have recommended conventional metal \nA\nB\nC\nD\n• Fig. 42.8  Soft Tissue Assessment.  (A) Edematous tissue surrounding dental implant. (B) Significant \ngingival recession leading to exposure of the implant bodies allowing for plaque accumulation. (C) Poor tis-\nsue quality resulting from facial bone loss. (D) Soft tissue recession resulting from apical positioned implant \nwhich leads to soft tissue loss and resultant black triangles.\nA\nB\n• Fig. 42.9  (A and B) Plaque accumulation as a result of recession and poor oral hygiene."
  },
  {
    "page": 59,
    "content": "1199\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\nprobes because they do not appear to damage the mucosal attach-\nment or mar the implant surface.44,45\nIdeally there should be baseline clinical probing depths acquired \nafter the initial insertion of the prosthesis. However, in some cases, \nbecause of malpositioned implants or an overcontoured prosthe-\nsis, obtaining true probing depths may be difficult. In these cases a \nmore routine radiographic evaluation is indicated to help ascertain \nperi-implant health.\nWhen bleeding on probing is present, usually this is indica-\ntive of positive peri-implant disease. Studies have shown that simi-\nlar to natural teeth, the absence of bleeding on probing may be \ninterpreted as highly predictive of stability of the peri-implant tis-\nsues.46,47 However, a positive correlation exists with bleeding on prob-\ning and histologic signs of inflammation at peri-implant tissue levels.48\nCare should be exercised to avoid false-positive readings \nfor bleeding on probing depths. Gerber et al.49 reported that a \npressure of approximately 0.15 N should be used to minimize \nincorrect readings. Probing around dental implants has been \nshown to be more sensitive to force variation in comparison with \nnatural teeth.50\nThe thickness and the type of tissue may influence the mucosa/\nepithelium surrounding a dental implant. Van Steenberghe et al.51 \ndetermined that shallow (minimal) probing depths are associated \nwith keratinized tissue, and deeper probing depths are consis-\ntent with alveolar mucosa (i.e., movable tissue) surrounding the \nimplant.\nOn probing the peri-implant tissues, if suppuration is pres-\nent, the implant clinician should be conscious of the strong \nevidence of the presence of infection or peri-implant disease. \nRadiographic evaluation should be immediately completed \nto determine the etiology of the exudate and the infectious \norigin.\nWhen evaluating probing depths, greater than 3 mm is not a \ndefinite sign of peri-implantitis; peri-implant tissue dimensions \nare influenced by the implant type and shape, the connections \nof the multiple components (material and retention mode), and \nthe prosthetic restoration design and configuration. Coveted soft \ntissue conditioning in the esthetic zone to simulate an interdental \npapilla can lead to an increase in the distance from the implant \nshoulder to the mucosal margin of up to 5 mm.52 Clinical pre-\nsentations may be misdiagnosed as peri-implantitis when factors \nsuch as mucositis and marginal bone remodeling ensue from deep \npositioning of the implant for more acceptable esthetic outcomes. \nThe diagnosis of peri-implantitis may also be caused by the local \nanatomic variations.53\nControversy surrounds the issue of using bleeding and gingi-\nval health as an implant health indicator. Unlike a natural tooth, \nimplant success in the first few years is related more often to bio-\nmechanical equilibrium than to gingival health. Compared with a \nnatural tooth, the soft tissue inflammation caused specifically by \nbacteria may be more restricted to above the crestal bone, because \nof the lack of a periodontal membrane or fibrous tissue between \nthe implant and the bone interface. As a result the bleeding index \nmay not be as significant when evaluating early implant health \nstatus.54 \nPresence of Keratinized Tissue\nIn recent literature, compelling clinical published reports have cor-\nrelated peri-implantitis with keratinized gingiva and biotype thick-\nness. A few studies have shown a minimal correlation between \nkeratinized tissue and implant success. However, other reports \nhave shown a lack of keratinized tissue is associated with bone \nloss,55 increased plaque acculumlation,56 increased gingival reces-\nsion,57 increased gingival inflammation,58 and a higher frequency \nof bleeding on probing.59\nThe soft tissue at the implant site has been recognized as a \ncrucial factor in long-term maintenance of healthy implant res-\ntorations. The soft tissue quality at the implant site, together \nwith the gingival biotype, is a predisposing factor in a patient’s \nresistance to plaque accumulation and inflammatory-mediated \nperi-implant disease.60,61 Unattached, nonkeratinized muco-\nsal tissue is more problematic because implants do not have \ninserting supracrestal gingival fibers, which serve as a barrier \nto bacterial insult; Sharpey’s fibers run parallel to the implant, \nleaving only the hemidesmosomal seal of the junctional epi-\nthelium at the neck of the implant to protect underlying soft \nand hard peri-implant structures. During the mastication pro-\ncess, this seal may be broken when the vestibule is shallow \nand frenum attachment is high, causing excess pressure on the \nLindquist Plaque Index\n0 = no visible plaque\n1 = local plaque accumulation\n2 = general plaque accumulation (>25%) \nMombelli Plaque Index\n0 = no visible plaque\n1 = plaque recognized by probing over smooth margin of implant\n2 = visible plaque\n3 = abundance of soft matter\n\t• BOX 42.3\t   \u0007Plaque Index Evaluations\nBone crest\nFGM\nCT\nJE\nSulcus\n• Fig. 42.10  A probe placed into the sulcus of a tooth goes through the \nsulcus and the epithelial attachment. It is stopped by the connective tissue \nattachment. The biological width of a natural tooth has a connective tissue \nzone that inserts into the cementum of the tooth. A periodontal probe will \npenetrate the sulcus and the junctional epithelial (JE) attachment. CT, Con-\nnective tissue; FGM, free gingival margin. (From Misch CE. An implant is \nnot a tooth: a comparison of periodontal indices. Dental Implant Prosthet-\nics. 2nd ed. St. Louis, MO: Mosby; 2015.)"
  },
  {
    "page": 60,
    "content": "1200\nPART VIII    Dental Implant Maintenance\ntissue. Microbial colonization may then progress to the crestal \nand peri-implant tissue, which may result in the early stages of \nperi-implant disease. If plaque control is not adequate around \nthe implants lacking keratinized gingiva, tissue may cause irri-\ntation and sensitivity, which may be uncomfortable for the \npatient.\nFor the existing soft tissue the quality may be classified as either \na thin or a thick biotype. Thin gingival biotype is indicative of \nthin underlying supporting bone. Thin structures are less vascular-\nized and more prone to recession and resorption in the presence \nof inflammation. Therefore patients with a thin biotype are more \nsusceptible to peri-implant complications, especially if keratinized \ntissue is compromised (Box 42.4).\nIn conclusion, there is increasing literature to support the advan-\ntage of keratinized tissue over nonkeratinized tissue. Many authors \nrecommend keratinized mucosa more intensely than others.\nIn specific clinical instances, attached, keratinized gingiva is \nmore often desirable. For example, a fixed prosthesis (FP-1) in the \nesthetic zone (anterior maxilla) will require keratinized mucosa to \ndevelop a soft tissue drape around the implant prosthesis. Another \nprime example is with a mandibular overdenture, which benefits \nfrom a stable vestibule and a zone of nonmobile tissue around the \nB\nD\nA\nC\n• Fig. 42.11  Controversies related to probing include the material of the probe and the difficulty in obtaining \naccurate measurements (A) probing around an implant retaining a bar overdenture; (B) if excessive prob-\ning pressure is used, probing depths will be inaccurate and traumatize the tissue; (C) if the prosthesis is \novercontoured, difficulty in probing will result; (D) difficulty probing with a plastic probe around the contours \nof a fixed prosthesis.\n\t1.\t \u0007Similar to natural teeth tissue in color, contour, and texture of the soft \ntissue drape\n\t2.\t \u0007More esthetic, especially when a high smile line exists\n\t3.\t \u0007Keratinized tissue is more resistant to abrasion\n\t4.\t \u0007Maintaining papillae is more predictable if keratinized tissue is present\n\t4.\t \u0007Hygiene aids are more comfortable to use\n\t5.\t \u0007Degree of gingival recession is proportional to the amount of keratinized \ngingiva\n\t6.\t \u0007Keratinized mucosa is more manageable during the retraction and \nimpression process\n\t7.\t \u0007Long-term tissue stability is greater with keratinized tissue\n\t8.\t \u0007With two-stage implant placement, wound dehiscence is less likely\n\t• BOX 42.4\t   \u0007Benefits of Keratinized Tissue Around an \nImplant"
  },
  {
    "page": 61,
    "content": "1201\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\nimplant abutments. When these conditions exist, it is less likely \nfor patients to exhibit tissue sensitivity. Current recommendations \nbased on clinical experience and current systematic reviews are \nto evaluate and, if possible, increase deficient sites of inadequate \nkeratinized gingiva around implants prophylactically if peri-\nimplant disease exists62,63 (Fig. 42.12). \nMobility of Implant/Prosthesis\nAt each maintenance appointment the mobility of the prosthesis \nand implants should be evaluated. If mobility exists, the etiology \nshould be ascertained, specifically if it is due to a loose screw \nor implant failure. Usually if pain is present when the prosthe-\nsis is moved in a buccal-lingual and apical direction, then it is \nmost likely due to an implant failure (i.e., unless the tissue is \nimpinging on the tissue, resulting in pain). When implant fail-\nure exists, pain will result because of the soft tissue interface. If \nno pain exists, then usually this is indicative of screw loosening \n(Fig. 42.13). \nPain/Sensitivity\nA component of the maintenance protocol is the determination of \nany possible subjective findings of pain, tenderness, and sensitiv-\nity concerning the patient’s peri-implant tissues, implant body, or \nimplant prosthesis. Pain and tenderness are subjective criteria and \ndepend on the patient’s interpretation of the degree of discomfort. \nPain is defined as an unpleasant sensation ranging from mild dis-\ncomfort to excruciating agony. Tenderness is more an unpleasant \nawareness of the region. An implant rarely is troubled by the sub-\njective criteria of pain or sensitivity after initial healing. In contrast \nto a natural tooth an implant does not become hyperemic and \nis not temperature sensitive. If a traumatic occlusion situation is \npresent, rarely will symptoms be present with an implant.\nImplant-Related Pain. After the implant has achieved primary \nhealing, absence of pain under vertical or horizontal forces is a pri-\nmary subjective criterion. Usually, but not always, pain does not \noccur unless the implant is mobile and surrounded by inflamed \ntissue or has rigid fixation but impinges on a nerve. The most \ncommon condition that causes discomfort from an implant is \nwhen a loose implant abutment is entrapping some of the soft \ntissue in the abutment-implant connection. Usually, after the soft \ntissue in the region is removed and the abutment is repositioned, \nthe discomfort or pain will subside.\nWhen an implant is mobile, pain may occur early or late in \ntreatment. In either case the condition rarely improves. Pain on \nloading of rigid implants has been observed more often on imme-\ndiately loaded implants compared with those healing unloaded \nfor an extended period. Implant sensitivity or mild tenderness \nrather than pain in a rigid implant is also most unusual and sig-\nnals a more significant complication for an implant than for a \ntooth. Tenderness during function or percussion usually implies \nA\nC\nD\nB\n• Fig. 42.12  Inadequate Keratinized Tissue.  (A) Lack of quality attached tissue on facial aspect of the \nhealing abutments. (B and C) Lack of keratinized tissue on facial of final prosthesis. (D) Bar overdenture \nexhibiting compromised attached tissue because of the facial placement of the implants."
  },
  {
    "page": 62,
    "content": "1202\nPART VIII    Dental Implant Maintenance\nhealing in the proximity of a nerve or, on rare occasions, bone \nstress beyond physiologic limits.\nOn occasion an implant body may fracture from fatigue. \nFatigue is related to the amount of force, the number of cycles, \nthe strength of the material, the diameter of the component, \nand the number of implants splinted together. This condition \nis similar to a fractured root. In any case, radiographic evidence \nof the fracture may be difficult to ascertain. Percussion and \nforces up to 500 g (1.2 psi) with a bite stick are used clinically \nto evaluate a tooth or implant for pain or discomfort. Percus-\nsion and heavy biting on a wood stick associated with pain \nare clinical indices. In these cases the implant is most often \nremoved, which especially in the mandible (i.e., dense bone) \nmay be difficult (Fig. 42.14). \nAbutment-Related Pain. When the abutment-implant connec-\ntion is not secure, pain may result because of tissue integration \ninto the void. This pain is usually persistent and occurs most often \nduring percussion or function. If this occurs, the prosthesis and \nabutment should be removed, soft tissue excised, and components \nrepositioned (Fig. 42.15). \nInfection-Related Pain. Especially in the early stages of peri-\nimplantitis, pain usually does not present as a primary clinical \nsymptom. Unless active infection with suppuration accompanies \nsufficient osseous destruction, patients do not experience pain. \nBecause dental implants do not have a PDL support and its sen-\nsory apparatus, low-grade infections and bone resorption are not \ndetected by marginal gingiva. As the disease process begins around \nan implant, the patient may feel slight irritation, but normally \nnot alarming pain.64,65 It is recommended that the implant clini-\ncian be proactive in evaluating the status of dental implants with \nthe incorporation of a routine maintenance protocol for implant \npatients. \nOcclusion\nIdeally, in most fixed implant cases an implant-protected occlu-\nsion should be present. Implant-protected occlusion (i.e., canine \nguidance) should be adhered to so the anterior teeth protect the \nposterior teeth (i.e., protrusive movements) and the posterior \nteeth protect the anterior (i.e., centric occlusion).\nTraumatic occlusion has been shown to be an etiologic factor \nin the loss of bone around the peri-implant region. A timed occlu-\nsion should always be present, which includes the natural teeth \ncontacting first before the contact of the implant (i.e., to compen-\nsate for the PDL compression during occlusal contacts). During \nlight contact, extrathin articulating paper (e.g., shimstock) should \nbe easily pulled through the occlusal contact with an implant. \nThen during heavy contact, minimal resistance should be pres-\nent. Miyata et al.66 reported with monkey studies that bone loss \nA\nB\nC\nD\n• Fig. 42.13  (A and B) Mobile implant prostheses diagnosed at the maintenance appointment. (C) Ill-fitting \nand loose full-arch fixed prosthesis. (D) Ill-fitting prosthesis which may result from loose abutment screw."
  },
  {
    "page": 63,
    "content": "1203\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\nmay occur with an excess occlusal contact of 180 μm, even in the \nabsence of peri-implant inflammation. Therefore it is imperative \nthat the implant clinician evaluate and modify the existing occlu-\nsion if necessary, at each appointment (Fig. 42.16).\nIn addition, the presence of parafunctional habits (e.g., clench-\ning, bruxism) should be documented and treated, most commonly \nwith an occlusal guard. A hard acrylic centric is most commonly \nused. \nProsthesis\nAt each maintenance appointment the prosthesis should be evalu-\nated for not only mobility but also any fractures of the prosthesis \nmaterial (e.g., porcelain, acrylic, zirconia). If material fracture is \npresent, the occlusion should be immediately evaluated and the \npossibility of replacement is determined. For a removable pros-\nthesis, all implant attachments should be evaluated for mobility \nand retention. \nRadiographic Evaluation of the Implant and \nProsthesis\nAn accurate and thorough radiographic examination should be \nperformed as a routine adjunct to the clinical maintenance exami-\nnation (Box 41.2). Ideally the radiographic modality used should \nbe able to standardize the evaluation of the implant interface and \nbone level. The selection of the radiographic modality is dictated \nby the number and position of implants, along with the type of \nprosthesis.\nUpon radiographic evaluation the crestal bone region is often \nthe most diagnostic for the ranges of optimum, satisfactory, and \ncompromised health conditions. Radiographic interpretation \nis one of the easiest clinical tools to use to assess implant crestal \nbone loss, but has many limitations. However, a two-dimensional \nradiograph will illustrate only the mesial and distal crestal levels of \nbone (Fig. 42.17).\nWhen early bone loss occurs, it is most often present \non the facial aspect of the implant. The absence of radiolu-\ncency around an implant does not indicate bone is pres-\nent at the interface. Therefore two-dimensional radiographs \n(i.e., periapical, bitewings, panographic films) may often \nbe misleading on revealing the amount of bone loss. In the \nmandibular anterior region, as much as a 40% decrease in \ndensity is necessary to produce a traditional radiographic dif-\nference in this region because of the dense cortical bone.67 \nWhen abundant bone width is present, a V-shaped crestal \ndefect around an implant may be surrounded by cortical bone \nand, as a result, the radiograph is less diagnostic for bone \nloss.\nA\nB\nC\nD\n•  Fig. 42.14  Implant Pain.  (A and B) If pain is present with an implant, it is usually a failure because of a \nsoft tissue encapsulation; radiographs reveal significant radiolucency surrounding the implant bodies. (C \nand D) If suppuration is present, usually the patient will be symptomatic."
  },
  {
    "page": 64,
    "content": "1204\nPART VIII    Dental Implant Maintenance\nRadiograph Type\nThe type of radiograph used in the evaluation of the implant \nand prosthesis is difficult to generalize. Standardized periapi-\ncal radiographs are usually recommended as the most com-\nmon type of radiographic modality in evaluation of dental \nimplants. The long cone paralleling technique should be used \nto minimize image distortion.68 Panoramic radiographs exhibit \ninherent disadvantages, including magnification, distortion, \noverlapping images, and poor resolution. Therefore panoramic \nradiographs are not the most ideal radiograph in evaluating \nbone loss (Fig. 42.18). However, in cases where periapical or \nbitewing radiographs cannot be obtained, panoramic films may \nbe used.\nCone beam computed tomography (CBCT) scans, although \nsuperior to plain film radiographs in the diagnosis and treat-\nment planning phases of implant dentistry, are usually not indi-\ncated for routine maintenance unless complications are present. \nStudies evaluating the visibility of the buccal plate showed that \nif the amount of bone present is less than 0.6 mm in thick-\nness, the bone will be invisible on a CBCT image.69 In addi-\ntion, CBCT images suffer from beam hardening, which leads to \nthe formation of a radiolucency surrounding the implant. This \noccurs from a greater number of photons being absorbed (Fig. \n42.19). In summary, the type of image modality should be spe-\ncifically tailored to each individual patient, according to clinical \nand anatomic circumstances. \nRadiograph Accuracy\nIt is often more difficult to obtain an accurate radiograph of the \nimplant body in comparison with a natural tooth. Most com-\nmonly, implants are placed more apical to the apex of the pre-\nexisting natural teeth. As a result the apex of the implant often is \nlocated beyond muscle attachments or in regions almost impossible \nto capture with a parallel radiographic method. A foreshortened \nA\nB\nC\nD\n• Fig. 42.15  Abutment-Related Pain.  (A) An incomplete abutment seating will result in tissue growth with \nresultant pain. (B) After implant is removed, tissue impingement is evident. (C and D) The excess tissue is \nremoved with a latch-type tissue punch."
  },
  {
    "page": 65,
    "content": "1205\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\nimage to encompass the apical portion of the implant results \nin poor display of the crestal bone. An accurate radiograph will \nshow a clear depiction of the threads on the radiograph and a \nproper angulation. If the implant threads are clear on one side \nbut blurry on the other, the angulation was incorrect by approxi-\nmately 10%70 (Fig. 42.20). If both sides of a threaded implant \nare unclear, the radiograph is not diagnostic for crestal bone loss \nassessment because of angulation issues. Ideally the abutment-\nimplant connection should appear as a clear line between the two \ncomponents. When the top of the implant is placed at the crest of \nthe regional bone, the amount of crestal bone loss is most easy to \nevaluate (Fig. 42.21).\nIn addition, the prosthesis should be evaluated for any \nradiographic changes from the baseline radiographs. Of \nutmost importance is the fit of the prosthesis because an ill-\nfitting or loose prosthesis may lead to peri-implant disease. If \na space is present between the prosthesis and the abutment, \nthe prosthesis should be immediately evaluated for passivity \nand mobility. \nRadiograph Timing\nThe most important radiograph for use in the maintenance phase \nis the postprosthetic baseline radiograph. This radiograph is most \noften taken at the prosthesis insertion appointment. By this time \nthe “biological width” most likely will have influenced the implant \ncrest module bone level.\nIn general, implants with machined surfaces or external hex \nconnections are usually subject to an initial remodeling of the \nbone level. Adell et al.71 reported an average bone loss of 1.5 mm \nduring the first year and 0.1 mm per year thereafter. However, \nrecent implant design changes have reduced this bone loss with \ninternal connections and platform switching.72,73\nIn most cases an individualized radiographic protocol should \nbe developed based on the number and location of implants, type \nof prosthesis, and any associated complications. A comprehensive \nand generalized radiologic protocol was established by Resnik74 in \n2016 (Box 42.5). \nRadiographic Crestal Bone Loss\nThe marginal bone around the implant crestal region is usually a \nsignificant indicator of implant health. The cause of crestal bone \nloss around an implant is multifactorial and may occur at different \nA\nB\n• Fig. 42.17  (A) Radiograph depicting significant bone loss surrounding the anterior implant; however, this \nmay be misleading because it depicts only the mesial and distal bone levels. (B) Vertical bitewing exhibiting \nideal angulation.\nA\nB\n• Fig. 42.16  Occlusal Contacts.  (A) The occlusion should be checked \nat each maintenance appointment to ensure lack of premature contacts. \n(B) Ideal occlusion consists of primary contact (i.e., light occlusion) on the \nnatural teeth and light contact on implants during heavy occlusion."
  },
  {
    "page": 66,
    "content": "1206\nPART VIII    Dental Implant Maintenance\ntime periods: surgical bone loss, initial “biologic width” bone loss, \nearly loading bone loss, intermediate-term bone loss, and long-\nterm bone loss. Each period may be associated with a different \ncause for the bone loss. Most often the surgical trauma results in \nminimal bone loss, but on occasion, bone loss may reach several \nmillimeters (Fig. 42.22).\nWhen the abutment is attached to the implant body, approxi-\nmately 0.5 to 1 mm of connective tissue forms apical to this \nconnection.75 This associated bone loss may be caused by an \n“implant biologic width.” Initial bone loss during the surgical \nhealing phase may vary for submerged and unsubmerged healing \nprotocols.76\nAfter the implant is connected with a permucosal element, \nthe marginal bone may be lost during the first month from: (1) \nthe position of the abutment-implant connection or (2) the crest \nmodule design of the implant. The abutment-implant connection \nmay cause 0.5 to 1.0 mm of bone loss when it is at or below \nthe bone. In addition, when smooth metal is present below the \nabutment-implant connection, additional bone loss will occur in \ndirect relation to the smooth metal region. The bone levels will \nmost often reside at the first thread or at a roughened surface after \nthe first month after permucosal element placement (Fig. 42.23 \nand Box 42.6). \nDiagnosis of Peri-implant Disease\nAfter the clinical and radiographic maintenance examination is \ncomplete, a diagnosis of the current peri-implant condition is war-\nranted. In the evaluation of the peri-implant tissues, three pos-\nsible conditions may exist: (1) healthy condition, (2) peri-implant \nmucositis, and (3) peri-implantitis.\nHealthy Condition\nIf there exist no signs of inflammation, bleeding, recession, bone \nloss, or implant/prosthesis mobility, then the patient’s implants/\nprosthesis is determined to be in a “healthy” state (Fig. 42.24 and \nBox 42.7).\nTreatment includes adherence to routine implant maintenance \n(i.e., usually 3–6 months). \nPeri-implant Mucositis\nPeri-implant mucositis is defined as a localized inflammation \nwithin the soft tissue surrounding the implant bodies. In addi-\ntion, redness and bleeding on probing may be present. However, \nthe bone level has not changed; therefore no hard tissue recession \n(i.e., bone loss) has occurred. Peri-implant mucositis is similar to \ngingivitis with respect to natural teeth (Fig. 42.25).\n• Fig. 42.18  Panoramic Image.  The determination of the amount of bone \nloss on a panoramic image is misleading because of the magnification, \ndistortion, overlapping images, and poor resolution.\nA\nB\n• Fig. 42.19  Inherent Cone Beam Computed Tomography Disadvantages.  (A) Beam hardening result-\ning in a radiolucency surrounding the implant. (B) Scatter that is caused by the presence metallic objects \n(e.g., crowns, implants)."
  },
  {
    "page": 67,
    "content": "1207\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\nTreatment includes remediation of the causative factors of peri-\nimplant mucositis and associated follow-up care. \nPeri-implantitis\nPeri-implantitis is defined as localized inflammation with concomi-\ntant bone loss. In most peri-implantitis cases suppuration and clini-\ncal probing depths are present, together with bleeding on probing. \nOn radiographic evaluation, marginal bone loss is present in com-\nparison with the original baseline radiographs (Fig. 42.26).\nTreatment includes remediation of the causative factors and \nusually hard and soft tissue surgical intervention, followed by con-\ntinued maintenance care. \nFrequency of Maintenance Visits\nPeri-implant disease may result from opportunistic infections that \nlead to soft and hard tissue complications; therefore it is manda-\ntory to monitor the peri-implant tissues at regular intervals. If early \nsigns of disease are diagnosed, aggressive intervention may prevent \nthe loss of hard tissue. Zitzman et al.77 reported that peri-implant \nmucositis may exhibit apical progression after only 3 months of \nplaque buildup around implants. Therefore a 3-month mainte-\nnance regimen is recommended within the first year of implant \nplacement to evaluate the tissue health and the patient’s home \ncare. If after the first year the peri-implant tissues are healthy, then \nthe maintenance interval may be extended to 6 months. However, \na stricter recall protocol should be adhered to if the patient does \nexhibit risk factors or comorbidities.78 \nPatient Home Care\nIdeally a home care assessment should be determined before the \ninitiation of dental implant treatment. In partially or completely \nedentulous patients, usually compromised home care is already \npresent. In addition, during the postsurgical phase of treatment, \npatients are often lax in their hygiene practices because of fear of \ncausing damage to the surgery site. Therefore it is imperative that \nthe patient be educated on the necessity and need for a compre-\nhensive home care regimen.\nWhen educating patients on home care, various techniques \nmay be used, as long as they are safe and effective. Depending on \nthe type of implant, implant position, location in the oral cavity, \nand type and size of the prosthesis, various devices along with the \nfrequency may be recommended. No single hygiene device has \nbeen shown to be ideal in all situations. There exists a full array of \n• Fig. 42.20  On this periapical radiograph the threads are clear. On the \nright side only, the central ray was not directed completely perpendicular \nto the implant body but was within 10 degrees. This film is not ideal to \nascertain the amount of bone loss.\nA\nB\n• Fig. 42.21  (A) Poor angulation resulting in no threads of the implants being seen. (B) Ideal positioning as \nimplant threads on mesial and distal are easily seen."
  },
  {
    "page": 68,
    "content": "1208\nPART VIII    Dental Implant Maintenance\nbrushes, floss threading systems, and other devices available to aid \npatients in their hygiene protocols.\nOne common mistake often employed by clinicians is to add \ntoo many oral hygiene devices for patient home care. Studies have \nshown that when multiple devices are recommended, patients are \nmore apt to become discouraged and less motivated. However, \nwhen a combination of toothbrushing devices, auxiliary aids, and \nantimicrobial mouthrinses are used, an increased plaque inhibi-\ntion is seen.79\nSpecific Dentifrices\nManual and Electromechanical Devices\nIn general most exposed facial and lingual surfaces may be \ncleaned with a soft, multitufted nylon toothbrush. The implant \nclinician should recommend to each individual patient which \nbrush angle would be ideal to access all areas within the mouth. \nThe modified Bass technique should be used or a short, hori-\nzontal, back-and-forth movement may be incorporated into the \nhygiene regimen. The brush may be held at a 45-degree angle to \nthe gingival tissue.80\nMost commonly, patients often prefer electromechanical \ndevices, which have been shown to be superior to manual brush-\ning around dental implants.81 When using electromechanical \ndevices (i.e., sonic toothbrushes, oscillating-rotating power tooth-\nbrushes), especially in difficult-to-access areas, end-tufted brushes \nand tapered rotary brushes tend to be beneficial. Studies have con-\nfirmed the benefits of these devices.82,83 Rasperini et al.82 reported \na reduction in bleeding (∼50% in the first year) and decrease in \nprobing depths (∼0.3 mm) with power toothbrushes.\nMost manufactured power brushes have soft, interchangeable \nbristle heads (flattened, rubber cuplike, short and long pointed \nPreoperative\nCone Beam Computed Tomography\n • \u0007All vital structures identified\n • \u0007Sinus-related procedures: must confirm patency of ostium and lack of \npathology \nIntraoperative\n • \u0007Peri-apical radiograph (PA) after pilot drill during placement to confirm \npositioning and proximity to vital structures and adjacent teeth\n • \u0007PA of final placement with cover screw or healing abutment\n • \u0007PA before uncover surgery (stage 2 procedure)\nProsthetic\n • \u0007PA to confirm implant is ready to restore\n • \u0007PA to confirm abutment is seated properly\n • \u0007PA to confirm proper seating of prosthesis/cement removal (will be \nbaseline for future evaluation radiographs) \nPostoperative\n • \u0007PA once annually for the first 3 years after implant prosthetics to monitor \nbone level\n • \u0007Normal (acceptable): <0.2 mm vertical bone loss per year for first 3 \nyears\n • \u0007After 3 years, PA should be taken every 2 years\nIn addition to radiographic evaluation, the following should be evaluated:\n • \u0007Presence of pain, suppuration\n • \u0007Implant and/or prosthesis mobility\n • \u0007Hyperocclusion\n • \u0007Soft tissue changes (bleeding, recession, hyperplasia)\nIn some cases a periapical radiograph cannot be accurately obtained \nbecause of positioning issues; therefore a panoramic radiograph may be used \nas an alternative radiographic modality.\n\t• BOX 42.5\t   \u0007Radiograph Timing Protocol\nA\nB\n• Fig. 42.22  Postprosthetic Images.  (A) Ideal radiograph showing no \nsigns of bone loss. (B) Image depicting significant early bone loss at first \nmaintenance appointment.\n• Fig. 42.23  When an implant is placed with the abutment connection \nat the crest of the ridge (left side), after the permucosal abutment is con-\nnected the bone is usually lost to the first thread, especially when the crest \nmodule is machined or smooth (right side)."
  },
  {
    "page": 69,
    "content": "1209\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\nin shape) that may be used. The short and long pointed tips are \nideal for reaching proximal areas, wide embrasures, and pontic \nareas under a splinted prosthesis. The hollowed rubber cup may \nbe used on the facial and lingual aspects of the implant and pros-\nthesis (Fig. 42.27). \nToothpaste/Gel\nThe selection of a toothpaste should be low abrasive as to not \nscratch the surface of the exposed implant. Dentifrices should be \navoided that contain harsh abrasive ingredients, including stain \nremovers and smoker’s toothpaste.84 Selective fluorides may result \nin etching and roughness on implant surfaces.85,86 \nInterproximal Brushes\nWith some types of prostheses (e.g., full-arch fixed prosthesis), \ninterproximal brushes with small brush heads may be indicated to \ngain easier access. Ideally these types of device should be plastic-\ncoated because metal may damage the implant surface.79 The inter-\ndental brush is used to massage the gingival tissue, which results \nin increased blood flow and healthier tissue. Patients should be \ninstructed to insert the tip interproximally in an occlusal direction \nand use a gentle rotary motion against the gingiva80 (Fig. 42.28). \nFloss Aids\nFlossing around dental implants is also a controversial topic. \nMost patients are resistant to flossing their natural teeth, espe-\ncially if floss threaders are required. Therefore flossing has an \ninherent disadvantage in patient compliance and also dexter-\nity issues. When flossing around implants, it is often difficult \nto manipulate and maneuver the floss around a malpositioned \nimplant or an overcontoured/atypical prosthesis. Floss is ideally \nused interproximally, especially when a splinted prosthesis is \npresent. Thicker floss is available (e.g., “yarnlike”) that allows for \ncleaning around abutments and prostheses, and ease of penetrat-\ning hard to reach interproximal areas. Floss may be used in con-\njunction with chlorhexidine or other antimicrobials to decrease \nplaque accumulation.\nIt is imperative that the patient is instructed on the proper \ntechnique on flossing around dental implants. Improper or over-\naggressive flossing may lead to tissue trauma and resultant peri-\nimplant soft tissue lesions (Fig. 42.29). \nTime\nEtiology\nSurgery\nTrauma to bone\nUncovery\n“Implant biologic width” related to abutment location \nand implant crest module design\nEarly\nOcclusal trauma\nIntermediate\nBacteria or occlusal trauma\nLong term\nBacteria\n\t• BOX 42.6\t   \u0007Etiology of Implant Crestal Bone Loss\n• Fig. 42.24  Healthy Implant Condition.  No signs of inflammation, bleed-\ning, tissue recession, or bone loss (lateral incisors).\n\t1.\t \u0007No signs of inflammation (pink, firm peri-implant mucosa)\n 2. \u0007No probing depths (<4 mm)\n 3. \u0007Absence of bleeding on gentle probing (<15 N)\n\t4.\t \u0007No suppuration\n\t5.\t \u0007No pain or sensitivity\n\t6.\t \u0007No radiographic bone changes\n\t• BOX 42.7\t   \u0007Healthy Clinical Findings\n• Fig. 42.25  Periimplant Mucositis.  Molar implant prosthesis exhibiting \nsigns of bleeding; however, no bone loss is present.\n• Fig. 42.26  Peri-implantitis.  Anterior implant prosthesis exhibiting signs \nof significant recession, inflamed gingival tissue, and plaque accumulation."
  },
  {
    "page": 70,
    "content": "1210\nPART VIII    Dental Implant Maintenance\nA\nB\nC\n• Fig. 42.27  (A) Manual brushing around a dental implant (Procter & Gamble, Cincinnati, Ohio). (B) Electro-\nmechanical toothbrush around a dental implant Philips Sonicare. (C) AirFloss Pro (Philips).\nA\nB\n• Fig. 42.28  (A) Interproximal brush (Sunstar Butler, Chicago, Ill.). (B) Hu-Friedy EMS Piezo implant tip, \nPIEZON® TECHNOLOGY."
  },
  {
    "page": 71,
    "content": "1211\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\nB\nA\n• Fig. 42.29  (A and B) Floss aids. (B) Microdroplets of air and liquid with AirFloss Pro (Philips).\nOral Irrigator\nThe oral irrigator (e.g., Air Floss Pro, Philips) may be beneficial \nin removing supragingival debris, especially when difficult access \nexists because of the prosthesis type. Numerous studies have \nshown an oral irrigator to be superior in reducing gingival bleed-\ning, inflammation, and plaque in comparison with string floss.87-89 \nMagnuson et al.90 found oral irrigators to reduce bleeding around \nimplants by 81% in contrast with 33% for flossing. However, cau-\ntion must be exercised in using an oral irrigator because excessive \nforce (i.e., high pressure) may damage the junctional epithelium, \nwhich may lead to a bacteremia.91 To minimize complications, \npatients should be instructed on the proper use of these devices, \nmainly using a low to medium speed and angulating the tip to be \nperpendicular to the long axis of the implant body.\nPatients should be instructed to use a nonmetal tip once to \ntwice daily.\nAn antimicrobial (e.g., chlorhexidine, cetylpyridinium chlo-\nride) may be used as an irrigant that decreases the bacterial count in \nthe oral cavity.92 Studies comparing rinsing with 0.12% chlorhexi-\ndine with irrigating with 0.06% chlorhexidine showed the irri-\ngation group to be 87% more effective in reducing gingivitis in \ncomparison with the rinsing group93 (Fig. 42.30 and Box 42.8). \nA\nB\nC\n• Fig. 42.30  Hu-Friedy AIRFLOW® DEVICES, EMS Dental (A) AIRFLOW® HANDY 3.0 PERIO. (B) AirFlow \ninterdental and supragingival. (C) Ideal placement of  Hu-Friedy PerioFlow tip into subgingival areas."
  },
  {
    "page": 72,
    "content": "1212\nPART VIII    Dental Implant Maintenance\nB\nA\n• Fig. 42.31  Subgingival irrigation therapeuticals. (A) AIRFLOW PERIO POWDER for Hu-Friedy EMS \nAIRFLOW® THERAPY SYSTEM, prophylaxis powder. (B) Irrigation with Chlorhexidine gluconate in monojet \nsyringe interproximally and subgingivally.\nAntimicrobial Rinses\nThe regular use of chemotherapeutic agents such as antimi-\ncrobial rinses may be used as an adjunct in plaque control. \nChlorhexidine gluconate is the most commonly used antimi-\ncrobial rinse in implant dentistry because it is safe, inexpensive, \nand nontoxic. It is very effective because of its substantivity, \nwhich is the binding of the medication to the soft tissues and \nimplant surfaces. Studies have shown that a 30-second rinse \nof chlorhexidine inhibits 90% of oral bacteria for more than \n5 hours.92 Chlorhexidine or cetylpyridinium chloride may be \nlocally applied with a cotton swab or may be used as a rinse \ntwice daily (Fig. 42.31 (B)). \nIn-Office Debridement\nIn certain situations a maintenance visit will lead to the need for \nin-office debridement. When excessive dental plaque and calcu-\nlus are present, the dental professional must use instruments for \nproper removal. However, care should be exercised in not dam-\naging the implant or prosthesis. Older implant systems made \nof commercially pure titanium, which is a softer metal, are eas-\nily damaged with conventional instruments. If surface damage \nresults, the titanium oxide surface layer will be altered, which may \ncause surface corrosion.94 However, more recent implant designs \nuse titanium alloy, which is far more resistant to surface alteration.\nThe use of ultrasonic instrumentation is not recommended \nwith dental implants, unless the stainless steel tips are covered \nwith a protective sleeve. Fig. 42.28 (B) these scalers may dis-\nrupt the titanium dioxide surface, which leads to plaque accu-\nmulation. These scratches and gouges may be detrimental to \nlong-term health and hygiene practices.95 Air polishers with \nbicarbonate particles (e.g., Prophy-Jet) may also be detrimen-\ntal to the implant surface. Studies have shown alteration of the \nimplant surface may result because random pitting and irregu-\nlarities within the surface may occur. Therefore air polishers with \nbicarbonate particles should not be used around implants or the \nprosthesis.96\nLow-abrasive amino acid glycine powder has been shown \nto be an effective treatment for removing biofilm with-\nout damaging the implant surface or hard and soft tissues. \nThis piezo instrument (Hu-Friedy, Chicago, Ill.) uses a spe-\ncial handpiece with a plastic tube nozzle with three orthogo-\nnally oriented holes. An air-powder mixture with reduced \npressure is expelled through the nozzle, which prevents the \nformation of air emphysema complications. The nozzle is \nmoved in a circumferential movement around the implant \nsurface Fig. 42.30 (A), (B), (C) and Fig. 42.31 (A).\nAlthough more extensive studies need to be conducted as \nto technique efficacy, glycine powder can be incorporated into \na treatment regimen. The clinician should be careful to use the \npowder only in areas where access is available and a posttreatment \nrinse can remove any residue. This modality is best used in cases \nwith buccal dehiscence and/or horizontal bone loss without crater \nor infrabony pocketing.\nAfter debridement procedures a follow-up visit should be \nscheduled approximately 1 month later. At this appointment the \nhealth of the peri-implant tissues should be evaluated together with \nhome care reinforcement. Usually after the 1-month follow-up the \npatient should be seen on a 3-month recall. If peri-implant health \nis normal, patients can usually be placed on a 3- to 6-month recall \nsystem. \n • \u0007May clean supragingival, subgingival, and interdental areas\n • \u0007May remove supragingival and subgingival plaque (biofilm)\n • \u0007Has been shown to be more effective than string floss for dental \nimplants\n • \u0007More effective than chlorhexidine with implant care\n • \u0007Has been shown to be safe if used properly\n • \u0007Easy to use\n\t• BOX 42.8\t   \u0007Benefits of Oral Irrigator3"
  },
  {
    "page": 73,
    "content": "1213\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\nConclusion\nThe ongoing maintenance of dental implants is one of the most \nimportant factors for long-term health. With increasing numbers \nof implants being placed each year, it is evident that the preven-\ntion of peri-implant disease is paramount to success. An individu-\nalized implant maintenance program needs to be implemented \nthat is tailored to the specific patient, the implants, and the pros-\nthesis. Successful implant maintenance depends on many factors, \nmost importantly communication and collaboration between the \ndental professional and the patient. Peri-implant disease is a preva-\nlent disease; therefore a comprehensive maintenance program is \nessential to decrease complications. The implant clinician must \nunderstand the factors and the need for a systematic maintenance \nprotocol, along with informing his or her patients of the most \nupdated information to ensure longevity of their implants and \nprosthesis.\nReferences\n\t 1.\t \u0007Corbella S, Del Fabbro M, Taschieri S, et al. Clinical evaluation of \nan implant maintenance protocol for the prevention of peri-implant \ndiseases in patients treated with immediately loaded full-arch reha-\nbilitations. Int J Dent Hyg. 2011;9:216–222.\n\t 2.\t \u0007Silverstein L, Garg A, Callan D, Shatz P. The key to success: main-\ntaining the long-term health of implants. Dent Today. 1998;17: 104, \n106, 108–111.\n\t 3.\t \u0007Lyle DM. Implant maintenance: is there an ideal approach? Com-\npend Contin Educ Dent. 2013;34(5):386–390.\n\t 4.\t \u0007Sanz M, Chapple IL. Clinical research on periimplant diseases: Con-\nsensus report of Working Group 4. J Clin Periodontol. 2012;39:202–\n206.\n\t 5.\t \u0007Glavind L, Attström R. Periodontal self-examination. A motiva-\ntional tool in periodontics. J Clin Periodontol. 1979;6:238–251.\n\t 6.\t \u0007Bidez MW, Misch CE. Force transfer in implant dentistry: basic \nconcepts and principles. J Oral Implantol. 1992;18:264–274.\n\t 7.\t \u0007Gargiulo A, Wentz F, Orban B. Dimensions and relations of the \ndentogingival junction in humans. J Periodontol. 1961;32:261–268.\n 8. \u0007Vacek JS, Gher ME, Assad DA, et  al. The dimensions of the \nhuman dentogingival junction. Int J Periodontics Restorative Dent. \n1994;14:154–165.\n\t 9.\t \u0007Rateitschak KH. Periodontology. In: Rateitschak KH, Rateitschak \nEM, Wolf HF, et al., eds. Color Atlas of Dental Medicine. 2nd ed. \nNew York: Thieme; 1989.\n\t10.\t \u0007James RA, Schultz RL. Hemidesmosomes and the adhesion of junc-\ntional epithelial cells to metal implants: a preliminary report. J Oral \nImplantol. 1974;4:294.\n\t11.\t \u0007Cochran DL, Herman JS, Schenk RK, et al. Biologic width around \ntitanium implants: a histometric analysis of the implanto-gingival \njunction around unloaded and loaded submerged implants in the \ncanine mandible. J Periodontol. 1997;68:186–198.\n\t12.\t \u0007Schroeder A, Pohler O, Sutter F. Tissue reaction to a titanium hol-\nlow cylinder implant with titanium plasma sprayed surface. Schweiz \nMonatsschr Zahnmed. 1976;86:713–727.\n\t13.\t \u0007Ericsson I, Lindhe J. Probing at implants and teeth: an experimental \nstudy in the dog. J Clin Periodontol. 1993;20:623–627.\n\t14.\t \u0007Abrahamsson I, Berglundh T, Lindhe J. The mucosal barrier follow-\ning abutment disreconnection: an experimental study in dogs. J Clin \nPeriodontol. 1997;24:568–572.\n\t15.\t \u0007Parfitt GS. Measurement of the physiologic mobility of individual \nteeth in an axial direction. J Dent Res. 1960;39:608–612.\n\t16.\t \u0007Sekine H, Komiyama Y, Hotta H, et  al. Mobility characteristics \nand tactile sensitivity of osseointegrated fixture-supporting systems. \nIn: Van Steenberghe D, ed. Tissue Integration in Oral Maxillofacial \nReconstruction. Amsterdam: Excerpta Medica; 1986.\n\t17.\t \u0007Muhlemann HR. Tooth mobility: a review of clinical aspects and \nresearch findings. J Periodontol. 1967;38:686–708.\n\t18.\t \u0007Rudd KD, O’Leary TJ, Stumpf AJ. Horizontal tooth mobility in \ncarefully screened subjects. Periodontics. 1964;2:65–68.\n\t19.\t \u0007Meredith N, Alleyne D, Cawley P. Quantitative determination of \nthe stability of the implant-tissue interface using resonance fre-\nquency analysis. Clin Oral Implant Res 1996;7:261-7.\n\t20.\t \u0007Sennerby L, Meredith N. Implant stability measurements using res-\nonance frequency analysis: biological and biomechanical aspects and \nclinical implications. Periodontology. 2000, 2008.\n\t21.\t \u0007Antoniazzi RP, Miranda LA, Zanatta FB, et  al. Periodontal con-\nditions of individuals with Sjögren’s syndrome. J Periodontol. \n2009;80:419–435.\n\t22.\t \u0007Habbab KM, Moles DR, Porter SR. Potential oral manifestations of \ncardiovascular drugs. Oral Dis. 2010;16:769–773.\n\t23.\t \u0007Smidt D, Torpet LA, Nauntofte B, Heegaard KM, Paedersen AM. \nAssociations between oral and ocular dryness, labial and whole \nsalivary flow rates, systemic diseases and medications in a sam-\nple of older people. Community Dent Oral Epidemiol. 2011;39: \n276–288. 40.\n\t24.\t \u0007Fejerskov O, Escobar G, Jøssing M, Baelum V. A functional natural \ndentition for all- and for life? The oral healthcare system needs revi-\nsion. J Oral Rehabil. 2013;40:707–722.\n\t25.\t \u0007Hernández G, Lopez-Pintor RM, Arriba L, Torres J, de Vicente JC. \nImplant treatment in patients with oral lichen planus: a prospective-\ncontrolled study. Clin Oral Implants Res. 2012;23:726–732.\n\t26.\t \u0007López-Jornet P, Camacho-Alonso F, Sánchez-Siles M. Dental \nimplants in patients with oral lichen planus:a cross-sectional study. \nClin Implant Dent Relat Res. 2014;16:107–115.\n\t27.\t \u0007Dvorak G, Reich KM, Tangl S, Goldhahn J, Haas R, Gruber R. \nCortical porosity of the mandible in an osteoporotic sheep model. \nClin Oral Implants Res. 2011;22:500–505.\n\t28.\t \u0007March and F, Raskin A, Dionnes-Hornes A, et al. Dental implants \nand diabetes: conditions for success. Diabetes Metab. 2012;38:14–19.\n\t29.\t \u0007Cavalcanti R, Oreglia F, Manfredonia MF, et  al. The influence \nof smoking on the survival of dental implants: a 5-year pragmatic \nmulticenter retrospective cohort study of 1727 patients. Eur J Oral \nImplantol. 2010;4(1):39–45.\n\t30.\t \u0007Marrone A, Lasserre J, Bercy P, Brecx MC. Prevalence and risk fac-\ntors for peri-implant disease in Belgian adults. Clin Oral Implants \nRes. 2013;24:934–940.\n\t31.\t \u0007Renvert S, Aghazadeh A, Hallstrom H, Persson GR. Factors related \nto peri-implantitis - a retrospective study. Clin Oral Implants Res. \n2014;25(4):522–529.\n\t32.\t \u0007Bormann KH, Stühmer C, Z’Graggen M, et al. IL-1 polymorphism \nand periimplantitis. A literature review. Schweiz Monatsschr Zahn-\nmed. 2010;120:510–520.\n\t33.\t \u0007Löe H. The gingival index, the plaque index and the retention index \nsystems. J Periodontol. 1967;38(6):610–616, ISSN 0022- 3492.\n\t34.\t \u0007Lekholm R, Adell R, Lindhe J, et al. Marginal tissue reactions at \nosseointegrated titanium fixtures (II). A cross-sectional study. Int J \nOral Maxillofac Surg. 1986;15:53–61.\n\t35.\t \u0007Mombelli A, Marxer M, Gaberthuel T, et  al. The microbiota of \nosseointegrated implants in patients with a history of periodontal \ndisease. J Clin Periodontol. 1995;22:124–130.\n\t36.\t \u0007Lindquist LW, Rocker B, CarlsonGE. Bone resorption around fix-\ntures in edentulous patients treated with mandibular fixed tissue-\nintegrated prostheses. J Prosthet Dent. 1988;59:59–63.\n\t37.\t \u0007Newman MG, Flemmig TF. Periodontal considerations of \nimplants and implant associated microbiota. Int J Oral Implantol. \n1988;5(1):65–70.\n\t38.\t \u0007Orton GS, Steele DL, Wolinsky LE. The dental professional’s role \nin monitoring and maintenance of tissue-integrated prostheses. Int J \nOral Maxillofac Implants. 1989;4(4):305–310.\n\t39.\t \u0007Etter TH, Håkanson I, Lang NP, Trejo PM, Caffesse RG. Heal-\ning after standardized clinical probing of the perlimplant soft tis-\nsue seal: a histomorphometric study in dogs. Clin Oral Implants Res. \n2002;13(6):571–580.\n\t40.\t \u0007Ericsson I, Lindhe J. Probing at implants and teeth: an experimental \nstudy in the dog. J Clin Periodontol. 1993;20:623–627."
  },
  {
    "page": 74,
    "content": "1214\nPART VIII    Dental Implant Maintenance\n\t41.\t \u0007Lang NP, Berglundh T, Heitz-Mayfield LJ, Pjetursson BE, Salvi \nGE, Sanz M. Consensus statements and recommended clinical pro-\ncedures regarding implant survival and complications. Int J Oral \nMaxillofac Implants. 2004;19(l):150–154.\n\t42.\t \u0007Heitz-Mayfield LJ. Peri-implant diseases: diagnosis and risk indica-\ntors. J Clin Periodontol. 2008;35(8 l):292–304.\n\t43.\t \u0007Humphrey S. Implant maintenance. Dent Clin North Am. \n2006;50(3):463–478.\n\t44.\t \u0007Lindhe J, Meyle J, Group D of European Workshop on Periodontol-\nogy. Peri-implant diseases: Consensus report of the Sixth European \nWorkshop on Periodontology. J Clin Periodontol. 2008;35(8):282–\n285.\n\t45.\t \u0007Lang NP, Berglundh T. Working group 4 of the Seventh European \nWorkshop on Periodontology. Periimplant diseases: where are we \nnow? – Consensus of the Seventh European Workshop on Periodon-\ntology. J Clin Periodontol. 2011;38(11):178–181.\n\t46.\t \u0007Jepsen S, Rühling A, Jepsen K, et al. Progressive peri-implantitis. \nIncidence and prediction of peri-implant attachment loss. Clin Oral \nImplants Res. 1996;7(2):133–141.\n\t47.\t \u0007Luterbacher, Mayfield L, Bragger U, Land NF. Diagnostic cheracter-\nistics of clinical and microbiological tests for monitoring periodontal \nand peri-implant mucosal tissue conditions during supportive peri-\nodontal therapy (SPT). Clin Oral Implants Res. 2000;11(6):521–\n529.\n\t48.\t \u0007Luterbacher S, Mayfield L, Bragger U, et al. Diagnostic characteris-\ntics of clinical and microbiological tests for monitoring periodontal \nand periimplant mucosal tissue conditions during supportive peri-\nodontal therapy (SPT). Clin Oral Implants Res. 2000;11:52–59.\n\t49.\t \u0007Gerber JA, Tan WC, Balmer TE, et al. Bleeding on probing and \npocket probing depth in relation to probing pressure and mucosal \nhealth around oral implants. Clin Oral Impl Res. 2009;20(1):75–78.\n\t50.\t \u0007Mombelli A, Buser D, Lang NP, et al. Comparison of periodontal \nand peri-implant probing by depth force pattern analysis. Clin Oral \nImplants Res. 1997;8:448–454.\n\t51.\t \u0007van Steenberghe D. Periodontal aspects of osseointegrated oral \nimplants modum Branemark. Dent Clin North Am. 1988;32:355–\n370.\n\t52.\t \u0007Gallucci GO, Grütter L, Chuang SK, Belser UC. Dimensional \nchanges of peri‐implant soft tissue over 2 years with single‐implant \ncrowns in the anterior maxilla. J Clin Periodontol. 2011;38:293–299.\n\t53.\t \u0007Mombelli A, Müller N, Cionca N. The epidemiology of peri-\nimplantitis. Clin Oral Implants Res. 2012;23(6):67–76.\n\t54.\t \u0007Misch CE, Resnik R. Misch’s Avoiding Complications in Oral Implan-\ntology-E-Book. Elsevier Health Sciences; 2017.\n\t55.\t \u0007Ross-Jansaker AM, Renvert H, Lindahl C, Renvert S. Nine-to four-\nteen-year follow-up of implant treatment. Part III: factors associated \nwith peri-implant lesions. J Clin Periodontol. 2006;33(4):296–301.\n\t56.\t \u0007Bouri Jr A, Bissada N, Al-Zahrani MS, Fadoul F, Nounen I. \nWidth of keratinized gingiva and the health status of the support-\ning tissues around dental implants. Int J Oral Maxillofac Implants. \n2008;23(2):323–326.\n\t57.\t \u0007Schrott AR, Jimenez M, Hwang JW, Fiorellini J, Weber HP. \nFive-year evaluation of the influence of keratinized mucosa on \nperi-implant soft-tissue health and stability around implants sup-\nporting full-arch mandibular fixed prostheses. Clin Oral Implants \nRes. 2009;20(10):1170–1177.\n\t58.\t \u0007Adibrad M, Shahabuei M, Sahabi M. Significance of the width \nof keratinized mucosa on the health status of the supporting tis-\nsue around implants supporting overdentures. J Oral Implantol. \n2009;35(5):232–237.\n\t59.\t \u0007Chung DM, Oh TJ, Shotwell JL, Misch CE, Wang HL. Significance \nof keratinized mucosa in maintenance of dental implants with differ-\nent surfaces. J Periodontol. 2006;77(8):1410–1420.\n\t60.\t \u0007Lin GH, Chan HL, Wang HL. The significance of keratinized \nmucosa on implant health: a systematic review. J Periodontol. \n2013;84:1755–1767.\n\t61.\t \u0007Gobbato L, Avila-Ortiz G, Sohrabi K, Wang CW, Karimbux N. The \neffect of keratinized mucosa width on peri-implant health: a system-\natic review. Int J Oral Maxillofac Implants. 2013;28:1536–1545.\n\t62.\t \u0007Bronstein D, Suzuki K, Garashi M, Suzuki JB. Contemporary \nesthetic periodontics. StomaEduJ. 2016;3(2):26–36.\n\t63.\t \u0007Esposito M, Maghaireh H, Grusovin MG, Ziounas I, Worthing-\nton HV. Soft tissue management for dental implants: what are the \nmost effective techniques? A Cochrane systematic review. Eur J Oral \nImplantol. 2012;5:221–238.\n\t64.\t \u0007Lang PL, Berglundh T. Working group 4 of the VII E.W.o.P. \nPeri-implant diseases: where are we now? Consensus of the Sev-\nenth European Workshop on Periodontology. J Clin Periodontol. \n2011;38(11):178–181.\n\t65.\t \u0007Froum S, Rosen P. A Proposed Classification for peri-implantitis. Int \nJ Periodontics Restorative Dent. 2012;32(5):533–540.\n\t66.\t \u0007Miyata T, Kobayashi Y, Araki H, Ohto T, Shin K. The influ-\nence of controlled occlusal overload on peri-implant tissue. Part \n3: a histological study in monkeys. Int J Oral Maxillofac Implants. \n2000;15(3):415–431.\n\t67.\t \u0007White SC, Pharoah M. Oral Radiology: Principles and Interpretation. \n5th ed. St Louis: Mosby; 2004.\n\t68.\t \u0007Friedland B. The clinical evaluation of dental implants: a review \nof the literature, with emphasis on the radiographic aspects. Oral \nImplantol. 1987;13:101–111.\n\t69.\t \u0007Naitoh M. Labial bone assessment surrounding dental implant \nusing cone-beam computed tomography:. Clin. Oral Impl. Res. \n2012;23:970–974.\n\t70.\t \u0007Gröndahl K, Ekestubbe A, Gröndahl HG. Radiography in Oral \nEndosseous Prosthetics. Goteborg, Sweden: Nobel Biocare AB; 1996.\n\t71.\t \u0007Adell R, Lekholm U, Rockler B, Brånemark PI. A 15-year study of \nosseointegrated implants in the treatment of the edentulous jaw. Int \nJ Oral Surg. 1981;10(6):387–416.\n\t72.\t \u0007Shin YK, Han CH, Heo SJ, Kim S, Chun HJ. Radiographic evalu-\nation of marginal bone level around implants with different neck \ndesigns after 1 year. Int J Oral Maxillofac Implants. 2006;21(5):789–\n794.\n\t73.\t \u0007Lazzara RJ, Porter SS. Platform switching: a new concept in implant \ndentistry for controlling postrestorative crestal bone levels. Int J Peri-\nodontics Restorative Dent. 2006;26(1):9–17.\n\t74.\t \u0007Resnik RR. Personal Communication; 2017.\n\t75.\t \u0007Quirynen M, Naert I, Teerlinck J, et al. Periodontal indices around \nosseointegrated oral implants supporting overdentures. In: Schepers \nE, Naert J, Theunier G, eds. Overdentures on Oral Implants. Leuwen, \nBelgium: Leuwen University Press; 1991.\n\t76.\t \u0007Herrmann JS, Cochran DL, Nummikoski PV, et al. Crestal bone \nchanges around titanium implants: a radiographic evaluation of \nunloaded non-submerged and submerged implants in the canine \nmandible. J Periodontol. 1997;68:1117–1130.\n\t77.\t \u0007Zitzmann N, Berglundh T, Marinello CP, et al. Experimental peri-\nimplant mucositis in man. J Clin Periodontol. 2001;28:517–523.\n\t78.\t \u0007Humphrey S. Implant maintenance. Dental Clin North Am. \n2006;50(3):463–478.\n\t79.\t \u0007Biesbrock AR, Bartizek RD, Gerlach RW, Terézhalmy GT. Oral \nhygiene regimens, plaque control, and gingival health: a two-month \nclinical trial with antimicrobial agents. J Clin Dent. 2007;18(4):101–\n105.\n\t80.\t \u0007Kracher CM, Smith WS. Oral health maintenance of dental \nimplants. Dent Assist. 2010;79(2):27–35.\n\t81.\t \u0007Esposito M, Worthington H, Coulthard P, et  al. Maintaining \nand reestablishing health around osseointegrated oral implants: a \nCochrane systematic review comparing the efficacy of various treat-\nments. Periodontology. 2003;33:204–212.\n\t82.\t \u0007Rasperini G, Pellegrini G, Cortella A, et al. The safety and accept-\nability mucosa in patients with oral implants in aesthetic areas: a \nprospective. Implantol. 1(3):221–228.\n 83. \u0007Vandekerckhove B, Quirynen M, Warren PR, et al. The safety and \nefficacy of a powered toothbrush on soft tissues in patients with"
  },
  {
    "page": 75,
    "content": "1215\nCHAPTER 42  Implant Maintenance: Long-Term Implant Success\nimplant-supported fixed prostheses. Clin Oral Investig. 2004;8(4). \n26–10.\n\t84.\t \u0007Wingrove S. Focus on implant home care: before, during, and after \nrestoration. RDH. 2013;33(9):52–58.\n\t85.\t \u0007Nakagawa M, Matsuya S, Shiraishi T, Ohta M. Effect of fluoride \nconcentration and pH on corrosion behavior of titanium for dental \nuse. J Dent Res. 1999;78(9):1568–1572. https://doi.org/10.1177/00\n220345990780091201.\n\t86.\t \u0007Matono Y, Nakagawa M, Matsuya S, Ishikawa K, Terada Y. Corro-\nsion behavior of pure titanium and titanium alloys in various con-\ncentrations of acidulated phosphate fluoride (APF) solutions. Dent \nMat J. 2006;25(1):104–112.\n\t87.\t \u0007Barnes CM, Russell CM, Reinhardt RA, et al. Comparison of irri-\ngation to floss as an adjunct to tooth brushing: effect on bleeding, \ngingivitis, and supragingival plaque. J Clin Dent. 2005;16(3):71–77.\n\t88.\t \u0007Rosema NA, Hennequin-Hoenderdos NL, Berchier CE, et  al. \nThe effect devices on gingival bleeding. J Int Acad Periodontol. \n2011;13(1):2–10.\n\t89.\t \u0007Sharma NC, Lyle DM, Qaqish JG, et al. Effect of a dental water jet \nwith bleeding in adolescent patients with fixed orthodontic appli-\nances. Am J. 2008;133(4):565–571.\n\t90.\t \u0007Magnuson B, Harsono M, Silberstein J, et al. Water Flosser Vs. Floss: \nComparing Reduction in Bleeding Around Implants [Abstract]. Seattle \nWA: Presented at the International Association for Dental Research \nMeeting; March 23, 2013.\n\t91.\t \u0007Brough Muzzin KM, Johnson R, Carr P, Daffron P. The den-\ntal hygienist’s role in the maintenance of osseointegrated dental \nimplants. J Dent Hyg. 1988;62(9):448–453.\n\t92.\t \u0007Friedman LA. Oral hygiene for dental implant patients. Tex Dent J. \n1991;108(5):21–23.\n\t93.\t \u0007Felo A, Shibly O, Ciancio SC, et  al. Effects of subgingival \nchlorhexidine irrigation on peri-implant maintenance. Am J Dent. \n1997;10(2):107–110.\n\t94.\t \u0007Meffert RM. The soft tissue interface in dental implantology. J Dent \nEduc. 1988;52(12):810–811.\n\t95.\t \u0007Koumjian JH, Kerner J, Smith RA. Implants: hygiene maintenance \nof dental implants. Ill Dent J. 1991;60(1):54–59.\n\t96.\t \u0007Thomson-Neal D, Evans GH, Meffert RM. Effects of various pro-\nphylactic treatments on titanium, sapphire, and hydroxyapatite-\ncoated implants: an SEM study. Int J Periodontics Restorative Dent. \n1989;9(4):300–311.\n\t97.\t \u0007Misch CE. Implant quality scale: a clinical assessment of the health-\ndisease continuum. Oral Health. 1998;88:15–25."
  },
  {
    "page": 76,
    "content": "1216\nEdentulous Maxilla\n\t1.\t \u0007No treatment\nDisadvantage: Difficulty in eating/speaking, continued bone \nloss, maintain current prosthesis (ill-fitting)\n\t2.\t \u0007Complete upper denture\nAdvantage: Minimal treatment, fast\nDisadvantage: Removable prosthesis disadvantages, difficulty \nin eating/speaking, palate coverage, continued bone loss\n\t3.\t \u0007Implant-supported overdenture (Removable, RP5)\nAdvantage: Removable prosthesis that “clips” in, added reten-\ntion, soft tissue support\nDisadvantage: Full denture with palate, needs to be removed some-\ntime each day removable, clips need changed on a regular basis \n(additional cost), may have associated mobility of prosthesis\n\t4.\t \u0007Implant-supported overdenture (removable, RP4)\nAdvantage: Removable prosthesis that clips in, horseshoe shaped (no \nfull palate), no soft tissue coverage, totally implant supported\nDisadvantage: needs to be removed sometime each day removable \nprosthesis, clips need changed on a regular basis (additional cost)\n\t5.\t \u0007Implant-supported fixed prosthesis (fixed)\nAdvantage: Fixed prosthesis (Non-Removable) increased biting \nforce, Closest prosthesis to natural teeth\nDisadvantage: Usually will require extensive bone grafting and more \nimplants, possible need for pink porcelain or acrylic because of \nthe amount of bone loss, teeth will be larger (FP-2/FP-3), may \nnot be able to increase soft tissue support, increased expense \nEdentulous Mandible\n\t1.\t \u0007No treatment\nDisadvantage: Difficulty in eating/speaking, continued bone \nloss, maintain current prosthesis (ill-fitting)\n\t2.\t \u0007Complete lower denture\nAdvantage: Minimal treatment, fast\nDisadvantage: Removable prosthesis, difficulty in eating/speak-\ning, continued bone loss\n\t3.\t \u0007Implant-supported overdenture (Removable, RP5)\nAdvantage: Removable prosthesis that clips in, less implants re-\nquired, soft tissue support\nDisadvantage: Full denture, needs to be removed sometime \neach day removable, clips need changed on a regular basis \n(additional cost),May have associated mobility\n\t4.\t \u0007Implant-supported overdenture (removable, RP4)\nAdvantage: Removable prosthesis that clips in, no soft tissue \ncoverage\nDisadvantage: needs to be removed sometime each day, remov-\nable, clips need changed on a regular basis (additional cost)\n\t5.\t \u0007Implant-supported fixed prosthesis (fixed), Requires more \nimplants than RP-5\nAdvantage: Fixed prosthesis (Non-Removable) increased biting \nforce, Closest prosthesis to natural teeth\nDisadvantage: Usually will require more implants, increased ex-\npense,  possible need for pink porcelain or acrylic because of \nthe amount of bone loss, teeth will be larger (FP-2/FP-3), \nmay not be able to increase soft tissue support \nSingle Tooth Missing\n\t1.\t \u0007No treatment\nDisadvantage: Esthetics, adjacent teeth may move (tilting), su-\npraeruption, decreased mastication, food impaction, con-\ntinued bone loss, occlusal force\n\t2.\t \u0007Removable Partial denture\nAdvantage: Minimal treatment, fast\nDisadvantage: Removable prosthesis, difficulty in eating/speak-\ning, extensive pressure on adjacent teeth/soft tissue which \nleads to additional tooth loss, poor long-term success rate, \nincreased bone loss, tissue soreness\n\t3.\t \u0007Fixed partial denture\nAdvantage: Fast, esthetic, usually no need for hard/soft tissue \ngrafting\nDisadvantage: Alteration of adjacent teeth, higher incidence of \ndecay, increased endodontic treatment (~15%), hygiene dif-\nficulty\n\t4.\t \u0007Implant-supported crown\nAdvantage: No alteration of adjacent teeth, higher success \nrate than fixed partial denture (most studies >90% suc-\ncess rate)\nDisadvantage: Longer treatment time, requires bone quality \nand quantity, esthetic issues possible \nMultiple Missing Teeth\n\t1.\t \u0007No treatment\nDisadvantage: Esthetics, adjacent teeth will move (tilting), su-\npraeruption, decreased mastication, continued bone loss, \nfood impaction, occlusal force\n\t2.\t \u0007Removable Partial denture\nAdvantage: Minimal treatment, fast\nDisadvantage: Removable prosthesis, difficulty in eating/speak-\ning, tissue soreness, places extensive pressure on adjacent \nteeth/soft tissue which leads to additional tooth loss, poor \nlong-term success rate\n\t3.\t \u0007Fixed partial denture (if indicated)\nAdvantage: Fast, esthetic\nDisadvantage: Alteration of adjacent teeth, higher incidence \nof decay, increased endodontic treatment (~ 15%), hygiene \ndifficulty\n\t4.\t \u0007Implant-supported prosthesis\nAdvantage: No alteration of adjacent teeth, higher success rate \nthan fixed partial denture (most studies >90% success rate)\nDisadvantage: Longer treatment time, requires bone quality \nand quantity, esthetic issues possible\nAppendix\nTreatment Plan Options"
  },
  {
    "page": 77,
    "content": "1217\nIndex\nA\nAATB. See American Association of \nTissue Banks\nAbsorbable sutures, 622–623, 625, \n628t–629t, 630f\nAbutment(s)\nangled, 43, 43f, 141\nfor cement-retained restorations, 547, \n548f\ncustom, 33f–34f, 36, 547, 548f\nexternal mechanism of, 100–101\nfor fixed partial denture, 13, 534\nforces on, 9\nhealing. See Healing abutment\nheight of, 509\nintermediary, 167\ninternal mechanism of, 101, 103f\nmodification of, 1175\nmultiunit, 39f, 549f, 881f\nnatural, 513b, 521–524\noptions for, 514\npain related to, 1202, 1204f\nperiodontal health of, 13\npermucosal, 32, 1208f\npier, 520–521, 520f–521f\nfor removable partial denture, 13\nroot surface area of, 523\nscanning, 34, 38f\nfor screw-retained restorations, \n548–551\nsize of, 521–522\ntemporary, 36, 41f\nterminal, 167, 469f\nAbutment-level impressions, 34\nAbutment screw\ncomposition of, 804\ndescription of, 51–52\ndiameter of, 804\nfracture of, 154–155, 156f\nimplant number and, 514\nloosening of, 152–153, 155f, 477, \n801–807\nmovement of, 806–807\nremoval of, 810f–811f\nAccessory foramen, 293, 293f, 757, 759f\nAcellular dermal matrix, 925, 978f, 1169, \n1171f\nAcetaminophen\ndrug interactions, 379t–380t\nnonsteroidal antiinflammatory drugs \nand, 371\npain management uses of, 370, 370b\nAcid etching, 198, 201t\nAcute rhinosinusitis, 307–308, 308f, \n1001–1002, 1002f, 1040t, 1041\nAddison’s disease, 242\nAdenocarcinoma, 310\nAdolescents, implants in, 258, 259f\nAdrenal gland disorders, 241–242, 243t\nAge-related macular degeneration, 264\nAgger nasi cells, 299, 303, 303f\nAggressive periodontitis, 347, 347f\nAging population\nforecasted growth of, 2, 3f\nimplant demand affected by, 2–4\nlife expectancy, 2, 3f–4f, 4\ntooth loss in, 4\nAir emphysema, 775–776, 777f\nAir space, 313\nAlanine aminotransferase, 223, \n224t–226t\nAlbumin, 224t–226t\nAlcohol, 259–260\nAldosterone, 242\nAlkaline phosphatase, 223, 224t–226t\nAll-on-four protocol, 584–585, 585f, \n586b, 594, 876, 877b\nAllergic rhinosinusitis, 308, 308f, \n1002–1003\nAllergies\nimplant-related, 268–269, 270f\ntitanium, 269, 794, 795f\nAlloDerm, 957\nAllografts\ndefinition of, 917, 969b\ndescription of, 28, 29t, 917, 968–969\ndistribution of, 921–922\nfreeze-dried bone, 923–925\nlayering of, 966–967\nmodification of, 930\nosteoconductive, 969b\nosteoinductive, 969b\nparticle form and size, 969\nprocessing of, 921–922\nAllografts (Continued)\nsource of, 921–922\ntypes of, 923–925, 929t, 968–969\nAlloplasts\ndefinition of, 917\ndescription of, 28, 29t, 969\ndistribution of, 923\nproduction of, 923\ntypes of, 925–926, 929t, 969–970\nAllowash XG process, 919–920\nAluminum oxide ceramics, 114, 114t, 126\nAlveolar bone\nformation of, 7, 7f\nheight of, losses in, 8, 8f\nimaging of, 316–318\nimplant-supported prostheses effect on, \n15, 15f\nloss of, 7, 8f, 933\nmaintenance of, 7\nremodeling and resorption of, 8\nAlveolar ridge\natrophic, mucosa thickness on, 9–10\naugmentation of, 962\nclassification of, 944\ncontours of, 955f\ndefects of, 944–946\ndeficiency of, 415\nedentulous, treatment planning in, \n937f, 941–946\nexpansion of, 30\npreservation of, 939f\nresorption of, 939, 953f\nAmerican Association of Tissue Banks, \n918, 921\nAmerican Society of Anesthesiologists \nphysical status classification, 227, \n227b, 360, 361t\nAminotransferases, 223\nAmoxicillin, 362, 364t, 1159b\nAmoxicillin/clavulanic acid, 362, 364t\nAnalgesics, 369–371, 369t–370t, \n369b–370b, 373b, 1010\nAnchorage\nexternal abutment mechanism for, \n100–101\ninternal abutment mechanism for, 101, \n103f\nNote: Page numbers followed by f indicate figures; t, tables; b, boxes"
  },
  {
    "page": 78,
    "content": "1218\nIndex\nAnchorage (Continued)\nmini-implants for, 101–103, 105f\nretromolar implant as, 100, 100f, 104f\ntitanium implants for, 98, 99f\nAndrogens, 90–93\nAnemia, 244–245, 247t\nAngina pectoris, 229–233, 234t\nAngiogenesis, 96f\nAngled abutments\ndescription of, 43, 43f\nforce generated by, 141\nAngled implants, 49\nAngular cheilitis, 1135–1136\nAnkylosing spondylitis, 264\nAnodontia\nillustration of, 873f\nsingle-tooth implant for, 535–536, \n726–727\nAnterior loop, 292–293, 292f, 757, 760f\nAnterior mandible, 737–738, 739f, 741f, \n743f\nbone density in, 649\ndescription of, 295, 296f\nextraosseous vessels in, 780–781\nradiographic imaging of, 1107f\nsurgical specimen of, 1108f\nAnterior nasal spine, 725\nAnterior superior alveolar nerve,  \n334, 813\nAnterior superior iliac spine,  \n1094–1095\nAnterior teeth\nbiting force of, 193\nmaxillary\nevaluation of, 706–710\nposition of, 495–496, 496f\nshape of, 707–708, 708f\nsize of, 707–708\nsoft tissue drape of, 708–710\nAnteroposterior distance/spread, 149, \n468, 469f, 513, 567–568, 568f, 577, \n862\nAntibiotics\nallergic reactions to, 361\nbacterial resistance to, 361\nbeta-lactam, 362, 362f, 362b\ncommonly used, 364t\ncomplications of, 361\nlocally applied, 1159, 1159f\npenicillin, 362, 362b, 379t–380t\nprophylactic use of, 353, 359–361, \n365, 1008–1009\nselection of, 361\nsystemic, 1159\ntherapeutic use of, 365\nAnticoagulants, 219–221, 238, 267t\nAntihistamines, 379t–380t\nAntihypertensive medications\nnonsteroidal antiinflammatory drugs \nand, 229\nAntimicrobials\nantibiotics. See Antibiotics\nperi-implant mucositis treated with, \n1148, 1159\nprophylaxis, 1008–1010\nrinses, 1212, 1212f\nAntinuclear antibody test, 256\nAntiseptics, 1148\nAntithrombotics, oral, 266–268\nAntroliths, maxillary sinus, 1006–1007, \n1007f\nApatites, 115\nApical peri-implantitis, 793\nApicocoronal (Z-axis) positioning, \n689–695, 692f\nApicoectomy, 510\nApnea, 228, 257\nAppliance, 385b\nArachidonic acid, 367, 370, 791\nArchaea, 345\nAromatase inhibitors, 263\nArthritis mutilans, 264\nArticaine, 373–374, 373t–374t\nArtifacts, 286–288, 287f–288f\n“As low as reasonably achievable”, 276\nAseptic technique, 360, 620–622, \n621b–622b, 621t, 623f–627f\nAspartate aminotransferase, 223, \n224t–226t\nAspirin, 266–268, 371\nAsthma, 249t\nAsymmetric psoriatic arthritis, 264\nAtopic dermatitis, 264–265\nAtraumatic tooth extraction\nbiomechanics of, 896, 896f\nforceps for, 896–899, 898f\nperiotomes in, 896–899, 897f\nroot tip retention after, 911f\nsocket\ndebridement of, 899, 899f–900f\nfour-wall defect, 902, 903f\nsocket grafting\ncomplications of, 909–911, 910f–911f\ncontraindications for, 908–909, 909f\nhealing after, 908, 908f\ninfection, 908, 909f\nmandibular canal proximity, \n908–909, 909f\nmandibular ramus donor site for, \n902–905, 904f–905f\nmaxillary sinus considerations, 909, \n910f\nmaxillary tuberosity donor site for, \n905–906, 905f–906f\nAtraumatic tooth extraction (Continued)\noverfilling of socket, 909, 911f\nprovisional restorations after, 907, \n908f\nseal surgery for, 906, 907f\ntechnique for, 899–907\ntechnique for, 893–907, 894f–903f\ntheory of, 893\nAtrial fibrillation, 215–216\nAutogenous bone grafts, 28, 29t, 969b\nblock graft, 1074–1076, 1076f–1077f, \n1080–1082\ncomplications of, 1077–1082, \n1078f–1082f\ndefinition of, 917, 969b\ndescription of, 28, 29t\ndonor sites\ncomparison of, 1076–1077, 1077t\nextraoral, 1088–1111\nintraoral, 1054–1087\nmandibular ramus, 293–294, 294f, \n902–905, 904f–905f, 980f, \n1064–1071, 1070f–1072f, \n1071b, 1077t, 1079–1080\nmandibular symphysis, 1056–1064, \n1056f–1066f, 1063b–1064b, \n1077t\nmaxillary tuberosity, 905–906, \n905f–906f, 1021, 1071–1073, \n1072f–1073f, 1077t\nharvesting of, 1021, 1022f\nhistory of, 1054–1055\niliac crest, 430, 431f, 869f\nimplant placement, 1082–1083\nmandibular ramus donor site for,  \n293–294, 294f, 902–905, \n904f–905f, 980f, 1064–1071, \n1070f–1072f, 1071b\nmandibular symphysis donor site \nfor, 1056–1064, 1056f–1066f, \n1063b–1064b\nmaxillary tuberosity donor site for, \n905–906, 905f–906f, 1021, \n1071–1073, 1072f–1073f\nmobility of, 1082f\npostoperative care and instructions, \n1077\nrecipient site for, 1055–1056, \n1056f–1057f\nAutografts, 963, 966\nAutoimmune diseases\nperi-implantitis and, 1196\nrheumatoid arthritis, 256\nscleroderma, 256\nSjögren syndrome, 255–256\nsystemic lupus erythematosus,  \n256"
  },
  {
    "page": 79,
    "content": "1219\nIndex\nAutoradiography\nof bone, 76, 80f\ndescription of, 72\nAvailable bone\nangulation of, 420, 421f, 836\ndensity of, 647–650, 649f, 649b\nDivision A, 420–422, 422f, 422b, \n432–433\nDivision B, 422–425, 423f–424f, \n423b, 425b, 432–433\nDivision C, 426–429, 426b, \n427f–429f, 428b, 433\nDivision D, 430–433, 430f–433f, \n430b\nheight of, 419, 419f\nideal amount of, 698\nfor immediate implant placement, \n834–839\nlength of, 420, 421f, 836\nmeasurement of, 418–420\nin posterior maxilla, 554\nwidth of, 419–420, 419f, 834–836\nAxonotmesis, 817–818, 819f\nAzithromycin, 364t\nB\nBackscatter emission, 73\nBackscatter emission imaging, 75–76, 79f\nBacterial endocarditis, 236–237, 237b\nBactericidal antibiotics, 361\nBacteriostatic antibiotics, 361\nBand of Büngner, 340\nBarium sulfate, 385, 386f\nBarrier membranes. See also Membranes\nguided bone regeneration, 28,  \n957–969\nideal characteristics of, 957b\nnonresorbable, 28, 957–961\nresorbable, 28, 960–961\nselection and placement of, 962–963\nBasal bone, 7–8, 9f\nBasic multicellular units, 913\nBasophils, 218, 224t–226t\nBeam hardening artifact, 286–287, 287f\nBenzodiazepines, 375–376, 379t–380t\nBeta-lactam antibiotics, 362, 362f, 362b, \n1038\nBeta-tricalcium phosphate, 116t\nBIC. See Bone-to-implant contact\nBig-nose variant, 305, 305f, 312f, 1000\nBiguanides, 239b\nBilirubin, 223, 224t–226t\nBio-Oss, 923\nBioactive ceramics, 114–119, 116t\nBioactive glass, 926, 969\nBiochemical profiles, 221–224\nBioCleanse process, 920\nBiofilm\ndescription of, 353\nin peri-implant mucositis, 1143–1144\nin peri-implantitis, 1149\nBiologic width, 24–25, 1192, 1193f\naverage, 159, 159f\nmarginal bone loss and, 159–160, \n159f–160f\nBiologics, 263b, 264–266, 352\nBiomaterials. See also Implant materials\nbiocompatibility of, 108\nbiodegradation of, 110\ncompatibility of, 108\ncorrosion of, 110\ndeformation of, 143\ndesign of, 108–109\nelastic strain of, 108\nfatigue behavior of, 150, 150f\nforces on, 109\nhistory of, 108–109\nmechanical properties of, 109\nphysical properties of, 109\nresearch and development of, 109\nstiffness of, 143\nstress corrosion cracking of, 110, 111f\ntoxicity of, 110–111\nBisphosphonates\ndrug-induced osteonecrosis of the jaw \ncaused by, 261, 261t\nimplant surfaces with, 201–202\nosteoporosis treated with, 252, 252b, \n261–262, 261t\nBite force, 141t, 174, 176t, 192–193\nBitewing radiographs, 317\nBiting force\nimplant-supported prosthesis effects \non, 16\nin posterior maxilla, 555–556, 556f\nBlack triangles, 694f, 1129, 1129f–1130f\nBlade implants, 22–23, 22f–23f, 48, 49t\nBleeding-related complications, 778–785, \n779f–784f\nBleeding tests, 218–221, 219f\nBleeding time, 220, 224t–226t\nBlock grafts, 1074–1076, 1076f–1077f, \n1080–1082, 1097–1099, 1099f\nBlood pressure\nclassification of, 233t\nelevated. See Hypertension\nmanagement of, 214–215\nBlood urea nitrogen, 224, 224t–226t\nBody temperature, 216\nBone\nandrogens’ effect on, 90–93\napposition of, 86f\nautoradiography of, 76, 80f\navailable. See Available bone\nBone (Continued)\nbackscatter emission imaging of, \n75–76, 79f\nbundle, 79, 82f\ncalcium in\nconservation of, 87–93\nhomeostasis of, 84–85, 89f\nmetabolism of, 84, 88f\nparathyroid hormone and, 84–85\nclassification of, 76–79, 416, 417f, \n453–454\ncomposite, 78–79, 82f\ncortical. See Cortical bone\nfluorescent labels of, 73–74\nfunctions of, 69\nimplant surface and, interactions \nbetween, 198f\nlamellar, 78, 165\nloss of. See Bone loss\nmacroscopic structure of, 454f\nmechanical properties of, 868, 868f\nmetabolism of, 84–87, 88f–89f\nmicrocomputed tomography of, \n75–76, 79f–80f\nmicroindentation of, 75–76\nmicroradiography of, 74–75, 75f–78f\nmineralization of, 74\nmineralized sections of, 73, 75f\nmodeling of, 79–84, 83f, 87t\nmorphology of, 69–71, 70f\nnuclear volume morphometry of, 76, \n81f\noverload zones for, 452–453\nphysiology of, 72–79, 164–165\npolarized light of, 73, 75f\nprimary mineralization of, 74\nproperties of, 69\nremodeling of\ncell signaling for, 913\ncell types in, 913\ncontrol factors for, 87b\ndefinition of, 893b, 913, 937b\nfunctional loading of implants and, \n82\nhistology of, 864f\nmicrocomputed tomography of, 76, \n80f\noverview of, 79–81, 251\nparathyroid hormone effects on, 87\nprimary stability in, 21\npurpose of, 69\nself-tapping implant and, 863\nstrain and, 161, 452\nstress and, 161\ntrabecular bone, 452\nresorption of\nAtwood’s stages of, 8f"
  },
  {
    "page": 80,
    "content": "1220\nIndex\nBone (Continued)\nin edentulous arches, 8f\nin maxillary sinus, 989\nin posterior maxilla, 554f–555f\nsecondary mineralization of, 74, 78\nsex hormones’ effect on, 90–93\nskeletal adaptation of, 79–81\nstrength of, 458, 460f\ntissue classification for, 76–79\ntrabecular. See Trabecular bone\nturnover of, 75f, 80–81, 82f\nwoven, 78, 165\nBone augmentation\nceramics for, 114–115\nin crown height space, 189\ndefinition of, 28\ndescription of, 913\nguided bone regeneration, 28\nprosthetic replacement versus, 506\nsocket-shield technique for, 30, \n30f–31f\nsurgical techniques for, 30\ntechniques for, 28–30, 28f\nvertical, 742–744, 746f\nBone dehiscence, 288, 288f\nBone density\nfor bone regeneration, 967\nbone strength based on, 458, 460f\nbone-to-implant contact and, 460–\n461, 462f–463f\nclassification of, 453–454, 454t, 648, \n649f\ncone beam computerized tomography \nof, 286, 393, 393f, 393b, 457, \n458f, 458b\nof cortical bone, 459f\nD1, 454–455, 454t–455t, 456f, 462f\nD2, 454–455, 454t–455t, 457f, 462f\nD3, 454–455, 454t–455t, 457f, 463f\nD4, 454–455, 454t–455t, 456f–457f, \n463f, 553f\nD5, 454, 454t–455t\ndescription of, 162, 167\ndetermination of, 454–458, 649b\nHounsfield units and, 457, 649b\nimmediate implant placement and, \n837–838\nfor immediate loading, 861\nimplant positioning and, 700–701\nimplant success rates affected by, 450, \n451f\nlocation differences in, 455–457\nMisch classification of, 454, 454t, 648, \n649f\nin posterior maxilla, 532–535\nradiographic evaluation of, 457–458\nstress transfer and, 461, 463f\nBone density (Continued)\ntactile sensation and, 458, 459f\ntreatment planning based on, 461–\n464, 464b\nvariable, 450–453, 451f\nBone diseases\ncemento-osseous dysplasia, 254, 255t\nectodermal dysplasia, 254, 255t\nfibrous dysplasia, 252\nmultiple myeloma, 253\nosteitis deformans, 253\nosteogenesis imperfecta, 254\nosteomalacia, 252–253, 255t\nosteomyelitis, 254\nosteoporosis. See Osteoporosis\nBone file, 612, 613f\nBone fixation screws, 960, 962–967, \n972f–973f, 976, 1082, 1083f\nBone graft(s)\nallografts, 28, 29t, 969b\napplication of, 962–963\nautogenous. See Autogenous bone \ngrafts\ncalvarial. See Calvarial grafts\nclassification of, 935b\nextraoral, 1088–1111\nhealing times for maturation of, \n974–980\nindications for, 28\ninfection, 985\nintraoral. See Autogenous bone grafts\nmaterials for, 28, 28f, 29t\nosteoconduction of, 30\nosteogenesis of, 30\nosteoinduction of, 30\npostoperative treatment of, 970–980\nproperties of, 30\nprovisional restoration, 973–974\nsimulation of, 393, 395f\nsite preparation for, 28\nsuturing of, 969–970\ntibial, 1099–1102, 1101f, 1101b\nvascularized composite graft, \n1102–1105, 1103b–1104b, \n1104f–1106f\nxenografts, 28, 29t, 969b\nBone graft substitutes\ncharacteristics of, 927–928\nclassification of, 917\ndefinition of, 913\nend-user responsibilities, 920–921\nfuture of, 928–930\nhandling of, 920–921\nideal, 917\noversight of, 917–918\nsingle-patient uses for, 921\nfor socket grafting, 909–911\nBone graft substitutes (Continued)\nsterility of, 919\nsummary of, 930\nBone grafting\ncomplications of, 974\nincision line opening, 796–797, 980\nincisions for, 951b, 960f\nindications for, 933–935\ninlay, 30\nmandibular ramus donor site for, \n902–905, 904f–905f\nmaxillary tuberosity donor site for, \n905–906, 905f–906f\nonlay, 30\ntooth extraction socket, 899–907\nBone healing\ndescription of, 245, 258\nsurgical trauma effects on, 862–863\ntriad of, 917f\nBone-implant interface, 51, 453f\nBone-level implant\ncollar for, 54, 55f\ndescription of, 24–25, 24f\nplacement of, 55f\nBone loss\nAtwood classification of, 416f\ndescription of, 935f\nfactors affecting the rate of, 8b\nin mandible, 8, 12f\nmarginal. See Marginal bone, loss of\nin maxilla, 9, 12f\nmechanical stress as cause of, 164f\nprostheses as cause of, 7, 8f\nin women, 90–93\nBone mass, 251\nBone modeling, 893b, 914, 937b\nBone morphogenetic proteins, 202–203, \n224t–226t, 915, 962\nBone regeneration\nbone density for, 967\ncellular process, 937–939\ndefinition of, 893b\nguided. See Guided bone regeneration\nmechanisms of, 915–917\nPASS principles for, 950b\nterminology associated with, 937b\nBone repair, 914–917, 937b\nBone scrapers, 961, 981f, 983f\nBone spreading, 425\nBone-supported guides, 398, 398f, \n879b–880b\nBone-to-implant contact, 17, 198,  \n200\nbone density based on, 460–461, \n462f–463f, 553, 989\nfor D1 bone, 654f\ndefinition of, 21"
  },
  {
    "page": 81,
    "content": "1221\nIndex\nBone-to-implant contact (Continued)\nimmediate loading effects on, 861\nof zirconia implants, 203\nBone turnover, 863, 914\nBone volume, 415, 416f\nBone wax, 790, 790f\nBone–implant interface, 154f\nBony defects, 840–841, 900–901, 942–949\nBosker implant, 40\nBotulinum toxin injections\nbotulinum toxin type A, 1112–1114, \n1114t, 1115f\ncomplications of, 1124–1125\ncontraindications for, 1124\nduration of action, 1114\ngummy smile treated with,  \n1120–1124, 1121f–1126f\nhistory of, 1112\nmasseter muscle hypertrophy treated \nwith, 1114–1118, 1116f–1118f\nmechanism of action, 1112, 1130f\nparafunctional habits treated with, \n1114–1118\npostoperative instructions for, 1124\npreparation of, 1112–1114\ntemporalis muscle treated with, 1118, \n1119f\ntemporomandibular joint syndrome/\ntemporomandibular dysfunction \ntreated with, 1119–1124, 1121f\nBotulinum toxin type A, 1112–1114, \n1114t, 1115f\nBrain natriuretic peptide, 236\nBrånemark, Per-Ingvar\nimplants designed by, 20, 23, 23f, 27, \n197–198, 544, 544f, 581, 860\nphotograph of, 21f\nBreast cancer, 265–266\nBromodeoxyuridine \nimmunocytochemistry, 76\nBronchodilators, 248\nBruising, 792f, 793\nBrushite, 116t\nBruxism\nbiting forces created by, 175\ncervical erosion associated with, 181\ncharacteristics of, 184t\ndescription of, 167\ndiagnosis of, 175–178, 176f–177f\nengram pattern of, 177, 177f\nincisal guidance in, 178, 178f\nmasticatory forces affected by, 177\nocclusal guards for, 179–180, 180f, 184\nsigns and symptoms of, 175–176\ntreatment planning for, 183–184, 184t\nwear patterns associated with,  \n176–177, 176f–177f, 179f\nBuccal artery, 748, 783, 783f\nBuccal plate, 893, 894f, 940f\nBuccinator muscle\nanatomy of, 332–333, 336–337\nattachments of, 11\nBuccolingual (“Y-axis”) positioning, \n682–687, 684f–687f\nBUN. See Blood urea nitrogen\nBundle bone, 79, 82f\nBupivacaine, 373t–374t, 374\nBurs, 611, 612f, 650, 824, 826f, 1061f\nButt-joint, 27\nButtress threads, 26f, 51f, 59, 60f\nC\nCAD/CAM technology\nchairside systems, 405\ncustom abutments created using, 36, \n39f\ndigital scanner process, 405, 406f–409f\ndigital systems, 405\nimmediate prosthesis fabrication, 1107f\nlaboratory implant applications of, 405\nmaterials, 405\noptical impressions, 404–405, 405b\nrestorative implant applications of, 405\ntreatment planning uses of, 405\nworkflow for, 404\nCalcified carotid artery atheroma, 306, \n307f\nCalcitonin, 87\nCalcium\nin bone\nconservation of, 87–93\nhomeostasis of, 84–85, 89f\nmetabolism of, 84, 88f\nparathyroid hormone and, 84–85\ndaily expenditure of, 87\ndietary recommendations for, 92t\nfood sources of, 92t\nmetabolism of, 84, 88f\nparathyroid hormone and, 84–85, 89f, \n250–251\nrecommended daily allowance of, 87–90, \n251\nserum, 87, 222, 222t, 224t–226t\nsupplementation of, 90, 251\nCalcium channel blockers, 229\nCalcium phosphate\nceramics, 114–119, 115b, 116t\nimplant surface treated with, 203\nCalcium sulfate, 923, 926\nCaldwell-Luc procedure, 558, 1010\nCalvarial grafts\nanatomy of, 1090, 1090f–1091f\ncase study of, 1092, 1093f–1094f\ncomplications of, 1090–1092\nCalvarial grafts (Continued)\ndescription of, 1089–1092\nharvesting of, 1090f\nincision for, 1091f\ntechnique for, 1090, 1091f\nCanalis sinuosus, 306, 307f, 813f\nCancellous compaction, 78–79\nCandida albicans, 1148\nCanines\nfixed prostheses for, 469–471, \n470f–471f\nmaxillary, 707\nCantilever length, 147f–148f, 149, 163\nCantilevers, 468, 468f, 514–516, 516f, \n584, 802\nCarbon compounds, 119\nCarbon dioxide, 224t–226t\nCarbon silicon compounds, 119\nCarbonate apatite, 969\nCardiovascular diseases\nangina pectoris, 229–233, 234t\nbacterial endocarditis, 236–237, 237b\ncerebrovascular accident, 238\ncongestive heart failure, 235–236, \n235b–236b\nhypertension, 227–229, 229b, 233t\nmyocardial infarction, 234–235, 235t\nvalvular heart disease, 236–237\nCaries\nfixed partial denture and, 534\nprevalence of, 4\nremoval of, 523\nrestoration for, 510\nstatistics regarding, 4\nCarotid artery atheromas, calcified, 306, \n307f\nCefadroxil, 364t\nCefuroxime axetil, 1008–1009\nCelecoxib, 370b\nCell-based products, 930\nCell culture technology, 928\nCell kinetics, 72\nCement, retained, 1172–1179, 1173f\nCement-enamel junction, 420, 514, 691\nCement-retained crown, 36, 545–546, \n545f\nCement-retained restorations\nabutments for, 547\nangulation of, 688f\nscrew loosening with, 805–806\ntooth replacement uses of, 36, 545–\n546, 545f\nCemento-osseous dysplasia, 254, 255t\nCentric occlusion, 504\nCentric relation occlusion, 504–505, 507\nCentripetal circulation, 338\nCephalexin, 364t"
  },
  {
    "page": 82,
    "content": "1222\nIndex\nCephalosporins, 362, 363b, 364t\nCeramics\naluminum oxide, 114, 114t, 126\nbioactive, 114–119, 116t\nbiodegradable, 114–119, 116t\nbone augmentation and replacement \nuses of, 114–115\ncalcium phosphate, 114–119, 115b, \n116t\ncarbon, 119\ncarbon silicon compounds, 119\nconductivity of, 118–119\ndefinition of, 114\ndensity of, 118–119\ndiscoloration of, 130\nengineering properties of, 114t\nsolubility of, 118–119\nsurface of, 126\ntitanium oxide, 114, 114t\nzirconium oxide, 114, 114t\nCerebrovascular accident, 238\nCervical abfraction, 181f\nCervical erosion, 181\nChemotaxis, 915\nChewing efficiency, implant-supported \nprosthesis effects on, 16\nCHF. See Congestive heart failure\nChlorhexidine, 240, 348, 365, 365b, \n1148, 1148f, 1212, 1212f\nCholecalciferol, 90\nChristensen phenomenon, 499\nChronic bronchitis, 246–248\nChronic obstructive pulmonary disease, \n216–217, 246–248, 248t\nChronic periodontitis, 347–348\nChronic rhinosinusitis, 308, 1002\nCHS. See Crown height space\nCigarette smoking. See Smoking\nCiprofloxacin, 363–364, 379t–380t\nCirrhosis, 248–249\nCitric acid, 365, 366f\nClarithromycin, 364t\nClass II malocclusion, 73f\nClavulanic acid, 362\nClearant process, 920\nClenching\ncervical erosion associated with, 181\ncharacteristics of, 184t\ndescription of, 167\ndiagnosis of, 180–181, 181f\nmasseter hypertrophy associated with, \n181, 182f\nmuscle evaluation for, 181\nsigns of, 180\ntongue scalloping associated with, 181, \n182f\ntreatment planning for, 183–184, 184t\nClindamycin\ndescription of, 363, 364t, 1038–1039\ndrug interactions, 379t–380t\nClopidogrel, 268\nClosed-tray technique, for impressions, \n34, 38f\nClotting, 219\nCoagulation cascade, 218, 219f\nCobalt alloys, 125–126\nCobalt-chromium-molybdenum–based \nalloy\ndescription of, 113\nmechanical properties of, 144t\nCodeine, 371\nCollagen, 788t, 789–790, 790f\nCollagen membranes, 925, 926f, 927, \n961, 971f\nColumella-philtrum angle, 11, 12f\nCombination prosthesis, 547, 547f\nCombination syndrome, 498–499,  \n499f\nComplete blood cell count, 217–218\nComplete denture\ndental adhesives for, 14–15\nmasticatory function and, 14\nmaxillary, 14–15\nmorbidity of, 14–15\nnegative effects of, 15b\npatient dissatisfaction with, 14\nComplete edentulism\nclassification of, 489–494, 490f–493f\nfixed prosthesis for, 422b\nimmediate loading of implants in, \n873f, 874–876, 875f–876f\nprosthesis design for, 436–437, 437f\nComplete-limiting surgical template, \n397, 398f, 702, 702f\nComplications\nbleeding-related, 778–785, 779f–784f\nintraoperative, 771–785\nneurosensory impairment, 811–821\nComposite beam analysis, 161–162\nComposite bone, 78–79, 82f\nComposites, 122–123\nCompound annual growth rate, for \nimplants, 17\nCompressive force, 141–142, 142t\nComputed tomography\nalveolar bone changes evaluated using, \n317–318\ncone beam. See Cone beam \ncomputerized tomography\ninteractive\ndescription of, 384\nideal implant position evaluations \nand determination, 384–388, \n385f–386f, 385b\nComputed tomography (Continued)\nmagnetic resonance imaging versus, \n278–279\nscanners used in, 280–286, 281f, 282t\nConcha bullosa, 302, 302f, 312f, 999\nCone beam computerized tomography\nartifacts, 286–288, 287f–288f\nbit depth of, 286\nbone dehiscence on, 288, 288f\nbone density on, 286, 393, 393f, 393b, \n457, 458f, 458b\nbone graft simulation, 393, 395f\nbone quality on, 281b\nbone-supported guides, 398, 398f, \n703f\ncomplication prevention, 289\ncontrast resolution of, 286\ndataset from, 389–390, 390f\ndescription of, 17\ndisadvantages of, 1206f\nDivision C available bone on, 427f\ndose range of, 282–286\ndouble scan, 386–387, 389f\ndrill guidance, 399, 399f\neffective dose, 282, 285f\nfield of view, 282, 284f, 289\nflapless full arch technique, 386–387, \n389f\nfocal spot of, 282, 284f\nimage acquisition, 279–280, 280f, \n283f, 388, 390f\nimage detection, 388\nimages using, 320f–328f\nin immediate implant placement, 840f\nimplant applications of\nmaintenance, 1204, 1206f\nplacement, 418f, 840f\nincidental findings, 288–289\nincisive canal on, 291–292, 292f\nlegal issues, 318–319\nmandible on, 753, 753f, 756f\nmandibular canal on, 290–291, \n290f–291f, 390–391, 391b, 392f\nmandibular symphysis on, 294, 296f, \n1059f\nmaxillary sinus on, 997\nnoise associated with, 287–288, 288f\nosseous defects on, 952f\npanoramic curve, 390, 391f\npilot guide, 399, 399f\npresurgical uses of, 275–276\nprosthetic plan created with, 939\nradiology report of, 289\nradiopaque prosthesis worn during, \n385, 386f\nradiopaque template, 385–386, \n386f–387f, 386b–387b"
  },
  {
    "page": 83,
    "content": "1223\nIndex\nCone beam computerized tomography \n(Continued)\nsafety zone, 393, 395f\nscanners, 280–286, 281f–282f, 282t\nscanning technique with, 286, 388\nsensors used in, 282\nsoft tissue-supported guides, 398, 399f, \n703f\nspatial resolution of, 282–286\nsurgical templates. See Surgical \ntemplate\ntooth-supported guides, 397, 398f, \n703f\ntreatment planning uses of, 279, 328, \n406f–409f\nuniversal guide, 399, 399f\nvirtual implant placement using, 393, \n394f\nvirtual teeth, 386, 388f, 388b\nCongestive heart failure, 235–236, \n235b–236b\nConnective tissue attachment, 24–25\nConscious sedation, 375\nContinuous positive airway pressure, 257, \n1197\nContinuous sutures, 630, 637f\nConventional loading, of implants, 33, \n37t\nCOPD. See Chronic obstructive \npulmonary disease\nCopings, 512\nCoralline grafts, 925\nCoronal incision, 951\nCortical bone\nD1, 454, 454t–455t, 653–657, 654f, \n655b, 656f–657f, 667t\nD2, 454, 454t–455t, 657–658, 659f, \n659b, 667t\nD3, 454, 454t–455t, 658–661, \n660f–661f, 661b, 667t\nD4, 454, 454t–455t, 661–663, \n662f–663f, 662b–663b, 667t\nD5, 454, 454t–455t\ndensity of, 459f\ngrowth of, 81–84\nharvesting of, 960, 1055\nmaturation of, 81–84\nmetabolic fraction of, 83–84, 88f\nmodeling and remodeling of, 80–81\nremodeling of, 70f\nstrength of, 142t\nstructural fraction of, 83–84\nCortical onlay grafts, 1093f\nCorticocancellous bone grafts, 1055, \n1092, 1096f, 1097–1099\nCorticosteroids, inhaled, 248\nCortisol, 242\nCortisone, 367t, 792t\nCosmetic smile, 1121\nCoughing, 249t\nCoumadin, 220\nCoupling factors, 81\nCover screw, 28, 31, 33f, 666f, 850f–851f\nCOX-1, 369\nCOX-2, 369\nCOX-2 inhibitors, 371\nCOX-3, 369\nCPAP. See Continuous positive airway \npressure\nCraniofacial complex\ngrowth cessation, 258\nosteology of, 69–71\nCreatinine, 223, 224t–226t\nCreatinine clearance, 224t–226t\nCreep, 181, 182f, 899\n“Creeping substitution”, 915, 916f\nCrest, 25f\nCREST syndrome, 256\nCrestal bone\nheight of, 348\nloss of, 155, 157b, 163, 1143, 1205–\n1206, 1208f, 1209b\nocclusal force transfer across, 50\nCrestal sinus lift, 30\nCrohn’s disease, 250\nCrown\nangled load to, 187\ncement-retained, 36, 39f\nfailure rate for, 4\nscrew-retained, 36, 39f\nsplinting of, 477, 803\nCrown height, 187–188\nCrown height space\nbiomechanics of, 186b, 506\nbone augmentation in, 189\nin bone measurements, 418, 418f\ndefinition of, 186–187, 505–506\nin edentulous patients, 500, 590–591\nexcessive, 187–191, 187f, 190f–191f, \n190b, 194f, 505f–507f, 506–507, \n506b\nfixed prosthesis considerations for, 190, \n192f\nfor hybrid prosthesis, 444\nideal, 187, 189\nin maxilla, 591, 591f\nmeasurement of, 186f, 505–506, 505f\nocclusal vertical dimension and, 496\nosteoplasty effects on, 426f\noverdentures affected by, 509\nin posterior maxilla, 554, 555f\nreduced, 507–509, 508f\nrestoration material selection based on, \n442\nCrown-implant ratio, 694f, 1012f\nCrown/root ratio, 522\nCryotherapy, 368, 368b, 792–793, 1010\nCT number, 280\nCTx test, 261–262\nCupping artifacts, 287\nCurettes, 612, 613f, 620, 621f, 1146–\n1147, 1146f\nCurve of Spee, 420, 500\nCurve of Wilson, 500\nCushing syndrome, 242\nCustom abutments, 33f–34f, 36\nCutting cones, 82–84, 157\nCVA. See Cerebrovascular accident\nCyclooxygenases, 366, 369f\nCylinder implants\ndescription of, 23, 23f\ndesign of, 417\nlong-term success rates for, 49t\nmoment of inertia of, 151\nsurface area of, 169\nCytostatics, 263–264\nD\nDabigatran, 220\nDanger space infections, 344\nDebridement, in-office, 1212\nDecongestants, 1009–1010, 1040\nDecortication, 955\nDefective hydroxyapatite biomaterials, \n116t\nDeformation, 143, 145\nDelayed loading, of implants, 33, 37t\nDelayed occlusal loading, 861b\nDemineralized freeze-dried bone \nallografts, 29t, 967, 1019\nDenosumab, 263\nDensah burs, 650\nDense polytetrafluoroethylene \nmembrane, 955, 966f\nDental adhesives, 14–15\nDental arch\nedentulous, bone resorption in, 8f\nform of, 512–513, 512f\nmandibular, 568f–569f\nmolar teeth for maintenance of, 4\nopposing, force affected by, 193–194\npartially edentulous. See Partially \nedentulous arches\nposition of, force affected by, 193\nDentifrices, 1208–1212, 1210f–1211f\nDentistry\nfuture of, 17\ngoals of, 2\nDentures\ncomplete. See Complete denture\nfixed partial. See Fixed partial denture"
  },
  {
    "page": 84,
    "content": "1224\nIndex\nDentures (Continued)\nphonetics affected by, 16\nremovable partial. See Removable \npartial denture\nsoft tissue changes caused by long-term \nuse of, 11f\nDermal fillers\nangular cheilitis treated with, 1135–1136\nblack triangles treated with, 1129, \n1129f–1130f\ncomplications of, 1136–1137\nduration of action, 1128\nfacial applications of, 1131–1136\nhyaluronic acid, 1126–1127\nindications for, 1128\ninjection techniques for, 1128, 1129f\nlips treated with, 1130–1131, 1131f, \n1134f\nmarionette lines treated with, 1134, \n1136f\nmechanism of action, 1127\nnasolabial folds/crease treated with, \n1134, 1135f\npermanent fillers, 1129\npreparation of, 1127–1128\nreversals for, 1136\nsupply of, 1127–1128, 1127f\ntypes of, 1125–1129, 1127t\nDeviated septum, 302, 303f, 312f, 999, \n999f\nDexamethasone, 367–368, 367t, 368b, \n792t, 820f\nDiabetes mellitus, 238–240, 239b, 240t, \n1146, 1149\nDiazepam, 375\nDifferentiation, 915\nDigestive system disorders\ninflammatory bowel disease, 250\nliver disease, 248–249\nstomach ulcers, 249–250\nDigital Imaging and Communication in \nMedicine format, 390, 702–704\nDigital impressions, 410f–411f\n1,25-Dihydroxy-cholecalciferol, 90\nDIONJ. See Drug-induced osteonecrosis \nof the jaw\nDip coating, of hydroxyapatite coating, \n200t\nDirect bone apposition, 98–99\nDistal psoriatic arthritis, 264\nDitching, 156\nDivine proportions, 497–498, 498f\nDivision A bone, 420–422, 422f, 422b\nDivision B bone, 422–425, 423f–424f, \n423b, 425b\nDouble-barrel fibula graft, 1105, \n1110f–1111f\nDouble foramen, 293, 293f, 757, 759f\nDoxycycline, 1039\nDrilling, 645–647, 645f–646f, 650, 650f, \n814–816\nDrivers, 31, 33f\nDrug-induced lupus, 256\nDrug-induced osteonecrosis of the jaw, \n261, 261t, 351\nDrug interactions, 379t–380t\nDry mouth. See Xerostomia\nDysphagia, 250t\nDyspnea, 249t\nE\nEarly loading, of implants, 33, 37t\nEarly loading failure, 153, 467\nEarly occlusal loading, 861b\nEcchymosis, 792f, 793, 1034–1035, \n1035f\nEctodermal dysplasia, 254, 255t\nEczema, 264–265\nEdema, postoperative, 791–794, 792t\nEdentulism\nbone density in, 193\nfree-end, 5\npartial. See Partial edentulism\nsite assessment, 941–946\ntotal. See Total edentulism\nEdentulous jaw\nbiomechanical sections of, 167\nbone loss classification in, 416f\nearly loading of implants in, 874\nfixed prosthesis for, 568f, 579–585, \n579b, 580f–585f, 586b\nfree-end, 5, 5f\nimmediate loading of implants in, 874, \n875f\nimplant-supported overdenture for, \n570–579, 570b, 571f, 573t, \n574f–578f, 577b–579b\nremovable prosthesis for, 568f\nresorption of, 10f\ntreatment planning principles for, \n567–570\nEdentulous space, 953f\nElderly\nimplants in, 257–258\ntooth loss in, 4, 7\ntotal edentulism in, 6–7\nElectrocautery/electrocauterization, \n786–787, 786f\nElectrophoretic deposition, of \nhydroxyapatite coating, 200t\nElectrospinning, 930\nEmbolic stroke, 238\nEmergency implants, 28\nEmphysema, 246–248\nEmpyema, 308\nEnameloplasty, 184, 500–501\nEndodontic therapy, 510–511\nEndosseous anastomosis, 1017\nEndosseous implants\nblade implants, 22–23, 22f–23f, 48, \n49t\ncylinder implants, 23, 23f\ndescription of, 22\ndesign of, 22, 22f\nimpingement of, 100f\nmacrostructure of, 22\nmicrostructure of, 22\ntransmandibular implants versus, 40\nEndosteal implants\nmarginal bone loss around, 159\nocclusal awareness with, 16\nroot form, 431–432\nEndosteal plexus, 338\nEndurance limit, 150, 178f\nEngineering strain, 143\nEntresto, 235\nEnvelope flaps, 606, 607f, 607b\nEosinophilic fungal rhinosinusitis, \n308–309, 309f, 1003\nEosinophils, 218, 224t–226t\nEpinephrine, 787\nEposteal implants\ndescription of, 37–40\nramus frame of, 40, 42f\nsubperiosteal implants, 37–40\nePTFE. See Expanded \npolytetrafluoroethylene membrane\nErythrocyte sedimentation rate, 224t–226t\nErythrocytic disorders, 244\nErythromycin, 362–363, 364t\nEsophageal reflux, 250t\nEssential thrombocythemia, 246\nEssix appliances, 970, 800, 800f\nEsthetics, total edentulism effects on, \n11–12, 11f, 12b\nEstimated glomerular filtration rate, \n223–224\nEstrogen replacement therapy, 93\nEthmoid bullae, 299\nEthmoid sinus, 299\nExpanded polytetrafluoroethylene \nmembrane, 28, 927, 955\nExternal hex, 27, 27f\nExtraoral examination, 211–214\nF\nFace\nage-related changes in, 11\nfascial spaces of, 342\nfiller injections applied to, 1131–1136\ninferior third of, 11f, 15"
  },
  {
    "page": 85,
    "content": "1225\nIndex\nFacial artery, 750, 780–781\nFacial measurements, 497–498\nFacial profile, 15\nFacial sutures, 95–98, 95f–97f\nFascia lata, 925\nFatigue curve, 178–179, 178f\nFatigue failure, 150, 150f\nFatigue fractures\nbruxism as cause of, 178–179\ndescription of, 63f\nFatigue strength, 62–64\nFentanyl, 376\nFerritin, 224t–226t\nFever, 216\nFibrin, 199–200\nFibrinogen, 789\nFibromyalgia, 265\nFibrous dysplasia, 252\nFibula graft, double-barrel, 1105, \n1110f–1111f\nField of view, 282, 284f, 289, 319\nFigure-eight suture, 626, 635f\nFillers, injectable\nangular cheilitis treated with, 1135–\n1136\nblack triangles treated with, 1129, \n1129f–1130f\ncomplications of, 1136–1137\nduration of action, 1128\nfacial applications of, 1131–1136\nhyaluronic acid, 1126–1127\nindications for, 1128\ninjection techniques for, 1128, 1129f\nlips treated with, 1130–1131, 1131f, \n1134f\nmarionette lines treated with, 1134, \n1136f\nmechanism of action, 1127\nnasolabial folds/crease treated with, \n1134, 1135f\npermanent fillers, 1129\npreparation of, 1127–1128\nreversals for, 1136\nsupply of, 1127–1128, 1127f\ntypes of, 1125–1129, 1127t\nFilling cones, 82–84\nFinite-element modeling, 72\nFive-walled bony defect, 901, 901f\n510(k), 917–918\nFixed partial denture\nabutment teeth for, 13\nfailure of, 13, 152\nillustration of, 13f\nlife span of, 13, 13b\nmandibular\nblade implant supporting, 22f\nmorbidity of, 12–13\nFixed partial denture (Continued)\nsingle-tooth replacement using, \n533–534, 534f, 534b\nthree-unit, 12–13, 13f\nFixed prostheses\nadvantages of, 422b\ncantilevers in, 468, 468f, 514–516\nclassification of, 438t\ncrown height space and, 190, 192f\nfor edentulous mandible, 568f, 579–\n585, 579b, 580f–585f, 586b\nfor edentulous maxilla, 591–594, \n592f–594f, 592t, 592b–593b\nfailure of, 514\nfive- to seven-unit, 470f\nFP-1, 438, 438t, 439f–440f, 448f\nFP-2, 438–440, 438t, 442f, 448f\nFP-3, 440–445, 442f–443f, 448f\nfull-arch, 471, 474f\nimplant-supported overdenture versus, \n437\nkey implant positions guidelines for, \n467–471, 467b\nmovement of, 518\nopposing arch of, 194f\nporcelain-metal, 442, 443t, 444f\nporcelain thickness for, 192f\npretreatment, 525, 525b\nsingle-tooth replacement using, \n533–534, 534f, 534b\nFixed provisional prostheses, 880–881, \n884f\nFlap(s)\naccess using, 603, 603f\nblood supply to, 602–603\ndesign of, 602–605, 602b, 603f–605f, \n644\nenvelope, 606, 607f, 607b\nfull-thickness reflection, 603, 603f\nguided bone regeneration, 949–969\nincision technique for, 607–610, \n608f–609f\nmobility of, 604–605, 604f\ntrapezoidal, 606–607, 607f, 607b\ntrauma minimization, 603–604\ntriangular, 606–607, 607f, 607b\ntypes of, 605–607, 606f–607f\nvestibular, 607, 607b\nFlapless full arch technique, 386–387, \n389f\nFlapless incision, 605, 606f, 606b\nFloss aids, 1209, 1211f\nFlumazenil, 376\nFluoroquinolones\ndescription of, 363–364, 364b\ndrug interactions, 379t–380t\nFocal spot, 282, 284f\nForce\nangled abutments, 141\nbite, 141t, 174, 176t, 192–193\ncompressive, 141–142, 142t\nconversion factors for, 141b\ndefinition of, 140\ndeformation caused by, 143\ndelivery of, 146\nmastication, 9, 174\nmechanical stress, 143\nmoment of, 146–147, 146f\nocclusal. See Occlusal forces\nparafunctional. See also Parafunctional \nhabits\nbruxism, 175–180, 176f–180f, \n183–184, 184t\ncategories of, 175\ncharacteristics of, 174–175\nclenching, 180–184, 184t\ntongue thrust and size, 184–186, \n185f\npatient factors\narch position, 193\nbite force, 141t, 174, 176t\nbruxism, 175–180, 176f–180f, \n183–184\nclenching, 180–184\ncrown height space, 186–191, \n186f–191f, 186b\ndescription of, 167\nmasticatory muscle dynamics, \n191–193, 192f\nsummary of, 194–195\ntongue thrust and size, 184–186, 185f\nshear, 142, 142t\ntensile, 141–142, 142t, 144f\ntypes of, 141–146, 142f\nvector quantities, 140–141\nForceps, 896–897\nFour-wall bony socket, 902, 903f\nFP-1\nangulation of, 687–689\ndescription of, 422, 438, 438t, \n439f–440f, 448f\nexcessive depth of, 693\nFP-2\nangulation of, 687–689\ndescription of, 422, 438–440, 438t, \n442f, 448f\nexcessive depth of, 693\nFP-3, 440–445, 442f–443f, 448f, 592f, \n688, 693\nFree-end edentulism, 5\nFree gingival graft, 1171f\nFree-standing implants, 36\nFreeze-dried bone allograft, 900,  \n923–925, 967, 1019"
  },
  {
    "page": 86,
    "content": "1226\nIndex\nFrenum attachment, 959f\nFretting corrosion, 110\nFrontal sinus, 299\nFunctional cross-sectional area, 143\nFunctional endoscopic sinus surgery, \n1043f\nFungal rhinosinusitis, 308–309, 309f, \n1003\nFurcation treatment, 511\nG\nGalvanic corrosion, 110\nGBR. See Guided bone regeneration\nGeneric terminology, 20\nGenial tubercles, 332f\nGenioglossus muscle, 336\nGerdy tubercle, 1101f\nGilbert syndrome, 223\nGingiva\nhyperplasia of, 1175–1179, 1179f, \n1179b\nkeratinized, lack of, 1168–1172, \n1169f–1172f\nrecession of, 1169\ntotal edentulism effects on, 9\nGingival fibers, 159–160, 1192\nGingival pockets, 1197\nGingivitis, 347, 1143, 1144f\nGlomerular filtration rate\nin elderly, 257\nestimated, 223–224\nGloving, 622b, 626f–627f\nGlucocorticoids\nadrenal suppression caused by, 367\ncontraindications to, 368\ndescription of, 263, 366\nedema treated with, 791–792, 792t\nimplant dentistry uses of, 367–368\nmechanism of action, 367\nsinus grafting uses of, 1009, 1009b\nsynthetic, 366–368, 367t\nGlucose, serum, 221–222, 222t, \n224t–226t\nGold alloy, 126, 549, 551f\nGolden ratio, 727\nGowning, 622b, 626f–627f\nGranulomatous rhinosinusitis, 308\nGrowth cessation, 258, 259f\nGuided bone regeneration\nbarrier membranes used in, 28, \n957–969\nclinical application of, 949–969\ndefinition of, 914–915\ndescription of, 28, 935\nflap design for, 949–969\nhistory of, 915\nillustration of, 936f\nGuided bone regeneration (Continued)\nincisions for, 949–969\nindications for, 917\nmembranes used in, 966\nprotocol for, 973b\nspace maintenance for, 967\nGuided surgery, 33, 35f–37f, 644, 754f\nGuided tissue regeneration, 915\nGummy smile, 502–503, 1120–1124, \n1121f–1126f\nGut sutures, 622–623, 628t–629t\nH\n3H-thymidine, 76\nHA. See Hydroxyapatite\nHahn guided surgery kit, 33, 35f–36f\nHahn implant, 33f, 36, 40f, 199f\nHahn implant surgery kit, 32f\nHaller cells, 299, 302–303\nHalo formation, 561\nHalsted, William Stewart, 602, 602b\nHandpieces/motors, 618, 619f, 776–777\nHard tissue, 7f–9f, 7b\nHashimoto’s thyroiditis, 241\nHaversian canals, 914f\nHead and neck\nfascial spaces of, 344\ninfections of, 341–344\nHealing abutment\ncustom, 33f–34f\ndefinition of, 32\nillustration of, 33f–34f, 666f\ntemporary, 28\nHealing collar, 32\nHealing cuff, 32\nHeight, 217\nHelix angle, 25f, 58f\nHematocrit, 218, 224t–226t\nHemoglobin, 218, 224t–226t\nHemoglobin A1c, 224t–226t,  \n239–240\nHemophilia A, 219\nHemophilia B, 219\nHemoptysis, 249t\nHemostasis\ndescription of, 219, 219f, 799\nmechanical methods of, 785–787\npharmacologic agents and techniques \nfor, 787–791, 789f–790f\nHemostat forceps, 786\nHemostats, 612–615, 615f\nHepatitis, 250t\nHepatitis C, 249\nHerbal supplements, 268, 269b\nHertwig root sheath, 7\nHiatal hernia, 250t\nHigh lip line, 502–503, 503f, 528\nHome care\nfor implant maintenance, 1207–1212, \n1210f–1212f\nfor peri-implant mucositis,  \n1148\nHooke’s law, 145\nHorizontal mattress suture, 630–631, \n638f\nHot isostatic pressing, of hydroxyapatite \ncoating, 200t\nHounsfield units, 281, 281b, 286, 286f, \n393b, 457, 649b\nHourglass mandible, 737\nHuman cellular and tissue-based products, \n918\nHyaluronic acid fillers, 1126–1127\nHybrid prostheses\ncrown height space for, 444, 507f\nFP-3, 179f, 443f, 445f\nmetal framework for, 192f\nHydrocodone, 371, 379t–380t\nHydrocortisone, 367t, 792t\nHydroxyapatite\ncoating of, on implant surface, \n128–129, 128f, 199, 200t, 203\ncrystallinity of, 118\ndescription of, 116, 116t, 925–926, \n967\nparticulate, 116–117, 117f\nsolubility of, 118–119, 118f\nsurface of, 126–127\nHyperalgesia, 369–370\nHyperbaric oxygen, for osteoradionecrosis, \n255\nHypercalcemia, 84–85, 87, 222\nHyperglycemia, 222, 239\nHyperparathyroidism, 242–243,  \n253\nHypertension, 227–229, 229b, 233t\nHyperthyroidism, 241\nHyperventilation, 217\nHypodontia, 535\nHypoglycemia, 222\nHypomineralization, of mandibular \ncanal, 293, 293f\nHypothyroidism, 241\nHypoventilation, 217\nI\nIBD. See Inflammatory bowel disease\nIbuprofen, 370–371, 370b\nIdeal load-bearing zone, 865\nIdiopathic thrombocytopenic purpura, \n246\nIliac crest bone grafts, 430, 431f, 869f, \n1092–1099, 1094f–1097f, 1094t, \n1095b, 1104f"
  },
  {
    "page": 87,
    "content": "1227\nIndex\nImaging\ncomputed tomography. See Computed \ntomography\ncone beam computerized tomography. \nSee Cone beam computerized \ntomography\nimportance of, 328\nintraoperative, 314, 317f\nmandibular anatomy, 289–296\nmaxilla anatomy, 296–302, 298f–301f\nobjectives for, 275\npostprosthetic, 314–318\npostsurgical, 314\npresurgical, 275–276, 276b\nradiographic. See Radiographic imaging\nImmediate implant placement, 830–859\nin active infection site, 346–347, 346f\nadvantages of, 830–832, 830b\nanatomic location and, 838\nanterior, 950\navailable bone for, 834–839\nbone density and, 837–838\nbuccal bone thickness and, 838–839\ncomplications of, 849–853, 856f\ncone beam computerized tomography \nin, 840f\ndescription of, 28, 346–347, 346f, \n411f, 764–767\ndisadvantages of, 832–834, 832b\nwith double-barrel fibula graft, 1105, \n1110f–1111f\nideal positioning for, 842–845\nimplant in\ndesign of, 845–846\nstability of, 846–848\nin infected sites, 849\nin mandible, 855f\nin maxilla, 854f\nin periodontal disease, 348\nrequirements for, 839\nstudies of, 834\ntechnique for, 839–849\ntissue-supported, 884f\ntissue thickness and, 838\ntreatment planning for, 834–839\nImmediate loading, of implants\nadvantages of, 860–861, 861b\nbenefit/risk ratio, 886\nbone microstrain and, 865, 866f\nin completely edentulous arches, 873f, \n874–876, 875f–876f\ndescription of, 33, 37t\ndisadvantages of, 861\nfibula reconstruction with, 1104–1105, \n1107f\nforce conditions and, 866f–867f, \n867–868\nImmediate loading, of implants \n(Continued)\nhistologic evaluation of, 864–865\nimplant overdentures, 881–884, 885f\nin partially edentulous patients, \n868–870, 869b, 871f–872f\npostoperative complications of, 885\npostoperative instructions for, 884\nprerequisites for, 861–862, 863f\nrationale for, 862–863, 886\nsummary of, 886\nsurface area and, 865–868, 866f–867f\nsurvival rates, 886\nterminology of, 860\ntrauma caused by, 863\nImmediate occlusal loading, 861b\nImmunosuppressive drugs, 263–266, 263b\nImpact, 145\nImplant(s). See also specific implant\nallergy to, 268–269, 270f\napical region of, 61, 61f–62f, 65\napically positioned, 515f\nappointments necessary for, 7\nattachment of, to teeth, 516–524\navailable bone for. See Available bone\nbone grafts for. See Bone graft(s)\nbone loss around, 1205f, 1209b\nclinical evaluation of, 1197–1206\ncomplications of\nabutment-screw loosening, 153, 155f\nmechanical, 187\ncomponents of\nbiomechanical complications of, \n154–155\ndescription of, 31–34, 33f–34f\nfit of, 804\nocclusal overload effects on, 153–155\nswallowing/aspiration of, 775, 776f\ncompound annual growth rate for, 17\nconical connection, 57, 64\nconnections for, 27, 27f, 57, 57f\nconnective tissue zone for, 1198\ncustom components of, 33–34\ndesign of\nbiomechanics of, 165–166\nbone loss affected by, 165–166\ndiameter, 50–52, 52f, 54, 55f\nendosseous implants, 22, 22f\nfailure rates, 48, 49t\nfunctional basis for, 64–65\nlength, 52–54\nocclusal forces and, 48–49, 165–166\nprogression of, 48, 64\nscrew loosening affected by, 804–805\nshape, 49–50, 64\nsuccess rates for, 48, 49t\nsurface area affected by, 169\nImplant(s) (Continued)\ndiameter of, 50–52, 52f, 54, 55f, \n416–417\nearly loading failure of, 153, 467\nemergency, 28\nendosseous. See Endosseous implants\nendosteal. See Endosteal implants\nengaging components of, 34\nexplantation of, 824–825\nfactors affecting demand for\nage-related tooth loss, 4\naging population, 2–4\nesthetics, 4\npartial edentulism, 4–6\nsocial activity, 4\ntotal edentulism, 6–12\nfailure of\nbiomechanical overload as cause of, \n152–153\nbone density and, 450, 648\ndiabetes mellitus as cause of, \n239–240\nearly loading, 153\nfatigue, 150, 150f\nforce delivery and, 146\nafter immediate implant placement, \n833\nimplant diameter effects on, 51\ninfections as cause of, 341, 347\nlack of keratinized tissue as cause of, \n1168–1169\noverheating of bone as cause of, \n154f, 773\nparafunctions as cause of, 174–175, \n181–183. See also Parafunctional \nhabits\nretained cement as cause of, 1172\nsurgical, 152–153, 154f\nfeatures of, 54–61\nfracture of\netiology of, 821–822, 823f\nfatigue as cause of, 63f, 178–179\nprevention of, 822\ntreatment of, 822\nfree-standing, 36\nfuture of, 17\ngeometry of, 49–54, 51f–53f, 150\nglobal prevalence of, 2, 3f\nhealthy, 1209f, 1209b\nheight of, 417–418\nideal position evaluations, 384–388, \n385f–386f, 385b\nimmediate loading of. See Immediate \nloading, of implants\nimmediate placement of, 28\nimpingement trauma, 816f\nindications for, 7, 48"
  },
  {
    "page": 88,
    "content": "1228\nIndex\nImplant(s) (Continued)\nindustry growth of, 2\njoining of, to teeth, 519–520\nkeratinized tissue around, 1199–1201, \n1200b, 1201f\nkey positions for, 167–169\nlength of, 417–418, 418f, 556, 847f\nloading of\nearly loading failure, 153\nmarginal bone loss after, 48\nprogressive, 528\ntypes of, 33, 37t\nloads applied to\ndeformation caused by, 143\ndescription of, 140\nimpact, 145–146\nmacrostructure of, 20–22, 25–26\nmacrothreads of, 25–26, 26f\nmaintenance of. See Implant \nmaintenance\nmalpositioned, 671f, 857f, 936f\nmicrostructure of, 22, 26\nmicrothreads of, 26, 55–56, 56f\nmigration of, into maxillary sinus, \n1044–1045, 1045t, 1046f–1049f\nmobility of, 518–519, 806, 824, \n1193–1195, 1195f, 1195b, 1201, \n1202f\nmovement of, 517–518, 518f, 1193–\n1195\nnonengaging components of, 34\nnumber of, 471–475, 474f, 514, \n556–557, 581f, 865\nocclusion, 1202–1203\none-stage, 27–28\nosteotomy preparation for. See \nOsteotomy\nplaque accumulation around, 1197, \n1198f, 1199b\nplatform-matched, 27, 27f\nplatform shifting, 56\nplatform-switched, 27, 27f\nprevalence of, 2\nprobing around, 1197–1199, \n1199f–1200f\nradiographic evaluation of, 1203–1206\nradiology report findings for, 314\nscrew-shaped. See Screw-shaped \nimplants\nshape of, 49–50\nsingle-tooth. See Single-tooth implant\nsize of, 168–169, 416–418, 866\nsoft tissue around\nassessment of, 1197\nfiber groups, 160f\nsplinting of, 476–477\nstandardized components of, 33–34\nImplant(s) (Continued)\nsurface area of, 52f, 61t, 168, 168f, \n183–184, 464, 865–868, \n866f–867f\nsurface of. See Implant surface\nsurgical instrumentation for, 30–33, \n32f–33f\nsurgical protocols for, 27–30\nsurvival rates for, 48\ntechnological advances in, 17\nteeth and, differences between, 1196t\nteeth replaced with, 2, 3f\nthreads of\nbuttress, 26f, 51f, 59, 60f\ndepth of, 60–61, 61f\ndescription of, 25–26, 25f–26f, \n57–58\npitch, 58–59, 58f\nprimary stability uses of, 57–58, 65\nreverse buttress, 26f, 59, 60f\nshape of, 59–60, 60f\nsquare, 26f, 51f, 59–60, 60f\nV-threads, 26, 59–60, 60f\ntreatment planning for, 48\ntwo-stage, 27–28\nwide, 51–52, 53f\nwidth of, 416–417\nImplant analog, 33–34, 38f\nImplant body\nabutment connection to, 159, 160f, \n1206\nangulation of, 686–687\ndesign of, 866–867\nforce on, 463\nfracture of, 154–155, 156f, 187, \n821–822, 1202\nload transfer by, 142\nradiographs of, 1204–1205\nImplant collar, 54–57, 55f–56f, 64, \n165–166\nImplant drills, 31\nImplant-level impression coping,  \n33–34\nImplant-level impressions, 33–34\nImplant-level prosthesis, 34\nImplant maintenance\ndental history for, 1197\ndentifrices used in, 1208–1212, \n1210f–1211f\nfrequency of visits for, 1207\nhome care, 1207–1212, 1210f–1212f\nin-office debridement, 1212\nmedical history for, 1195–1197\noverview of, 1142\npain/sensitivity assessments,  \n1201–1202, 1203f\nprotocol for, 1195–1206\nImplant materials. See also Biomaterials; \nspecific material\nbiocompatibility of, 62, 108\nbiodegradation of, 110\ncorrosion of, 110\ncorrosion resistance of, 64\nmodulus of elasticity, 64\noverview of, 61–65\nstandardization of, 111\ntitanium. See Titanium\ntoxicity of, 110–111\nImplant mounts, 31\nImplant overdentures. See also Implant-\nsupported overdenture\ndefinition of, 36\nimmediate loading of, 881–884,  \n885f\nin limited crown height space, 509\nImplant placement\nautogenous bone grafts, 1082–1083\nbone density factors involved in, \n647–650, 649f, 649b\ncone beam computerized tomography \nimage of, 418f\ndefinition of, 844t\nfacial dehiscence after, 771–772,  \n772f\nguided surgery in, 33, 35f–37f\nimmediate. See Immediate implant \nplacement\nin inadequate bone, 950f\ninfection before, 346–348, 346f\nnavigational systems for, 400, 402f\none-stage, 665–666, 666b\nosseodensification for, 649–650\nosteotomy preparation for, 645–647, \n645f–646f, 648b, 650–653, \n650f–652f\npressure necrosis caused by, 774\nprimary stability assessments, 663–664, \n664f–665f, 665b\nprotocols\nfor D1 bone, 653–657, 654f, 655b, \n656f–657f, 667t\nfor D2 bone, 657–658, 659f, 659b, \n667t\nfor D3 bone, 658–661, 660f–661f, \n661b, 667t\nfor D4 bone, 661–663, 662f–663f, \n662b–663b, 667t\ndescription of, 644–645\nafter radiotherapy, 255\nsurgical approaches for, 644–645\nsurgical template used in, 394–398\nthread pitch and, 59\ntwo-stage, 665–666, 666f, 666b\nvirtual, 393, 394f"
  },
  {
    "page": 89,
    "content": "1229\nIndex\nImplant position/positioning\napicocoronal (Z-axis), 689–695, 692f\nbuccolingual (“Y-axis”), 682–687, \n684f–687f\nexcessive depth, 691–695, 693f–694f,  \n695b\nexcessive implant–tooth distance, \n677–679, 678f–680f, 680b\nideal, 670–705, 704b\nimmediate loading affected by, \n867–868\ninadequate depth, 695–696, 695f–696f\ninsufficient implant–tooth distance, \n670–676, 671f–674f\nlack of implant–implant distance, \n679–682, 680f–683f, 684b\nverification of, 650\nvital structures and, 698\n“X”-axis, 670–682, 671f–681f\nImplant quality scale, 1179–1183, 1180t, \n1181f–1183f\nImplant stability quotient, 17, 22\nImplant-supported overdenture. See also \nImplant overdentures\ndescription of, 437\nfor edentulous mandible, 570–579, \n570b, 571f, 573t, 574f–578f, \n577b–579b\nfor edentulous maxilla, 594–596, \n595f–598f, 595t, 596b, 598b\nImplant-supported prostheses\nadvantages of, 15–17, 15b\nalveolar bone maintenance using,  \n15, 15f\nbiting force affected by, 16\nchewing efficiency with, 16\ngeneral health benefits of, 16\nmasticatory efficiency using, 16\nnutritional benefits of, 16\nocclusal awareness with, 16\nocclusion stability using, 16\nphonetics affected by, 16\npsychological health affected by, \n16–17, 17b\nsuccess rate for, 16\nImplant surface\nacid etching of, 198, 201t\nadditive processes, 199\nanodization of, 199, 201t\nantibiotic coating on, 202\nbiological responses, 199–201\nbisphosphonate, 201–202\nblasting techniques for, 198–199\nbone and, interactions between, 198f\ncalcium phosphate, 203\nchemical cleaning of, 129\ncleanliness of, 129\nImplant surface (Continued)\ncoatings on, 127–129\nenergy of, 129\nfunctionalization of, with biologically \nactive substances, 202–203\nhydroxyapatite coatings on, 128–129, \n128f, 199, 200t, 203\nlaser treatment of, 199\nmodifications to, 129\nin osseointegration, 197\noxidation of, 199, 201t\nperi-implantitis and, 1170\nporous coatings on, 127–129\nfor press-fit implants, 23\nresorbable blast media, 26, 26f, 127f, \n198, 199f\nreview of, 197–199\nroughening/roughness of, 126–127, \n197, 200t, 201\nstatins on, 202\nsterilization of, 130\nsubtractive processes, 26, 198–199\ntitanium plasma-sprayed, 127–128, \n127f, 199\ntypes of, 23\nzirconia implants, 202\nImplant systems, 30–31\nImplant verification jig, 34, 38f\nImplant–abutment connection, 666\ndesigns for, 57, 57f\nexternal, 27, 27f, 57\ninternal, 27, 27f, 57\nImpressions\nabutment-level, 34\nclosed-tray technique for, 34, 38f\ndigital, 410f–411f\nimplant-level, 33–34\nopen-tray technique for, 34, 38f\noptical, 404–405, 405b\ntechniques for, 34, 38f\nIMZ implant, 27\nIn-office debridement, 1212\nIncision line opening, 794–801, \n795f–800f, 795b, 801t, 980, 1030–\n1032, 1077–1078, 1080, 1081f\nIncisions, for flaps, 607–610, 608f–609f\nIncisive artery, 748, 779–780\nIncisive canal, 291–292, 292f, 748, 780f, \n974\nIncisive foramen, 297–298, 298f, \n721–725, 724f\nIncisive nerve, 757, 760f, 1079\nIncisivus labii superioris muscle, 332\nIndependent prosthesis, 475–476, 476f\nInfections. See also specific infection\nantibiotic prophylaxis for, 353, 359–361\napical, 909f\nInfections (Continued)\naseptic technique and, 360\nbiofilm associated with, 353\nbone graft, 985\ncauses of, 346\nhead and neck, 341–344\nbefore implant placement, 346–348, \n346f\nmicrobiology of, 341, 344–346\noverview of, 341–344\npain caused by, 1202\nperiodontal disease, 347–348, 347f\nperisurgical, 348\npostsurgical, 349–352, 349f–350f\nrisks of, 346, 360, 360b\nsigns and symptoms of, 341, 365\nin socket-grafting site, 908, 909f\nspread of, 342–344, 343f\nInferior alveolar artery, 338–339, 748, \n779\nInferior alveolar canal, 289–290, \n754–755, 765f\nInferior alveolar nerve, 337, 698, 752, \n754f–755f, 811\nInferior meatus, 300\nInferior turbinate and meatus \npneumatization, 305, 305f, 1000\nInflammation\ncryotherapy for, 368, 368b\nglucocorticoids for. See Glucocorticoids\npostoperative, 365–368\nInflammatory bowel disease, 250\nInformed consent, 920–921\nInfraorbital artery, 334, 338, 994\nInfraorbital foramen, 298–299, 299f\nInfraorbital nerve, 299, 299f, 334, \n813–814, 1032\nInjectable botulinum toxin. See \nBotulinum toxin injections\nInjectable fillers\nangular cheilitis treated with,  \n1135–1136\nblack triangles treated with, 1129, \n1129f–1130f\ncomplications of, 1136–1137\nduration of action, 1128\nfacial applications of, 1131–1136\nhyaluronic acid, 1126–1127\nindications for, 1128\ninjection techniques for, 1128, 1129f\nlips treated with, 1130–1131, 1131f, \n1134f\nmarionette lines treated with, 1134, \n1136f\nmechanism of action, 1127\nnasolabial folds/crease treated with, \n1134, 1135f"
  },
  {
    "page": 90,
    "content": "1230\nIndex\nInjectable fillers (Continued)\npermanent fillers, 1129\npreparation of, 1127–1128\nreversals for, 1136\nsupply of, 1127–1128, 1127f\ntypes of, 1125–1129, 1127t\nInlay grafting, 30\nInner diameter, 25\nInsertion torque, 647, 861\nInserts, 123\nInstruments. See also specific instrument\nbone compaction, 663f\nbone-grafting, 612\nhandpieces/motors, 618, 619f, \n776–777\nfor holding drapes, 618, 618f\nfor holding mouth open, 615–618, \n617f–618f\nosteotomes, 620, 620f\nscalpel, 608–610, 610f\nsurgical blades, 610, 610f\nfor suturing, 640, 640f–641f\ntissue forceps, 611, 611f\nfor tissue reflection, 611, 611f\nfor tissue removal, 611–620\nfor tissue retraction, 615, 616f–617f\nInteractive computed tomography\ndescription of, 384\nideal implant position evaluations \nand determination, 384–388, \n385f–386f, 385b\nInterarch distance, 186, 505–506\nInterdental papillae, 503f, 709f, 719f, \n720–721\nInterimplant distance, 680f\nInterleukin-12, 264\nInterleukin-17 inhibitors, 264\nIntermediary abutments, 167\nInternational normalized ratio, 220, 220t\nInterocclusal distance, 497\nInterocclusal space, 424f, 444f–445f, \n555, 590–591, 697f–699f\nInterproximal bone, 954f\nInterproximal brushes, 1209, 1210f\nIntramobile elements, 123\nIntraoperative imaging, 314, 317f\nIntraoral examination, 211–214\nIntraoral scanning, 17\nIntraosseous anastomosis, 306, 306f, \n1033f\nInvestigational device exemption, 918\nIon beam-assisted deposition, of \nhydroxyapatite coating, 200t\nIron, 224t–226t\nIron alloys, 125–126\nIron-chromium-nickel–based alloys, \n113–114\nIsolated systolic hypertension, 258\nIVJ. See Implant verification jig\nJ\nJaundice, 250t\nJaw. See also Mandible\nbone density in, 451\ndrug-induced osteonecrosis of, 261, \n261t\nedentulous. See Edentulous jaw\nosteomyelitis of, 349–351, 349f–350f\nJunctional epithelium, 24–25\nK\nKeratinized tissue\naround implants, 1199–1201, 1200b, \n1201f\nlack of, 1168–1172, 1169f–1172f\nKey implant positions\ndescription of, 167–169\nfirst molar, 471, 473f\nfor fixed prostheses, 467–471, 467b\nKidney, calcium conservation in, 87\nL\nLabiomental angle, 11\nLaboratory evaluation\nbiochemical profiles, 221–224\nbleeding tests, 218–221, 219f\ncomplete blood cell count, 217–218\nhematocrit, 218\nhemoglobin, 218\noverview of, 217–224\nred blood cell count, 218\nurinalysis, 217\nwhite blood cell count, 218\nLactic dehydrogenase, 223\nLamellar bone, 78, 165\nLANAP. See Laser-assisted new \nattachment procedure\nLAPIP. See Laser-assisted peri-implantitis \nprotocol\nLaser(s)\nhemostatic uses of, 787\nimplant surface treated with, 199\nLaser-assisted new attachment procedure, \n1157, 1160f\nLaser-assisted peri-implantitis protocol, \n1156–1157, 1158f, 1159\nLateral access drilling tube, 412f\nLateral incisors, congenitally missing, \n727–732\nLateral pharyngeal space, 344\nLateral pterygoid muscle, 336\nLateral tongue thrust, 185\nLeft-sided congestive heart failure, 236\nLeukemia, 247t\nLeukocyte disorders, 245–246\nLeukocyte platelet-rich fibrin, 1166\nLeukocytosis, 245–246\nLeukopenia, 246\nLevator anguli oris muscle, 333\nLevator labii superioris muscle, 333\nLevofloxacin, 364t\nLichen planus, 1196\nLidocaine, 373–375, 373t–374t, \n379t–380t\nLife expectancy, 2, 3f–4f, 4\nLindemann drill, 844, 845f\nLingual artery, 780\nLingual canal, 295–296\nLingual concavities, 294, 295f\nLingual flap, 963f\nLingual foramen, 295–296\nLingual nerve, 337, 750–752, 751f,  \n811–813\nLingual tori, 72f, 960, 983f\nLingual undercut, 746–748, 749f, \n782–783, 783f\nLinkow blades, 22–23\nLip(s)\nanatomy of, 1130–1131\nanesthesia of, 1131, 1131f\nfiller injections applied to, 1130–1131, \n1131f–1134f\nvermilion border of, 11\nLip lines, 501–504, 502f–503f\nLip support, 590, 590f\nLipoprotein lipase, 224t–226t\nLithium disilicate, 549, 550f–551f\nLithium silicate, 549\nLiver disease, 248–249\nLiver function tests, 224t–226t\nLoading, of implants, 33, 37t\nLocal anesthetics, 373–375, 373t–374t, \n373b–374b, 814\nLocally applied antibiotics, 1159, 1159f\nLoe and Silness bleeding index, 1197, \n1197b\nLong buccal nerve, 338\nLow-abrasive amino acid glycine powder, \n1156, 1157f, 1212\nLymphocytes, 218, 224t–226t\nM\nMacrolides, 362–363, 363b, 379t–380t, \n1038\nMacroporosity, 916, 916f\nMacrostructure, 20–22, 25–26\nMacrothreads, implant, 25–26, 26f\nMagnetic resonance imaging\ncomputed tomography versus, 278–279\ndescription of, 278–279\ntreatment planning uses of, 278–279"
  },
  {
    "page": 91,
    "content": "1231\nIndex\nMandible. See also Jaw\nanatomy of, 289–296, 335–338, 572, \n572f, 738f\nanterior, 737–738, 739f, 741f, 743f\nbone density in, 649\ndescription of, 295, 296f\nextraosseous vessels in, 780–781\nradiographic imaging of, 1107f\nsurgical specimen of, 1108f\natrophy of, 10f\nblood supply to, 338–340\nbody of, pathologic fracture of, 8\nbone height losses in, 8, 8f\nbone loss in, 8, 12f, 415–416, 416f\ncone beam computed tomography of, \n753, 753f, 756f\ndeformation of, 744–746\nedentulous\nbiomechanical sections of, 167\nearly loading of implants in, 874\nfixed prosthesis for, 568f, 579–585, \n579b, 580f–585f, 586b\nfree-end, 5, 5f\nimmediate loading of implants in, \n874, 875f\nimplant-supported overdenture for,  \n570–579, 570b, 571f, 573t, \n574f–578f, 577b–579b\nremovable prosthesis for, 568f\nresorption of, 10f\ntreatment planning principles for, \n567–570\nflexure of, 569f–570f, 569, 744–746,  \n747f\nfree-end edentulism in, 5, 5f\nhourglass, 737\nimmediate implant placement in, 855f\ninnervation of, 337–338, 750–752, 751f\nlack of bone height in, 742–748\nlack of keratinized tissue in, 739\nlingual nerve of, 750–752, 751f\nlingual undercut of, 746–748, 749f, \n782–783, 783f\nmedial movement of, 569, 569f\nmedian vascular canal of, 296, 297f, \n738, 741f, 779\nmuscle attachment to, 335–338\nneurosensory complications of, \n760–767\nosteology of, 69\nosteoplasty of, 742, 745f\nposterior, 742, 746f, 937f\nradiographic anatomy of, 289–296\nresorption stages in, 8f\nseverely angled, 738–739\nthree-dimensional radiography of, \n753–754, 753f\nMandible (Continued)\ntorsion of, 569–570, 744\ntwo-dimensional radiography of, \n752–753, 752f\nMandibular canal\ncone beam computerized tomography \nof, 390–391, 391b, 392f\nhypomineralization of, 293, 293f\nimplant placement in, 780f\nradiographic anatomy of, 289–291, \n290f–291f\nsocket-grafting proximity to, 908–909, \n909f\nMandibular condyle, 75\nMandibular incisors, 499–500\nMandibular lip line, 504\nMandibular premolars, congenitally \nmissing, 535–536\nMandibular ramus\nanatomy of, 293–294, 294f,  \n1064–1067\nautogenous bone grafts from, 293–294, \n294f, 902–905, 904f–905f, 980f, \n982f, 1064–1071, 1070f–1072f, \n1071b, 1079–1080\nradiographic anatomy of, 293–294, 294f\nMandibular symphysis\nanatomy of, 294–296, 296f, 949f, \n1056, 1058f\nautogenous bone grafts from, \n1056–1064, 1056f–1066f, \n1063b–1064b, 1077–1079\nbone grafting from, 1054–1055, 1055f\nbone loss in, 415\nradiographic anatomy of, 294–296, 296f\nMarginal bone\nloss of\nanimal studies of, 162, 163f\nautoimmune response of host as \ncause of, 158–159\nbacteria as cause of, 158–159\nbiological width as cause of,  \n159–160, 159f–160f\ncantilevers and, 164f\ncellular biomechanics, 161\nclinical reports on, 163–164\nhygiene as cause of, 159\nimaging of, 158f\nafter implant loading, 48\nimplant osteotomy as cause of, \n157–158\nocclusal trauma as cause of,  \n155–157, 161\nperiosteal reflection as cause of, 157, \n158f\nmaintenance of, 48\nMarionette lines, 1134, 1136f\nMass, 140, 141b\nMasseter muscle\nanatomy of, 337, 1114\nblood supply to, 1114\nbotulinum toxin injection in, 1114–\n1118, 1116f–1118f\nhypertrophy of, 181, 182f, 509–510, \n1114–1118, 1116f–1118f\ninnervation of, 1114\nMasseteric space infections, 342\nMastication\ncomplete denture and, 14\nforces generated by, 9, 174\nimplant-supported prosthesis effects \non, 16\ntooth loss effects on, 14\nMasticatory muscles\nforce affected by dynamics of,  \n191–193, 192f\npalpation of, in clenching examination, \n180\nMaterial safety data sheets, 921\nMaxilla\nanatomy of, 296–302, 298f–301f, \n331–335, 331f, 589f\narterial supply to, 334–335, 334f\nblood supply to, 338–340\nbone loss in, 9, 12f, 415–416, 416f\ncrown height space in, 591, 591f\nedentulous\nearly loading of implants in, 874\nfixed prostheses for, 591–594, \n592f–594f, 592t, 592b–593b\nimmediate loading of implants in, \n874\nimplant overdenture for, 594–596, \n595f–598f, 595t, 596b, 598b\nregions of, 168\nremovable prostheses for, 594–596, \n595f, 595t, 596b, 598b\ntreatment planning for, 589–591\nesthetic zone in, 438\nfree-end edentulism in, 5, 5f\nimmediate implant placement in, 854f\nlateral wall/nasal bleeding, 783–785\nlymphatic drainage of, 335\nmuscles to, 332–333, 332f–333f\nosteology of, 69\npalatal resorption pattern of, 504\npremaxilla, 296–297, 298f, 305–306, \n305f\nradiographic anatomy of, 296–302, \n298f–301f\nradiology report findings for, 312\nsensory innervation of, 333–334, 333f\nsurgical anatomy of, 331–335, 331f\nvenous drainage of, 335"
  },
  {
    "page": 92,
    "content": "1232\nIndex\nMaxillary anterior implant\nanatomic challenges for, 710–715\nangulation of, 714–717\nbody angulation of, 714–715\nbone height, 710–711\nbone width, 713f\ncomplications of, 720–721\nfor congenitally missing lateral incisors, \n727–732\ndiameter of, 714b\nfaciopalatal width, 711–712\nideal angulation of, 716–717\nmesiodistal space, 711\nnasopalatine canal, 721–732\nplacement of, 706–725\nposition of, 714\nsize of, 712–714\nsoft tissue closure, 719\nsoft tissue incision, 717–719,  \n718b\nstudies of, 706\ntransitional prosthesis, 719–720\nMaxillary anterior teeth\nevaluation of, 706–710\nposition of, 495–496, 496f\nshape of, 707–708, 708f\nsize of, 707–708\nsoft tissue drape of, 708–710\nMaxillary arch, edentulous, 15\nMaxillary artery, 334, 992\nMaxillary complete denture, 14–15\nMaxillary incisors\ncongenitally missing, 535–536,  \n536f\nextraction of, 896f\nMaxillary nerve, 333\nMaxillary sinus\nanatomical variants of, 998–1000\nanatomy of, 299, 300f, 332f, 987–997, \n988f\nanterior wall of, 990, 997t\nantroliths of, 310–311, 311f–312f, \n1006–1007, 1007f\nbacterial flora of, 996\nblood supply to, 992–995, 993f\nbone density in, 989\nbone resorption process in, 989\nbony walls of, 990–992, 990f–991f\nclinical assessment of, 996–997\ncone beam computed tomography of, \n997\ncyst of, 309–310, 310f\ncystic lesions of, 1003–1007\ndevelopment of, 987–989, 988f\nexpansion of, 987–989, 988f–989f\nextraosseous anastomosis of, 993\nforeign bodies in, 1006–1007, 1007f\nMaxillary sinus (Continued)\ngrafting of, 558–564, 559f–563f, 559t, \n560b–561b, 563b, 1008–1010, \n1016–1024, 1019b, 1020f\nhypoplasia of, 304–305, 304f, 999–\n1000, 1000f\nimplant migration, 1044–1045, 1045t, \n1046f–1049f\nimplant penetration into, 1043–1044, \n1044f\nimplant placement near, 698, 701f\ninferior floor of, 304f\ninferior wall of, 992, 997t\nintraosseous anastomosis of, 306, 306f, \n993–994\nlateral wall of, 992, 1016–1024\nmedial wall of, 991–992, 991f, 997t\nmild mucosal thickening of, 1001, \n1001f\nmucocele of, 309, 310f, 1005, 1006f\nmucociliary clearance of, 994–995, \n995f\nmucosa of, 994\nostiomeatal complex of, 300–302, 313, \n992, 998\nostium of, 301, 301f, 991–992\noverfilling of, 1044, 1045f\npathology of, 557, 557f, 1000–1007\nphysical examination of, 997, 997t\npneumatization of, 554, 554f, 987\nposterior wall of, 990–991, 991f, 997t\npostoperative cyst of, 309–310, 310f\nprimary mucocele of, 309, 310f, 1005, \n1005f\npseudocysts of, 1003–1004, 1004f\nradiographic evaluation of, 997\nretention cysts of, 1004\nSchneiderian membrane of, 300, 300f, \n333, 992, 995f, 997\nsensory innervation of, 992–995\nsepta of, 304, 304f\nsmoking effects on, 1007\nsocket grafting considerations, 909, \n910f\nsquamous cell carcinoma of, 311f\nsuperior wall of, 990, 991f, 997t\nsurgical treatment of, 1010\nMaxillary sinus floor augmentation, 30\nMaxillary tuberosity\nanatomy of, 1072\nbone grafting from, 905–906, \n905f–906f, 1021, 1071–1073, \n1072f–1073f, 1074b\ndescription of, 44–45\nharvesting of, 1073f\nMaxillomandibular arch relationship, 504\nMaximal intercuspation, 504–505, 505f\nMean corpuscular volume, 224t–226t\nMechanical stress, 143\nMechanostat concept, 94, 94f\nMedial pterygoid muscle, 336\nMedian vascular canal, 296, 297f, 738, \n741f, 779\nMedical consultation and clearance, 269, \n270f\nMedical history\nextraoral examination, 211–214\nform for, 211f–214f\nintraoral examination, 211–214\noverview of, 210–217\nvital signs. See Vital signs\nMedication-related osteonecrosis of the \njaw, 351. See also Drug-induced \nosteonecrosis of the jaw\nMedullary plexus, 338\nMembranes. See also Barrier membranes\ncharacteristics of, 927–928\nclassification of, 917\nfuture of, 928–930\nin guided bone regeneration, 955\nideal, 917\nlayering of, 966–967\noversight of, 917–918\nresorbable, 927\nsingle-patient uses for, 921\nsterility of, 919\nsummary of, 930\nMental foramen, 278, 291, 291f, 392f, \n698, 755–757, 756f, 835f, 908–909, \n1058\nMental nerve, 755–757\nMental protuberance, 336\nMentalis muscle, 11, 336–337\nMeperidine, 371\nMepivacaine, 373, 373t–374t\nMetabolic bone disease, 93–94\nMetabolic screening, 221\nMetal-ceramic restorations, 549, 551f\nMetals and alloys\ncobalt-chromium-molybdenum, 113\nengineering properties of, 112t\niron-chromium-nickel, 113–114\noverview of, 111–114\nsurfaces of, 123–124\ntitanium. See Titanium\nMethotrexate, 256\nMetronidazole, 364, 364t, 379t–380t, \n1039–1040, 1159, 1159b\nMicrocomputed tomography\nbone on, 75–76, 79f–80f\ndescription of, 73\nMicroindentation, 75–76\nMicroindentation testing, 73\nMicroporosity, 916, 916f"
  },
  {
    "page": 93,
    "content": "1233\nIndex\nMicroradiography, 72, 74–75\nof bone, 74–75, 75f–78f\nMicrosieverts, 282, 285f\nMicrostrain, 865, 866f\nMicrostructure, implant, 22, 26\nMicrothreads, 26, 55–56, 56f\nMidazolam, 375\nMiddle meatus, 300\nMiddle superior alveolar nerve, 334\nMiddle turbinate, 999\nMild pain, 372\nMineralized allografts, 29t\nMineralocorticoids, 366\nMini-implants\ndescription of, 23–24, 24f\northodontic anchorage uses of, \n101–103, 105f\nMinocycline, 1159, 1159b\nMisch classification, of bone density, 454, \n454t, 648, 649f\nMisch occlusal analyzer, 501f\nMitosis, 915\nModel, 385b\nModerate pain, 372\nModulus of elasticity, 64, 143, 161–162, \n162f, 460, 868f\nModulus of rigidity, 145\nMolars\nbiting force of, 569f\ndental arch maintained by, 4\nfirst, single-tooth implant for, 539–\n541, 540f\nfurcation treatment of, 511\nloss of, 5, 5f\nsecond, single-tooth implant for, \n541–542, 542f, 542t\nMolt periosteal elevator, 611\nMoment arms\ncantilever length as, 147f–148f, 149\ndefinition of, 146–147\nocclusal height as, 147, 147f–148f\nocclusal width as, 149\nMoment loads, 146–147, 146f, 188f, \n188t\nMoment of force, 898\nMoment of inertia, 151\nMonetite, 116t\nMonoclonal antibodies, 262–263\nMonocytes, 218, 224t–226t\nMonolithic zirconia, 442–444, 443t\nMonopolar electrosurgery units, 777, \n777f\nMotion-related artifacts, 287, 287f\nMoxifloxacin, 364t\nMucocele, 309, 310f, 1005\nMucositis, peri-implant. See Peri-implant \nmucositis\nMucous retention cyst, 309, 312f, \n1003–1004\nMultiple myeloma, 253\nMultiple sclerosis, 265\nMultiple-teeth replacement\nimplant-supported multiple crowns, \n543–544, 543f\nno treatment, 542–543\nrecommendations for, 551t\nMylohyoid muscle\nanatomy of, 335–336\nnerve to, 337\nMyocardial infarction, 234–235, 235t\nN\nN-FIT, 870\nN-terminal-pro-brain natriuretic peptide, \n236\nNaloxone, 376\nNasal cavity\nanatomy of, 299–300, 999, 999f\nimplant position, 698, 725–732\nradiology report findings for, 313\nNasal turbinates, 998\nNasolabial crease, 1134, 1135f\nNasolabial folds, 1134, 1135f\nNasolabial groove, 11\nNasopalatine canal, 297–298, 298f, 715f, \n721–725\nNasopalatine nerve, 334, 813\nNational Center for Health Statistics, 2, 4\nNavigational systems, 400, 402f, 645\nNecrotizing periodontal diseases, 347\nNeedle holders, 640, 641f\nNeuropraxia, 817, 819f, 1078\nNeurosensory impairment, 811–821, \n853, 857f\nNeurotmesis, 818, 819f\nNeutrophils, 218, 224t–226t\nNew York Heart Association congestive \nheart failure classification, 236, 236b\nNewton’s laws of motion, 140\nNicotine, 260t\nNight guards\nfor bruxism, 179–180, 180f, 184\nfor clenching, 181, 182f, 184\nNoise, 287–288, 288f\nNon-ST segment elevation myocardial \ninfarction, 234\nNonabsorbable sutures, 623–624, 631f\nNonfunctional early prosthesis, 861b\nNonfunctional immediate prosthesis, \n861b, 871f\nNonfunctional immediate teeth, 869b, \n872b\nNonlimiting surgical template, 394–395, \n701, 702f\nNonocclusal loading, 861b\nNonresorbable membranes, 28\nNonrigid connectors, 519–520\nNonsteroidal antiinflammatory drugs \n(NSAIDs)\nacetaminophen and, 371\nantihypertensive medications affected \nby, 229\nclasses of, 370, 370t\ndrug interactions, 379t–380t\nedema treated with, 791\ngastrointestinal complications of, 370t\nmechanism of action, 366, 366f\npain management uses of, 370–371, \n370t\nNovaSterilis, 920\nNovel oral anticoagulants, 220, 268\nNuclear volume morphometry, 76, 81f\nNutrition, implant-supported prostheses \neffects on, 16\nO\nObesity, 90\nObsidian, 549\nObstructive sleep apnea, 228, 257\nOcclusal awareness, 16\nOcclusal contacts, 1202–1203, 1205f\nOcclusal forces\nbone response to, 49\ndirection of, 49\nduration of, 49\nimmediate loading and, 866f–867f, \n867–868\nmagnitude of, 49\nmarginal bone affected by, 152–153\nnonaxial, 49\ntransfer of, to bone, 48–50, 51f\ntype of, 49\nOcclusal guards\nfor bruxism, 179–180, 180f\nfor clenching, 181, 182f, 184\nOcclusal height, 147, 147f–148f\nOcclusal loading, 861b\nOcclusal overload\nimmediate, 863, 864f\nmechanical components affected by, \n153–155\nOcclusal planes, 500–501, 500f\nOcclusal stress, 1149\nOcclusal trauma\ndefinition of, 161\nmarginal bone loss caused by, 155–\n157, 161\ntooth mobility caused by, 1194–1195\nOcclusal vertical dimension\nbruxism effects on, 177–178\ncorrelations, 498b"
  },
  {
    "page": 94,
    "content": "1234\nIndex\nOcclusal vertical dimension (Continued)\ncrown height space and, 496\ndefinition of, 496\nwith denture, 9f\ndenture effects on, 11f\nevaluation of, 497–499, 498b\nexisting, 496–500\nfacial height affected by, 11\nfacial measurements and, 497–498\nimplant loading affected by, 496–497, \n497f\nmodification of, 497\nradiographic assessment of, 498\ntransitional prosthesis for restoration \nof, 527\nOcclusal width, 149\nOcclusion\ncentric, 504\nimplant-supported prosthesis for \nstability of, 16\nload direction established with, 141\nin preimplant prosthodontics \nevaluation, 504–505, 505f\nOctacalcium phosphate, 116t\nOdontogenic rhinosinusitis, 306–307, \n307f, 1000–1001, 1001f\nOffset loading, 142–143\nOne-piece implants, 23, 24f\nOnlay grafting, 30\nOnodi cells, 299\nOpen bite, 91b\nOpen-tray technique, for impressions,  \n34, 38f\nOpioids\ndrug interactions, 379t–380t\nmechanism of action, 369\npain management uses of, 371\nOptical impressions, 404–405, 405b\nOral anticoagulants, 220–221\nOral irrigator, 1211, 1211f, 1212b\nOrbicularis oris muscle, 332\nOrgan procurement organizations,  \n921–922\nOroantral fistulae, 1035–1036, 1037f\nOrthodontics, implant-anchored, 98–103\nOsseodensification, 649–650\nOsseointegration\nbone-to-implant contact, 21\ndefinition of, 20–22, 913\ndeterminants of, 197\nillustration of, 21f, 1194f\nimplant surface in, 197\nsecondary stability created by, 21\nstages of, 199–200\nzirconia implants, 121\nOsseous defects, 951f\nOsteitis deformans, 253\nOstene, 790–791, 791f\nOsteoblasts, 80f, 913\nOsteocel, 925\nOsteoclasts, 203, 913\nOsteoconduction, 30, 915\nOsteoconductive grafts, 935b\nOsteocutaneous grafts, 1105f\nOsteocytes, 914, 914f\nOsteogenesis\ndefinition of, 30, 915\ngrowth factors in, 202\nOsteogenesis imperfecta, 254\nOsteogenic grafts, 935b\nOsteoinduction, 30, 915\nOsteoinductive grafts, 935b\nOsteology, of craniofacial complex, \n69–71\nOsteomalacia, 252–253, 255t\nOsteomyelitis, 254, 349–351\nOsteonecrosis of the jaw, drug-induced/\nmedication-related, 261, 261t, 351\nOsteons\nOsteopenia, 94f\nOsteoplasty, 423f–424f, 470, 742, 745f,  \n1011\nOsteoporosis\nbisphosphonates for. See \nBisphosphonates\ndefinition of, 93, 251\nestrogen therapy for, 251, 252b\nin jaw, 251\nmedications for, 252b\nmonoclonal antibodies for, 262–263\nobesity and, 90\nrisk factors for, 93\ntreatment of, 252b\nvitamin D and, 251–252\nOsteopromotion, 916–917\nOsteoradionecrosis, 254–255\nOsteotomes, 620, 620f\nOsteotomy\nbone overheating during, 645–647, \n645f–646f, 773, 773f–774f\ndrilling, 645–647, 645f–646f, 650, \n650f, 814–816\nheat generated during, 645–647, \n645f–646f\nfor immediate implant placement, 842\ninferior, 1065f–1066f\nmalpositioned site for, 771, 772f\nmandibular symphysis technique, \n1064b\nmarginal bone loss caused by, 157–158\nsinus elevation and, 1013, 1014f\nsuperior cuts, 1070f\ntechnique for, 645–647, 645f–646f, \n648b\nOstiomeatal complex, 300–302, 313, \n992, 998\nOuter diameter, 56f\nOverdenture(s)\ndefinition of, 36\nimmediate loading of, 881–884,  \n885f\nin limited crown height space, 509\nOverdenture attachments, 36, 41f, 189\nOverdenture bars, 509\nOxycodone, 371\nOxygen supplementation\nfor chronic obstructive pulmonary \ndisease, 248\nfor congestive heart failure, 236\nP\nPaget disease, 253\nPain\nabutment-related, 1202, 1204f\nanalgesics for, 369–371, 369t–370t, \n369b–370b, 373b\ndefinition of, 1201\nimplant-related, 1201–1202\nlocal anesthetics for, 373–375, \n373t–374t, 373b–374b\nmechanism of, 368–369\npostsurgical, 368–372\nprotocol for controlling, 372–375, \n373t–374t, 373b–374b\nPalatine bone, 331\nPalatine nerve, 334\nPanoramic curve, 390, 391f\nPanoramic radiographs\nalveolar bone changes evaluated using, \n317\ndisadvantages of, 1204\nlimitations of, 277–278, 277f–278f\nmagnification from, 277, 277f\nvital structures on, 277–278\nPapilla-sparing incision, 605–606, 606f, \n798–799, 961f, 1057f\nParadoxical middle turbinate, 302, 303f\nParafunctional habits, 1012f\nbotulinum toxin injections for, \n1114–1118, 1116f–1118f\nbruxism. See Bruxism\ncategories of, 175\ncharacteristics of, 174–175\nclenching, 180–184, 184t\nimplant-supported overdenture affected \nby, 571–572\nmasseter muscle hypertrophy,  \n1114–1118, 1116f–1118f\nscrew loosening caused by, 802–803\nin temporalis muscle, 1118, 1119f\ntongue thrust and size, 184–186, 185f"
  },
  {
    "page": 95,
    "content": "1235\nIndex\nParallel-sided screw-shaped implants, 25, \n25f, 50\nParanasal sinuses. See also specific sinus\nanatomy of, 299, 300f, 998f\npathologic conditions in, 306–311, \n997\nradiology report findings for,  \n312–313\nsquamous cell carcinoma of, 310,  \n311f\nParapharyngeal space, 344\nParathyroid hormone\ncalcium and, 84–85, 89f, 250–251\nhyperparathyroidism, 242–243\nphosphorus regulation by, 222\nPartial denture. See Fixed partial denture; \nRemovable partial denture\nPartial edentulism\nfactors associated with, 5\nfree-end, 5\nimplant demand affected by, 4–6\nprevalence of, 4–6\nprosthesis design for, 437–446\nPartial-limiting surgical template, 397\nPartial thromboplastin time, 220–221, \n224t–226t\nPartially edentulous arches\nClass I, 480–483, 481f–483f\nClass II, 483–485, 484f–485f\nClass III, 485–487, 486f–487f\nClass IV, 487–489, 488f–489f\nclassification of, 480\nhistory-taking, 480\nimmediate loading of implants in, \n868–870, 869b, 871f–872f\nKennedy classification of, 480\nParticulate grafts, 974b, 976–977\nParticulate hydroxyapatite, 116–117,  \n117f\nPassivation, 129\nPathologic fracture, of mandibular body, \n8, 1109f\nPathologic overload zone, 865\nPatient\nheight of, 217\nlaboratory evaluation of. See Laboratory \nevaluation\nmedical evaluation of, 210\nmedical history of. See Medical history\nrisk assessment of, 210b\nvital signs of. See Vital signs\nweight of, 217\nPDL. See Periodontal ligament\nPenicillin V, 362\nPenicillins, 362, 362b, 379t–380t\nPeptic ulcers, 249–250\nPercussion testing, 22, 846–847, 847f\nPeri-implant disease\nbiofilm associated with, 1143–1144\ndefinition of, 36–37\ndescription of, 1143–1144\ndiabetes mellitus and, 1146\ndiagnosis of, 1206–1207, 1209f\nillustration of, 41f\nimplant surface roughness and, 201\nprevention of, 1192\nprotocol for, 1184f–1185f\nretained cement, 1172–1179, 1173f\nPeri-implant mucosal hyperplasia, \n1175–1179, 1179f, 1179b\nPeri-implant mucositis\nantimicrobials for, 1148, 1159\nbacteria associated with, 1145b\ndefinition of, 1143–1145, 1206\ndescription of, 36–37, 352–353\netiology of, 1145, 1146f\nhome care for, 1148\nillustration of, 1145f, 1209f\nmanagement of, 1146–1148, \n1147f–1148f, 1159, 1159f\nmechanical debridement of, 1146–\n1147\nprevalence of, 1145\nprevention of, 1145–1146\nprosthesis-related, 1146f\ntreatment of, 1167t\nultrasonic devices for, 1147–1148, \n1148f\nPeri-implant tissue, 1192–1195, \n1193f–1195f\nPeri-implantitis\napically repositioned surgical technique \nfor, 1162\nautoimmune diseases associated with, \n1196\nbiofilm associated with, 1149, 1166\ncement-retained, 1172–1179, 1173f\ndefinition of, 1143, 1148–1149, 1207\ndescription of, 36–37, 41f, 252, 259, \n352–353, 352f, 793–794, 794f\ndiabetes mellitus and, 1149\netiology of, 1149–1155\nhuman studies on, 1151t–1155t\nillustration of, 1150f, 1209f\nimplant surface and, 1170\nlaser treatment of, 1156–1167, 1158f\nmanagement of, 1155–1167\nocclusal stress as cause of, 1149\npathogens associated with, 1148–1149\nperiodontitis and, 1149\nplatelet concentrate growth factors for, \n1162–1166\npredictive profiles associated with, \n1156t\nPeri-implantitis (Continued)\nprevalence of, 1149\nprevention of, 1149–1155\nregenerative procedures for, 1161–\n1162, 1161f\nsmoking and, 1149\nstudies of, 1151t–1155t\nsurgical management of, 1159–1172\nsymptoms of, 1149b\ntreatment of, 1163f–1166f, 1167t\nPeriapical lesions, 793–794, 794f\nPeriapical mucositis, 306–307, 307f, \n1000–1001\nPeriapical radiograph, 276–279, 276f, 317, \n318f\nPericardium membranes, 961, 971f\nPeriodontal disease\ndescription of, 347–348, 347f\ngingivitis, 347, 1143, 1144f\nimmediate loading in, 348\ntooth extractions because of, 511–512\nPeriodontal ligament, 1193\nbundle bone with, 79, 82f\ndefinition of, 74\nPeriodontitis, 347, 347f, 1143, 1149\nPeriosteal implant, 22\nPeriosteal reflection, 157, 158f\nPeriosteal release, 965f\nPeriosteal releasing incisions, 955, \n964f–965f\nPeriotest, 663, 664f, 847, 847f\nPeriotomes, 896–899, 897f\nPerisurgical infection, 348\nPermucosal abutment, 32, 1208f\nPermucosal extension, 32\nPetechiae, 219–220\nPGA sutures, 623\nPharmacology\nanalgesics, 369–371, 369t–370t, \n369b–370b, 373b\nantibiotics. See Antibiotics\ndrug interactions, 379t–380t\nglucocorticoids. See Glucocorticoids\nlocal anesthetics, 373–375, 373t–374t, \n373b–374b\nprotocol for, 376, 377t\nsedatives, 375–376\nPhenytoin, 1197\nPhiltrum, 1131, 1131f\nPhonetics, implant-supported prosthesis \neffects on, 16\nPhosphorus, inorganic, 222–223\nPhysics Forceps, 898–899, 898f\nPick-up technique, for impressions, 34, \n38f\nPier abutments, 520–521, 520f–521f\nPiezosurgery units, 980, 980f, 618, 619f"
  },
  {
    "page": 96,
    "content": "1236\nIndex\nPiezotome surgery, 1060, 1061f\nPilot drill, 650, 650f\nPilot guide, 399, 399f\nPitch\ndefinition of, 25f\nthread, 58–59, 58f\nPixels, 279–280, 280f\nPlaque, 1197, 1198f, 1199b\nPlasma-spraying technique\nhydroxyapatite, 128–129, 128f, 200t\ntitanium, 127–128, 127f, 199\nPlatelet count, 220, 224t–226t\nPlatelet-derived growth factor-B, \n202–203\nPlatelet disorders, 246\nPlatelet-rich fibrin, 961–969, 972f, 1024, \n1102, 1166\nPlatelet-rich plasma, 202, 1162\nPlatform-matched implants, 27, 27f\nPlatform-switched implants, 27, 27f\nPneumatization, of maxillary sinus, 554, \n554f\nPocket depths, 1143b\nPolycythemia, 244\nPolymers, 121–123\nengineering properties of, 122, 122t\nfiber-reinforced, 121–122\nPolymethylmethacrylate prosthesis, \n526–527, 526f–527f, 527b, 551, \n551f, 551t, 884f\nPolymyalgia rheumatica, 264–265\nPolyposis, 308, 308f, 312f\nPolypropylene sutures, 624\nPolytetrafluoroethylene membrane, 968f, \n970f\nPolytetrafluoroethylene sutures, 624\nPontics, 468–469\nPorcelain-metal fixed prostheses, 442, 443t, \n444f\nPosterior implants\nin maxilla, 51\nsurgical template for placement of, 411, \n412f\nPosterior lateral nasal artery, 784–785, \n784f, 994\nPosterior maxilla, edentulous\naccess-related issues, 555, 556f\nanatomic location of, 555, 556f\narterial supply to, 994b\navailable bone in, 554\nbiting force in, 555–556, 556f\nbone density in, 532–535\nbone resorption in, 554f–555f\ncrown height space in, 554, 555f\nimplants in, 557–558, 698, 701f\nlingual oriented ridge position in, \n554–555\nPosterior maxilla, edentulous (Continued)\nmaxillary sinus pneumatization, 554, \n554f\nMisch-Resnik classification, 558–564, \n559f–563f, 559t, 560b–561b, \n563b\nsinus grafting for, 558–564, 559f–563f, \n559t, 560b–561b, 563b\nsubantral treatment options for, \n558–564, 559f–563f, 559t, \n560b–561b, 563b, 1011–1028\nsurface area requirements, 556–557, \n557f\ntreatment classifications for, 1010–\n1028, 1011f–1013f\nPosterior superior alveolar artery, 338\nPosterior superior alveolar nerve, 333–\n334\nPosterior teeth, 4, 5f\nPosterior tongue thrust, 185\nPostoperative maxillary cyst, 309–310, \n310f\nPostsurgical period\nbleeding control in, 785–794\nedema in, 791–794, 792t\nimaging in, 314\ninfections in, 349–352, 349f–350f\npain management in, 368–372\nPotassium, 224t–226t\nPrednisolone, 367t, 792t\nPrednisone, 367t, 792t\nPreemptive analgesia, 369–370, 370b\nPregnancy, 244\nPreload, 153\nPremature ventricular contraction, 216\nPremaxilla\nbuccal thickness of bone in, 305–306, \n305f\nradiographic anatomy of, 296–297, \n298f\nPremolars\ncongenitally missing, 535–536\nimmediate implants, 765f\nsingle-tooth implant for, 538–542, \n538f\nPreosteoblasts, 76, 80f\nPress-fit cylinders, 48\nPress-fit implants\ndescription of, 23, 23f\nplacement of, 48\nPressure necrosis, 774\nPrimary hyperparathyroidism, 243\nPrimary maxillary sinus mucocele, 309, \n310f\nPrimary mineralization, 74\nPrimary osteons, 78–79\nPrimary spongiosa, 74–75\nPrimary stability\nassessment of, 663–664, 664f–665f, \n665b, 846–848\ndefinition of, 21\ndetermination of, 21–22, 862\nimplant threads for, 57–58, 65\ninability to obtain, 849–852\ninsertion torque, 21\nresonance frequency analysis of, 21\nthreads for, 57–58\nProbing, 1197–1199, 1199f–1200f\nProphylactic antibiotics, 353, 359–361, \n365\nPropofol, 376\nProprietary terminology, 20\nProstate specific antigen, 224t–226t\nProstheses\nbone loss caused by, 7, 8f\nfracture of, 157f\nimplant-supported. See Implant-\nsupported prostheses\nmaintenance of, 1203\nmobility of, 1201, 1202f\nradiographic evaluation of, 1203–1206\nremovable. See Removable prostheses\nsplinting of, 168, 168f\nProsthodontics evaluation, preimplant\narch form, 512–513\ncrown height space, 505–509, \n505f–508f, 506b–507b\nexisting prostheses, 512\nextraction of teeth with hopeless or \nguarded prognosis, 510–512\nlip lines, 501–504, 502f–503f\nmandibular incisor edge position, \n499–500\nmaxillary anterior tooth position, \n495–496, 496f\nmaxillomandibular arch relationship, \n504\nnatural teeth adjacent to implant site, \n513–516, 515f\nocclusal planes, 500–501, 500f\nocclusal vertical dimension, 496–500\nocclusion, 504–505, 505f\noverall evaluation, 495\nsequence of, 496b\nsoft tissue support, 524–525\ntemporomandibular joint, 509–510\nProthrombin time, 220–221, 224t–226t\nProvisional implants\nall-on-four surgical protocol, 876–884, \n877f, 877b\ndefinition of, 874–876\nfixed, 880–881\nfully guided immediate placement, \n876–884, 879b–880b"
  },
  {
    "page": 97,
    "content": "1237\nIndex\nProvisional prostheses\nbone grafts, 967, 973–974\ndefinition of, 861b\nsingle-tooth, 872f\nProvisional restoration\nafter socket grafting, 907, 908f\nPseudocysts, 309, 309f\nPseudomembranous colitis, 361, 362t\nPseudoperiodontium, 79\nPseudopockets, 1197\nPsoriatic arthritis, 264\nPsychological disorders, 260–261\nPsychological health, 16–17, 17b\nPterygoid implants, 990–991\nadvantages of, 43–44\ndescription of, 40–45\ndisadvantages of, 43–44\norigin of, 44–45\nzygoma implant and, 44–45, 44f\nPulse, 215–216\nPulse oximeter, 217\nPulse rate, 215–216\nPulse rhythm, 216\nPulse strength, 216\nPulsed laser deposition, of hydroxyapatite \ncoating, 200t\nPyocele, 308\nR\nRa, 26, 197\nRadiation therapy, 254–255, 255b\nRadiofrequency glow discharge \ntechnique, 130\nRadiographic imaging\n“as low as reasonably achievable” \nprinciple for, 276\nbitewing radiographs, 317\ncrestal bone loss, 1205–1206, 1208f\nimplants, 1203–1206\nmagnetic resonance imaging, 278–279\noverview of, 275\npanoramic radiograph. See Panoramic \nradiographs\nperiapical radiograph, 276–279, 276f, \n317, 318f\nprostheses, 1203–1206\nRadiographic template, 384–386\nRadiology reports, 289, 311–312,  \n315f–316f\nRadiopaque template, 385–386, \n386f–387f, 386b–387b\nRaloxifene, 93\nRamus frame, 40, 42f\nRanulas, 778, 778f\nRaynaud phenomenon, 256\nReactive woven bone, 863\nReclast, 262\nRecombinant human bone \nmorphogenetic proteins, 202–203, \n915, 967\nRed blood cell count, 218, 224t–226t\nRed blood cell disorders, 244\nRed blood cells, 217\nRegional acceleratory phenomenon, 82, \n862–863, 865, 1021, 1074\nRemodeling, of bone\ncell signaling for, 913\ncell types in, 913\ncontrol factors for, 87b\ndefinition of, 893b, 913, 937b\nfunctional loading of implants and, 82\nhistology of, 864f\nmicrocomputed tomography of, 76, 80f\noverview of, 79–81, 251\nparathyroid hormone effects on, 87\nprimary stability in, 21\npurpose of, 69\nself-tapping implant and, 863\nstrain and, 161, 452\nstress and, 161\ntrabecular bone, 452\nRemovable partial denture\nabutment teeth for, 13\nbone loss associated with, 7\nmorbidity of, 13–14\nnegative effects of, 14b\nsingle-tooth replacement using, \n532–533, 533f, 533b\nRemovable prostheses\ndescription of, 445\nfor edentulous maxilla, 594–596, 595f, \n595t, 596b, 598b\nRP-4, 445–446, 446f, 448f\nRP-5, 446, 447f–448f\nRemovable soft tissue–borne partial \ndentures\nacceptance rates for, 13\nforce transmission in, 193\nmorbidity of, 13–14\nRemovable soft tissue–borne prosthesis\nin partial edentulism, 9\npretreatment, 525–526\nRenal osteodystrophy, 87\nRepair bone, 863\nResin-bonded prosthesis, for single-tooth \nreplacement, 533, 533f, 533b\nResnik technique, 1175, 1176b, 1177f\nResonance frequency analysis, 17\ndefinition of, 847–848\ndevices used in, 22, 22f, 665f, 848f\nprimary stability determination using, \n663–664, 665f, 862\nResorbable blast media, 26, 26f, 127f, \n198, 199f\nResorbable collagen membranes, 925, \n926f\nResorbable membranes, 28, 927\nRespiration, 216–217\nRetained cement peri-implant disease, \n1172–1179, 1173f\nRete peg formation, 159\nRetention cysts, 309\nRetrograde peri-implantitis, 793–794, 794f\nRetromolar canal, 294, 295f\nRetromolar foramen, 294, 295f\nRetromolar implant, 100, 100f, 104f\nRetromolar triangle, 336\nRetropharyngeal space, 344\nRetrovisceral space, 344\nReverse buttress threads, 26f, 59, 60f\nReverse screw technique, 825f\nReverse torque testing, 22\nRFA. See Resonance frequency analysis\nRFGDT. See Radiofrequency glow \ndischarge technique\nRheumatoid arthritis, 256\nRheumatoid factor, 224t–226t\nRhinosinusitis\nacute, 307–308, 308f, 1001–1002, \n1002f, 1040t, 1041\nallergic, 308, 308f, 1002–1003\nchronic, 308, 1002\nclinical examination for, 997\nfungal, 308–309, 309f, 1003\nodontogenic, 306–307, 307f, 1000–1001\nRidge expansion, 30\nRight-sided congestive heart failure, 236\nRivaroxaban, 220–221\nRongeur forceps, 611–612, 612f\nRoot form implants\nanterior, 432f\ndesign of, 416–417\nmoment of inertia of, 151\nsmaller-diameter, 424\nRoot resection, 511f\nRoot tip retention, after tooth extraction, \n911f\nRP-4\nangulation of, 689\ndescription of, 186, 445–446, 446f, \n448f\nfor edentulous maxilla, 595, 596b\npositioning of, 696–698, 698f–699f\nRP-5\nangulation of, 689\ndescription of, 186, 446, 447f–448f\nfor edentulous mandible, 570–579, \n570b, 571f\nfor edentulous maxilla, 595–596\nloading of, 881\npositioning of, 696–698, 698f–699f"
  },
  {
    "page": 98,
    "content": "1238\nIndex\nS\nSa, 26, 197\nSA-4, 1027f, 1027b\nSaline rinses, 1040–1041\nSalivary gland injury, 778, 778f\nSalvin implant rescue kit, 812f\nSaucerization, 156\nScaffolds, 928\nScalers, 1147, 1148f\nScalpel, 608–610, 610f\nScanning abutments, 34, 38f\nScanning template, 384–386\nSCC. See Stress corrosion cracking\nSchneiderian membrane, 300, 300f, 333, \n992, 995f, 997, 1033\nSchwann cell column, 340\nScissors, 612, 614f, 640, 641f\nScleroderma, 256\nScrew(s). See also Abutment screw\nfracture of, 154–155, 155f, 807–809, \n809f\nloosening of, 152–153, 155f, 477, \n801–807\nremoval of, 810f–811f\nScrew-cementable prosthesis, 547, 547f\nScrew-retained crown\ndescription of, 36\nillustration of, 39f, 544f\nScrew-retained restorations, 544–545, \n544f–545f, 545b, 591, 688f, 803f, \n805–806\nScrew-shaped implants\nbone-level implants, 24–25, 24f\ndefinition of, 23\nmacrostructure of, 25, 25f\none-piece, 23, 24f\nparallel-sided, 25, 25f\nparallel-walled design of, 23\nsmall diameter implants, 23–24, 24f\ntapered screw design of, 23, 24f–25f, \n25\nthread characteristics of, 58f\ntissue-level implants, 24–25, 24f\ntwo-piece, 23, 24f\nScrew tap instrument, 26\nSDIs. See Small diameter implants\nSecond molar implants, 767f\nSecond-stage surgery, 28\nSecondary hyperparathyroidism, 243\nSecondary maxillary sinus mucocele, \n1005, 1006f\nSecondary mineralization, 74, 78\nSecondary osteons, 82, 98f\nSecondary stability\nbiomechanical concept of, 21\ndefinition of, 20–21, 848\nosseointegration as, 20–21\nSedatives, 375–376\nSegmental degeneration, 817, 818f\nSelective serotonin reuptake inhibitors, \n268\nSelf-tapping implants, 26\nSerum glucose, 221–222, 222t\nSevere pain, 372\nSharpey’s fibers, 79, 1199–1200\nShear force, 142, 142t\nSickle cell anemia, 244–245, 247t\nSilk sutures, 623–624\nSimple interrupted suture, 626–630, \n633f–634f, 637f\nSimple loop suture, 626–630, 633f–634f\nSingle-tooth implant\nadvantages of, 534–535, 535b\nanodontia treated with, 535–536\nanterior teeth, 551t\nmandibular, 536–537, 537f\nmaxillary, 537–538, 720\ndisadvantages of, 535, 535b\nillustration of, 534f\nimmediate loading of, 868–870, 872f\nindications for, 535–536\nposterior teeth, 551t\nfirst molar, 539–541, 540f\npremolars, 538–542, 538f\nsecond molar, 541–542, 542f, 542t\nsize of, 536–542\nSingle-tooth replacement\nfixed partial denture for, 533–534, \n534f, 534b\nimplant for. See Single-tooth implant\nno treatment for, 532, 532f\noptions for, 531–532, 532b\nprevalence of, 531\nremovable partial denture for, 532–\n533, 533f, 533b\nresin-bonded prosthesis for, 533, 533f, \n533b\nthree-unit fixed partial denture for, \n12–13, 13f, 13b\nSinus augmentation, 30, 319f\nSinus bump, 30\nSinus curettes, 620, 621f\nSinus graft surgery, 558–564, 559f–563f, \n559t, 560b–561b, 563b, 1008–\n1010, 1016–1026, 1019b, 1020f\nantibiotic prophylaxis for, 1008–1010, \n1009b\nbleeding, 1030, 1032f\nbottom layer, 1021\ncomplications of, 1008–1010\ncontraindications for, 1007–1008, \n1008b\necchymosis after, 1034–1035, 1035f\nedema after, 1034\nSinus graft surgery (Continued)\nimplant insertion, 1027–1028\ninfections after, 1036–1041, 1042f, \n1045\nintraoperative complications of, \n1028–1030\nlateral wall approach, 1016–1024\nlayered approach, 1018–1021, 1019b\nmembrane perforations, 1028–1029, \n1028b\noroantral fistulae after, 1035–1036, \n1037f\npain after, 1035\npostoperative complications of, \n1030–1032\npostoperative instructions for, 1026–\n1027, 1028b\nrevision surgery of, 1033, 1035f\nSA-1, 1011\nSA-2, 1012–1014, 1014f\nSA-3, 1014–1024\nSA-4, 1024–1028, 1027f, 1027b\nsecond layer, 1021\nvascular healing of, 1025–1026\nSinus membrane perforations, 1028–\n1029, 1028b\nSjögren syndrome, 255–256\nSkeletal system\nbiomechanics of, 94–95\ncompromise of, 93–94\nmechanical loading of, 94\nmetabolic bone disease of, 93–94\nregulatory mechanisms of, 93\nSmall diameter implants, 23–24, 24f, 51\nSmall intestine, calcium absorption in, 87\nSmile, gummy, 502–503, 1120–1124, \n1121f–1126f\nSmile line, 589–590, 590f\nSmiling, 502\nSmoking, 258–259, 260t, 1007, 1146, \n1149, 1197\nSmooth Staple implant, 40\nSNAP-25, 1112, 1113f\nSocial smile, 1121\nSocket grafting\ncomplications of, 909–911, 910f–911f\ncontraindications for, 908–909, 909f\nhealing after, 908, 908f\ninfection, 908, 909f\nmandibular canal proximity, 908–909, \n909f\nmandibular ramus donor site for, \n902–905, 904f–905f\nmaxillary sinus considerations, 909, \n910f\nmaxillary tuberosity donor site for, \n905–906, 905f–906f"
  },
  {
    "page": 99,
    "content": "1239\nIndex\nSocket grafting (Continued)\noverfilling of socket, 909, 911f\nprovisional restorations after, 907, 908f\nseal surgery for, 906, 907f\ntechnique for, 899–907\nSocket preservation/restoration, 937b\nSocket seal surgery, 906, 907f\nSocket-shield technique, 30, 30f–31f\nSodium, 224t–226t\nSoft tissue, 946\nbiological width of, 1192\nbiotypes, 949–950, 957f–958f\nperi-implant, 1192–1193\nreduction of, 508–509\nreflection of, 814–816\ntotal edentulism effects on, 9–10, 10b\nSoft tissue grafts, 930\nSoft tissue-supported guides, 398, 399f\nSol-gel, 200t\nSphenoid sinus, 299\nSphenopalatine artery, 994\nSphenopalatine nerve, 333–334\nSpirochetes, 345\nSplinting, 168, 168f, 476–477, 477f\nSpondylitis, 264\nSputter coating, of hydroxyapatite \ncoating, 200t\nSquamous cell carcinoma, 310\nSquare threads, 26f, 51f, 59–60, 60f\nSSRIs. See Selective serotonin reuptake \ninhibitors\nST segment elevation myocardial \ninfarction, 234\nStability\ndetermination of, 21–22\ninsertion torque of, 647, 861\npercussion testing of, 22\nprimary\nassessment of, 663–664, 664f–665f, \n665b, 846–848\ndefinition of, 21\ndetermination of, 21–22, 862\nimplant threads for, 57–58, 65\ninability to obtain, 849–852\ninsertion torque, 21\nresonance frequency analysis of, 21\nthreads for, 57–58\nresonance frequency analysis of, 22f\nreverse torque testing of, 22\nsecondary\nbiomechanical concept of, 21\ndefinition of, 20–21, 848\nosseointegration as, 20–21\nStability dip, 21\nStackable guides, 403f–404f\nStaged occlusal loading, 861b\nStainless-steel curettes, 1147\nStainless-steel fracture fixation screw, 111f\nStaple bone implant system, 40\nStatins, 202\nStent, 385b\nStereolithographic guide, 404b\nStereolithographic models, 400, 401f\nStereolithography, 400\nSterile field, 620–622, 623f\nSterility assurance level, 919\nStomach ulcers, 249–250\nStrain, 143, 145f\nbone remodeling and, 161, 452\ndefinition of, 161\nStreak artifacts, 287, 288f\nStress\nbone remodeling and, 161\ncrown height space and, 190\nimplant surface area and, 168, 168f\nmagnitude of, 143, 174\nmechanical, 143\ntreatment planning affected by, \n166–167\nStress corrosion cracking, 110, 111f\nStress-strain relationship, 143–145\nStress treatment theorem, 152–173, 153b, \n169b\nStroke, 238\nSubacute bacterial endocarditis, 236–237, \n237b\nSubantral implants, 558–564, 559f–563f, \n559t, 560b–561b, 563b, 996–997, \n996f, 1011–1028\nSubcondylar fractures, 71\nSublingual artery, 780, 781f\nSublingual hematoma, 782f\nSublingual space, 343f\nSubmandibular space, 343f\nSubmental artery, 780–781, 781f\nSubmental space, 343f\nSubmucosal space technique, 604–605, \n605b, 799, 799b\nSubperiosteal implants\ndescription of, 37–40\nillustration of, 42f\nlong-term success rates for, 49t\nSubtractive processes, 26\nSulcular incisions, 1060f\nSulcus depth, 24–25\nSulfonamides, 1039\nSuperior meatus, 300\nSupragingival implant, 54, 55f\nSurface. See also Implant surface\nof ceramics, 126\nof cobalt alloys, 125–126\nof hydroxyapatite, 126–127\nof iron alloys, 125–126\nof titanium alloys, 123–124\nSurgical blades, 610, 610f\nSurgical burs, 611, 612f\nSurgical guide, 33, 35f–36f, 702–704\nSurgical scrub, 622, 624f–627f\nSurgical templates\naccess inadequacies with, 411, \n411f–412f\nbone overheating concerns, 411\ncomplete-limiting, 397, 398f, 702, \n702f\ncomplications of, 411–413\ndefinition of, 394, 701\ndescription of, 33, 35f–36f\ndifficulty in template seating, 413, 413f\nfabrication of, 393–394, 400–401\nfully guided, 399, 400f\nillustration of, 395f\nimplant placement using, 394–398\nnonlimiting, 394–395, 701, 702f\npartial-limiting, 397, 701\nas pilot guide, 399, 399f\nin posterior implant placement, 411, \n412f\nrequirements of, 399–400\nsummary of, 399f\nas universal guide, 399, 399f\nSuture needle, 626, 632f\nSutures/suturing\nabsorbable, 622–623, 625, 628t–629t, \n630f\natraumatic removal of, 800\nbleeding control using, 785\ncontinuous, 630, 637f\nfacial, 95–98, 95f–97f\nfigure-eight, 626, 635f\nhorizontal mattress, 630–631, 638f\ninstruments for, 640, 640f–641f\ninterrupted, 626–630, 633f–635f\nknots for, 640–641, 642f\nnonabsorbable, 623–624, 631f\nprinciples of, 640b\nqualities of, 625–626\nsimple loop, 626–630, 633f–634f\nsize of, 626, 632f\ntechniques for, 626–631\ntypes of, 628t–629t\nvertical mattress, 630–631, 639f\nSuzuki-Misch-Hsaio implant health scale, \n1180, 1180t\nSymmetric psoriatic arthritis, 264\nSystemic lupus erythematosus, 256\nT\nT3, 224t–226t, 241\nT4, 224t–226t, 241\nT-cell inhibitors, 264\nTamoxifen, 93, 263"
  },
  {
    "page": 100,
    "content": "1240\nIndex\nTapered screw-shaped implants\ndescription of, 23, 24f–25f, 25\nillustration of, 417f, 856f\nlong-term performance of, 50\nTCP. See Tricalcium phosphate\nTeeth. See also Anterior teeth; Posterior \nteeth; specific tooth\nadjacent, injury to, 774\nimplants and, differences between, \n1196t\nmesiodistal width of, 676t\nmovement of, 1193–1195, 1194f\nTemplate, 385b. See also Surgical \ntemplates\nTemporal fossa, 74–75\nTemporalis muscle\nbotulinum toxin injections in, 1118, \n1119f\ndescription of, 336\nTemporary abutments, 36, 41f\nTemporary healing abutment, 28\nTemporomandibular joint\ndescription of, 70–71\ndysfunction of, 509–510\nradiology report findings for, 313\nTemporomandibular joint syndrome/\ntemporomandibular dysfunction, \n1119–1120, 1121f\nTensile force, 141–142, 142t, 144f\nTension-free incision closure, 799, 799f\nTenting screws, 974–976\nTerminal abutments, 167, 469f\nTerminology\ngeneric, 20\nproprietary, 20\nTertiary hyperparathyroidism, 243\nTetracyclines, 363, 364t, 1039, 1159\nThalassemia, 247t\nThe Joint Commission, 918\nThermal spraying, of hydroxyapatite \ncoating, 200t\nThermometers, 216\nThread pitch, 58–59, 58f\nThreadformer, 26\nThreads, implant\nbuttress, 26f, 51f, 59, 60f\ndepth of, 60–61, 61f, 867\ndescription of, 25–26, 25f–26f, 57–58\ngeometry of, 867\nloading of, 166f\npitch, 58–59, 58f\nprimary stability uses of, 57–58, 65\nreverse buttress, 26f, 59, 60f\nshape of, 59–60, 60f\nsquare, 26f, 51f, 59–60, 60f\nV-threads, 26, 59–60, 60f\n3D printers, 393–394, 396f–397f\nThrombin, 787–789, 788t, 789f\nThrombin time, 220\nThrombocytopenia, 246\nThrombotic stroke, 238\nThrombotic thrombocytopenic purpura, \n246\nThyroid disorders, 240–241, 241t\nThyroid-stimulating hormone, 224t–226t\nThyroid storm, 241\nThyroxine, 224t–226t, 241\nTibial bone graft, 1099–1102, 1101f, \n1101b\nTissue forceps, 611, 611f\nTissue-level implants, 24–25, 24f\nTissue pickups, 640, 640f\nTissue sterilization, 919\nTitanium\nacid etching of, 198\nallergy to, 269, 794, 795f\nbiocompatibility of, 62\ncorrosion of, 113, 125\nengineering properties of, 112,  \n112t\nfatigue strength of, 62–64\nhypersensitivity to, 794, 795f\nintegration with, 124–125\nmechanical properties of, 64t, 144t\nmodulus of elasticity of, 161–162\nproperties of, 112–113\nstrength of, 62–64, 804\nsurfaces of, 123–124\ntissue interactions, 124\nTitanium-6 aluminum-4 vanadium\ndescription of, 112–113, 112t\nmechanical properties of, 144t\nTitanium curettes, 1146–1147, 1146f\nTitanium implants\nacid-etching of, 126f\nanchorage uses of, 98, 99f\nsurface etching of, 126f\nsurface of, 26\nTitanium mesh, 926, 927f, 960–961,  \n970f\nTitanium nitride, 129\nTitanium oxide ceramics, 114, 114t\nTitanium plasma-sprayed surface, \n127–128, 127f, 199\nTMJ. See Temporomandibular joint\nTongue\nin edentulous ridges, 10\nscalloping of, 181, 182f\nTongue thrust, 184–186, 185f\nTooth extraction\natraumatic. See Atraumatic tooth \nextraction\nbuccal plate in, 893, 894f\nendodontic therapy versus, 510\nTooth extraction (Continued)\nwith hopeless or guarded prognosis, \n510–512\nindications for, 511t\nsocket healing after, 892–893, 894f\nTooth loss\nage-related, 4, 7\nalveolar bone remodeling and \nresorption caused by, 8\nbone loss after, 415, 416f\nin elderly, 7\nmasticatory efficiency affected by, 14\nmolars, 5, 5f\nin posterior regions, 4, 5f\nstatistics regarding, 4\nthree-unit fixed partial denture for, \n12–13, 13f\nTooth mobility, 517–518, 518f\nTooth replacement\ncement-retained crown for, 36, \n545–546, 545f\nglobal strategies for, 3f\nmultiple teeth. See Multiple-teeth \nreplacement\nscrew-retained restorations for, \n544–545, 547\nsingle. See Single-tooth replacement\nstatistics regarding, 531–532, 531f\nTooth-supported guides, 397, 398f\nToothbrush abrasion, 181, 181f\nTori, lingual, 72f, 960, 983f\nTorque\ndefinition of, 146–147\ninsertion, 647, 861\nTorque controller, 31\nTorque wrench, 31\nTorsades de pointes, 363\nTorsional load, 146–147\nTotal edentulism\nage-related prevalence of, 6, 6f\nanatomic consequences of, 7–12, 7b\ncomplications of, 9b\nconsequences of, 7b\nin elderly, 6–7\nesthetic consequences of, 11–12, 11f, \n12b\nglobal prevalence of, 6\nhard tissue loss caused by, 7f–9f, 7b\nimplant demand affected by, 6–12\nprevalence of, 6, 6f\npsychological effects of, 14\nsocioeconomic factors, 6\nsoft tissue consequences of, 9–10, 10b\nTrabecular bone\nadaptability of, 450–451\ncalcium reserves in, 83–84\ndensity of, 165"
  },
  {
    "page": 101,
    "content": "1241\nIndex\nTrabecular bone (Continued)\nin dentate mandible, 451f\nmodeling and remodeling of, 80–81, \n452\nocclusal force transfer across, 50\nvariations of, 451f–452f\nTrabeculation, 15\nTramadol, 370b, 371, 379t–380t\nTranexamic acid, 787, 788f\nTransfer technique, for impressions, 34, \n38f\nTransient ischemic attacks, 238\nTransitional prosthesis, 526–528, \n526f–527f, 527b, 719–720, 800, \n857f\nTransmandibular implants\ndefinition of, 40\nendosseous implants versus, 40\nTransosteal implants, 22, 40, 43f\nTransplant, 917\nTrapezoidal flaps, 606–607, 607f, 607b\nTreatment planning\nbiomechanical stress effects on, 166–167\nbone density in, 455–457, 461–464,  \n464b\nfor bruxism, 183–184, 184t\nCAD/CAM systems in, 405\nfor clenching, 183–184, 184t\ncone beam computerized tomography \nfor, 279, 328\ndescription of, 48\nhard tissue considerations, 935b\nimmediate implant placement, 834–839\nmagnetic resonance imaging \napplications for, 278–279\nstress treatment theorem of, 167b\nfor tongue thrust and size, 186\nTrephine burs, 903–904\nTreponema denticola, 345\nTriangular flaps, 606–607, 607f, 607b\nTriazolam, 376\nTricalcium phosphate, 116, 926, 969\nTriiodothyronine, 224t–226t, 241\nTrimethoprim/sulfamethoxazole, 364t\nTubero-pterygo-maxillary implants. See \nPterygoid implants\nTuberosity implants\ndescription of, 44–45\nillustration of, 45f\nTutoplast process, 919\nTwo-piece implants, 23, 24f\nType IV hypersensitivity reaction, 270f\nU\nUlcerative colitis, 250\nUlcers, stomach, 249–250\nUltracet, 370b\nUltram, 370b\nUltrasonic devices\nfor peri-implant mucositis,  \n1147–1148, 1148f\nfor peri-implantitis, 1156\nUncinate process, 301–302, 312f, 999\nUniversal guide, 399, 399f\nUnstable angina, 229–233\nUrinalysis, 217\nV\nV-thread(s), 26, 59–60, 60f\nV-thread implants\ndescription of, 48\nforce transmission of, 51f\nsurvival rate of, 50t\nVacuum-formed radiopaque template, \n388\nValvular heart disease, 236–237\nVascular endothelial growth factors, 264\nVascularized composite graft, 1102–1105, \n1103b–1104b, 1104f–1106f\nVasoconstrictors, 234, 379t–380t\nVector quantities, 140–141\nVermilion zone, 1130–1131, 1131f\nVertical bone augmentation, 742–744,  \n746f\nVertical dimension of the dentogingival \njunction, 24–25\nVertical mattress suture, 630–631, 639f\nVertical release incisions, 604, 604f, 797, \n798f, 951, 953–954\nVestibular flaps, 607, 607b\nVestibular incisions, 1060f, 1078f\nVirtual teeth, 386, 388f, 388b\nVital signs\nblood pressure, 214–215\nbody temperature, 216\npulse, 215–216\nrespiration, 216–217\nVitamin D\nactive metabolite of, 84–85\ndescription of, 90\ndisorders involving, 252–253\nosteoporosis and, 251–252\nvon Mises stress, 58–59\nVoxels, 278, 280, 280f, 282\nW\nWallerian degeneration, 340, 817, 819f\nWarfarin sodium, 266\nWeight, 140, 217\nWheezing, 249t\nWhite blood cell count, 218, 224t–226t\nWhitlockite, 116t\nWolff ’s law, 7\nWomen, bone loss in, 90–93\nWorld Health Organization analgesic \nladder, 372, 373b\nWound classification, 360b\nWoven bone, 78, 165, 863, 915\nWrenches, 31\nX\nXenografts\ndefinition of, 921, 969b\ndescription of, 28, 29t, 917, 969\ndistribution of, 921–922\nprocessing of, 921–922\nsource of, 922–923\ntypes of, 925–926, 929t\nXerostomia, 4, 243–244, 243b,  \n1195–1197\nY\nYankauer suction, 618f\nYonsei point, 1121–1123, 1123f\nYttria-stabilized tetragonal zirconia \npolycrystal, 202\nZ\nZinc phosphate cement, 155\nZirconia\nadvantages of, 17\nchemical composition of, 119–120\ndescription of, 119–121\nfinal prosthesis, 876f\nmonolithic, 442–444, 443t, 548–549,  \n550f\northopedic uses of, 119\nphysical properties of, 120\nsurface roughness of, 120\nZirconia implants\nadvantages of, 122b\nbone-to-implant contact of, 203\ndescription of, 119\ndisadvantages of, 122b\nfabrication of, 119\nfracture of, 121f\nfracture resistance of, 120–121\none-piece, 120, 202\nosseointegration of, 121\nsuccess rates for, 121\nsurface modification of, 202–203\ntwo-piece, 120\ntypes of, 120–121, 120f\nZirconia restorations, 548–549,  \n550f\nZirconium ceramic, 64\nZirconium dioxide, 64\nZirconium oxide ceramics, 114, 114t\nZygomatic implants\ndescription of, 40–45\nillustration of, 43f"
  },
  {
    "page": 102,
    "content": "This page intentionally left blank"
  },
  {
    "page": 103,
    "content": "This page intentionally left blank"
  },
  {
    "page": 104,
    "content": "This page intentionally left blank"
  },
  {
    "page": 105,
    "content": "This page intentionally left blank"
  },
  {
    "page": 106,
    "content": "This page intentionally left blank"
  },
  {
    "page": 107,
    "content": "This page intentionally left blank"
  },
  {
    "page": 108,
    "content": "This page intentionally left blank"
  },
  {
    "page": 109,
    "content": "Evidence-based answers, continually updated\nConf idence\nis ClinicalKey\nA subscription to ClinicalKey draws content from\ncountless procedural videos, peer-reviewed journals,\npatient education materials, and books authored by\nthe most respected names in medicine.\nYour patients trust you. You can trust ClinicalKey.\nEquip yourself with trusted, current content that provides you with \nthe clinical knowledge to improve patient outcomes.\nGet to know ClinicalKey at store.clinicalkey.com.\n2019v1.0"
  }
]